PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9274810-0	1997	Potential role for IL-5 and IL-6 in enhanced IgA secretion by Peyer"s patch cells isolated from mice acutely exposed to vomitoxin.	deoxynivalenol	120-129	interleukin 5	Mus musculus	19-23
9473534-0	1998	Role of macrophages in elevated IgA and IL-6 production by Peyer"s patch cultures following acute oral vomitoxin exposure.	deoxynivalenol	103-112	interleukin 6	Mus musculus	40-44
9439728-0	1997	Superinduction of IL-2 gene expression by vomitoxin (deoxynivalenol) involves increased mRNA stability.	deoxynivalenol	42-51	interleukin 2	Mus musculus	18-22
9439728-0	1997	Superinduction of IL-2 gene expression by vomitoxin (deoxynivalenol) involves increased mRNA stability.	deoxynivalenol	53-67	interleukin 2	Mus musculus	18-22
9274810-0	1997	Potential role for IL-5 and IL-6 in enhanced IgA secretion by Peyer"s patch cells isolated from mice acutely exposed to vomitoxin.	deoxynivalenol	120-129	interleukin 6	Mus musculus	28-32
9274810-7	1997	In contrast, IL-5 levels were increased significantly in 7-day PP cell cultures obtained 2 h after VT exposure both with and without PMA + ION exposure but not in other cultures.	deoxynivalenol	99-101	interleukin 5	Mus musculus	13-17
9274810-8	1997	IL-6 levels were increased significantly in LPS-treated cultures prepared from PP at 2 and 24 h following exposure to VT.	deoxynivalenol	118-120	interleukin 6	Mus musculus	0-4
8887449-0	1996	Effects of vomitoxin (deoxynivalenol) on transcription factor NF-kappa B/Rel binding activity in murine EL-4 thymoma and primary CD4+ T cells.	deoxynivalenol	11-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	62-72
8887449-0	1996	Effects of vomitoxin (deoxynivalenol) on transcription factor NF-kappa B/Rel binding activity in murine EL-4 thymoma and primary CD4+ T cells.	deoxynivalenol	11-20	epilepsy 4	Mus musculus	104-108
8887449-0	1996	Effects of vomitoxin (deoxynivalenol) on transcription factor NF-kappa B/Rel binding activity in murine EL-4 thymoma and primary CD4+ T cells.	deoxynivalenol	22-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	62-72
8887449-0	1996	Effects of vomitoxin (deoxynivalenol) on transcription factor NF-kappa B/Rel binding activity in murine EL-4 thymoma and primary CD4+ T cells.	deoxynivalenol	22-36	epilepsy 4	Mus musculus	104-108
8887449-1	1996	The trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) superinduces the gene expression of IL-2 and several other cytokines in both cellular and murine models.	deoxynivalenol	28-37	interleukin 2	Mus musculus	95-99
8887449-1	1996	The trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) superinduces the gene expression of IL-2 and several other cytokines in both cellular and murine models.	deoxynivalenol	39-41	interleukin 2	Mus musculus	95-99
8887449-1	1996	The trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) superinduces the gene expression of IL-2 and several other cytokines in both cellular and murine models.	deoxynivalenol	43-57	interleukin 2	Mus musculus	95-99
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	interleukin 2	Mus musculus	19-23
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	interleukin 4	Mus musculus	25-29
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	interleukin 5	Mus musculus	35-39
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	65-68
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	304-307
8078091-0	1994	Role of gender and strain in vomitoxin-induced dysregulation of IgA production and IgA nephropathy in the mouse.	deoxynivalenol	29-38	immunoglobulin heavy constant alpha	Mus musculus	64-67
7657054-0	1995	Effects of dihydrotestosterone and estradiol on experimental IgA nephropathy induced by vomitoxin.	deoxynivalenol	88-97	IGAN1	Homo sapiens	61-76
7657054-1	1995	Ingestion of the trichothecene vomitoxin (VT) by mice induces effects that mimic the common human glomerulonephritis, IgA nephropathy (IgAN).	deoxynivalenol	31-40	IGAN1	Homo sapiens	118-133
7657054-1	1995	Ingestion of the trichothecene vomitoxin (VT) by mice induces effects that mimic the common human glomerulonephritis, IgA nephropathy (IgAN).	deoxynivalenol	31-40	IGAN1	Homo sapiens	135-139
7657054-1	1995	Ingestion of the trichothecene vomitoxin (VT) by mice induces effects that mimic the common human glomerulonephritis, IgA nephropathy (IgAN).	deoxynivalenol	42-44	IGAN1	Homo sapiens	118-133
7657054-1	1995	Ingestion of the trichothecene vomitoxin (VT) by mice induces effects that mimic the common human glomerulonephritis, IgA nephropathy (IgAN).	deoxynivalenol	42-44	IGAN1	Homo sapiens	135-139
8658534-0	1996	Vomitoxin-mediated IL-2, IL-4, and IL-5 superinduction in murine CD4+ T cells stimulated with phorbol ester calcium ionophore: relation to kinetics of proliferation.	deoxynivalenol	0-9	interleukin 2	Mus musculus	19-23
8658534-0	1996	Vomitoxin-mediated IL-2, IL-4, and IL-5 superinduction in murine CD4+ T cells stimulated with phorbol ester calcium ionophore: relation to kinetics of proliferation.	deoxynivalenol	0-9	interleukin 5	Mus musculus	35-39
8658534-0	1996	Vomitoxin-mediated IL-2, IL-4, and IL-5 superinduction in murine CD4+ T cells stimulated with phorbol ester calcium ionophore: relation to kinetics of proliferation.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	65-68
8658534-1	1996	The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4+ T cells.	deoxynivalenol	44-46	CD4 antigen	Mus musculus	135-138
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	deoxynivalenol	187-189	CD4 antigen	Mus musculus	4-7
7597700-3	1995	Specifically, IL-1 beta and IL-6 mRNA levels increased in spleen and PP following exposure to VT.	deoxynivalenol	94-96	interleukin 1 beta	Mus musculus	14-23
7597700-3	1995	Specifically, IL-1 beta and IL-6 mRNA levels increased in spleen and PP following exposure to VT.	deoxynivalenol	94-96	interleukin 6	Mus musculus	28-32
8078091-0	1994	Role of gender and strain in vomitoxin-induced dysregulation of IgA production and IgA nephropathy in the mouse.	deoxynivalenol	29-38	immunoglobulin heavy constant alpha	Mus musculus	83-86
8206428-0	1994	Polyclonal autoreactive IgA increase and mesangial deposition during vomitoxin-induced IgA nephropathy in the BALB/c mouse.	deoxynivalenol	69-78	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	24-27
8048072-0	1994	Elevated gene expression and production of interleukins 2, 4, 5, and 6 during exposure to vomitoxin (deoxynivalenol) and cycloheximide in the EL-4 thymoma.	deoxynivalenol	90-99	epilepsy 4	Mus musculus	142-146
8048072-0	1994	Elevated gene expression and production of interleukins 2, 4, 5, and 6 during exposure to vomitoxin (deoxynivalenol) and cycloheximide in the EL-4 thymoma.	deoxynivalenol	101-115	epilepsy 4	Mus musculus	142-146
7913905-1	1994	The exposure of lymphocyte cultures to vomitoxin was used to determine possible mechanisms by which this naturally occurring toxin induces serum immunoglobulin A (IgA) elevation and IgA nephropathy in the mouse.	deoxynivalenol	39-48	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	145-161
7913905-1	1994	The exposure of lymphocyte cultures to vomitoxin was used to determine possible mechanisms by which this naturally occurring toxin induces serum immunoglobulin A (IgA) elevation and IgA nephropathy in the mouse.	deoxynivalenol	39-48	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	163-166
7913905-1	1994	The exposure of lymphocyte cultures to vomitoxin was used to determine possible mechanisms by which this naturally occurring toxin induces serum immunoglobulin A (IgA) elevation and IgA nephropathy in the mouse.	deoxynivalenol	39-48	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	182-185
7913905-2	1994	Vomitoxin exposure within the range of 10 to 1000 ng/ml inhibited DNA synthesis, protein synthesis as well as IgA, IgG and IgM production in lymphocyte cultures prepared from the Peyer"s patch (PP) and spleen.	deoxynivalenol	0-9	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	110-113
7913905-3	1994	When purified B cells were cultured in the presence of vomitoxin, inhibition of IgA, IgG and IgM production was similarly observed.	deoxynivalenol	55-64	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	80-83
7913905-4	1994	However, on 24-hr pulsed co-exposure to vomitoxin and the mitogen concanavalin A (ConA), CD4+/CD8+ cells were capable of inducing a three- to five-fold increase in production of IgA, but not IgG and IgM by cocultured B cells when compared with B cells cocultured with control T cells exposed to the mitogen only.	deoxynivalenol	40-49	CD4 antigen	Mus musculus	89-92
7913905-4	1994	However, on 24-hr pulsed co-exposure to vomitoxin and the mitogen concanavalin A (ConA), CD4+/CD8+ cells were capable of inducing a three- to five-fold increase in production of IgA, but not IgG and IgM by cocultured B cells when compared with B cells cocultured with control T cells exposed to the mitogen only.	deoxynivalenol	40-49	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	178-181
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	CD4 antigen	Mus musculus	25-28
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	interleukin 4	Mus musculus	131-135
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	interleukin 5	Mus musculus	137-141
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	interleukin 6	Mus musculus	146-150
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	CD4 antigen	Mus musculus	217-220
7913905-7	1994	These results suggest that vomitoxin was capable of enhancing CD4(+)-mediated help for IgA production by B cells and that this could possibly be mediated by way of increased cytokine production.	deoxynivalenol	27-36	CD4 antigen	Mus musculus	62-65
7913905-7	1994	These results suggest that vomitoxin was capable of enhancing CD4(+)-mediated help for IgA production by B cells and that this could possibly be mediated by way of increased cytokine production.	deoxynivalenol	27-36	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	87-90
8206428-0	1994	Polyclonal autoreactive IgA increase and mesangial deposition during vomitoxin-induced IgA nephropathy in the BALB/c mouse.	deoxynivalenol	69-78	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	87-90
8206428-1	1994	To establish the relationship between autoreactive antibodies and vomitoxin-induced immunoglobulin A (IgA) nephropathy, the effects of dietary vomitoxin exposure on the antigen specificity of serum IgA, IgA-producing cells and accumulated mesangial IgA in BALB/c mice were assessed.	deoxynivalenol	66-75	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	84-100
8206428-1	1994	To establish the relationship between autoreactive antibodies and vomitoxin-induced immunoglobulin A (IgA) nephropathy, the effects of dietary vomitoxin exposure on the antigen specificity of serum IgA, IgA-producing cells and accumulated mesangial IgA in BALB/c mice were assessed.	deoxynivalenol	66-75	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	102-105
8206428-2	1994	Exposure to dietary vomitoxin for 8 wk caused a significant increase in total serum IgA.	deoxynivalenol	20-29	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	84-87
8206428-5	1994	When enzyme-linked immunospot assay was used to monitor autoreactive IgA production, trends were observed towards increased IgA-secreting cells specific for TNP, cardiolipin and sphingomyelin in Peyer"s patches from vomitoxin-fed mice compared with control mice.	deoxynivalenol	216-225	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	69-72
8206428-5	1994	When enzyme-linked immunospot assay was used to monitor autoreactive IgA production, trends were observed towards increased IgA-secreting cells specific for TNP, cardiolipin and sphingomyelin in Peyer"s patches from vomitoxin-fed mice compared with control mice.	deoxynivalenol	216-225	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	124-127
8206428-6	1994	IgA-producing cells reactive with TNP were increased in the spleen of vomitoxin-fed mice whereas effects on IgA-secreting cells for the other antigens were marginal.	deoxynivalenol	70-79	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	0-3
8206428-7	1994	Marked deposition of mesangial IgA was also observed in vomitoxin-fed mice compared with controls.	deoxynivalenol	56-65	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	31-34
8206428-9	1994	These data suggest that dietary vomitoxin induced the polyclonal activation of IgA-producing cells and that resultant autoreactive IgA was subsequently deposited in the kidney mesangium.	deoxynivalenol	32-41	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	79-82
8206428-9	1994	These data suggest that dietary vomitoxin induced the polyclonal activation of IgA-producing cells and that resultant autoreactive IgA was subsequently deposited in the kidney mesangium.	deoxynivalenol	32-41	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	131-134
1611247-0	1992	Bioassay for deoxynivalenol based on the interaction of T-2 toxin with trichothecene mycotoxins.	deoxynivalenol	13-27	solute carrier family 25 member 5	Homo sapiens	56-59
1500035-0	1992	Vomitoxin-induced dysregulation of serum IgA, IgM and IgG reactive with gut bacterial and self antigens.	deoxynivalenol	0-9	immunoglobulin heavy constant mu	Mus musculus	46-49
1500035-2	1992	Ingestion of 25 ppm vomitoxin for 4 and 8 wk resulted in significantly elevated total IgA but depressed total IgG and IgM in serum when compared with control mice fed semi-purified diet only.	deoxynivalenol	20-29	immunoglobulin heavy constant mu	Mus musculus	118-121
34677630-0	2022	Deoxynivalenol induces apoptosis and autophagy in human prostate epithelial cells via PI3K/Akt signaling pathway.	deoxynivalenol	0-14	AKT serine/threonine kinase 1	Homo sapiens	91-94
33765170-4	2021	Increasing amounts of evidence have shown that mitochondria are significant targets of apoptosis caused by T-2 toxin- and DON-induced oxidative stress via regulation of Bax/B-cell lymphoma-2 and caspase-3/caspase-9 signaling.	deoxynivalenol	122-125	BCL2 associated X, apoptosis regulator	Homo sapiens	169-172
33765170-4	2021	Increasing amounts of evidence have shown that mitochondria are significant targets of apoptosis caused by T-2 toxin- and DON-induced oxidative stress via regulation of Bax/B-cell lymphoma-2 and caspase-3/caspase-9 signaling.	deoxynivalenol	122-125	caspase 3	Homo sapiens	195-204
33765170-4	2021	Increasing amounts of evidence have shown that mitochondria are significant targets of apoptosis caused by T-2 toxin- and DON-induced oxidative stress via regulation of Bax/B-cell lymphoma-2 and caspase-3/caspase-9 signaling.	deoxynivalenol	122-125	caspase 9	Homo sapiens	205-214
32795851-6	2021	Applying to estimate the exposure of DON and T-2 toxin in commercial samples, maize samples were 100% DON positive and rice samples were 40% DON positive while T-2 toxin was negative in all tested samples.	deoxynivalenol	102-105	solute carrier family 25 member 5	Homo sapiens	45-48
32795851-6	2021	Applying to estimate the exposure of DON and T-2 toxin in commercial samples, maize samples were 100% DON positive and rice samples were 40% DON positive while T-2 toxin was negative in all tested samples.	deoxynivalenol	102-105	solute carrier family 25 member 5	Homo sapiens	45-48
2145206-1	1990	Recent investigations indicate that dietary exposure to the trichothecene vomitoxin increases total and antigen-specific serum immunoglobulin A (IgA) and glomerular IgA accumulation in mice.	deoxynivalenol	74-83	immunoglobulin heavy constant alpha	Mus musculus	127-149
2312012-5	1990	Uptake of alpha-[3H]T-2 toxin was also inhibited by verrucarin A, roridin A and deoxynivalenol, and the inhibition followed a trichothecene structure-activity rank similar to that established for protein synthesis inhibition and in vivo toxicity.	deoxynivalenol	80-94	brachyury 2	Mus musculus	20-23
33818898-6	2021	Deoxynivalenol (IC50 = 20 muM) activated mitochondrial apoptotic pathway by modulating antioxidant protein expressions (Nrf2, HO-1 and NQO1).	deoxynivalenol	0-14	NFE2 like bZIP transcription factor 2	Homo sapiens	120-124
33818898-6	2021	Deoxynivalenol (IC50 = 20 muM) activated mitochondrial apoptotic pathway by modulating antioxidant protein expressions (Nrf2, HO-1 and NQO1).	deoxynivalenol	0-14	heme oxygenase 1	Homo sapiens	126-130
33818898-6	2021	Deoxynivalenol (IC50 = 20 muM) activated mitochondrial apoptotic pathway by modulating antioxidant protein expressions (Nrf2, HO-1 and NQO1).	deoxynivalenol	0-14	NAD(P)H quinone dehydrogenase 1	Homo sapiens	135-139
33806705-5	2021	CER alone (10 and 100 ng/mL) and in combination with DON (10 ng/mL CER with 1 microg/mL DON) was found to alter the barrier function by increasing the transepithelial electrical resistance and the expression of the tight junction protein claudin-4.	deoxynivalenol	53-56	claudin 4	Homo sapiens	238-247
34677630-6	2022	The aim of the study was to evaluate the effect of DON on the apoptosis and autophagy in normal prostate epithelial cells via modulation of PI3K/Akt signaling pathway.	deoxynivalenol	51-54	AKT serine/threonine kinase 1	Homo sapiens	145-148
34677630-8	2022	The higher concentration of DON induces apoptosis, whereas lower one autophagy in PNT1A cells, indicating that modulation of PI3K/Akt by DON results in the induction of autophagy triggering apoptosis in normal prostate epithelial cells.	deoxynivalenol	137-140	AKT serine/threonine kinase 1	Homo sapiens	130-133
34975906-8	2021	In female CT+OVA-sensitized offspring of DON-exposed mothers ASR and OVA-specific plasma immunoglobulins were significantly higher, compared to the female offspring of control mothers.	deoxynivalenol	41-44	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	13-16
34975906-8	2021	In female CT+OVA-sensitized offspring of DON-exposed mothers ASR and OVA-specific plasma immunoglobulins were significantly higher, compared to the female offspring of control mothers.	deoxynivalenol	41-44	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	69-72
34975906-10	2021	In both models a significant reduction in regulatory T cells, Tbet+ Th1 cells and Th1-related cytokine production of the offspring of DON-exposed mothers was observed.	deoxynivalenol	134-137	T-box 21	Mus musculus	62-66
34607188-0	2021	Mycotoxin deoxynivalenol affects myoblast differentiation via downregulating cytoskeleton and ECM-integrin-FAK-RAC-PAK signaling pathway.	deoxynivalenol	10-24	p21 (RAC1) activated kinase 1	Mus musculus	115-118
34607188-12	2021	Taken together, our findings suggest that DON has the potent to affect the differentiation of myoblasts via downregulating of cytoskeleton and ECM-integrin-FAK-RAC-PAK signaling pathway.	deoxynivalenol	42-45	p21 (RAC1) activated kinase 1	Mus musculus	164-167
34831041-9	2021	Moreover, DON-induced inflammatory response is due to the activation of the NF-kappaB and MAPK signaling pathways.	deoxynivalenol	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-85
34769473-6	2021	In serum, several microRNAs were differentially expressed upon DON exposure, four of which were validated by qPCR (ssc-miR-16, ssc-miR-128, ssc-miR-451, ssc-miR-205).	deoxynivalenol	63-66	glycerophosphodiester phosphodiesterase 1	Homo sapiens	119-125
34414528-0	2021	Retraction Note to: Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	20-34	NFE2 like bZIP transcription factor 2	Homo sapiens	143-147
34414528-0	2021	Retraction Note to: Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	20-34	kelch like ECH associated protein 1	Homo sapiens	148-153
34322792-4	2022	Therefore, in this study, we aimed to examine the ability of BBP to remove other 12 mycotoxins (including aflatoxin B1, aflatoxin M1, citrinin, dihydrocitrinone, cyclopiazonic acid, deoxynivalenol, ochratoxin A, patulin, sterigmatocystin, zearalanone, alpha-zearalanol, and beta-zearalanol) from different buffers (pH 3.0, 5.0, and 7.0).	deoxynivalenol	182-196	TM2 domain containing 1	Homo sapiens	61-64
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	deoxynivalenol	54-57	mitogen-activated protein kinase 1	Homo sapiens	104-107
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	deoxynivalenol	54-57	mitogen-activated protein kinase 8	Homo sapiens	109-112
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	deoxynivalenol	54-57	nuclear factor kappa B subunit 1	Homo sapiens	118-127
34358871-8	2021	In conclusion, BBR can regulate DON-induced intestinal injury, immunosuppression and oxidative stress by regulating the NF-kappaB and MAPK signaling pathways and ultimately maintain the intestinal health of piglets.	deoxynivalenol	32-35	nuclear factor kappa B subunit 1	Homo sapiens	120-129
34679025-0	2021	The Protective Effect of Heme Oxygenase-1 on Liver Injury Caused by DON-Induced Oxidative Stress and Cytotoxicity.	deoxynivalenol	68-71	heme oxygenase 1	Homo sapiens	25-41
34679025-10	2021	Significantly, AAV-mediated liver-specific overexpression of HO-1 reduced DON-induced liver damage and indirectly protected the abilities of antioxidant enzyme/DNA damage repair system, while AAV-mediated silence of HO-1 produced the opposite effect.	deoxynivalenol	74-77	heme oxygenase 1	Homo sapiens	61-65
34679025-11	2021	In addition, we found that overexpression of HO-1 could enhance autophagy and combined it with an antioxidant enzyme/DNA damage repair system to inhibit DON-induced hepatocyte damage.	deoxynivalenol	153-156	heme oxygenase 1	Homo sapiens	45-49
34679025-12	2021	Altogether, these data suggest that HO-1 reduces the oxidative stress and DNA damage caused by DON sub-chronic exposure through maintaining DNA repair, antioxidant activity, as well as autophagy.	deoxynivalenol	95-98	heme oxygenase 1	Homo sapiens	36-40
34506767-0	2021	Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis.	deoxynivalenol	23-37	thymoma viral proto-oncogene 1	Mus musculus	94-97
34679022-6	2021	The results reveal that DON significantly (p < 0.05) induced aryl hydrocarbon receptor (AhR) and cytochrome P450 enzyme (CYP) expression mainly at the duodenum.	deoxynivalenol	24-27	aryl hydrocarbon receptor	Homo sapiens	61-86
34506767-0	2021	Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis.	deoxynivalenol	23-37	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	105-109
34506767-8	2021	Furthermore, LA reversed the DON-mediated inhibition of the Akt/mTORC1/S6K1 signaling axis in the jejunum.	deoxynivalenol	29-32	thymoma viral proto-oncogene 1	Mus musculus	60-63
34506767-8	2021	Furthermore, LA reversed the DON-mediated inhibition of the Akt/mTORC1/S6K1 signaling axis in the jejunum.	deoxynivalenol	29-32	CREB regulated transcription coactivator 1	Mus musculus	64-70
34506767-8	2021	Furthermore, LA reversed the DON-mediated inhibition of the Akt/mTORC1/S6K1 signaling axis in the jejunum.	deoxynivalenol	29-32	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	71-75
34573125-7	2021	Furthermore, LYC treatment stabilized the functions of intestinal epithelial cells (Lgr5, PCNA, MUC2, LYZ, and Villin) under DON exposure.	deoxynivalenol	125-128	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	84-88
34573125-7	2021	Furthermore, LYC treatment stabilized the functions of intestinal epithelial cells (Lgr5, PCNA, MUC2, LYZ, and Villin) under DON exposure.	deoxynivalenol	125-128	proliferating cell nuclear antigen	Mus musculus	90-94
34573125-7	2021	Furthermore, LYC treatment stabilized the functions of intestinal epithelial cells (Lgr5, PCNA, MUC2, LYZ, and Villin) under DON exposure.	deoxynivalenol	125-128	mucin 2	Mus musculus	96-100
34573125-7	2021	Furthermore, LYC treatment stabilized the functions of intestinal epithelial cells (Lgr5, PCNA, MUC2, LYZ, and Villin) under DON exposure.	deoxynivalenol	125-128	lysozyme 1	Mus musculus	102-105
34573125-8	2021	Additionally, LYC alleviated DON-induced oxidative stress by reducing ROS and MDA accumulation and enhancing the activity of antioxidant enzymes (CAT, T-SOD, T-AOC, and GSH-Px), which was linked with the activation of Nrf2 signaling and degradation of Keap1 expression.	deoxynivalenol	29-32	catalase	Mus musculus	146-149
34261220-0	2021	Zearalenone and deoxynivalenol reduced Th1-mediated cellular immune response after Listeria monocytogenes infection by inhibiting CD4+ T cell activation and differentiation.	deoxynivalenol	16-30	negative elongation factor complex member C/D, Th1l	Mus musculus	39-42
34519265-8	2021	The results showed that DON increased ER damage, the content of MDA and ROS, the ratio of X-box binding protein 1s (XBP-1s)/X-box binding protein 1u (XBP-1u), the concentration of Fe2+, and the activity of TFR1.	deoxynivalenol	24-27	transferrin receptor	Sus scrofa	206-210
34579070-5	2021	Exposure to DON significantly reduced vaccine-specific immune responses and the percentages of Tbet+ Th1 cells and B cells in the spleen.	deoxynivalenol	12-15	T-box transcription factor 21	Homo sapiens	95-99
34261220-0	2021	Zearalenone and deoxynivalenol reduced Th1-mediated cellular immune response after Listeria monocytogenes infection by inhibiting CD4+ T cell activation and differentiation.	deoxynivalenol	16-30	CD4 antigen	Mus musculus	130-133
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	deoxynivalenol	43-46	CD4 antigen	Mus musculus	130-133
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	deoxynivalenol	43-46	negative elongation factor complex member C/D, Th1l	Mus musculus	147-150
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	deoxynivalenol	43-46	CD28 antigen	Mus musculus	217-221
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	deoxynivalenol	43-46	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	226-231
34261220-6	2021	Our findings more clearly revealed that exposure to low-dose ZEA and DON caused immunosuppression in the body by mechanisms including inhibition of CD4+ T cells activation and reduction of Th1 cell differentiation, thus exacerbating infection of animals by Listeria monocytogenes.	deoxynivalenol	69-72	CD4 antigen	Mus musculus	148-151
34261220-6	2021	Our findings more clearly revealed that exposure to low-dose ZEA and DON caused immunosuppression in the body by mechanisms including inhibition of CD4+ T cells activation and reduction of Th1 cell differentiation, thus exacerbating infection of animals by Listeria monocytogenes.	deoxynivalenol	69-72	negative elongation factor complex member C/D, Th1l	Mus musculus	189-192
34350223-0	2021	The Effect of 42-Day Exposure to a Low Deoxynivalenol Dose on the Immunohistochemical Expression of Intestinal ERs and the Activation of CYP1A1 and GSTP1 Genes in the Large Intestine of Pre-pubertal Gilts.	deoxynivalenol	39-53	cytochrome P450 family 1 subfamily A member 1	Sus scrofa	137-143
34111455-8	2021	Moreover, DON decreased the serum total protein (TP) and albumin (ALB) concentrations.	deoxynivalenol	10-13	albumin	Gallus gallus	57-64
34111455-8	2021	Moreover, DON decreased the serum total protein (TP) and albumin (ALB) concentrations.	deoxynivalenol	10-13	albumin	Gallus gallus	66-69
34216418-6	2021	Furthermore, LC activated Nrf2 signaling by binding to Keap1 to reverse the striking DON-induced increase in ROS levels.	deoxynivalenol	85-88	nuclear factor, erythroid derived 2, like 2	Mus musculus	26-30
34216418-6	2021	Furthermore, LC activated Nrf2 signaling by binding to Keap1 to reverse the striking DON-induced increase in ROS levels.	deoxynivalenol	85-88	kelch-like ECH-associated protein 1	Mus musculus	55-60
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	cholecystokinin	Mus musculus	112-115
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	peptide YY	Mus musculus	117-120
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	gastric inhibitory polypeptide	Mus musculus	122-125
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	glucagon	Mus musculus	131-136
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	cholecystokinin	Mus musculus	207-210
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	peptide YY	Mus musculus	212-215
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	gastric inhibitory polypeptide	Mus musculus	217-220
34437383-5	2021	We found that 1 and 2.5 mg/kg bw of DON can acutely induce anorexia and increase the plasma intestinal hormones CCK, PYY, GIP, and GLP-1 in mice within 3 h. Direct injection of exogenous intestinal hormones CCK, PYY, GIP, and GLP-1 can trigger anorexia behavior in mice.	deoxynivalenol	36-39	glucagon	Mus musculus	226-231
34350223-0	2021	The Effect of 42-Day Exposure to a Low Deoxynivalenol Dose on the Immunohistochemical Expression of Intestinal ERs and the Activation of CYP1A1 and GSTP1 Genes in the Large Intestine of Pre-pubertal Gilts.	deoxynivalenol	39-53	glutathione S-transferase P-like	Sus scrofa	148-153
34350223-5	2021	This is the first in vivo study to show that per os administration of low DON doses probably contributes to specific dysfunctions in steroidogenesis processes by inducing the immunohistochemical expression of estrogen receptors alpha (ERalpha) in the entire gastrointestinal tract in strongly stained cells (3 points) and estrogen receptors beta (ERbeta), but only in both investigated segments of the duodenum in pre-pubertal gilts.	deoxynivalenol	74-77	estrogen receptor 1	Sus scrofa	235-242
34350223-5	2021	This is the first in vivo study to show that per os administration of low DON doses probably contributes to specific dysfunctions in steroidogenesis processes by inducing the immunohistochemical expression of estrogen receptors alpha (ERalpha) in the entire gastrointestinal tract in strongly stained cells (3 points) and estrogen receptors beta (ERbeta), but only in both investigated segments of the duodenum in pre-pubertal gilts.	deoxynivalenol	74-77	estrogen receptor 2	Sus scrofa	347-353
34350223-6	2021	Therefore, the aim of this study was to determine whether a NOAEL dose of DON (12 mug DON/kg BW) administered per os over a period of 42 days induces changes in the immunohistochemical expression of ER in different intestinal segments and the transcriptional activation of CYP1A1 and GSTP1 genes in the large intestine of pre-pubertal gilts.	deoxynivalenol	74-77	cytochrome P450 family 1 subfamily A member 1	Sus scrofa	273-279
34350223-6	2021	Therefore, the aim of this study was to determine whether a NOAEL dose of DON (12 mug DON/kg BW) administered per os over a period of 42 days induces changes in the immunohistochemical expression of ER in different intestinal segments and the transcriptional activation of CYP1A1 and GSTP1 genes in the large intestine of pre-pubertal gilts.	deoxynivalenol	74-77	glutathione S-transferase P-like	Sus scrofa	284-289
34209652-7	2021	Moreover, DON exposure downregulated reproductive hormone gene expression and significantly increased nuclear factor kappa B (p65) activation and mitogen-activated protein kinase phosphorylation.	deoxynivalenol	10-13	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	126-129
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	tumor necrosis factor	Mus musculus	165-173
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	tumor necrosis factor	Mus musculus	175-202
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 6	Mus musculus	205-208
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 6	Mus musculus	210-223
34095117-4	2021	In this study, we demonstrated that Don downregulated the expression of miR-221/222 in intestinal epithelial cells, and exosome treatment reversed the inhibitory effect of Don on miR-221/222.	deoxynivalenol	36-39	microRNA 221	Homo sapiens	72-79
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 1 alpha	Mus musculus	230-237
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 1 beta	Mus musculus	239-257
34199278-4	2021	Here, we explored whether the mRNA expression of IL-1beta and IL-6, induced by the combination of DON and PCV2, would depend on the MAPK signaling pathway.	deoxynivalenol	98-101	interleukin 1 alpha	Homo sapiens	49-57
34199278-4	2021	Here, we explored whether the mRNA expression of IL-1beta and IL-6, induced by the combination of DON and PCV2, would depend on the MAPK signaling pathway.	deoxynivalenol	98-101	interleukin 6	Homo sapiens	62-66
34199278-6	2021	Then, the mRNA expression of IL-1beta and IL-6 in PK-15 cells was detected to explore the effect of the MAPK signaling pathway on IL-1beta and IL-6 mRNA induced by DON and PCV2.	deoxynivalenol	164-167	interleukin 1 alpha	Sus scrofa	29-37
34199278-6	2021	Then, the mRNA expression of IL-1beta and IL-6 in PK-15 cells was detected to explore the effect of the MAPK signaling pathway on IL-1beta and IL-6 mRNA induced by DON and PCV2.	deoxynivalenol	164-167	interleukin 1 alpha	Sus scrofa	130-138
34199278-6	2021	Then, the mRNA expression of IL-1beta and IL-6 in PK-15 cells was detected to explore the effect of the MAPK signaling pathway on IL-1beta and IL-6 mRNA induced by DON and PCV2.	deoxynivalenol	164-167	interleukin 6	Sus scrofa	143-147
34199278-7	2021	The results showed that PK-15 cells treated with DON or PCV2 induced the mRNA expression of IL-1beta and IL-6 in a time- and dose-dependent manner.	deoxynivalenol	49-52	interleukin 1 alpha	Homo sapiens	92-100
34199278-7	2021	The results showed that PK-15 cells treated with DON or PCV2 induced the mRNA expression of IL-1beta and IL-6 in a time- and dose-dependent manner.	deoxynivalenol	49-52	interleukin 6	Homo sapiens	105-109
34199278-8	2021	The combination of DON and PCV2 has an additive effect on inducing the mRNA expression of IL-1beta and IL-6.	deoxynivalenol	19-22	interleukin 1 alpha	Homo sapiens	90-98
34199278-8	2021	The combination of DON and PCV2 has an additive effect on inducing the mRNA expression of IL-1beta and IL-6.	deoxynivalenol	19-22	interleukin 6	Homo sapiens	103-107
34199278-9	2021	Additionally, both DON and PCV2 could induce the mRNA expression of IL-1beta and IL-6 via the ERK and the p38 MAPK signal pathways, while PCV2 could induce it via the JNK signal pathway.	deoxynivalenol	19-22	interleukin 1 alpha	Homo sapiens	68-76
34199278-9	2021	Additionally, both DON and PCV2 could induce the mRNA expression of IL-1beta and IL-6 via the ERK and the p38 MAPK signal pathways, while PCV2 could induce it via the JNK signal pathway.	deoxynivalenol	19-22	interleukin 6	Homo sapiens	81-85
34199278-9	2021	Additionally, both DON and PCV2 could induce the mRNA expression of IL-1beta and IL-6 via the ERK and the p38 MAPK signal pathways, while PCV2 could induce it via the JNK signal pathway.	deoxynivalenol	19-22	mitogen-activated protein kinase 1	Homo sapiens	94-97
34199278-9	2021	Additionally, both DON and PCV2 could induce the mRNA expression of IL-1beta and IL-6 via the ERK and the p38 MAPK signal pathways, while PCV2 could induce it via the JNK signal pathway.	deoxynivalenol	19-22	mitogen-activated protein kinase 8	Homo sapiens	167-170
34199278-10	2021	Taken together, our results suggest that MAPKs play a contributory role in IL-1beta and IL-6 mRNA expression when induced by both DON and PCV2.	deoxynivalenol	130-133	interleukin 1 alpha	Homo sapiens	75-83
34095117-0	2021	MiR-221/222 Ameliorates Deoxynivalenol-Induced Apoptosis and Proliferation Inhibition in Intestinal Epithelial Cells by Targeting PTEN.	deoxynivalenol	24-38	microRNA 221	Homo sapiens	0-7
34095117-0	2021	MiR-221/222 Ameliorates Deoxynivalenol-Induced Apoptosis and Proliferation Inhibition in Intestinal Epithelial Cells by Targeting PTEN.	deoxynivalenol	24-38	phosphatase and tensin homolog	Homo sapiens	130-134
34367255-0	2021	SLC4A11 and MFSD3 Gene Expression Changes in Deoxynivalenol Treated IPEC-J2 Cells.	deoxynivalenol	45-59	solute carrier family 4 member 11	Sus scrofa	0-7
34367255-0	2021	SLC4A11 and MFSD3 Gene Expression Changes in Deoxynivalenol Treated IPEC-J2 Cells.	deoxynivalenol	45-59	major facilitator superfamily domain containing 3	Sus scrofa	12-17
34367255-3	2021	This study explored the role of SLC4A11 and MFSD3 in alleviating DON toxicity and analyzed the DNA methylation changes of these two genes.	deoxynivalenol	65-68	solute carrier family 4 member 11	Sus scrofa	32-39
34367255-3	2021	This study explored the role of SLC4A11 and MFSD3 in alleviating DON toxicity and analyzed the DNA methylation changes of these two genes.	deoxynivalenol	65-68	major facilitator superfamily domain containing 3	Sus scrofa	44-49
34367255-5	2021	Expression of the SLC4A11 and MFSD3 genes was significantly downregulated upon DON exposure (P < 0.01).	deoxynivalenol	79-82	solute carrier family 4 member 11	Sus scrofa	18-25
34367255-5	2021	Expression of the SLC4A11 and MFSD3 genes was significantly downregulated upon DON exposure (P < 0.01).	deoxynivalenol	79-82	major facilitator superfamily domain containing 3	Sus scrofa	30-35
34367255-9	2021	Our findings revealed the novel biological functions of porcine SLC4A11 and MFSD3 genes in regulating the cytotoxic effects induced by DON, and may contribute to the detection of biomarkers and drug targets for predicting and eliminating the potential toxicity of DON.	deoxynivalenol	135-138	solute carrier family 4, sodium bicarbonate transporter-like, member 11	Mus musculus	64-71
34367255-9	2021	Our findings revealed the novel biological functions of porcine SLC4A11 and MFSD3 genes in regulating the cytotoxic effects induced by DON, and may contribute to the detection of biomarkers and drug targets for predicting and eliminating the potential toxicity of DON.	deoxynivalenol	135-138	major facilitator superfamily domain containing 3	Mus musculus	76-81
34367255-9	2021	Our findings revealed the novel biological functions of porcine SLC4A11 and MFSD3 genes in regulating the cytotoxic effects induced by DON, and may contribute to the detection of biomarkers and drug targets for predicting and eliminating the potential toxicity of DON.	deoxynivalenol	264-267	solute carrier family 4, sodium bicarbonate transporter-like, member 11	Mus musculus	64-71
34367255-9	2021	Our findings revealed the novel biological functions of porcine SLC4A11 and MFSD3 genes in regulating the cytotoxic effects induced by DON, and may contribute to the detection of biomarkers and drug targets for predicting and eliminating the potential toxicity of DON.	deoxynivalenol	264-267	major facilitator superfamily domain containing 3	Mus musculus	76-81
34199278-10	2021	Taken together, our results suggest that MAPKs play a contributory role in IL-1beta and IL-6 mRNA expression when induced by both DON and PCV2.	deoxynivalenol	130-133	interleukin 6	Homo sapiens	88-92
34071941-8	2021	In mice exposed to DON, supplementation with fullerene C60 significantly improved growth performance, and enhanced the total antioxidant status and the activities of SOD and GPX in the intestine and liver (p < 0.05).	deoxynivalenol	19-22	peroxiredoxin 6 pseudogene 2	Mus musculus	174-177
34095117-4	2021	In this study, we demonstrated that Don downregulated the expression of miR-221/222 in intestinal epithelial cells, and exosome treatment reversed the inhibitory effect of Don on miR-221/222.	deoxynivalenol	36-39	microRNA 221	Homo sapiens	179-186
34095117-4	2021	In this study, we demonstrated that Don downregulated the expression of miR-221/222 in intestinal epithelial cells, and exosome treatment reversed the inhibitory effect of Don on miR-221/222.	deoxynivalenol	172-175	microRNA 221	Homo sapiens	72-79
34095117-4	2021	In this study, we demonstrated that Don downregulated the expression of miR-221/222 in intestinal epithelial cells, and exosome treatment reversed the inhibitory effect of Don on miR-221/222.	deoxynivalenol	172-175	microRNA 221	Homo sapiens	179-186
34095117-5	2021	Through immunofluorescence and flow cytometry analysis, we identified that miR-221/222 ameliorates Don-induced apoptosis and proliferation inhibition in intestinal epithelial cells.	deoxynivalenol	99-102	microRNA 221	Homo sapiens	75-82
34095117-7	2021	Through the PTEN interfering experiment, we found Don-induced apoptosis and proliferation inhibition relied on PTEN.	deoxynivalenol	50-53	phosphatase and tensin homolog	Homo sapiens	12-16
34095117-7	2021	Through the PTEN interfering experiment, we found Don-induced apoptosis and proliferation inhibition relied on PTEN.	deoxynivalenol	50-53	phosphatase and tensin homolog	Homo sapiens	111-115
34095117-8	2021	Finally, through adenovirus to overexpress miR-221/222 in mice intestinal epithelial cells specifically, our results showed that miR-221/222 ameliorated Don-induced apoptosis and proliferation inhibition in intestinal epithelial cells by targeting PTEN.	deoxynivalenol	153-156	microRNA 221	Mus musculus	43-50
34095117-8	2021	Finally, through adenovirus to overexpress miR-221/222 in mice intestinal epithelial cells specifically, our results showed that miR-221/222 ameliorated Don-induced apoptosis and proliferation inhibition in intestinal epithelial cells by targeting PTEN.	deoxynivalenol	153-156	microRNA 221	Mus musculus	129-136
34095117-8	2021	Finally, through adenovirus to overexpress miR-221/222 in mice intestinal epithelial cells specifically, our results showed that miR-221/222 ameliorated Don-induced apoptosis and proliferation inhibition in intestinal epithelial cells by targeting PTEN.	deoxynivalenol	153-156	phosphatase and tensin homolog	Mus musculus	248-252
34095117-9	2021	This study not only expands our understanding of how miR-221/222 and the host gene PTEN regulate intestinal epithelial cells defending against Don-induced damage, but also provides a new way to protect the development of the intestine.	deoxynivalenol	143-146	microRNA 221	Mus musculus	53-60
34095117-9	2021	This study not only expands our understanding of how miR-221/222 and the host gene PTEN regulate intestinal epithelial cells defending against Don-induced damage, but also provides a new way to protect the development of the intestine.	deoxynivalenol	143-146	phosphatase and tensin homolog	Mus musculus	83-87
35381244-0	2022	Low dose of arsenic exacerbates toxicity to mice and IPEC-J2 cells exposed with deoxynivalenol: Aryl hydrocarbon receptor and autophagy might be novel therapeutic targets.	deoxynivalenol	80-94	aryl hydrocarbon receptor	Sus scrofa	96-121
35609454-0	2022	A novel bionic magnetic SERS aptasensor for the ultrasensitive detection of Deoxynivalenol based on "dual antennae" nano-silver.	deoxynivalenol	76-90	seryl-tRNA synthetase 1	Homo sapiens	24-28
35609454-6	2022	There was a good linear relationship in the range of 0.0001-100 ng mL-1 between the SERS intensity and the logarithm of DON concentration, and the limit of detection (LOD) was as low as 0.032 pg mL-1.	deoxynivalenol	120-123	seryl-tRNA synthetase 1	Homo sapiens	84-88
35381244-5	2022	The results showed that low dose of NaAsO2 exacerbated DON-induced intestinal impairment by increasing intestinal permeability and decreasing the abundance of tight junction proteins (ZO-1, Occludin, Claudin-1).	deoxynivalenol	55-58	zonula occludens 1	Sus scrofa	184-188
35381244-5	2022	The results showed that low dose of NaAsO2 exacerbated DON-induced intestinal impairment by increasing intestinal permeability and decreasing the abundance of tight junction proteins (ZO-1, Occludin, Claudin-1).	deoxynivalenol	55-58	occludin	Sus scrofa	190-198
35381244-5	2022	The results showed that low dose of NaAsO2 exacerbated DON-induced intestinal impairment by increasing intestinal permeability and decreasing the abundance of tight junction proteins (ZO-1, Occludin, Claudin-1).	deoxynivalenol	55-58	claudin 1	Sus scrofa	200-209
35447471-5	2022	Moreover, the transepithelial electrical resistance (TEER) values of MAC-T cells exposed to DON were gradually decreased in a time- and concentration- dependent manner, but lactate dehydrogenase (LDH) leakage was significantly increased with the maximum increase of 2.4-fold, indicating the cell membrane and tight junctions were damaged by DON.	deoxynivalenol	341-344	LDH	Bos taurus	173-194
35381244-6	2022	Further, low dose of NaAsO2 enhanced the AhR signaling pathway and autophagy-related mRNA/protein expressions induced by DON.	deoxynivalenol	121-124	aryl hydrocarbon receptor	Sus scrofa	41-44
35381244-11	2022	Hence, AhR and autophagy might be novel therapeutic targets to prevent or alleviate NaAsO2 combined with DON-induced intestinal barrier impairment.	deoxynivalenol	105-108	aryl hydrocarbon receptor	Sus scrofa	7-10
35278444-0	2022	Genome-wide transcriptional profiling and functional analysis reveal miR-330-MAPK15 axis involving in cellular responses to deoxynivalenol exposure.	deoxynivalenol	124-138	microRNA 330	Homo sapiens	69-76
35278444-0	2022	Genome-wide transcriptional profiling and functional analysis reveal miR-330-MAPK15 axis involving in cellular responses to deoxynivalenol exposure.	deoxynivalenol	124-138	mitogen-activated protein kinase 15	Homo sapiens	77-83
35278444-5	2022	Interactive network analysis showed that miR-330 was one hub noncoding RNA, expression of which was significantly increased upon DON exposure.	deoxynivalenol	129-132	microRNA 330	Homo sapiens	41-48
35278444-7	2022	Further functional analysis revealed that high expression of miR-330 inhibits the reactive oxygen species production, cell apoptosis, and autophagic flux in cells upon DON exposure.	deoxynivalenol	168-171	microRNA 330	Homo sapiens	61-68
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	102-105	mitogen-activated protein kinase 15	Homo sapiens	13-19
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	102-105	microRNA 330	Homo sapiens	135-142
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	102-105	mitogen-activated protein kinase 15	Homo sapiens	143-149
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	180-183	mitogen-activated protein kinase 15	Homo sapiens	13-19
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	180-183	microRNA 330	Homo sapiens	135-142
35278444-9	2022	Knockdown of MAPK15 resulted in decreased reactive oxygen species level and cell apoptosis induced by DON, indicating the existence of miR-330-MAPK15 regulatory axis in regulating DON toxicity.	deoxynivalenol	180-183	mitogen-activated protein kinase 15	Homo sapiens	143-149
35278444-10	2022	Our work shed novel insights into the mode of action of DON at cellular level and indicated the potential of miR-330 as a biomarker for toxicity monitoring of DON contamination, which contributes to the development of effective biomonitoring and prevention strategies to reduce the toxicological effects of DON.	deoxynivalenol	56-59	microRNA 330	Homo sapiens	109-116
35278444-10	2022	Our work shed novel insights into the mode of action of DON at cellular level and indicated the potential of miR-330 as a biomarker for toxicity monitoring of DON contamination, which contributes to the development of effective biomonitoring and prevention strategies to reduce the toxicological effects of DON.	deoxynivalenol	159-162	microRNA 330	Homo sapiens	109-116
35278444-10	2022	Our work shed novel insights into the mode of action of DON at cellular level and indicated the potential of miR-330 as a biomarker for toxicity monitoring of DON contamination, which contributes to the development of effective biomonitoring and prevention strategies to reduce the toxicological effects of DON.	deoxynivalenol	307-310	microRNA 330	Homo sapiens	109-116
35588983-7	2022	Moreover, DON exposure induced an increase in the level of ERalpha phosphorylation at serine 167.	deoxynivalenol	10-13	estrogen receptor 1	Homo sapiens	59-66
35447471-5	2022	Moreover, the transepithelial electrical resistance (TEER) values of MAC-T cells exposed to DON were gradually decreased in a time- and concentration- dependent manner, but lactate dehydrogenase (LDH) leakage was significantly increased with the maximum increase of 2.4-fold, indicating the cell membrane and tight junctions were damaged by DON.	deoxynivalenol	341-344	LDH	Bos taurus	196-199
35447471-6	2022	Importantly, DON significantly reduced the synthesis of beta-casein and lipid droplets, along with the significantly decreases of phospho-mTOR, phospho-4EBP1, phospho-JAK2, and phospho-STAT5.	deoxynivalenol	13-16	mechanistic target of rapamycin kinase	Bos taurus	138-142
35447471-6	2022	Importantly, DON significantly reduced the synthesis of beta-casein and lipid droplets, along with the significantly decreases of phospho-mTOR, phospho-4EBP1, phospho-JAK2, and phospho-STAT5.	deoxynivalenol	13-16	Janus kinase 2	Bos taurus	167-171
35448300-0	2022	Rapid Detection of Deoxynivalenol in Dry Pasta Using a Label-Free Immunosensor.	deoxynivalenol	19-33	solute carrier family 45 member 1	Homo sapiens	41-46
35452771-4	2022	Regarding type B trichothecene, DON inhibits activation marker and beta-catenin synthesis by acting on immune cells and the wingless/integrated (Wnt) pathway; it also inhibits cell proliferation and immune surveillance.	deoxynivalenol	32-35	catenin beta 1	Homo sapiens	67-79
35452771-5	2022	In addition, DON has been shown to destroy tight junctions, glucose transport, and tumor endothelial marker 8, thus disturbing intestinal function and changing cell migration.	deoxynivalenol	13-16	ANTXR cell adhesion molecule 1	Homo sapiens	83-109
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	solute carrier family 10 member 2	Homo sapiens	69-114
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	solute carrier family 10 member 2	Homo sapiens	116-120
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	fatty acid binding protein 6	Homo sapiens	127-158
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	fatty acid binding protein 6	Homo sapiens	160-165
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	solute carrier family 51 subunit alpha	Homo sapiens	175-207
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	solute carrier family 51 subunit alpha	Homo sapiens	209-217
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	nuclear receptor subfamily 1 group H member 4	Homo sapiens	263-283
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	deoxynivalenol	12-15	nuclear receptor subfamily 1 group H member 4	Homo sapiens	285-288
35351591-0	2022	Nicotinamide N-methyltransferase protects against deoxynivalenol-induced growth inhibition by suppressing pro-inflammatory cytokine expression.	deoxynivalenol	50-64	nicotinamide N-methyltransferase	Homo sapiens	0-32
35351591-4	2022	An exogenous increase of methylnicotinamide, a metabolite produced by nicotinamide N-methyltransferase (NNMT), has anti-inflammatory effects, but it is not clear whether NNMT has the same effect, and the role of NNMT in DON-induced inflammation and growth impairment remains indistinct.	deoxynivalenol	220-223	nicotinamide N-methyltransferase	Homo sapiens	104-108
35351591-5	2022	The present research reports that NNMT is an inflammatory self-protective factor in DON-exposed L02 cells.	deoxynivalenol	84-87	nicotinamide N-methyltransferase	Homo sapiens	34-38
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	13-16	nicotinamide N-methyltransferase	Homo sapiens	27-31
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	13-16	interleukin 1 alpha	Homo sapiens	80-102
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	13-16	interleukin 11	Homo sapiens	104-109
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	13-16	interleukin 6	Homo sapiens	114-118
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	13-16	insulin like growth factor 1	Homo sapiens	139-144
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	215-218	nicotinamide N-methyltransferase	Homo sapiens	27-31
35351591-7	2022	Furthermore, DON increased NNMT to reduce pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-11 and IL-6, and thus increased IGF-1 and cell viability, alleviating the cell growth inhibition induced by DON.	deoxynivalenol	215-218	interleukin 1 alpha	Homo sapiens	80-102
35600548-4	2022	DON significantly raised the activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutamyl transpeptidase (GGT) (P < 0.01), leading to liver injury.	deoxynivalenol	0-3	solute carrier family 17 member 5	Homo sapiens	41-67
35171597-8	2022	To determine the purity of DON by quantitative proton NMR, the collective integrals of all isomeric and tautomeric signals belonging to H-10 provided the most accurate value.	deoxynivalenol	27-30	H1.0 linker histone	Homo sapiens	136-140
35090964-0	2022	Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells.	deoxynivalenol	66-80	microRNA 221	Homo sapiens	97-108
35090964-0	2022	Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells.	deoxynivalenol	66-80	phosphatase and tensin homolog	Homo sapiens	118-122
35090964-0	2022	Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells.	deoxynivalenol	66-80	AKT serine/threonine kinase 1	Homo sapiens	128-131
35090964-3	2022	Moreover, apoptosis and inflammatory response were promoted after the co-exposure of ZEA and DON, indicated by the increased expression of BAX, Caspase-3, IL-1beta and IL-6 genes.	deoxynivalenol	93-96	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
35090964-3	2022	Moreover, apoptosis and inflammatory response were promoted after the co-exposure of ZEA and DON, indicated by the increased expression of BAX, Caspase-3, IL-1beta and IL-6 genes.	deoxynivalenol	93-96	caspase 3	Homo sapiens	144-153
35600548-0	2022	Cytochrome P450 enzymes mediated by DNA methylation is involved in deoxynivalenol-induced hepatoxicity in piglets.	deoxynivalenol	67-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	nitric oxide synthase 2	Homo sapiens	70-101
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	nitric oxide synthase 2	Homo sapiens	103-107
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	113-129
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	131-136
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	glutathione peroxidase 1	Homo sapiens	223-247
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	glutathione peroxidase 1	Homo sapiens	249-253
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	superoxide dismutase 2	Homo sapiens	256-278
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	superoxide dismutase 2	Homo sapiens	280-284
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	catalase	Homo sapiens	287-295
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	catalase	Homo sapiens	297-300
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	heme oxygenase 1	Homo sapiens	306-322
35024467-5	2022	Meanwhile, PEITC treatment ameliorated DON-induced an increase of the inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) mRNA levels and intracellular reactive oxygen species (ROS) level, and a decrease of glutathione peroxidase 1 (GPx1), superoxide dismutase 2 (SOD2), catalase (CAT) and heme oxygenase 1 (HO-1) mRNA levels.	deoxynivalenol	39-42	heme oxygenase 1	Homo sapiens	324-328
35068605-8	2022	The activity of Caspase 3 was significantly increased in DON-induced apoptosis.	deoxynivalenol	57-60	caspase 3	Homo sapiens	16-25
35068605-12	2022	Furthermore, an in vivo test indicated that DON had toxicity to mice by causing weight loss and swollen spleen, and significantly increased expression of AST and ALT.	deoxynivalenol	44-47	transmembrane protease, serine 11d	Mus musculus	154-157
35068605-12	2022	Furthermore, an in vivo test indicated that DON had toxicity to mice by causing weight loss and swollen spleen, and significantly increased expression of AST and ALT.	deoxynivalenol	44-47	glutamic pyruvic transaminase, soluble	Mus musculus	162-165
35068605-13	2022	In conclusion, the DON was toxic to mice and could induce the apoptosis of tested cells undergoing a Caspase-3 related pathway.	deoxynivalenol	19-22	caspase 3	Mus musculus	101-110
35090964-3	2022	Moreover, apoptosis and inflammatory response were promoted after the co-exposure of ZEA and DON, indicated by the increased expression of BAX, Caspase-3, IL-1beta and IL-6 genes.	deoxynivalenol	93-96	interleukin 1 alpha	Homo sapiens	155-163
35090964-3	2022	Moreover, apoptosis and inflammatory response were promoted after the co-exposure of ZEA and DON, indicated by the increased expression of BAX, Caspase-3, IL-1beta and IL-6 genes.	deoxynivalenol	93-96	interleukin 6	Homo sapiens	168-172
35090964-5	2022	MiR-221 could influence cell viability and ROS level to counter the combined toxicity of ZEA and DON through targeting directly PTEN gene.	deoxynivalenol	97-100	microRNA 221	Homo sapiens	0-7
35090964-5	2022	MiR-221 could influence cell viability and ROS level to counter the combined toxicity of ZEA and DON through targeting directly PTEN gene.	deoxynivalenol	97-100	phosphatase and tensin homolog	Homo sapiens	128-132
35600548-4	2022	DON significantly raised the activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutamyl transpeptidase (GGT) (P < 0.01), leading to liver injury.	deoxynivalenol	0-3	solute carrier family 17 member 5	Homo sapiens	69-72
35600548-4	2022	DON significantly raised the activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutamyl transpeptidase (GGT) (P < 0.01), leading to liver injury.	deoxynivalenol	0-3	glutamic--pyruvic transaminase	Homo sapiens	75-99
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	90-96
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	98-104
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	nicotinamide N-methyltransferase	Homo sapiens	159-191
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	nicotinamide N-methyltransferase	Homo sapiens	193-197
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	galanin like peptide	Homo sapiens	200-220
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	galanin like peptide	Homo sapiens	222-226
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	insulin like growth factor 1	Homo sapiens	232-260
35600548-5	2022	In vivo study found that DON exposure increased the expression of CYP450 enzymes (such as CYP1A1, CYP2E1, CYP3A29) (P < 0.05), and disturbed the expression of nicotinamide N-methyltransferase (NNMT), galanin-like peptide (GALP) and insulin-like growth factor 1 (IGF-1) (P < 0.05), in which DNA methylation affected the expression of these genes.	deoxynivalenol	25-28	insulin like growth factor 1	Homo sapiens	262-267
35600548-7	2022	More importantly, knockdown of CYP1A1 or CYP2E1 could alleviate DON-induced growth inhibition by promoting IGF-1 expression.	deoxynivalenol	64-67	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	31-37
35600548-7	2022	More importantly, knockdown of CYP1A1 or CYP2E1 could alleviate DON-induced growth inhibition by promoting IGF-1 expression.	deoxynivalenol	64-67	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	41-47
35600548-7	2022	More importantly, knockdown of CYP1A1 or CYP2E1 could alleviate DON-induced growth inhibition by promoting IGF-1 expression.	deoxynivalenol	64-67	insulin like growth factor 1	Homo sapiens	107-112
35202179-0	2022	Cereulide and Deoxynivalenol Increase LC3 Protein Levels in HepG2 Liver Cells.	deoxynivalenol	14-28	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	38-41
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	PTEN induced kinase 1	Homo sapiens	158-163
35051765-0	2022	Deoxynivalenol aggravates the immunosuppression in piglets and PAMs under the condition of PEDV infection through inhibiting TLR4/NLRP3 signaling pathway.	deoxynivalenol	0-14	toll like receptor 4	Homo sapiens	125-129
35051765-0	2022	Deoxynivalenol aggravates the immunosuppression in piglets and PAMs under the condition of PEDV infection through inhibiting TLR4/NLRP3 signaling pathway.	deoxynivalenol	0-14	NLR family pyrin domain containing 3	Homo sapiens	130-135
35051765-7	2022	The in vivo results showed that 2.25 mg/kg feed DON significantly exacerbated the immunosuppressive effects on the PEDV-infected piglets, as demonstrated by the decreases in growth performance, the numbers of goblet cells and CD3+T cells, as well as the protein expressions of ZO-1, Claudin1 and Muc2, in addition to the increases in anti-inflammatory factors levels and the intestinal injury.	deoxynivalenol	48-51	tight junction protein 1	Homo sapiens	277-281
35051765-7	2022	The in vivo results showed that 2.25 mg/kg feed DON significantly exacerbated the immunosuppressive effects on the PEDV-infected piglets, as demonstrated by the decreases in growth performance, the numbers of goblet cells and CD3+T cells, as well as the protein expressions of ZO-1, Claudin1 and Muc2, in addition to the increases in anti-inflammatory factors levels and the intestinal injury.	deoxynivalenol	48-51	claudin 1	Homo sapiens	283-291
35051765-7	2022	The in vivo results showed that 2.25 mg/kg feed DON significantly exacerbated the immunosuppressive effects on the PEDV-infected piglets, as demonstrated by the decreases in growth performance, the numbers of goblet cells and CD3+T cells, as well as the protein expressions of ZO-1, Claudin1 and Muc2, in addition to the increases in anti-inflammatory factors levels and the intestinal injury.	deoxynivalenol	48-51	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	296-300
35051765-9	2022	Furthermore, DON significantly suppressed the expressions of TLR4/NLRP3 in vivo and in vitro.	deoxynivalenol	13-16	toll like receptor 4	Homo sapiens	61-65
35051765-9	2022	Furthermore, DON significantly suppressed the expressions of TLR4/NLRP3 in vivo and in vitro.	deoxynivalenol	13-16	NLR family pyrin domain containing 3	Homo sapiens	66-71
35051765-11	2022	Our findings suggest that DON could aggravate host immunosuppression under the condition of PEDV infection through inhibiting TLR4/NLRP3 signaling pathway, and provide novel theoretical insights into the further studies on the immunotoxicity of DON contamination and PEDV-induced immunosuppression.	deoxynivalenol	26-29	toll like receptor 4	Homo sapiens	126-130
35051765-11	2022	Our findings suggest that DON could aggravate host immunosuppression under the condition of PEDV infection through inhibiting TLR4/NLRP3 signaling pathway, and provide novel theoretical insights into the further studies on the immunotoxicity of DON contamination and PEDV-induced immunosuppression.	deoxynivalenol	26-29	NLR family pyrin domain containing 3	Homo sapiens	131-136
35051765-11	2022	Our findings suggest that DON could aggravate host immunosuppression under the condition of PEDV infection through inhibiting TLR4/NLRP3 signaling pathway, and provide novel theoretical insights into the further studies on the immunotoxicity of DON contamination and PEDV-induced immunosuppression.	deoxynivalenol	245-248	toll like receptor 4	Homo sapiens	126-130
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	beclin 1	Homo sapiens	173-181
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	lysosomal associated membrane protein 3	Homo sapiens	183-187
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	autophagy related 5	Homo sapiens	189-193
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	BCL2 interacting protein 3	Homo sapiens	203-208
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	FUN14 domain containing 1	Homo sapiens	210-216
35097052-3	2021	The results showed that dietary supplementation with DON significantly increase the mRNA expression levels of mitophagy- related genes, and protein level for PINK1, Parkin, Beclin-1, Lamp, Atg5, Map1lc, Bnip3, Fundc1, Bcl2l1 and SQSTMS1 (P < 0.05), while supplementation with both RES and DON decreased those indexes in the ileum.	deoxynivalenol	53-56	BCL2 like 1	Homo sapiens	218-224
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	cytochrome c, somatic	Homo sapiens	78-90
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	mitofusin 1	Homo sapiens	92-96
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	OPA1 mitochondrial dynamin like GTPase	Homo sapiens	98-102
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	prohibitin 1	Homo sapiens	108-112
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	prohibitin 1	Homo sapiens	197-201
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	8-11	succinate dehydrogenase complex flavoprotein subunit A	Homo sapiens	203-207
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	165-168	mitofusin 1	Homo sapiens	92-96
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	165-168	OPA1 mitochondrial dynamin like GTPase	Homo sapiens	98-102
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	165-168	prohibitin 1	Homo sapiens	108-112
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	165-168	prohibitin 1	Homo sapiens	197-201
35097052-4	2021	Besides DON significantly decreased protein level for Pyruvate Dehydrogenase, Cytochrome c, MFN1, OPA1, and PHB1 (P < 0.05), while supplementation with both RES and DON increased protein level for PHB1, SDHA, and VDAC in the ileum.	deoxynivalenol	165-168	succinate dehydrogenase complex flavoprotein subunit A	Homo sapiens	203-207
35051025-7	2022	The pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha was secreted in the microglia in response to DON exposure.	deoxynivalenol	110-113	tumor necrosis factor	Mus musculus	30-64
35201764-5	2022	Results showed that significant growth slowdown, severe diarrhea, and intestinal damage, bacterial multiplication, and translocation were observed in the experimental group (low-dose DON, 0.75 mg/kg in feed for piglets, and 1 mg/kg body weight for mice, combined with the ETEC infection).	deoxynivalenol	183-186	ETEC	Sus scrofa	272-276
3782346-2	1986	Abundant (M + H)+ and/or (M + NH4)+ pseudo-molecular ions were observed for T-2 toxin, HT-2 toxin, T-2 triol, diacetoxyscirpenol, deoxynivalenol and verrucarol under the conditions developed.	deoxynivalenol	130-144	solute carrier family 25 member 5	Homo sapiens	76-79
35307453-0	2022	Deoxynivalenol triggers porcine intestinal tight junction disorder through hijacking SLC5A1 and PGC1alpha-mediated mitochondrial function.	deoxynivalenol	0-14	solute carrier family 5 member 1	Homo sapiens	85-91
35307453-0	2022	Deoxynivalenol triggers porcine intestinal tight junction disorder through hijacking SLC5A1 and PGC1alpha-mediated mitochondrial function.	deoxynivalenol	0-14	PPARG coactivator 1 alpha	Homo sapiens	96-105
35307453-8	2022	A marked loss of Na+/glucose cotransporter (SLC5A1) and peroxisome proliferator activated receptor-gamma co-activator 1alpha (PGC1alpha) was observed in DON-treated cells.	deoxynivalenol	153-156	solute carrier family 5 member 1	Homo sapiens	44-50
35307453-8	2022	A marked loss of Na+/glucose cotransporter (SLC5A1) and peroxisome proliferator activated receptor-gamma co-activator 1alpha (PGC1alpha) was observed in DON-treated cells.	deoxynivalenol	153-156	PPARG coactivator 1 alpha	Homo sapiens	56-124
35307453-8	2022	A marked loss of Na+/glucose cotransporter (SLC5A1) and peroxisome proliferator activated receptor-gamma co-activator 1alpha (PGC1alpha) was observed in DON-treated cells.	deoxynivalenol	153-156	PPARG coactivator 1 alpha	Homo sapiens	126-135
2676788-1	1989	The effect of dietary exposure to vomitoxin on serum immunoglobulin A (IgA) was evaluated in the B6C3F1 mouse.	deoxynivalenol	34-43	immunoglobulin heavy constant alpha	Mus musculus	53-75
2676788-2	1989	Levels of serum IgA were elevated maximally in mice fed 25 ppm vomitoxin in comparison with levels in mice fed 2, 10 or 50 ppm vomitoxin.	deoxynivalenol	63-72	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	16-19
2676788-4	1989	Serum IgA also exhibited a marked shift from primarily monomeric IgA to primarily polymeric IgA during vomitoxin treatment.	deoxynivalenol	103-112	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	6-9
2676788-4	1989	Serum IgA also exhibited a marked shift from primarily monomeric IgA to primarily polymeric IgA during vomitoxin treatment.	deoxynivalenol	103-112	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	65-68
2676788-4	1989	Serum IgA also exhibited a marked shift from primarily monomeric IgA to primarily polymeric IgA during vomitoxin treatment.	deoxynivalenol	103-112	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	65-68
2676788-6	1989	Elevated serum IgA was not observed in mice when control diet was fed at levels equivalent to those consumed by vomitoxin-treated mice, which exhibited feed refusal.	deoxynivalenol	112-121	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	15-18
2676788-7	1989	IgA production was significantly increased in both spontaneous and mitogen-stimulated splenocyte cultures from mice exposed to vomitoxin in comparison with cultures prepared from ad lib.	deoxynivalenol	127-136	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	0-3
2676788-9	1989	Immunofluorescence staining revealed marked accumulation of mesangial IgA and electron microscopy showed electron-dense deposits in the glomeruli of vomitoxin-treated mice but not in those of controls.	deoxynivalenol	149-158	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	70-73
6609858-3	1984	These data showed that the lethal toxicity of T-2 toxin and nivalenol was about 10 times higher than deoxynivalenol .	deoxynivalenol	101-115	brachyury 2	Mus musculus	46-49
3782592-6	1986	After incubating urine with beta-glucuronidase, the concentration of unconjugated deepoxydeoxynivalenol increased by 7 to 15-fold whereas unconjugated deoxynivalenol increased 1.6 to 3-fold.	deoxynivalenol	89-103	beta-glucuronidase	Bos taurus	28-46
3491023-4	1986	Both DON and AcDON were shown to induce interleukin 1 (IL-1) release in peritoneal macrophages by a mode of action similar to that of cycloheximide.	deoxynivalenol	5-8	interleukin 1 alpha	Homo sapiens	55-59
3491023-5	1986	In the presence of DON, cellular IL-1 did not decay, and this resulted in a marked release of IL-1 from the cell during the period of exposure to the inhibitor.	deoxynivalenol	19-22	interleukin 1 alpha	Homo sapiens	33-37
3491023-5	1986	In the presence of DON, cellular IL-1 did not decay, and this resulted in a marked release of IL-1 from the cell during the period of exposure to the inhibitor.	deoxynivalenol	19-22	interleukin 1 alpha	Homo sapiens	94-98
6661722-3	1983	Up to 3 micrograms/ml, vomitoxin was non-mutagenic to V79 cells at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus, with or without hepatocyte-mediated activation; and did not significantly increase the number of 6-thioguanine-resistant mutants at marginally cytotoxic levels of 6 and 8 micrograms/ml (data not shown).	deoxynivalenol	23-32	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	120-125
33665736-1	2021	The heat shock protein (Hsp70) level was assessed after 14 days of oral gavage-exposure to fumonisin B1 (FB1: 150 microg/animal/day), deoxynivalenol (DON: 30 microg/animal/day) and zearalenone (ZEN: 150 microg/animal/day), alone or in combinations (in additive manner: FD = FB1 + DON, FZ = FB1 + ZEN, DZ = DON + ZEN and FDZ = FB1 + DON + ZEN) in the liver, kidneys and lung of 24 adult male Wistar rats (n = 3/group).	deoxynivalenol	134-148	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	4-29
33847777-6	2021	Interestingly, pretreatment of cells with dynasore (a dynamin-dependent endocytosis inhibitor) protected against DON-induced degradation of claudin-3 and 4.	deoxynivalenol	113-116	claudin-3	Sus scrofa	140-155
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	109-112	claudin 4	Sus scrofa	79-88
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	109-112	zonula occludens 1	Sus scrofa	93-97
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	109-112	actin alpha 2, smooth muscle	Sus scrofa	201-206
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	109-112	claudin 1	Sus scrofa	268-283
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	295-298	claudin 4	Sus scrofa	79-88
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	295-298	zonula occludens 1	Sus scrofa	93-97
33847777-7	2021	Immunofluorescence analysis also shows that the decreased membrane presence of claudin-4 and ZO-1 induced by DON is reversible with dynamin inhibition, whereas the pretreatment with cytochalasin D (an actin-dependent endocytosis inhibitor) reverses the degradation of claudin-1 and 4 induced by DON.	deoxynivalenol	295-298	actin alpha 2, smooth muscle	Sus scrofa	201-206
33847777-11	2021	Therefore, natural bioactive compounds with p38 MAPK and JNK inhibitory activities may be effective in preventing the DON-induced TJP disruption and preserve gut barrier function in vivo.	deoxynivalenol	118-121	mitogen-activated protein kinase 8	Sus scrofa	57-60
33545470-5	2021	DON+Cd2+, DON, and Cd2+ induced dose-dependent fluorescence signal in the biosensors (at environmental exposure levels).	deoxynivalenol	0-4	CD2 molecule	Homo sapiens	19-22
33545470-5	2021	DON+Cd2+, DON, and Cd2+ induced dose-dependent fluorescence signal in the biosensors (at environmental exposure levels).	deoxynivalenol	0-3	CD2 molecule	Homo sapiens	4-7
34058674-0	2021	Ginsenoside Rb1 prevents deoxynivalenol-induced immune injury via alleviating oxidative stress and apoptosis in mice.	deoxynivalenol	25-39	RB transcriptional corepressor 1	Mus musculus	12-15
34058674-6	2021	Our results demonstrated that Rb1 markedly increased the ADG (30%) and ADFI (25.10%) of mice compared with DON group.	deoxynivalenol	107-110	RB transcriptional corepressor 1	Mus musculus	30-33
34058674-7	2021	Furthermore, Rb1 alleviated the DON-induced immune injury by relieving the splenic histopathological alteration, enhancing the T-lymphocytes subsets (CD4+, CD8+), the levels of cytokines (IL-2, IL-6, IFN-gamma, and TNF-alpha), as well as production of immunoglobulins (IgA, IgM, and IgG).	deoxynivalenol	32-35	RB transcriptional corepressor 1	Mus musculus	13-16
34058674-8	2021	Moreover, Rb1 ameliorated DON-inflicted oxidative stress by reducing the ROS, MDA and H2O2 contents and boosting the antioxidant defense system (T-AOC, T-SOD, CAT, and GSH-Px).	deoxynivalenol	26-29	RB transcriptional corepressor 1	Mus musculus	10-13
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	RB transcriptional corepressor 1	Mus musculus	14-17
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	BCL2-associated X protein	Mus musculus	266-269
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	caspase 3	Mus musculus	271-280
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	caspase 9	Mus musculus	282-291
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	BCL2-associated X protein	Mus musculus	319-322
34058674-9	2021	Additionally, Rb1 significantly reversed the DON-induced excessive splenic apoptosis via modulating the mitochondria-mediated apoptosis pathway in mice, depicting the decreased percentage of splenocyte apoptotic cells by 26.65%, down-regulated the mRNA abundance of Bax, caspase-3, caspase-9, and protein expression of Bax, cleaved caspase-3, and Cyt-c.	deoxynivalenol	45-48	caspase 3	Mus musculus	332-341
34058674-11	2021	Taken together, Rb1 mitigates DON-induced immune injury by suppressing the oxidative damage and regulating the mitochondria-mediated apoptosis pathway in mice.	deoxynivalenol	30-33	RB transcriptional corepressor 1	Mus musculus	16-19
34058674-12	2021	Conclusively, our current research provides an insight into the preventive mechanism of Rb1 against DON-induced immune injury in mice and thus, presents a scientific baseline for the therapeutic application of Rb1.	deoxynivalenol	100-103	RB transcriptional corepressor 1	Mus musculus	88-91
34058674-12	2021	Conclusively, our current research provides an insight into the preventive mechanism of Rb1 against DON-induced immune injury in mice and thus, presents a scientific baseline for the therapeutic application of Rb1.	deoxynivalenol	100-103	RB transcriptional corepressor 1	Mus musculus	210-213
33922863-10	2021	Mycotoxin adsorbent agents can attenuate DON-induced inflammatory responses in IPEC-J2 cells through modulation of the phosphorylation of p38, ERK, and JNK.	deoxynivalenol	41-44	mitogen-activated protein kinase 8	Sus scrofa	152-155
33907797-0	2021	Melatonin alleviates deoxynivalenol-induced apoptosis of human granulosa cells by reducing mutually accentuated FOXO1 and ER stress.	deoxynivalenol	21-35	forkhead box O1	Homo sapiens	112-117
33907797-0	2021	Melatonin alleviates deoxynivalenol-induced apoptosis of human granulosa cells by reducing mutually accentuated FOXO1 and ER stress.	deoxynivalenol	21-35	epiregulin	Homo sapiens	122-124
33907797-3	2021	Here, we demonstrated that suppression of FOXO1 and endoplasmic reticulum (ER) stress was engaged in melatonin-mediated protection against oxidative damage in human granulosa cells upon DON exposure in vitro.	deoxynivalenol	186-189	forkhead box O1	Homo sapiens	42-47
33907797-3	2021	Here, we demonstrated that suppression of FOXO1 and endoplasmic reticulum (ER) stress was engaged in melatonin-mediated protection against oxidative damage in human granulosa cells upon DON exposure in vitro.	deoxynivalenol	186-189	epiregulin	Homo sapiens	75-77
33907797-7	2021	We further found that FOXO1 is a pivotal downstream effector of melatonin and ER stress in regulating DON-induced apoptosis in human granulosa cells.	deoxynivalenol	102-105	forkhead box O1	Homo sapiens	22-27
33907797-7	2021	We further found that FOXO1 is a pivotal downstream effector of melatonin and ER stress in regulating DON-induced apoptosis in human granulosa cells.	deoxynivalenol	102-105	epiregulin	Homo sapiens	78-80
33907797-8	2021	Blocking of FOXO1 reduced DON-induced cells death and FOXO1 activation could be suppressed by melatonin or ER stress inhibitor.	deoxynivalenol	26-29	forkhead box O1	Homo sapiens	12-17
33907797-8	2021	Blocking of FOXO1 reduced DON-induced cells death and FOXO1 activation could be suppressed by melatonin or ER stress inhibitor.	deoxynivalenol	26-29	epiregulin	Homo sapiens	107-109
33907797-10	2021	Collectively, our results reveal a new mechanism of melatonin in protecting against DON-induced apoptosis and dysfunction by suppressing ER stress and FOXO1 in human granulosa cells.	deoxynivalenol	84-87	epiregulin	Homo sapiens	137-139
33907797-10	2021	Collectively, our results reveal a new mechanism of melatonin in protecting against DON-induced apoptosis and dysfunction by suppressing ER stress and FOXO1 in human granulosa cells.	deoxynivalenol	84-87	forkhead box O1	Homo sapiens	151-156
33922863-4	2021	Results showed that phosphorylation of MAPK signaling pathways (p38, ERK, and JNK) was increased after treatment of DON or lipopolysaccharide (LPS) in IPEC-J2 cells.	deoxynivalenol	116-119	mitogen-activated protein kinase 8	Sus scrofa	78-81
33922863-6	2021	The inos and cox-2 mRNA expression were significantly induced at 6 h after treatment of DON.	deoxynivalenol	88-91	cytochrome c oxidase subunit II	Sus scrofa	13-18
33922863-7	2021	DON treatment significantly increased the claudin 3 and occludin mRNA expression at 12 h. DON in combination with LPS treatment did not further increase the inflammation and tight junction-associated gene expression.	deoxynivalenol	0-3	claudin-3	Sus scrofa	42-51
33922863-7	2021	DON treatment significantly increased the claudin 3 and occludin mRNA expression at 12 h. DON in combination with LPS treatment did not further increase the inflammation and tight junction-associated gene expression.	deoxynivalenol	0-3	occludin	Sus scrofa	56-64
33515572-0	2021	Deoxynivalenol downregulates NRF2-induced cytoprotective response in human hepatocellular carcinoma (HepG2) cells.	deoxynivalenol	0-14	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
33515572-3	2021	We investigated the cytotoxicity of DON and its effect on the NRF2 antioxidant response in HepG2 cells.	deoxynivalenol	36-39	NFE2 like bZIP transcription factor 2	Homo sapiens	62-66
33515572-10	2021	In conclusion, DON induced oxidative stress and downregulated NRF2-induced cytoprotection by suppressing the antioxidant signalling mechanism in HepG2 cells.	deoxynivalenol	15-18	NFE2 like bZIP transcription factor 2	Homo sapiens	62-66
33556388-11	2021	Based on our in vivo and in vitro experiments, we suggest that ZEA, DON, and ZEA + DON inhibit the expression of costimulatory molecules on CD4+ T cell, and inhibit the IL-4R-mediated Th2 cell differentiation.	deoxynivalenol	68-71	CD4 antigen	Mus musculus	140-143
32896217-9	2021	Suppression of DON induced reactive oxygen species by AtLTP4.4 might be the mechanism by which fungal spread and mycotoxin accumulation are inhibited in the transgenic wheat plants.	deoxynivalenol	15-18	lipid transfer protein 4	Arabidopsis thaliana	54-60
33011476-4	2021	Under optimal conditions, the PITS exhibited sensitive and specific detection of DON from 0.19 ng mL-1 to 12 ng mL-1 with detection limits of 0.013 ng mL-1, which were over 15-fold and 58-fold more sensitive than visual FMD-G-ITS and traditional GNPs-ITS.	deoxynivalenol	81-84	L1 cell adhesion molecule	Mus musculus	98-102
33011476-4	2021	Under optimal conditions, the PITS exhibited sensitive and specific detection of DON from 0.19 ng mL-1 to 12 ng mL-1 with detection limits of 0.013 ng mL-1, which were over 15-fold and 58-fold more sensitive than visual FMD-G-ITS and traditional GNPs-ITS.	deoxynivalenol	81-84	L1 cell adhesion molecule	Mus musculus	112-116
33011476-4	2021	Under optimal conditions, the PITS exhibited sensitive and specific detection of DON from 0.19 ng mL-1 to 12 ng mL-1 with detection limits of 0.013 ng mL-1, which were over 15-fold and 58-fold more sensitive than visual FMD-G-ITS and traditional GNPs-ITS.	deoxynivalenol	81-84	L1 cell adhesion molecule	Mus musculus	112-116
33556388-11	2021	Based on our in vivo and in vitro experiments, we suggest that ZEA, DON, and ZEA + DON inhibit the expression of costimulatory molecules on CD4+ T cell, and inhibit the IL-4R-mediated Th2 cell differentiation.	deoxynivalenol	68-71	interleukin 4 receptor, alpha	Mus musculus	169-174
33124065-0	2021	Mangiferin protect oxidative stress against deoxynivalenol induced damages through Nrf2 signaling pathways in endothelial cells.	deoxynivalenol	44-58	NFE2 like bZIP transcription factor 2	Homo sapiens	83-87
33756194-0	2021	Deoxynivalenol-induced cell apoptosis monitoring using a cytochrome c-specific fluorescent probe based on a photoinduced electron transfer reaction.	deoxynivalenol	0-14	cytochrome c	Cricetulus griseus	57-69
33756194-3	2021	Cytochrome c (Cyt c), as an important biomarker of DON-induced apoptosis that may lead to a bipartite "point-of-no return" event, is of great significance to be detected using cell imaging.	deoxynivalenol	51-54	cytochrome c	Cricetulus griseus	0-12
33756194-3	2021	Cytochrome c (Cyt c), as an important biomarker of DON-induced apoptosis that may lead to a bipartite "point-of-no return" event, is of great significance to be detected using cell imaging.	deoxynivalenol	51-54	cytochrome c	Cricetulus griseus	14-19
33756194-4	2021	Herein, we synthesized a DON-deactivated emission fluorescent probe, the molecularly imprinted polymer-coated quantum dots (CdTe@MIP), for monitoring the Cyt c level with a photoinduced electron transfer strategy.	deoxynivalenol	25-28	cytochrome c	Cricetulus griseus	154-159
33124065-2	2021	The current paper examines the ameliorative effect of mangiferin (MAN) in vascular endothelial cells induced through activating the Nrf2 signaling pathway on dietary DON-induced oxidative changes.	deoxynivalenol	166-169	NFE2 like bZIP transcription factor 2	Homo sapiens	132-136
33309878-0	2021	MAPK/AP-1 and ROS participated in ratio- and time-dependent interaction effects of deoxynivalenol and cadmium on HT-29 cells.	deoxynivalenol	83-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	5-9
33181164-8	2021	Additionally, ELISA revealed that PTE inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and IL-6 proteins produced in DON-induced MAC-T cells.	deoxynivalenol	136-139	tumor necrosis factor	Bos taurus	66-93
33181164-7	2021	PTE also significantly reduced inducible nitric oxide synthase (iNOS) and nitric oxide (NO) levels in DON-induced MAC-T cells.	deoxynivalenol	102-105	nitric oxide synthase 2	Bos taurus	31-62
33498252-0	2021	Deoxynivalenol Induces Caspase-8-Mediated Apoptosis through the Mitochondrial Pathway in Hippocampal Nerve Cells of Piglet.	deoxynivalenol	0-14	caspase 8	Homo sapiens	23-32
33498252-6	2021	The obtained results demonstrated that DON treatment inhibited PHNC proliferation and led to morphological, biochemical, and transcriptional changes consistent with apoptosis, including decreased mitochondrial membrane potential, mitochondrial release of cytochrome C (CYCS) and apoptosis inducing factor (AIF), and increased abundance of active cleaved-caspase-9 and cleaved-caspase-3.	deoxynivalenol	39-42	cytochrome c, somatic	Homo sapiens	269-273
33498252-6	2021	The obtained results demonstrated that DON treatment inhibited PHNC proliferation and led to morphological, biochemical, and transcriptional changes consistent with apoptosis, including decreased mitochondrial membrane potential, mitochondrial release of cytochrome C (CYCS) and apoptosis inducing factor (AIF), and increased abundance of active cleaved-caspase-9 and cleaved-caspase-3.	deoxynivalenol	39-42	apoptosis inducing factor mitochondria associated 1	Homo sapiens	279-304
33498252-6	2021	The obtained results demonstrated that DON treatment inhibited PHNC proliferation and led to morphological, biochemical, and transcriptional changes consistent with apoptosis, including decreased mitochondrial membrane potential, mitochondrial release of cytochrome C (CYCS) and apoptosis inducing factor (AIF), and increased abundance of active cleaved-caspase-9 and cleaved-caspase-3.	deoxynivalenol	39-42	apoptosis inducing factor mitochondria associated 1	Homo sapiens	306-309
33498252-6	2021	The obtained results demonstrated that DON treatment inhibited PHNC proliferation and led to morphological, biochemical, and transcriptional changes consistent with apoptosis, including decreased mitochondrial membrane potential, mitochondrial release of cytochrome C (CYCS) and apoptosis inducing factor (AIF), and increased abundance of active cleaved-caspase-9 and cleaved-caspase-3.	deoxynivalenol	39-42	caspase 9	Homo sapiens	354-363
33498252-7	2021	Increasing concentrations of DON led to decreased B-cell lymphoma-2 (Bcl-2) expression and increased expression of BCL2-associated X (Bax) and B-cell lymphoma-2 homology 3 interacting domain death agonist (Bid), which in turn increased transcriptional activity of the transcription factors AIF and P53 (a tumor suppressor gene, promotes apoptosis).	deoxynivalenol	29-32	apoptosis regulator BAX	Cricetulus griseus	115-132
33498252-7	2021	Increasing concentrations of DON led to decreased B-cell lymphoma-2 (Bcl-2) expression and increased expression of BCL2-associated X (Bax) and B-cell lymphoma-2 homology 3 interacting domain death agonist (Bid), which in turn increased transcriptional activity of the transcription factors AIF and P53 (a tumor suppressor gene, promotes apoptosis).	deoxynivalenol	29-32	apoptosis regulator BAX	Cricetulus griseus	134-137
33498252-7	2021	Increasing concentrations of DON led to decreased B-cell lymphoma-2 (Bcl-2) expression and increased expression of BCL2-associated X (Bax) and B-cell lymphoma-2 homology 3 interacting domain death agonist (Bid), which in turn increased transcriptional activity of the transcription factors AIF and P53 (a tumor suppressor gene, promotes apoptosis).	deoxynivalenol	29-32	BH3-interacting domain death agonist	Cricetulus griseus	206-209
33498252-7	2021	Increasing concentrations of DON led to decreased B-cell lymphoma-2 (Bcl-2) expression and increased expression of BCL2-associated X (Bax) and B-cell lymphoma-2 homology 3 interacting domain death agonist (Bid), which in turn increased transcriptional activity of the transcription factors AIF and P53 (a tumor suppressor gene, promotes apoptosis).	deoxynivalenol	29-32	apoptosis inducing factor mitochondria associated 1	Homo sapiens	290-293
33498252-7	2021	Increasing concentrations of DON led to decreased B-cell lymphoma-2 (Bcl-2) expression and increased expression of BCL2-associated X (Bax) and B-cell lymphoma-2 homology 3 interacting domain death agonist (Bid), which in turn increased transcriptional activity of the transcription factors AIF and P53 (a tumor suppressor gene, promotes apoptosis).	deoxynivalenol	29-32	cellular tumor antigen p53	Cricetulus griseus	298-301
33181164-8	2021	Additionally, ELISA revealed that PTE inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and IL-6 proteins produced in DON-induced MAC-T cells.	deoxynivalenol	136-139	tumor necrosis factor	Bos taurus	95-104
33181164-8	2021	Additionally, ELISA revealed that PTE inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and IL-6 proteins produced in DON-induced MAC-T cells.	deoxynivalenol	136-139	interleukin 6	Bos taurus	110-114
32877744-5	2020	Our results showed that nontoxic-dose DON aggravated LPS-induced cellular inflammatory response, reflecting on more significant changes of inflammatory cytokines mRNA expression, higher protein expression of NOD-like receptor protein 3 (NLRP3) and procaspase-1.	deoxynivalenol	38-41	NLR family pyrin domain containing 3	Sus scrofa	208-235
33379255-5	2020	The antibody was consecutively used to develop deoxynivalenol-specific ELISA and TRF-immunoassays, which can detect deoxynivalenol and two of the most common metabolic isoforms in the range of 78-115 ng/mL.	deoxynivalenol	116-130	telomeric repeat binding factor 1	Homo sapiens	81-84
33170220-10	2021	Following exposure to deoxynivalenol, the secretion of interleukin (IL)-1beta, IL-6, IL-8, and/or tumor necrosis factor (TNF)-alpha in BEAS-2B cells, as well as EoL-1 cells, increased significantly.	deoxynivalenol	22-36	interleukin 1 alpha	Homo sapiens	55-77
33170220-10	2021	Following exposure to deoxynivalenol, the secretion of interleukin (IL)-1beta, IL-6, IL-8, and/or tumor necrosis factor (TNF)-alpha in BEAS-2B cells, as well as EoL-1 cells, increased significantly.	deoxynivalenol	22-36	interleukin 6	Homo sapiens	79-83
33170220-10	2021	Following exposure to deoxynivalenol, the secretion of interleukin (IL)-1beta, IL-6, IL-8, and/or tumor necrosis factor (TNF)-alpha in BEAS-2B cells, as well as EoL-1 cells, increased significantly.	deoxynivalenol	22-36	C-X-C motif chemokine ligand 8	Homo sapiens	85-89
33170220-10	2021	Following exposure to deoxynivalenol, the secretion of interleukin (IL)-1beta, IL-6, IL-8, and/or tumor necrosis factor (TNF)-alpha in BEAS-2B cells, as well as EoL-1 cells, increased significantly.	deoxynivalenol	22-36	tumor necrosis factor	Homo sapiens	98-131
31930515-0	2020	Autophagy protects PC12 cells against deoxynivalenol toxicity via the Class III PI3K/beclin 1/Bcl-2 pathway.	deoxynivalenol	38-52	beclin 1	Rattus norvegicus	85-93
31930515-0	2020	Autophagy protects PC12 cells against deoxynivalenol toxicity via the Class III PI3K/beclin 1/Bcl-2 pathway.	deoxynivalenol	38-52	BCL2, apoptosis regulator	Rattus norvegicus	94-99
31930515-3	2020	Here, we determined the effect of DON on the Class III phosphatidylinositol 3-kinase (PIK3C3)/beclin 1/B cell lymphoma-2 (Bcl-2) pathway in PC12 cells and the relationship between autophagy and apoptosis.	deoxynivalenol	34-37	phosphatidylinositol 3-kinase catalytic subunit type 3	Mus musculus	86-92
31930515-3	2020	Here, we determined the effect of DON on the Class III phosphatidylinositol 3-kinase (PIK3C3)/beclin 1/B cell lymphoma-2 (Bcl-2) pathway in PC12 cells and the relationship between autophagy and apoptosis.	deoxynivalenol	34-37	beclin 1, autophagy related	Mus musculus	94-120
31930515-3	2020	Here, we determined the effect of DON on the Class III phosphatidylinositol 3-kinase (PIK3C3)/beclin 1/B cell lymphoma-2 (Bcl-2) pathway in PC12 cells and the relationship between autophagy and apoptosis.	deoxynivalenol	34-37	B cell leukemia/lymphoma 2	Mus musculus	122-127
31930515-7	2020	PIK3C3, beclin 1, and LC3 increased in tandem with the DON concentration used; Bcl-2 and p62 expression decreased as DON concentrations increased.	deoxynivalenol	117-120	BCL2, apoptosis regulator	Rattus norvegicus	79-84
31930515-7	2020	PIK3C3, beclin 1, and LC3 increased in tandem with the DON concentration used; Bcl-2 and p62 expression decreased as DON concentrations increased.	deoxynivalenol	117-120	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	89-92
31930515-8	2020	Moreover, the PIK3C3/beclin 1/Bcl-2 signaling pathway played a role in DON-induced autophagy.	deoxynivalenol	71-74	phosphatidylinositol 3-kinase, catalytic subunit type 3	Rattus norvegicus	14-20
31930515-8	2020	Moreover, the PIK3C3/beclin 1/Bcl-2 signaling pathway played a role in DON-induced autophagy.	deoxynivalenol	71-74	beclin 1	Rattus norvegicus	21-29
31930515-8	2020	Moreover, the PIK3C3/beclin 1/Bcl-2 signaling pathway played a role in DON-induced autophagy.	deoxynivalenol	71-74	BCL2, apoptosis regulator	Rattus norvegicus	30-35
31930515-9	2020	Our findings suggest that DON can induce autophagy by activating the PIK3C3/beclin 1/Bcl-2 signaling pathway and that autophagy may play a positive role in reducing DON-induced apoptosis.	deoxynivalenol	26-29	phosphatidylinositol 3-kinase, catalytic subunit type 3	Rattus norvegicus	69-75
31930515-9	2020	Our findings suggest that DON can induce autophagy by activating the PIK3C3/beclin 1/Bcl-2 signaling pathway and that autophagy may play a positive role in reducing DON-induced apoptosis.	deoxynivalenol	26-29	beclin 1	Rattus norvegicus	76-84
31930515-9	2020	Our findings suggest that DON can induce autophagy by activating the PIK3C3/beclin 1/Bcl-2 signaling pathway and that autophagy may play a positive role in reducing DON-induced apoptosis.	deoxynivalenol	26-29	BCL2, apoptosis regulator	Rattus norvegicus	85-90
32877744-5	2020	Our results showed that nontoxic-dose DON aggravated LPS-induced cellular inflammatory response, reflecting on more significant changes of inflammatory cytokines mRNA expression, higher protein expression of NOD-like receptor protein 3 (NLRP3) and procaspase-1.	deoxynivalenol	38-41	NLR family pyrin domain containing 3	Sus scrofa	237-242
33163144-8	2020	Transcriptome analysis revealed that MAPK, TNF, and NF-kappaB signaling pathways and some chemokines played significant roles in the regulation of inflammation and apoptosis induced by DON.	deoxynivalenol	185-188	tumor necrosis factor	Sus scrofa	43-46
33163144-9	2020	GA may alleviate DON cytotoxicity via the TNF signaling pathway by downregulating IL-15, CCL5, and other gene expressions.	deoxynivalenol	17-20	tumor necrosis factor	Sus scrofa	42-45
33163144-9	2020	GA may alleviate DON cytotoxicity via the TNF signaling pathway by downregulating IL-15, CCL5, and other gene expressions.	deoxynivalenol	17-20	interleukin 15	Sus scrofa	82-87
33163144-9	2020	GA may alleviate DON cytotoxicity via the TNF signaling pathway by downregulating IL-15, CCL5, and other gene expressions.	deoxynivalenol	17-20	C-C motif chemokine 5	Sus scrofa	89-93
33163144-10	2020	These results indicated that GA could alleviate DON-induced oxidative stress, inflammation, and apoptosis via the TNF signaling pathway in IPEC-J2 cells.	deoxynivalenol	48-51	tumor necrosis factor	Sus scrofa	114-117
32738333-0	2020	Epigenetic upregulation of galanin-like peptide mediates deoxynivalenol induced-growth inhibition in pituitary cells.	deoxynivalenol	57-71	galanin like peptide	Homo sapiens	27-47
32794227-7	2020	Only treatment of RTgill-W1 with deoxynivalenol resulted in a significant increase in expression of type I interferon.	deoxynivalenol	33-47	type i interferon	None	100-117
32783910-4	2020	In the first period, even the selected low doses of DON or ZEA in the diet resulted in intestinal inflammation, diminish protein expression (claudin-4) and altered gut microbiota populations.	deoxynivalenol	52-55	claudin 4	Homo sapiens	141-150
32783910-5	2020	Whereas upon switching to the CON diet for another 2 weeks, the deleterious effect of ZEA and DON on IL-1beta and Bifidobacterium population could not be recovered.	deoxynivalenol	94-97	interleukin 1 alpha	Homo sapiens	101-109
32673909-11	2020	Pretreatment with p38 signaling inhibitor could significantly block the induction of autophagy, indicating that DON could promote the PEDV infection by triggering p38-mediated autophagy.	deoxynivalenol	112-115	mitogen-activated protein kinase 14	Homo sapiens	18-21
32673909-11	2020	Pretreatment with p38 signaling inhibitor could significantly block the induction of autophagy, indicating that DON could promote the PEDV infection by triggering p38-mediated autophagy.	deoxynivalenol	112-115	mitogen-activated protein kinase 14	Homo sapiens	163-166
32738333-3	2020	Previous studies have shown that DON causes stunting in children through intestinal dysfunction, insulin-like growth factor-1 (IGF-1) axis disorder and peptide YY (PYY).	deoxynivalenol	33-36	insulin like growth factor 1	Homo sapiens	97-125
32738333-3	2020	Previous studies have shown that DON causes stunting in children through intestinal dysfunction, insulin-like growth factor-1 (IGF-1) axis disorder and peptide YY (PYY).	deoxynivalenol	33-36	insulin like growth factor 1	Homo sapiens	127-132
32738333-3	2020	Previous studies have shown that DON causes stunting in children through intestinal dysfunction, insulin-like growth factor-1 (IGF-1) axis disorder and peptide YY (PYY).	deoxynivalenol	33-36	peptide YY	Homo sapiens	152-162
32738333-3	2020	Previous studies have shown that DON causes stunting in children through intestinal dysfunction, insulin-like growth factor-1 (IGF-1) axis disorder and peptide YY (PYY).	deoxynivalenol	33-36	peptide YY	Homo sapiens	164-167
32738333-5	2020	In this study, we report the important role of GALP during DON-induced growth inhibition in the rat pituitary tumour cell line GH3.	deoxynivalenol	59-62	galanin-like peptide	Rattus norvegicus	47-51
32738333-10	2020	The present findings provide new mechanistic insights into the toxicity of DON-induced growth retardation and suggest a therapeutic potential of GALP in DON-related diseases.	deoxynivalenol	75-78	galanin-like peptide	Rattus norvegicus	145-149
32738333-10	2020	The present findings provide new mechanistic insights into the toxicity of DON-induced growth retardation and suggest a therapeutic potential of GALP in DON-related diseases.	deoxynivalenol	153-156	galanin-like peptide	Rattus norvegicus	145-149
32878107-4	2020	BCU decreased the serum concentration of IgG, IL-2, IFN-gamma, and IgA in DON treated piglets (p < 0.05), and promoted the serum concentration of IL-1beta, IgG, IL-2, IFN-gamma, IgA, IL-6, IgM, and TNFalpha in normal piglets (p < 0.05).	deoxynivalenol	74-77	CD79a molecule	Homo sapiens	67-70
32617661-7	2020	DON increased morphological damage, pro-inflammatory markers (myeloperoxidase, CXCL-1 and IL-1beta) and immune cell responses.	deoxynivalenol	0-3	myeloperoxidase	Rattus norvegicus	62-77
32617661-7	2020	DON increased morphological damage, pro-inflammatory markers (myeloperoxidase, CXCL-1 and IL-1beta) and immune cell responses.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 1	Rattus norvegicus	79-85
32617661-7	2020	DON increased morphological damage, pro-inflammatory markers (myeloperoxidase, CXCL-1 and IL-1beta) and immune cell responses.	deoxynivalenol	0-3	interleukin 1 alpha	Rattus norvegicus	90-98
32472169-5	2020	DON-induced neuronal activation was assessed by c-Fos immunohistochemistry.	deoxynivalenol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	48-53
32472169-6	2020	DON injection resulted in profound c-Fos activation in only the elements of the reward system, such as the accumbens nucleus, the medial prefrontal cortex, and the ventral tegmental area.	deoxynivalenol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	35-40
32679628-10	2020	After using the inhibitors of extracellular regulated protein kinases (ERK) and c-Jun N-terminal kinase (JNK) in the MAPK pathway, we found that the apoptosis of the cells induced by the ZEA was significantly decreased, and the apoptosis of the cells induced by DON had no significant changes.	deoxynivalenol	262-265	mitogen-activated protein kinase 1	Mus musculus	30-69
32679628-10	2020	After using the inhibitors of extracellular regulated protein kinases (ERK) and c-Jun N-terminal kinase (JNK) in the MAPK pathway, we found that the apoptosis of the cells induced by the ZEA was significantly decreased, and the apoptosis of the cells induced by DON had no significant changes.	deoxynivalenol	262-265	mitogen-activated protein kinase 1	Mus musculus	71-74
32679628-10	2020	After using the inhibitors of extracellular regulated protein kinases (ERK) and c-Jun N-terminal kinase (JNK) in the MAPK pathway, we found that the apoptosis of the cells induced by the ZEA was significantly decreased, and the apoptosis of the cells induced by DON had no significant changes.	deoxynivalenol	262-265	mitogen-activated protein kinase 8	Mus musculus	105-108
32416428-7	2020	Then, we proved that DON induced BTB disruption as well as decreased the expressions of BTB junction proteins, including Occludin, Connexin 43 and N-cadherin.	deoxynivalenol	21-24	occludin	Mus musculus	121-129
32416428-7	2020	Then, we proved that DON induced BTB disruption as well as decreased the expressions of BTB junction proteins, including Occludin, Connexin 43 and N-cadherin.	deoxynivalenol	21-24	gap junction protein, alpha 1	Mus musculus	131-142
32416428-7	2020	Then, we proved that DON induced BTB disruption as well as decreased the expressions of BTB junction proteins, including Occludin, Connexin 43 and N-cadherin.	deoxynivalenol	21-24	cadherin 2	Mus musculus	147-157
32878107-6	2020	Dietary BCU supplementation significantly promoted the secretion of somatostatin, and inhibited the secretion of leptin in piglets challenged with DON (p < 0.05).	deoxynivalenol	147-150	leptin	Homo sapiens	113-119
32903433-8	2020	At a DON concentration, that already negatively affects proliferation after Concanavalin A stimulation (0.8 muM) an increase of T-bet expression in CD4+ and CD8+ T cells was observed.	deoxynivalenol	5-8	T-box transcription factor 21	Homo sapiens	128-133
32878272-0	2020	Deoxynivalenol Exposure Suppresses Adipogenesis by Inhibiting the Expression of Peroxisome Proliferator-Activated Receptor Gamma 2 (PPARgamma2) in 3T3-L1 Cells.	deoxynivalenol	0-14	peroxisome proliferator activated receptor gamma	Mus musculus	80-130
32878272-0	2020	Deoxynivalenol Exposure Suppresses Adipogenesis by Inhibiting the Expression of Peroxisome Proliferator-Activated Receptor Gamma 2 (PPARgamma2) in 3T3-L1 Cells.	deoxynivalenol	0-14	peroxisome proliferator activated receptor gamma	Mus musculus	132-142
32878272-5	2020	DON exposure significantly downregulated the expression of PPARgamma2 and C/EBPalpha, along with that of other adipogenic marker genes in 3T3-L1 cells and BALB/c mice.	deoxynivalenol	0-3	peroxisome proliferator activated receptor gamma	Mus musculus	59-69
32878272-5	2020	DON exposure significantly downregulated the expression of PPARgamma2 and C/EBPalpha, along with that of other adipogenic marker genes in 3T3-L1 cells and BALB/c mice.	deoxynivalenol	0-3	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	74-84
32878272-8	2020	DON exposure specifically decreased the di-/trimethylation levels of Histone 3 at lysine 4 in 3T3-L1 cells, therefore weakening the enrichment of H3K4me2 and H3K4me3 at the Ppargamma2 promoter and suppressing its expression.	deoxynivalenol	0-3	peroxisome proliferator activated receptor gamma	Mus musculus	173-183
32878272-9	2020	Conclusively, DON exposure inhibited PPARgamma2 expression via decreasing H3K4 methylation, downregulated the expression of PPARgamma2-regulated adipogenic marker genes, and consequently suppressed the intermediate and late stages of adipogenesis.	deoxynivalenol	14-17	peroxisome proliferator activated receptor gamma	Mus musculus	37-47
32878272-9	2020	Conclusively, DON exposure inhibited PPARgamma2 expression via decreasing H3K4 methylation, downregulated the expression of PPARgamma2-regulated adipogenic marker genes, and consequently suppressed the intermediate and late stages of adipogenesis.	deoxynivalenol	14-17	peroxisome proliferator activated receptor gamma	Mus musculus	124-134
32903433-8	2020	At a DON concentration, that already negatively affects proliferation after Concanavalin A stimulation (0.8 muM) an increase of T-bet expression in CD4+ and CD8+ T cells was observed.	deoxynivalenol	5-8	CD4 molecule	Homo sapiens	148-151
32903433-8	2020	At a DON concentration, that already negatively affects proliferation after Concanavalin A stimulation (0.8 muM) an increase of T-bet expression in CD4+ and CD8+ T cells was observed.	deoxynivalenol	5-8	CD8a molecule	Homo sapiens	157-160
32076947-14	2020	Zn administration led to significant protection of HepG2 cells against DON-induced adverse effects, probably via activation of the Nrf2-Keap1 pathway.	deoxynivalenol	71-74	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
32416088-6	2020	Using Ro-31-8220 (Protein-Kinase-C inhibitor), it was observed PKC was responsible for DON induced upregulation of COX-2 and iNOS proteins.	deoxynivalenol	87-90	prostaglandin-endoperoxide synthase 2	Mus musculus	115-120
32416088-6	2020	Using Ro-31-8220 (Protein-Kinase-C inhibitor), it was observed PKC was responsible for DON induced upregulation of COX-2 and iNOS proteins.	deoxynivalenol	87-90	nitric oxide synthase 2, inducible	Mus musculus	125-129
32076947-0	2020	Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	0-14	NFE2 like bZIP transcription factor 2	Homo sapiens	123-127
32076947-0	2020	Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	0-14	kelch like ECH associated protein 1	Homo sapiens	128-133
32076947-13	2020	DON caused significant downregulation of Nrf2-regulated antioxidant enzymes.	deoxynivalenol	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	41-45
32076947-14	2020	Zn administration led to significant protection of HepG2 cells against DON-induced adverse effects, probably via activation of the Nrf2-Keap1 pathway.	deoxynivalenol	71-74	kelch like ECH associated protein 1	Homo sapiens	136-141
32329021-0	2020	Correction to: Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	15-29	NFE2 like bZIP transcription factor 2	Homo sapiens	138-142
32329021-0	2020	Correction to: Deoxynivalenol-induced alterations in the redox status of HepG2 cells: identification of lipid hydroperoxides, the role of Nrf2-Keap1 signaling, and protective effects of zinc.	deoxynivalenol	15-29	kelch like ECH associated protein 1	Homo sapiens	143-148
32229166-2	2020	This study aimed to determine the effects of PI3K/Akt/mTOR pathway on DON-induced autophagy of piglet hippocampal nerve cells (PHNCs), and the relationship between autophagy and apoptosis.	deoxynivalenol	70-73	AKT serine/threonine kinase 1	Sus scrofa	50-53
32229166-2	2020	This study aimed to determine the effects of PI3K/Akt/mTOR pathway on DON-induced autophagy of piglet hippocampal nerve cells (PHNCs), and the relationship between autophagy and apoptosis.	deoxynivalenol	70-73	mechanistic target of rapamycin kinase	Sus scrofa	54-58
32229166-6	2020	The expression levels of LC3 protein and gene increased, while the expression levels of PI3K/Akt/mTOR pathway-related genes and proteins decreased, when the concentration of DON increased.	deoxynivalenol	174-177	AKT serine/threonine kinase 1	Sus scrofa	93-96
32229166-6	2020	The expression levels of LC3 protein and gene increased, while the expression levels of PI3K/Akt/mTOR pathway-related genes and proteins decreased, when the concentration of DON increased.	deoxynivalenol	174-177	mechanistic target of rapamycin kinase	Sus scrofa	97-101
32229166-9	2020	PI3K/Akt/mTOR signaling pathway plays a negative regulatory role in DON-induced autophagy of PHNCs.	deoxynivalenol	68-71	AKT serine/threonine kinase 1	Sus scrofa	5-8
32229166-9	2020	PI3K/Akt/mTOR signaling pathway plays a negative regulatory role in DON-induced autophagy of PHNCs.	deoxynivalenol	68-71	mechanistic target of rapamycin kinase	Sus scrofa	9-13
32229166-11	2020	KEYWORDS: Apoptosis Autophagy PI3K/Akt/mTOR pathway Deoxynivalenol Hippocampal nerve cell.	deoxynivalenol	52-66	AKT serine/threonine kinase 1	Sus scrofa	35-38
32229166-11	2020	KEYWORDS: Apoptosis Autophagy PI3K/Akt/mTOR pathway Deoxynivalenol Hippocampal nerve cell.	deoxynivalenol	52-66	mechanistic target of rapamycin kinase	Sus scrofa	39-43
32439590-0	2020	Long noncoding RNA Gm20319, acting as competing endogenous RNA, regulated GNE expression by sponging miR-7240-5p to involve in deoxynivalenol-induced liver damage in vitro.	deoxynivalenol	127-141	predicted gene, 20319	Mus musculus	19-26
32439590-0	2020	Long noncoding RNA Gm20319, acting as competing endogenous RNA, regulated GNE expression by sponging miR-7240-5p to involve in deoxynivalenol-induced liver damage in vitro.	deoxynivalenol	127-141	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Mus musculus	74-77
32439590-0	2020	Long noncoding RNA Gm20319, acting as competing endogenous RNA, regulated GNE expression by sponging miR-7240-5p to involve in deoxynivalenol-induced liver damage in vitro.	deoxynivalenol	127-141	microRNA 7240	Mus musculus	101-109
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	129-132	predicted gene, 20319	Mus musculus	13-20
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	129-132	microRNA 7240	Mus musculus	21-29
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	129-132	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Mus musculus	33-36
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	161-164	predicted gene, 20319	Mus musculus	13-20
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	161-164	microRNA 7240	Mus musculus	21-29
32439590-3	2020	Here, lncRNA Gm20319-miR-7240-5p-GNE (glucosamine UDP-N-acetyl-2-epimerase/N-acetylmannosamine kinase) network was identified in DON exposed-liver tissues after DON exposure for 90 days.	deoxynivalenol	161-164	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Mus musculus	33-36
32439590-5	2020	In DON-treated liver tissues and Hepa 1-6 cell line, the expression of Gm20319 and GNE were both downregulated while miR-7240-5p expression was upregulated.	deoxynivalenol	3-6	predicted gene, 20319	Mus musculus	71-78
32439590-5	2020	In DON-treated liver tissues and Hepa 1-6 cell line, the expression of Gm20319 and GNE were both downregulated while miR-7240-5p expression was upregulated.	deoxynivalenol	3-6	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Mus musculus	83-86
32439590-5	2020	In DON-treated liver tissues and Hepa 1-6 cell line, the expression of Gm20319 and GNE were both downregulated while miR-7240-5p expression was upregulated.	deoxynivalenol	3-6	microRNA 7240	Mus musculus	117-125
32439590-9	2020	This study revealed Gm20319-miR-7240-5p-GNE network reduced sialic acid level to influence the expression of SOD1 and IL-1beta in liver, which might involve in liver damage induced by DON.	deoxynivalenol	184-187	predicted gene, 20319	Mus musculus	20-27
32439590-9	2020	This study revealed Gm20319-miR-7240-5p-GNE network reduced sialic acid level to influence the expression of SOD1 and IL-1beta in liver, which might involve in liver damage induced by DON.	deoxynivalenol	184-187	microRNA 7240	Mus musculus	28-36
32439590-9	2020	This study revealed Gm20319-miR-7240-5p-GNE network reduced sialic acid level to influence the expression of SOD1 and IL-1beta in liver, which might involve in liver damage induced by DON.	deoxynivalenol	184-187	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Mus musculus	40-43
32439590-9	2020	This study revealed Gm20319-miR-7240-5p-GNE network reduced sialic acid level to influence the expression of SOD1 and IL-1beta in liver, which might involve in liver damage induced by DON.	deoxynivalenol	184-187	superoxide dismutase 1, soluble	Mus musculus	109-113
32439590-9	2020	This study revealed Gm20319-miR-7240-5p-GNE network reduced sialic acid level to influence the expression of SOD1 and IL-1beta in liver, which might involve in liver damage induced by DON.	deoxynivalenol	184-187	interleukin 1 alpha	Mus musculus	118-126
32439590-10	2020	Gm20319 might be a potential research molecular target for DON-induced liver damage.	deoxynivalenol	59-62	predicted gene, 20319	Mus musculus	0-7
32229367-4	2020	Our results revealed that low doses of DON increased the expressions of TNF-alpha and IL-6 in piglets and PAMs, promoted the chemotaxis and phagocytosis of PAMs and transformed macrophages to M1 phenotype (P < 0.05).	deoxynivalenol	39-42	tumor necrosis factor	Homo sapiens	72-81
32229367-4	2020	Our results revealed that low doses of DON increased the expressions of TNF-alpha and IL-6 in piglets and PAMs, promoted the chemotaxis and phagocytosis of PAMs and transformed macrophages to M1 phenotype (P < 0.05).	deoxynivalenol	39-42	interleukin 6	Homo sapiens	86-90
32229367-5	2020	Conversely, high doses of DON increased the expressions of TGF-beta and IL-10 in piglets and PAMs, inhibited the chemotaxis and phagocytosis of PAMs and induced macrophages M2-type polarization (P < 0.05).	deoxynivalenol	26-29	transforming growth factor alpha	Homo sapiens	59-67
32229367-5	2020	Conversely, high doses of DON increased the expressions of TGF-beta and IL-10 in piglets and PAMs, inhibited the chemotaxis and phagocytosis of PAMs and induced macrophages M2-type polarization (P < 0.05).	deoxynivalenol	26-29	interleukin 10	Homo sapiens	72-77
32229367-6	2020	Mechanistically, DON exposure significantly activated the TLR4/NFkappaB pathway at low doses and induced mitophagy-mediated mitochondrial dysfunction at high doses in vitro and vivo.	deoxynivalenol	17-20	toll like receptor 4	Homo sapiens	58-62
32229367-6	2020	Mechanistically, DON exposure significantly activated the TLR4/NFkappaB pathway at low doses and induced mitophagy-mediated mitochondrial dysfunction at high doses in vitro and vivo.	deoxynivalenol	17-20	nuclear factor kappa B subunit 1	Homo sapiens	63-71
32194137-7	2020	Ingestion of DON induced histological alterations in the intestine, liver and lymphoid organs, as well as an overexpression of pro-inflammatory cytokines, E-cadherin and occludin.	deoxynivalenol	13-16	cadherin 1	Homo sapiens	155-165
32194137-7	2020	Ingestion of DON induced histological alterations in the intestine, liver and lymphoid organs, as well as an overexpression of pro-inflammatory cytokines, E-cadherin and occludin.	deoxynivalenol	13-16	occludin	Homo sapiens	170-178
32229121-8	2020	Growing crop year affected corn silage vomitoxin (0.60, 1.45, and 1.56 mg/kg) concentrations, which may have affected lactational performance as STA corn silage was from 2013, whereas LF1 and LF2 were from the 2012 crop year.	deoxynivalenol	39-48	STA	Bos taurus	145-148
32302720-8	2020	We suspect that DON causes oxidative damage, which in turn leads to down-regulation of MFN1, MFN2, OPA1 and up-regulation of LC3 and P62 mRNA, thereby inhibiting mitochondrial fusion and promoting mitochondrial autophagy.	deoxynivalenol	16-19	mitofusin-2	Cricetulus griseus	93-97
32302720-8	2020	We suspect that DON causes oxidative damage, which in turn leads to down-regulation of MFN1, MFN2, OPA1 and up-regulation of LC3 and P62 mRNA, thereby inhibiting mitochondrial fusion and promoting mitochondrial autophagy.	deoxynivalenol	16-19	dynamin-like 120 kDa protein, mitochondrial	Cricetulus griseus	99-103
31808557-0	2020	Inhibiting the aberrant activation of Wnt/beta-catenin signaling by selenium supplementation ameliorates deoxynivalenol-induced toxicity and catabolism in chondrocytes.	deoxynivalenol	105-119	catenin beta 1	Homo sapiens	42-54
32135158-0	2020	Low doses of deoxynivalenol inhibit the cell migration mediated by H3K27me3-targeted downregulation of TEM8 expression.	deoxynivalenol	13-27	ANTXR cell adhesion molecule 1	Homo sapiens	103-107
32135158-5	2020	Further analysis showed that DON inhibited the expression of tumour endothelial marker 8 (TEM8), a key gene in cell migration.	deoxynivalenol	29-32	ANTXR cell adhesion molecule 1	Homo sapiens	61-88
32135158-5	2020	Further analysis showed that DON inhibited the expression of tumour endothelial marker 8 (TEM8), a key gene in cell migration.	deoxynivalenol	29-32	ANTXR cell adhesion molecule 1	Homo sapiens	90-94
32135158-6	2020	Furthermore, we showed that DON inhibited the expression of TEM8 through increasing the level of H3K27me3 in the TEM8 promoter.	deoxynivalenol	28-31	ANTXR cell adhesion molecule 1	Homo sapiens	60-64
32135158-6	2020	Furthermore, we showed that DON inhibited the expression of TEM8 through increasing the level of H3K27me3 in the TEM8 promoter.	deoxynivalenol	28-31	ANTXR cell adhesion molecule 1	Homo sapiens	113-117
32135158-7	2020	Finally, overexpression of TEM8 or treating by H3K27me3-specific inhibitor GSK126 attenuated the inhibitory effect of DON on cell migration.	deoxynivalenol	118-121	ANTXR cell adhesion molecule 1	Homo sapiens	27-31
32135158-8	2020	In summary, low doses of DON at approximately dietary exposure significantly inhibited cell migration by downregulating the expression of TEM8 in a manner mediated by H3K27me3, which may generate increasing concerns for the risk of DON exposure.	deoxynivalenol	25-28	ANTXR cell adhesion molecule 1	Homo sapiens	138-142
32135158-8	2020	In summary, low doses of DON at approximately dietary exposure significantly inhibited cell migration by downregulating the expression of TEM8 in a manner mediated by H3K27me3, which may generate increasing concerns for the risk of DON exposure.	deoxynivalenol	232-235	ANTXR cell adhesion molecule 1	Homo sapiens	138-142
32302720-7	2020	With increasing DON concentrations, the expression levels of MFN1/2, OPA1 and mitochondrial respiratory chain complex activities decreased, while LC3, P62 increased.	deoxynivalenol	16-19	mitofusin 1	Sus scrofa	61-67
32302720-7	2020	With increasing DON concentrations, the expression levels of MFN1/2, OPA1 and mitochondrial respiratory chain complex activities decreased, while LC3, P62 increased.	deoxynivalenol	16-19	dynamin-like 120 kDa protein, mitochondrial	Cricetulus griseus	69-73
32302720-8	2020	We suspect that DON causes oxidative damage, which in turn leads to down-regulation of MFN1, MFN2, OPA1 and up-regulation of LC3 and P62 mRNA, thereby inhibiting mitochondrial fusion and promoting mitochondrial autophagy.	deoxynivalenol	16-19	Mfn1	Cricetulus griseus	87-91
31808557-4	2020	In the present study, exposure to DON dose-dependently suppressed cell viability and expression of pro-proliferation marker PCNA in human chondrocytes, whereas it enhanced lactate dehydrogenase release, cell apoptosis, and caspase-3/9 activity.	deoxynivalenol	34-37	caspase 3	Homo sapiens	223-232
31808557-5	2020	In addition, DON incubation shifted metabolism homeostasis towards catabolism by suppressing the transcription of collagen II and aggrecan, and the production of sulphated glycosaminoglycans and TIMP-1, while increasing matrix metalloproteinase levels (MMP-1 and MMP-13).	deoxynivalenol	13-16	TIMP metallopeptidase inhibitor 1	Homo sapiens	195-201
31808557-5	2020	In addition, DON incubation shifted metabolism homeostasis towards catabolism by suppressing the transcription of collagen II and aggrecan, and the production of sulphated glycosaminoglycans and TIMP-1, while increasing matrix metalloproteinase levels (MMP-1 and MMP-13).	deoxynivalenol	13-16	matrix metallopeptidase 1	Homo sapiens	253-258
31808557-5	2020	In addition, DON incubation shifted metabolism homeostasis towards catabolism by suppressing the transcription of collagen II and aggrecan, and the production of sulphated glycosaminoglycans and TIMP-1, while increasing matrix metalloproteinase levels (MMP-1 and MMP-13).	deoxynivalenol	13-16	matrix metallopeptidase 13	Homo sapiens	263-269
31808557-6	2020	Mechanistically, DON exposure induced the activation of Wnt/beta-catenin signaling.	deoxynivalenol	17-20	catenin beta 1	Homo sapiens	60-72
31808557-8	2020	Notably, supplementation with selenium reduced DON-induced activation of the Wnt/beta-catenin pathway.	deoxynivalenol	47-50	catenin beta 1	Homo sapiens	81-93
31808557-10	2020	These findings confirm that DON may facilitate the development of KBD by inducing cell injury, inhibiting matrix synthesis, and increasing cellular catabolism by activating the Wnt/beta-catenin signaling, which were partially reversed by selenium supplementation.	deoxynivalenol	28-31	catenin beta 1	Homo sapiens	181-193
31992135-0	2020	Deoxynivalenol globally affects the selection of 3" splice sites in human cells by suppressing the splicing factors, U2AF1 and SF1.	deoxynivalenol	0-14	U2 small nuclear RNA auxiliary factor 1	Homo sapiens	117-122
32056954-8	2020	The limit of detection attained is 2.11 pg mL-1 and displays high stability whereby it retains 30.65% of activity after 48 h. The designed INFGN demonstrates remarkable discrimination of DON against similar mycotoxins (zearalenone and ochratoxin A).	deoxynivalenol	187-190	L1 cell adhesion molecule	Mus musculus	43-47
32208605-8	2020	Additionally, the NOD2/caspase-12 pathway participated in the alleviation of SB on DON-induced diminished HDP expression.	deoxynivalenol	83-86	nucleotide binding oligomerization domain containing 2	Sus scrofa	18-22
31992135-0	2020	Deoxynivalenol globally affects the selection of 3" splice sites in human cells by suppressing the splicing factors, U2AF1 and SF1.	deoxynivalenol	0-14	splicing factor 1	Homo sapiens	127-130
31992135-7	2020	Among these DON-induced changes in alternative splicing, the expression levels of two related splicing factors, SF1 and U2AF1, which are essential for 3" splice site recognitions, were strongly suppressed.	deoxynivalenol	12-15	splicing factor 1	Homo sapiens	112-115
31992135-7	2020	Among these DON-induced changes in alternative splicing, the expression levels of two related splicing factors, SF1 and U2AF1, which are essential for 3" splice site recognitions, were strongly suppressed.	deoxynivalenol	12-15	U2 small nuclear RNA auxiliary factor 1	Homo sapiens	120-125
31992135-9	2020	Moreover, SF1 was required for human cell proliferation in DON exposure, and the restoration of SF1 expression partially reinstated the proliferation potential for DON-treated cells.	deoxynivalenol	59-62	splicing factor 1	Homo sapiens	10-13
31992135-9	2020	Moreover, SF1 was required for human cell proliferation in DON exposure, and the restoration of SF1 expression partially reinstated the proliferation potential for DON-treated cells.	deoxynivalenol	164-167	splicing factor 1	Homo sapiens	96-99
32197345-7	2020	After DON exposure, the expression of cytokine genes decreased, with the exception of IL-1beta and IL-8, which increased after 18 h exposure to 100 ng/mL of DON.	deoxynivalenol	157-160	interleukin 1 alpha	Sus scrofa	86-94
32197345-7	2020	After DON exposure, the expression of cytokine genes decreased, with the exception of IL-1beta and IL-8, which increased after 18 h exposure to 100 ng/mL of DON.	deoxynivalenol	157-160	C-X-C motif chemokine ligand 8	Sus scrofa	99-103
32197345-8	2020	Among lymphocyte subpopulations, helper T-cells and gammadelta T-cells exhibiting lower production of IL-17, IFNgamma and TNFalpha were most affected by DON exposure (10 ng/mL).	deoxynivalenol	153-156	interleukin-17A	Sus scrofa	102-107
32197345-8	2020	Among lymphocyte subpopulations, helper T-cells and gammadelta T-cells exhibiting lower production of IL-17, IFNgamma and TNFalpha were most affected by DON exposure (10 ng/mL).	deoxynivalenol	153-156	interferon gamma	Sus scrofa	109-117
32197345-8	2020	Among lymphocyte subpopulations, helper T-cells and gammadelta T-cells exhibiting lower production of IL-17, IFNgamma and TNFalpha were most affected by DON exposure (10 ng/mL).	deoxynivalenol	153-156	tumor necrosis factor	Sus scrofa	122-130
32183451-7	2020	The results showed that DON increased the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine (Cr), decreased those of immunoglobulin G (IgG) and IgM in serum, and resulted in severe pathological damage of the liver, kidney, and spleen.	deoxynivalenol	24-27	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	52-78
31863870-9	2020	Our results provide a comprehensive understanding of the toxic mechanism of T-2 toxin and DON on human chondrocytes and suggest that although T-2 toxin and DON showed some similar toxic mechanisms in human chondrocytes, they also had different toxic characteristics.	deoxynivalenol	90-93	solute carrier family 25 member 5	Homo sapiens	142-145
31863870-9	2020	Our results provide a comprehensive understanding of the toxic mechanism of T-2 toxin and DON on human chondrocytes and suggest that although T-2 toxin and DON showed some similar toxic mechanisms in human chondrocytes, they also had different toxic characteristics.	deoxynivalenol	156-159	solute carrier family 25 member 5	Homo sapiens	76-79
32183451-7	2020	The results showed that DON increased the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine (Cr), decreased those of immunoglobulin G (IgG) and IgM in serum, and resulted in severe pathological damage of the liver, kidney, and spleen.	deoxynivalenol	24-27	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	80-83
32183451-7	2020	The results showed that DON increased the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine (Cr), decreased those of immunoglobulin G (IgG) and IgM in serum, and resulted in severe pathological damage of the liver, kidney, and spleen.	deoxynivalenol	24-27	glutamic pyruvic transaminase, soluble	Mus musculus	86-110
32183451-7	2020	The results showed that DON increased the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine (Cr), decreased those of immunoglobulin G (IgG) and IgM in serum, and resulted in severe pathological damage of the liver, kidney, and spleen.	deoxynivalenol	24-27	glutamic pyruvic transaminase, soluble	Mus musculus	112-115
32102452-4	2020	An indirect preliminary method was used based on the cleavage of deoxynivalenol glucuronides through the use of enzymes (beta-glucuronidase) and subsequent determination of "total deoxynivalenol" (sum of free and released mycotoxins by hydrolysis).	deoxynivalenol	65-79	glucuronidase beta	Homo sapiens	121-139
32183221-0	2020	Deoxynivalenol Induces Inflammation in IPEC-J2 Cells by Activating P38 Mapk And Erk1/2.	deoxynivalenol	0-14	mitogen-activated protein kinase 3	Sus scrofa	80-86
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	interleukin 1 alpha	Sus scrofa	14-18
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	interleukin 6	Sus scrofa	20-23
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	tumor necrosis factor	Sus scrofa	28-37
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	mitogen-activated protein kinase 3	Sus scrofa	87-132
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Sus scrofa	143-164
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Sus scrofa	166-169
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	50-53	mitogen-activated protein kinase 3	Sus scrofa	87-132
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	50-53	mitogen-activated protein kinase 3	Sus scrofa	134-140
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	50-53	mitogen-activated protein kinase 8	Sus scrofa	143-164
32183221-6	2020	DON increased IL1A, IL6 and TNF-alpha release and DON activated the phosphorylation of extracellular signal-regulated kinase-1 and-2 (ERK1/2), JUN N-terminal kinase (JNK) and p38 MAPK.	deoxynivalenol	50-53	mitogen-activated protein kinase 8	Sus scrofa	166-169
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 6	Sus scrofa	39-42
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	tumor necrosis factor	Sus scrofa	44-53
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	C-X-C motif chemokine 2	Sus scrofa	55-60
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	C-X-C motif chemokine ligand 8	Sus scrofa	62-67
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 12A	Sus scrofa	69-74
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 1 alpha	Sus scrofa	76-80
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	C-C motif chemokine ligand 20	Sus scrofa	82-87
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	C-C motif chemokine 4	Sus scrofa	89-93
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 15	Sus scrofa	98-102
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	mitogen-activated protein kinase 3	Sus scrofa	124-130
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 15	Sus scrofa	179-183
32183221-7	2020	A p38 inhibitor attenuated DON-induced IL6, TNF-alpha, CXCL2, CXCL8, IL12A, IL1A, CCL20, CCL4 and IL15 production, while an ERK1/2 inhibitor had only a small inhibitory effect on IL15 and IL6.	deoxynivalenol	27-30	interleukin 6	Sus scrofa	188-191
32183221-9	2020	These data demonstrate that DON induces proinflammatory factor production in IPEC-J2 cells by activating p38 and ERK1/2.	deoxynivalenol	28-31	mitogen-activated protein kinase 3	Sus scrofa	113-119
32065293-9	2020	Notably, DON-induced interleukin-8 transcription and secretion were diminished by the presence of 10 and 25 ng/mL CER after short-term (5 h) incubation, indicating immunosuppressive properties.	deoxynivalenol	9-12	C-X-C motif chemokine ligand 8	Homo sapiens	21-34
31932723-5	2020	Notably, SPG is able to transform acetylated deoxynivalenol, the prevalent mycotoxin contaminating cereals and foods.	deoxynivalenol	45-59	SPG16	Homo sapiens	9-12
31877851-0	2019	Development of a Direct Competitive ELISA Kit for Detecting Deoxynivalenol Contamination in Wheat.	deoxynivalenol	60-74	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	42-45
31848666-0	2020	Heme oxygenase-1 regulates autophagy through carbon-oxygen to alleviate deoxynivalenol-induced hepatic damage.	deoxynivalenol	72-86	heme oxygenase 1	Homo sapiens	0-16
31848666-3	2020	In the present study, we demonstrated for the first time that estimated human daily DON exposure (25 mug/kg bw) for 30 and 90 days caused low-grade inflammatory infiltration around hepatic centrilobular veins, elevated systemic IL-1beta, IL-6 and TNF-alpha and impaired liver function evidenced by increased serum ALT activity.	deoxynivalenol	84-87	interleukin 1 alpha	Homo sapiens	228-236
31848666-3	2020	In the present study, we demonstrated for the first time that estimated human daily DON exposure (25 mug/kg bw) for 30 and 90 days caused low-grade inflammatory infiltration around hepatic centrilobular veins, elevated systemic IL-1beta, IL-6 and TNF-alpha and impaired liver function evidenced by increased serum ALT activity.	deoxynivalenol	84-87	interleukin 6	Homo sapiens	238-242
31848666-3	2020	In the present study, we demonstrated for the first time that estimated human daily DON exposure (25 mug/kg bw) for 30 and 90 days caused low-grade inflammatory infiltration around hepatic centrilobular veins, elevated systemic IL-1beta, IL-6 and TNF-alpha and impaired liver function evidenced by increased serum ALT activity.	deoxynivalenol	84-87	tumor necrosis factor	Homo sapiens	247-256
31848666-4	2020	At the molecular level, expressions of autophagy-related proteins as well as Cleaved Caspase-3 and Cleaved Caspase-7 were upregulated during DON exposure, which indicated the activation of autophagy and apoptosis.	deoxynivalenol	141-144	caspase 3	Homo sapiens	85-94
31848666-4	2020	At the molecular level, expressions of autophagy-related proteins as well as Cleaved Caspase-3 and Cleaved Caspase-7 were upregulated during DON exposure, which indicated the activation of autophagy and apoptosis.	deoxynivalenol	141-144	caspase 7	Homo sapiens	107-116
31848666-5	2020	Importantly, AAV-mediated liver-specific overexpression of HO-1 reversed DON-induced liver damages, upregulated autophagy and attenuated apoptosis in liver, while AAV-mediated HO-1 silence aggravated DON-induced liver damages, inhibited autophagy and increased apoptosis.	deoxynivalenol	73-76	heme oxygenase 1	Homo sapiens	59-63
31848666-5	2020	Importantly, AAV-mediated liver-specific overexpression of HO-1 reversed DON-induced liver damages, upregulated autophagy and attenuated apoptosis in liver, while AAV-mediated HO-1 silence aggravated DON-induced liver damages, inhibited autophagy and increased apoptosis.	deoxynivalenol	200-203	heme oxygenase 1	Homo sapiens	59-63
31848666-5	2020	Importantly, AAV-mediated liver-specific overexpression of HO-1 reversed DON-induced liver damages, upregulated autophagy and attenuated apoptosis in liver, while AAV-mediated HO-1 silence aggravated DON-induced liver damages, inhibited autophagy and increased apoptosis.	deoxynivalenol	200-203	heme oxygenase 1	Homo sapiens	176-180
31848666-8	2020	Therefore, we suppose that HO-1 might be a potential research target to protect human and animal from liver injuries induced by low dose of DON exposure.	deoxynivalenol	140-143	heme oxygenase 1	Homo sapiens	27-31
31861743-6	2019	The 5 muM DON treatment also downregulated Bcl-2 expression and upregulated caspase-3 and Bax expression.	deoxynivalenol	10-13	apoptosis regulator Bcl-2	Sus scrofa	43-48
31861743-6	2019	The 5 muM DON treatment also downregulated Bcl-2 expression and upregulated caspase-3 and Bax expression.	deoxynivalenol	10-13	caspase 3	Sus scrofa	76-85
31861743-6	2019	The 5 muM DON treatment also downregulated Bcl-2 expression and upregulated caspase-3 and Bax expression.	deoxynivalenol	10-13	apoptosis regulator BAX	Sus scrofa	90-93
31877851-1	2019	This study was conducted to develop a self-assembled direct competitive enzyme-linked immunosorbent assay (dcELISA) kit for the detection of deoxynivalenol (DON) in food and feed grains.	deoxynivalenol	141-155	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	116-119
31877851-1	2019	This study was conducted to develop a self-assembled direct competitive enzyme-linked immunosorbent assay (dcELISA) kit for the detection of deoxynivalenol (DON) in food and feed grains.	deoxynivalenol	157-160	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	116-119
31877851-4	2019	The minimum detection limit of DON with the kit was 0.62 ng/mL, the linear range was from 1.0 to 113.24 ng/mL and the half-maximal inhibition concentration (IC50) was 6.61 ng/mL in the working buffer; there was a limit of detection (LOD) of 62 ng/g, and the detection range was from 100 to 11324 ng/g in authentic agricultural samples.	deoxynivalenol	31-34	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	44-47
31877851-10	2019	These tests showed that the dcELISA kit had good performance and met relevant technical requirements, and it had the characteristics of accuracy, reliability, convenience and high-throughput screening for DON detection.	deoxynivalenol	205-208	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	36-39
31877851-11	2019	Therefore, the developed kit is suitable for rapid screening of DON in marketed products.	deoxynivalenol	64-67	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	25-28
31731782-4	2019	Piglets exposed to DON had lower mRNA expression of TFF1, TFF2, TFF3, as well as Claudin-4 in the intestine (P &lt; 0.05).	deoxynivalenol	19-22	trefoil factor 2	Sus scrofa	58-62
31844123-9	2019	In addition, Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion.	deoxynivalenol	33-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-61
31731782-4	2019	Piglets exposed to DON had lower mRNA expression of TFF1, TFF2, TFF3, as well as Claudin-4 in the intestine (P &lt; 0.05).	deoxynivalenol	19-22	trefoil factor 1	Sus scrofa	52-56
31888297-5	2019	With the increase of DON concentration in the culture medium, the action of diamine oxidase (DAO) in the culture supernatant also increased.	deoxynivalenol	21-24	amine oxidase copper containing 1	Sus scrofa	76-91
31888297-5	2019	With the increase of DON concentration in the culture medium, the action of diamine oxidase (DAO) in the culture supernatant also increased.	deoxynivalenol	21-24	amine oxidase copper containing 1	Sus scrofa	93-96
31888297-6	2019	The activities of IL-6, TNF-alpha, and NO in the cells were increased with the increasing DON concentration.	deoxynivalenol	90-93	interleukin 6	Sus scrofa	18-22
31888297-6	2019	The activities of IL-6, TNF-alpha, and NO in the cells were increased with the increasing DON concentration.	deoxynivalenol	90-93	tumor necrosis factor	Sus scrofa	24-33
31888297-8	2019	The mRNA relative expression of NF-kappaB p65, IKKalpha, and IKKbeta were upregulated with the increasing of DON concentration, while the relative expression of IkappaB-alpha mRNA was downregulated.	deoxynivalenol	109-112	component of inhibitor of nuclear factor kappa B kinase complex	Sus scrofa	47-55
31888297-8	2019	The mRNA relative expression of NF-kappaB p65, IKKalpha, and IKKbeta were upregulated with the increasing of DON concentration, while the relative expression of IkappaB-alpha mRNA was downregulated.	deoxynivalenol	109-112	NFKB inhibitor alpha	Sus scrofa	161-174
31731782-4	2019	Piglets exposed to DON had lower mRNA expression of TFF1, TFF2, TFF3, as well as Claudin-4 in the intestine (P &lt; 0.05).	deoxynivalenol	19-22	trefoil factor 3	Sus scrofa	64-68
31731782-4	2019	Piglets exposed to DON had lower mRNA expression of TFF1, TFF2, TFF3, as well as Claudin-4 in the intestine (P &lt; 0.05).	deoxynivalenol	19-22	claudin 4	Sus scrofa	81-90
31731782-5	2019	Dietary DON exposure decreased the protein levels of TFF2 and TFF3 in the jejunum as demonstrated by western blot and immunohistochemistry.	deoxynivalenol	8-11	trefoil factor 2	Sus scrofa	53-57
31731782-5	2019	Dietary DON exposure decreased the protein levels of TFF2 and TFF3 in the jejunum as demonstrated by western blot and immunohistochemistry.	deoxynivalenol	8-11	trefoil factor 3	Sus scrofa	62-66
31731782-6	2019	In intestinal porcine epithelial cells (IPEC-J2), DON depressed the mRNA expression of TFF2, TFF3, and Claudin-4.	deoxynivalenol	50-53	trefoil factor 2	Sus scrofa	87-91
31731782-6	2019	In intestinal porcine epithelial cells (IPEC-J2), DON depressed the mRNA expression of TFF2, TFF3, and Claudin-4.	deoxynivalenol	50-53	trefoil factor 3	Sus scrofa	93-97
31731782-6	2019	In intestinal porcine epithelial cells (IPEC-J2), DON depressed the mRNA expression of TFF2, TFF3, and Claudin-4.	deoxynivalenol	50-53	claudin 4	Sus scrofa	103-112
31731782-7	2019	Overexpression of sterile alpha motif (SAM) pointed domain E26 transformation-specific (ETS) factor (SPDEF) was found to attenuate DON-induced suppression of TFFs in IPEC-J2 cells.	deoxynivalenol	131-134	SAM pointed domain containing ETS transcription factor	Sus scrofa	101-106
31521211-8	2019	Down-regulation of two TaSnRK1alphas homoeolog groups using virus induced gene silencing (VIGS) increased the DON-induced damage of wheat spikelets.	deoxynivalenol	110-113	snRK1	Triticum aestivum	23-30
31423645-5	2019	DON at 0.25 mug/ml increased lactate dehydrogenase (LDH) leakage (p &lt; .05); decreased glutathione (GSH) levels (p &lt; .001), total superoxide dismutase (T-SOD) activity and total antioxidant capacity (T-AOC; p &lt; .01); and increased malondialdehyde (MDA) concentration (p &lt; .01) in MAC-T cells after 24 hr of exposure.	deoxynivalenol	0-3	LDH	Bos taurus	29-50
31423645-5	2019	DON at 0.25 mug/ml increased lactate dehydrogenase (LDH) leakage (p &lt; .05); decreased glutathione (GSH) levels (p &lt; .001), total superoxide dismutase (T-SOD) activity and total antioxidant capacity (T-AOC; p &lt; .01); and increased malondialdehyde (MDA) concentration (p &lt; .01) in MAC-T cells after 24 hr of exposure.	deoxynivalenol	0-3	LDH	Bos taurus	52-55
31739564-7	2019	The distribution and optical density (OD) values of zonula occludens 1 (ZO-1) protein in the intestinal tissues of DON-treated groups were decreased.	deoxynivalenol	115-118	tight junction protein 1	Homo sapiens	52-70
31739564-7	2019	The distribution and optical density (OD) values of zonula occludens 1 (ZO-1) protein in the intestinal tissues of DON-treated groups were decreased.	deoxynivalenol	115-118	tight junction protein 1	Homo sapiens	72-76
31739564-8	2019	At higher DON dosage, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha mRNA levels were elevated in the intestinal tissues.	deoxynivalenol	10-13	interleukin 1 alpha	Homo sapiens	22-44
31739564-8	2019	At higher DON dosage, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha mRNA levels were elevated in the intestinal tissues.	deoxynivalenol	10-13	interleukin 6	Homo sapiens	46-50
31739564-8	2019	At higher DON dosage, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha mRNA levels were elevated in the intestinal tissues.	deoxynivalenol	10-13	tumor necrosis factor	Homo sapiens	56-83
31739564-9	2019	The mRNA and protein levels of NF-kappaB p65, IkappaB-alpha, IKKalpha/beta, iNOS, and COX-2 in the small intestinal mucosa were abnormally altered with an increase in DON concentration.	deoxynivalenol	167-170	RELA proto-oncogene, NF-kB subunit	Homo sapiens	31-44
31400600-10	2019	A decrease in E-cadherin expression was observed in rats exposed to the two contaminants alone or combined, whereas occludin expression only decreased in animals exposed to DON and DON+Cd.	deoxynivalenol	173-176	occludin	Rattus norvegicus	116-124
31304937-5	2019	When used for vomitoxin detection, the BCN-800-based electrochemical biosensor exhibits high sensitivity with a detection limit of 0.32 pg mL-1 and superior selectivity to other interfering agents.	deoxynivalenol	14-23	L1 cell adhesion molecule	Mus musculus	139-143
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	interleukin-1 beta	Sus scrofa	134-152
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	interleukin-1 beta	Sus scrofa	154-162
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	interleukin-6	Sus scrofa	190-203
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	interleukin-6	Sus scrofa	205-209
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	tumor necrosis factor	Sus scrofa	242-251
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	caspase 3	Sus scrofa	254-263
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	caspase 8	Sus scrofa	265-274
31108302-4	2019	Compared with the control group, DON treatment increased the expressions of genes associated with inflammation and apoptosis, such as interleukin-1 beta (IL-1beta), cyclooxgenase-2 (COX-2), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), caspase-3, caspase-8, caspase-9, and decreased the cell anti-oxidative status.	deoxynivalenol	33-36	caspase 9	Sus scrofa	276-285
31720552-0	2019	Deoxynivalenol-Induced Cytotoxicity and Apoptosis in IPEC-J2 Cells Through the Activation of Autophagy by Inhibiting PI3K-AKT-mTOR Signaling Pathway.	deoxynivalenol	0-14	AKT serine/threonine kinase 1	Sus scrofa	122-125
31720552-0	2019	Deoxynivalenol-Induced Cytotoxicity and Apoptosis in IPEC-J2 Cells Through the Activation of Autophagy by Inhibiting PI3K-AKT-mTOR Signaling Pathway.	deoxynivalenol	0-14	mechanistic target of rapamycin kinase	Sus scrofa	126-130
31532211-8	2019	In addition, DON-induced decreases in ISC activity were rescued Wnt/beta-catenin signaling reactivation by Met or HMB in vivo and ex vivo.	deoxynivalenol	13-16	catenin (cadherin associated protein), beta 1	Mus musculus	68-80
31532211-9	2019	Collectively, our findings reveal that Met and HMB alleviated DON-induced intestinal injury by improving ISC expansion and reactivating Wnt/beta-catenin signaling.	deoxynivalenol	62-65	catenin (cadherin associated protein), beta 1	Mus musculus	140-152
31202940-0	2019	Hydrolyzed wheat gluten alleviates deoxynivalenol-induced intestinal injury by promoting intestinal stem cell proliferation and differentiation via upregulation of Wnt/beta-catenin signaling in mice.	deoxynivalenol	35-49	catenin (cadherin associated protein), beta 1	Mus musculus	168-180
31202940-8	2019	The DON-induced decrease in Wnt/beta-catenin activity, the expression of Ki67, PCNA and KRT20 were rescued by HWG in the jejunum, crypt and enteroid, as well as the number of goblet cells and Paneth cells.	deoxynivalenol	4-7	catenin (cadherin associated protein), beta 1	Mus musculus	32-44
31202940-8	2019	The DON-induced decrease in Wnt/beta-catenin activity, the expression of Ki67, PCNA and KRT20 were rescued by HWG in the jejunum, crypt and enteroid, as well as the number of goblet cells and Paneth cells.	deoxynivalenol	4-7	antigen identified by monoclonal antibody Ki 67	Mus musculus	73-77
31202940-8	2019	The DON-induced decrease in Wnt/beta-catenin activity, the expression of Ki67, PCNA and KRT20 were rescued by HWG in the jejunum, crypt and enteroid, as well as the number of goblet cells and Paneth cells.	deoxynivalenol	4-7	proliferating cell nuclear antigen	Mus musculus	79-83
31202940-8	2019	The DON-induced decrease in Wnt/beta-catenin activity, the expression of Ki67, PCNA and KRT20 were rescued by HWG in the jejunum, crypt and enteroid, as well as the number of goblet cells and Paneth cells.	deoxynivalenol	4-7	keratin 20	Mus musculus	88-93
31202940-10	2019	In conclusion, HWG alleviates DON-induced intestinal injury by enhancing ISC proliferation and differentiation in a Wnt/beta-catenin-dependent manner.	deoxynivalenol	30-33	catenin (cadherin associated protein), beta 1	Mus musculus	120-132
31075268-0	2019	Deoxynivalenol induces inhibition of cell proliferation via the Wnt/beta-catenin signaling pathway.	deoxynivalenol	0-14	catenin beta 1	Homo sapiens	68-80
31075268-4	2019	Here, we identified beta-catenin, the key signal transducer of the Wnt cascade, as a novel target of DON by quantitative real-time PCR and Western blot analysis in human embryonic kidney 293T and colorectal SW480 cells treated with DON at half IC50 (50 ng/mL for HEK293T and 1 mug/mL for SW480).	deoxynivalenol	101-104	catenin beta 1	Homo sapiens	20-32
31075268-4	2019	Here, we identified beta-catenin, the key signal transducer of the Wnt cascade, as a novel target of DON by quantitative real-time PCR and Western blot analysis in human embryonic kidney 293T and colorectal SW480 cells treated with DON at half IC50 (50 ng/mL for HEK293T and 1 mug/mL for SW480).	deoxynivalenol	232-235	catenin beta 1	Homo sapiens	20-32
31075268-6	2019	Moreover, we found that the beta-catenin-dependent canonical Wnt signaling pathway, which regulates many biological processes during embryonic development and adult tissue homeostasis, was involved in DON-induced inhibition of cell proliferation.	deoxynivalenol	201-204	catenin beta 1	Homo sapiens	28-40
31075268-7	2019	Then, we determined that the beta-catenin/c-Myc axis was essential for this process, as the DON-induced inhibition of cell proliferation was efficiently rescued by restoration of beta-catenin or c-Myc levels.	deoxynivalenol	92-95	catenin beta 1	Homo sapiens	29-41
31075268-7	2019	Then, we determined that the beta-catenin/c-Myc axis was essential for this process, as the DON-induced inhibition of cell proliferation was efficiently rescued by restoration of beta-catenin or c-Myc levels.	deoxynivalenol	92-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	42-47
31075268-7	2019	Then, we determined that the beta-catenin/c-Myc axis was essential for this process, as the DON-induced inhibition of cell proliferation was efficiently rescued by restoration of beta-catenin or c-Myc levels.	deoxynivalenol	92-95	catenin beta 1	Homo sapiens	179-191
31075268-7	2019	Then, we determined that the beta-catenin/c-Myc axis was essential for this process, as the DON-induced inhibition of cell proliferation was efficiently rescued by restoration of beta-catenin or c-Myc levels.	deoxynivalenol	92-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	195-200
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	133-136
31034930-0	2019	Heme oxygenase-1 attenuates low-dose of deoxynivalenol-induced liver inflammation potentially associating with microbiota.	deoxynivalenol	40-54	heme oxygenase 1	Mus musculus	0-16
31034930-9	2019	Importantly, liver-specific knockdown of HO-1 caused more severe pathological alterations in liver after DON administration and overexpression of HO-1 protected against DON-induced liver inflammation.	deoxynivalenol	105-108	heme oxygenase 1	Mus musculus	41-45
31034930-9	2019	Importantly, liver-specific knockdown of HO-1 caused more severe pathological alterations in liver after DON administration and overexpression of HO-1 protected against DON-induced liver inflammation.	deoxynivalenol	169-172	heme oxygenase 1	Mus musculus	146-150
31034930-12	2019	HO-1 could attenuate DON-induced inflammation in liver, where gut microbiota may play an important role.	deoxynivalenol	21-24	heme oxygenase 1	Mus musculus	0-4
31034930-13	2019	HO-1 also could be a potential protective factor between homeostasis of gut microbiota and DON-induced hepatotoxicity in animal models.	deoxynivalenol	91-94	heme oxygenase 1	Mus musculus	0-4
31338007-0	2019	Deoxynivalenol enhances IL-1ss expression in BV2 microglial cells through activation of the NF-?B pathway and the ASC/NLRP3 inflammasome.	deoxynivalenol	0-14	steroid sulfatase	Mus musculus	114-117
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-0	2019	Deoxynivalenol enhances IL-1ss expression in BV2 microglial cells through activation of the NF-?B pathway and the ASC/NLRP3 inflammasome.	deoxynivalenol	0-14	NLR family, pyrin domain containing 3	Mus musculus	118-123
31338007-2	2019	However, it is unknown whether DON stimulates IL-1beta expression through the activation of the nuclear factor-kappaB (NF-kappaB) pathway and the ACS/NLRP3 inflammasome.	deoxynivalenol	31-34	interleukin 1 beta	Mus musculus	46-54
31338007-4	2019	DON also upregulated IL-1beta expression from between 0.5 h and 6 h after treatment, and enhanced the nuclear localization of the NF-kappaB subunits, p50 and p65.	deoxynivalenol	0-3	interleukin 1 beta	Mus musculus	21-29
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	182-190
31338007-4	2019	DON also upregulated IL-1beta expression from between 0.5 h and 6 h after treatment, and enhanced the nuclear localization of the NF-kappaB subunits, p50 and p65.	deoxynivalenol	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	150-153
31338007-4	2019	DON also upregulated IL-1beta expression from between 0.5 h and 6 h after treatment, and enhanced the nuclear localization of the NF-kappaB subunits, p50 and p65.	deoxynivalenol	0-3	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	158-161
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	210-218
31338007-5	2019	NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB.	deoxynivalenol	90-93	interleukin 1 beta	Mus musculus	102-110
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	210-218
31338007-5	2019	NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB.	deoxynivalenol	90-93	interleukin 1 beta	Mus musculus	158-166
31338007-5	2019	NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB.	deoxynivalenol	144-147	interleukin 1 beta	Mus musculus	102-110
31338007-5	2019	NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB.	deoxynivalenol	144-147	interleukin 1 beta	Mus musculus	158-166
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	78-81	interleukin 1 beta	Mus musculus	33-41
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	78-81	caspase 1	Mus musculus	182-191
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	128-131	interleukin 1 beta	Mus musculus	33-41
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	128-131	caspase 1	Mus musculus	97-106
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	128-131	interleukin 1 beta	Mus musculus	141-149
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	133-136
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	128-131	caspase 1	Mus musculus	182-191
31338007-6	2019	In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form.	deoxynivalenol	128-131	interleukin 1 beta	Mus musculus	141-149
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	steroid sulfatase	Mus musculus	46-49
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	NLR family, pyrin domain containing 3	Mus musculus	54-59
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	46-49
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	steroid sulfatase	Mus musculus	133-136
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	133-136
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	interleukin 1 beta	Mus musculus	182-190
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	interleukin 1 beta	Mus musculus	210-218
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	interleukin 1 beta	Mus musculus	210-218
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	182-190
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	steroid sulfatase	Mus musculus	133-136
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	88-91	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	46-49
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	210-218
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	interleukin 1 beta	Mus musculus	210-218
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	steroid sulfatase	Mus musculus	133-136
31338007-7	2019	Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome.	deoxynivalenol	170-173	NLR family, pyrin domain containing 3	Mus musculus	141-146
31338007-8	2019	Collectively, the data suggested that DON induced IL-1beta expression in BV2 microglial cells through the activation of the NF-kappaB signaling pathway and the subsequent upregulation of the ASC/NLRP3 inflammasome.	deoxynivalenol	38-41	interleukin 1 beta	Mus musculus	50-58
31338007-8	2019	Collectively, the data suggested that DON induced IL-1beta expression in BV2 microglial cells through the activation of the NF-kappaB signaling pathway and the subsequent upregulation of the ASC/NLRP3 inflammasome.	deoxynivalenol	38-41	steroid sulfatase	Mus musculus	191-194
31338007-8	2019	Collectively, the data suggested that DON induced IL-1beta expression in BV2 microglial cells through the activation of the NF-kappaB signaling pathway and the subsequent upregulation of the ASC/NLRP3 inflammasome.	deoxynivalenol	38-41	NLR family, pyrin domain containing 3	Mus musculus	195-200
31338007-9	2019	Therefore, DON may induce inflammatory diseases or disorders by activating IL-1beta expression.	deoxynivalenol	11-14	interleukin 1 beta	Mus musculus	75-83
30422742-5	2019	In this work, we tested whether DON detoxification by UGT could confer to wheat a broad-spectrum resistance against Fusarium graminearum and F. culmorum.	deoxynivalenol	32-35	UDP-glycosyltransferase 73C10	Triticum aestivum	54-57
31083547-6	2019	The effects of DON application in PCa cells are influenced by the mitogen-activated protein kinase (MAPK) and NFKappaB- HIF-1alpha signaling pathways.	deoxynivalenol	15-18	hypoxia-inducible factor 1-alpha	Cricetulus griseus	120-130
30977367-5	2019	Exposure to DON increased the serum concentrations of glucagon-like peptide-1 and peptide YY but reduced the levels of serum growth hormone and insulin-like growth factor 1.	deoxynivalenol	12-15	glucagon	Homo sapiens	54-77
30977367-5	2019	Exposure to DON increased the serum concentrations of glucagon-like peptide-1 and peptide YY but reduced the levels of serum growth hormone and insulin-like growth factor 1.	deoxynivalenol	12-15	peptide YY	Homo sapiens	82-92
30422742-10	2019	The transgenic bread wheat exhibited a UGT dose-dependent efficacy of DON detoxification.	deoxynivalenol	70-73	UDP-glycosyltransferase 73C10	Triticum aestivum	39-42
30955803-0	2019	Protecting intestinal epithelial cells against deoxynivalenol and E. coli damage by recombinant porcine IL-22.	deoxynivalenol	47-61	interleukin 22	Sus scrofa	104-109
30690062-0	2019	Acute exposure to deoxynivalenol inhibits porcine enteroid activity via suppression of the Wnt/beta-catenin pathway.	deoxynivalenol	18-32	catenin beta 1	Homo sapiens	95-107
30690062-4	2019	Here, we show that intestinal epithelial cell activity, B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi1) protein level, and Wnt/beta-catenin pathway activity were suppressed with acute expose to deoxynivalenol.	deoxynivalenol	216-230	catenin beta 1	Homo sapiens	149-161
30690062-8	2019	Simultaneously, protein levels of beta-catenin and leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) in enteroids were reduced by deoxynivalenol exposure.	deoxynivalenol	147-161	catenin beta 1	Homo sapiens	34-46
30690062-8	2019	Simultaneously, protein levels of beta-catenin and leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) in enteroids were reduced by deoxynivalenol exposure.	deoxynivalenol	147-161	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	51-110
30690062-8	2019	Simultaneously, protein levels of beta-catenin and leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) in enteroids were reduced by deoxynivalenol exposure.	deoxynivalenol	147-161	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	112-116
30690062-9	2019	In conclusion, we established a reliable culture system for porcine enteroids and demonstrated for the first time that the activity of ISCs and the Wnt/beta-catenin pathway is sensitively suppressed by acute deoxynivalenol exposure.	deoxynivalenol	208-222	catenin beta 1	Homo sapiens	152-164
30854615-4	2019	Results showed that very low doses of DON (nanomolar range) inhibit the secretion of TFFs by human goblet cells (IC50 of 361, 387 and 243 nM for TFF1, 2 and 3, respectively) and prevent wound healing.	deoxynivalenol	38-41	trefoil factor 1	Homo sapiens	145-158
30854615-7	2019	Finally, the use of specific inhibitors of signal pathways demonstrated that DON-mediated suppression of TFFs expression mainly involved Protein Kinase R and the MAP kinases (MAPK) p38 and ERK1/2.	deoxynivalenol	77-80	mitogen-activated protein kinase 3	Homo sapiens	175-179
30854615-7	2019	Finally, the use of specific inhibitors of signal pathways demonstrated that DON-mediated suppression of TFFs expression mainly involved Protein Kinase R and the MAP kinases (MAPK) p38 and ERK1/2.	deoxynivalenol	77-80	mitogen-activated protein kinase 1	Homo sapiens	181-184
30854615-7	2019	Finally, the use of specific inhibitors of signal pathways demonstrated that DON-mediated suppression of TFFs expression mainly involved Protein Kinase R and the MAP kinases (MAPK) p38 and ERK1/2.	deoxynivalenol	77-80	mitogen-activated protein kinase 3	Homo sapiens	189-195
30955803-6	2019	Furthermore, rIL-22 reversed apoptosis induced by deoxynivalenol (DON) and played a vital part in repairing the intestinal injury.	deoxynivalenol	66-69	interleukin 22	Rattus norvegicus	13-19
30955803-8	2019	This study provided a theoretical basis for curing intestinal inflammation caused by ETEC infection and epithelial apoptosis induced by DON with rIL-22 in pigs.	deoxynivalenol	136-139	interleukin 22	Rattus norvegicus	145-151
30955803-6	2019	Furthermore, rIL-22 reversed apoptosis induced by deoxynivalenol (DON) and played a vital part in repairing the intestinal injury.	deoxynivalenol	50-64	interleukin 22	Rattus norvegicus	13-19
30707021-12	2019	Furthermore, DON upregulated the expression of stress-induced JNK/c-Jun signaling pathway proteins as well as JNK/c-Jun phosphorylation proteins.	deoxynivalenol	13-16	mitogen-activated protein kinase 8	Mus musculus	62-65
30707021-14	2019	These results suggest that DON exposure can cause sperm damage, oxidative stress, testicular apoptosis, and phosphorylation of JNK/c-Jun signaling pathway.	deoxynivalenol	27-30	mitogen-activated protein kinase 8	Mus musculus	127-130
30826469-0	2019	Deoxynivalenol-induced oxidative stress and Nrf2 translocation in maternal liver on gestation day 12.5 d and 18.5 d. Deoxynivalenol (DON) contamination is indicated as a worldwide problem since it causes economic losses for the grain and is a potential threat to both animal and human health.	deoxynivalenol	117-131	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48
30826469-0	2019	Deoxynivalenol-induced oxidative stress and Nrf2 translocation in maternal liver on gestation day 12.5 d and 18.5 d. Deoxynivalenol (DON) contamination is indicated as a worldwide problem since it causes economic losses for the grain and is a potential threat to both animal and human health.	deoxynivalenol	133-136	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48
30826469-1	2019	This study concentrated on DON-induced oxidative damage and the accompanying nuclear factor erythroid 2-related factor 2 (Nrf2) translocation during DON-induced maternal hepatotoxicity.	deoxynivalenol	149-152	NFE2 like bZIP transcription factor 2	Homo sapiens	77-120
30826469-1	2019	This study concentrated on DON-induced oxidative damage and the accompanying nuclear factor erythroid 2-related factor 2 (Nrf2) translocation during DON-induced maternal hepatotoxicity.	deoxynivalenol	149-152	NFE2 like bZIP transcription factor 2	Homo sapiens	122-126
30826469-3	2019	DON slightly increased the levels of ALT and AST in GD12.5 d instead of GD18.5 d. Oxidative stress and anti-oxidization system were both found to be activated in the experiment which marked by ROS, MDA and GSH increasing, especially on GD12.5 d. The levels of HO-1 were significantly increased by DON exposure at different two time points.	deoxynivalenol	0-3	solute carrier family 17 member 5	Homo sapiens	45-48
30826469-3	2019	DON slightly increased the levels of ALT and AST in GD12.5 d instead of GD18.5 d. Oxidative stress and anti-oxidization system were both found to be activated in the experiment which marked by ROS, MDA and GSH increasing, especially on GD12.5 d. The levels of HO-1 were significantly increased by DON exposure at different two time points.	deoxynivalenol	0-3	heme oxygenase 1	Homo sapiens	260-264
30826469-4	2019	Moreover, Nrf2 translocation appeared both in GD 12.5 d and GD 18.5 d. In conclusion, DON-induced ROS accumulation may cause maternal liver damage in the initial stages, but the related stimulation of Nrf2/HO-1 pathway improves the removal of ROS and decreases the level of oxidative stress thereby protecting the liver damage.	deoxynivalenol	86-89	NFE2 like bZIP transcription factor 2	Homo sapiens	10-14
30826469-4	2019	Moreover, Nrf2 translocation appeared both in GD 12.5 d and GD 18.5 d. In conclusion, DON-induced ROS accumulation may cause maternal liver damage in the initial stages, but the related stimulation of Nrf2/HO-1 pathway improves the removal of ROS and decreases the level of oxidative stress thereby protecting the liver damage.	deoxynivalenol	86-89	NFE2 like bZIP transcription factor 2	Homo sapiens	201-205
30826469-4	2019	Moreover, Nrf2 translocation appeared both in GD 12.5 d and GD 18.5 d. In conclusion, DON-induced ROS accumulation may cause maternal liver damage in the initial stages, but the related stimulation of Nrf2/HO-1 pathway improves the removal of ROS and decreases the level of oxidative stress thereby protecting the liver damage.	deoxynivalenol	86-89	heme oxygenase 1	Homo sapiens	206-210
30826469-5	2019	Therefore, upregulating the Nrf2-dependent response is one of the potential methods that protects maternal liver from DON-induced oxidative damage.	deoxynivalenol	118-121	NFE2 like bZIP transcription factor 2	Homo sapiens	28-32
30944693-0	2019	Toxicity of DON on GPx1-Overexpressed or Knockdown Porcine Splenic Lymphocytes In Vitro and Protective Effects of Sodium Selenite.	deoxynivalenol	12-15	glutathione peroxidase 1	Sus scrofa	19-23
30944693-6	2019	In order to explore the effect of the GPx1 gene on toxicity of DON, in this study, we overexpressed or knockdown GPx1 in porcine splenic lymphocytes, then added different concentrations of DON (0.1025, 0.205, 0.41, and 0.82 mug/mL) and sodium selenite (2 mumol/L) to the culture system.	deoxynivalenol	63-66	glutathione peroxidase 1	Sus scrofa	38-42
30944693-7	2019	Using various techniques, we detected antioxidant function, free radical content, cell apoptosis, and methylation-related gene expression to explore the effect of GPx1 expression on DON-induced cell damage.	deoxynivalenol	182-185	glutathione peroxidase 1	Sus scrofa	163-167
30944693-11	2019	(3) DON can cause oxidative damage, apoptosis, and methylation injury in GPx1-overexpressing or knockdown pig splenic lymphocytes in a concentration-dependent manner.	deoxynivalenol	4-7	glutathione peroxidase 1	Sus scrofa	73-77
30944693-12	2019	(4) Na2SeO3 (2 mumol/L) can antagonize the toxic effect of DON on GPx1-overexpressing or knockdown pig splenic lymphocytes.	deoxynivalenol	59-62	glutathione peroxidase 1	Sus scrofa	66-70
30707021-12	2019	Furthermore, DON upregulated the expression of stress-induced JNK/c-Jun signaling pathway proteins as well as JNK/c-Jun phosphorylation proteins.	deoxynivalenol	13-16	jun proto-oncogene	Mus musculus	66-71
30707021-12	2019	Furthermore, DON upregulated the expression of stress-induced JNK/c-Jun signaling pathway proteins as well as JNK/c-Jun phosphorylation proteins.	deoxynivalenol	13-16	mitogen-activated protein kinase 8	Mus musculus	110-113
30707021-12	2019	Furthermore, DON upregulated the expression of stress-induced JNK/c-Jun signaling pathway proteins as well as JNK/c-Jun phosphorylation proteins.	deoxynivalenol	13-16	jun proto-oncogene	Mus musculus	114-119
30707021-14	2019	These results suggest that DON exposure can cause sperm damage, oxidative stress, testicular apoptosis, and phosphorylation of JNK/c-Jun signaling pathway.	deoxynivalenol	27-30	jun proto-oncogene	Mus musculus	131-136
30707021-15	2019	The underlying mechanisms may be that DON induces sperm damage by exacerbating oxidative stress-mediated testicular apoptosis via JNK/c-Jun signaling pathway.	deoxynivalenol	38-41	mitogen-activated protein kinase 8	Mus musculus	130-133
30707021-15	2019	The underlying mechanisms may be that DON induces sperm damage by exacerbating oxidative stress-mediated testicular apoptosis via JNK/c-Jun signaling pathway.	deoxynivalenol	38-41	jun proto-oncogene	Mus musculus	134-139
30289512-3	2018	The present objective was to investigate the effect of increasing dietary DON concentrations on the relative expression of genes for tight junction proteins, mucins, toll-like receptors (TLR), and cytokines in duodenum and jejunum, jejunal mucosal permeability, as well as on alpha-1-acid glycoprotein and IgA in serum with or without an additional oral lipopolysaccharide (LPS) challenge.	deoxynivalenol	74-77	toll-like receptor 2 type-1	Gallus gallus	187-190
30619419-2	2018	The Bradi5g03300 UGT-encoding gene from the model plant Brachypodium distachyon was previously shown to confer tolerance to the mycotoxin deoxynivalenol (DON) through glucosylation into DON 3-O-glucose (D3G).	deoxynivalenol	138-152	UDP-glycosyltransferase 73C10	Triticum aestivum	17-20
30619419-2	2018	The Bradi5g03300 UGT-encoding gene from the model plant Brachypodium distachyon was previously shown to confer tolerance to the mycotoxin deoxynivalenol (DON) through glucosylation into DON 3-O-glucose (D3G).	deoxynivalenol	154-157	UDP-glycosyltransferase 73C10	Triticum aestivum	17-20
30619419-5	2018	We showed that this UGT-encoding gene was highly inducible upon infection by a DON-producing Fusarium graminearum strain while not induced upon infection by a strain unable to produce DON.	deoxynivalenol	79-82	UDP-glycosyltransferase 73C10	Triticum aestivum	20-23
30619419-5	2018	We showed that this UGT-encoding gene was highly inducible upon infection by a DON-producing Fusarium graminearum strain while not induced upon infection by a strain unable to produce DON.	deoxynivalenol	184-187	UDP-glycosyltransferase 73C10	Triticum aestivum	20-23
30619419-6	2018	Transformation of this wheat UGT-encoding gene into B. distachyon revealed its ability to confer FHB resistance and root tolerance to DON as well as to potentially conjugate DON into D3G in planta and its impact on total DON reduction.	deoxynivalenol	134-137	UDP-glycosyltransferase 73C10	Triticum aestivum	29-32
30619419-6	2018	Transformation of this wheat UGT-encoding gene into B. distachyon revealed its ability to confer FHB resistance and root tolerance to DON as well as to potentially conjugate DON into D3G in planta and its impact on total DON reduction.	deoxynivalenol	174-177	UDP-glycosyltransferase 73C10	Triticum aestivum	29-32
30619419-6	2018	Transformation of this wheat UGT-encoding gene into B. distachyon revealed its ability to confer FHB resistance and root tolerance to DON as well as to potentially conjugate DON into D3G in planta and its impact on total DON reduction.	deoxynivalenol	174-177	UDP-glycosyltransferase 73C10	Triticum aestivum	29-32
30518949-0	2018	Sodium selenite inhibits deoxynivalenol-induced injury in GPX1-knockdown porcine splenic lymphocytes in culture.	deoxynivalenol	25-39	glutathione peroxidase 1	Cricetulus griseus	58-62
30518949-5	2018	We established GPX1-knockdown porcine spleen lymphocytes, and treated them with DON and Se.	deoxynivalenol	80-83	glutathione peroxidase 1	Cricetulus griseus	15-19
30518949-8	2018	DON caused greater oxidative damage to the GPX1-knockdown porcine splenic lymphocytes than to the normal control cells.	deoxynivalenol	0-3	glutathione peroxidase 1	Cricetulus griseus	43-47
30518949-9	2018	When Na2SeO3 was combined with DON, it reduced the damage in the GPX1-knockdown porcine splenic lymphocytes, but less effectively than in the normal porcine splenic lymphocytes.	deoxynivalenol	31-34	glutathione peroxidase 1	Cricetulus griseus	65-69
30788454-4	2019	The goal of this study was to determine whether ribotoxic stress induced by ANS or a second ribotoxin, deoxynivalenol (DON), specifically regulates transport of IGFBP-3 to the nucleus and to determine the pathway by which it traffics.	deoxynivalenol	103-117	insulin like growth factor binding protein 3	Bos taurus	161-168
30788454-4	2019	The goal of this study was to determine whether ribotoxic stress induced by ANS or a second ribotoxin, deoxynivalenol (DON), specifically regulates transport of IGFBP-3 to the nucleus and to determine the pathway by which it traffics.	deoxynivalenol	119-122	insulin like growth factor binding protein 3	Bos taurus	161-168
30788454-12	2019	In summary, ANS and DON specifically induced nuclear localization of nonsecreted IGFBP-3 via an importin-beta-mediated event, which may play a role in their ability to induce apoptosis in MECs.	deoxynivalenol	20-23	insulin like growth factor binding protein 3	Bos taurus	81-88
30286430-0	2018	EGR1 is essential for deoxynivalenol-induced G2/M cell cycle arrest in HepG2 cells via the ATF3DeltaZip2a/2b-EGR1-p21 pathway.	deoxynivalenol	22-36	early growth response protein 1	Cricetulus griseus	0-4
30286430-0	2018	EGR1 is essential for deoxynivalenol-induced G2/M cell cycle arrest in HepG2 cells via the ATF3DeltaZip2a/2b-EGR1-p21 pathway.	deoxynivalenol	22-36	early growth response 1	Homo sapiens	109-113
30286430-0	2018	EGR1 is essential for deoxynivalenol-induced G2/M cell cycle arrest in HepG2 cells via the ATF3DeltaZip2a/2b-EGR1-p21 pathway.	deoxynivalenol	22-36	H3 histone pseudogene 16	Homo sapiens	114-117
30286430-4	2018	In this study, we showed that DON induced strong G2/M cell cycle arrest in HepG2 cells, and the cell cycle-inhibitory protein p21 was highly upregulated by DON.	deoxynivalenol	156-159	H3 histone pseudogene 16	Homo sapiens	126-129
30286430-7	2018	ATF3DeltaZip2a/2b, which is a DNA binding domain truncated isoform of ATF3, was upregulated by DON.	deoxynivalenol	95-98	activating transcription factor 3	Homo sapiens	0-4
30286430-10	2018	H3K9ac and H3K27ac were enriched at the promoter region of ATF3 following the DON treatment, and the knocking down of the genes responsible for H3K9ac and H3K27ac abolished the upregulation of ATF3 by DON.	deoxynivalenol	78-81	activating transcription factor 3	Homo sapiens	59-63
30286430-10	2018	H3K9ac and H3K27ac were enriched at the promoter region of ATF3 following the DON treatment, and the knocking down of the genes responsible for H3K9ac and H3K27ac abolished the upregulation of ATF3 by DON.	deoxynivalenol	78-81	activating transcription factor 3	Homo sapiens	193-197
30286430-10	2018	H3K9ac and H3K27ac were enriched at the promoter region of ATF3 following the DON treatment, and the knocking down of the genes responsible for H3K9ac and H3K27ac abolished the upregulation of ATF3 by DON.	deoxynivalenol	201-204	activating transcription factor 3	Homo sapiens	59-63
30286430-10	2018	H3K9ac and H3K27ac were enriched at the promoter region of ATF3 following the DON treatment, and the knocking down of the genes responsible for H3K9ac and H3K27ac abolished the upregulation of ATF3 by DON.	deoxynivalenol	201-204	activating transcription factor 3	Homo sapiens	193-197
30286430-11	2018	In summary, we found that DON induced G2/M cell cycle arrest by sequentially inducing the expression of ATF3DeltaZip2a/2b, EGR1 and p21, and EGR1 played an essential role in this process, which is a novel molecular mechanism of cell cycle arrest by DON and is important for understanding its toxicology.	deoxynivalenol	26-29	early growth response protein 1	Cricetulus griseus	123-127
30286430-11	2018	In summary, we found that DON induced G2/M cell cycle arrest by sequentially inducing the expression of ATF3DeltaZip2a/2b, EGR1 and p21, and EGR1 played an essential role in this process, which is a novel molecular mechanism of cell cycle arrest by DON and is important for understanding its toxicology.	deoxynivalenol	26-29	H3 histone pseudogene 16	Homo sapiens	132-135
30286430-11	2018	In summary, we found that DON induced G2/M cell cycle arrest by sequentially inducing the expression of ATF3DeltaZip2a/2b, EGR1 and p21, and EGR1 played an essential role in this process, which is a novel molecular mechanism of cell cycle arrest by DON and is important for understanding its toxicology.	deoxynivalenol	26-29	early growth response protein 1	Cricetulus griseus	141-145
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	11-14	toll-like receptor 2 type-1	Gallus gallus	102-106
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	11-14	interleukin 6	Gallus gallus	108-111
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	11-14	claudin 1	Gallus gallus	117-126
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	11-14	claudin 1	Gallus gallus	128-133
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	44-47	toll-like receptor 2 type-1	Gallus gallus	102-106
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	44-47	interleukin 6	Gallus gallus	108-111
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	44-47	claudin 1	Gallus gallus	117-126
30289512-7	2018	Increasing DON concentrations of up to 5-mg DON/kg increased (P &lt; 0.05) the duodenal expression of TLR2, IL6, and Claudin 1 (CLDN1) by up to 84%, 88%, and 48%, respectively, compared with the noncontaminated diet.	deoxynivalenol	44-47	claudin 1	Gallus gallus	128-133
30289512-8	2018	Likewise, jejunal CLDN1 expression increased up to 23% in the chickens fed DON concentrations of up to 5-mg DON/kg diet (P &lt; 0.05).	deoxynivalenol	75-78	claudin 1	Gallus gallus	18-23
30289512-8	2018	Likewise, jejunal CLDN1 expression increased up to 23% in the chickens fed DON concentrations of up to 5-mg DON/kg diet (P &lt; 0.05).	deoxynivalenol	108-111	claudin 1	Gallus gallus	18-23
30289512-9	2018	Moreover, increasing DON concentrations linearly and quadratically decreased (P &lt; 0.05) the jejunal expression of TLR2 and transforming growth factor-beta 1, respectively.	deoxynivalenol	21-24	toll-like receptor 2 type-1	Gallus gallus	117-121
30289512-9	2018	Moreover, increasing DON concentrations linearly and quadratically decreased (P &lt; 0.05) the jejunal expression of TLR2 and transforming growth factor-beta 1, respectively.	deoxynivalenol	21-24	transforming growth factor beta 1	Gallus gallus	126-159
30169763-5	2018	Namely, knockdown of FOXO3a decreased the cytotoxicity of DON to GES-1 cells.	deoxynivalenol	58-61	forkhead box O3	Homo sapiens	21-27
30064753-3	2018	An enzyme-linked immunosorbent assay (ELISA) and urchin-like gold nanoparticle immunochromatographic assay was developed based on D8-MBP for detection of DON in maize and wheat.	deoxynivalenol	154-157	membrane steroid-binding protein 1	Triticum aestivum	133-136
30169763-6	2018	Moreover, knockdown of the FOXO ortholog DAF16 in Caenorhabditis elegans increased the resistance to DON-induced cytotoxicity.	deoxynivalenol	101-104	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	41-46
30290166-0	2018	Deoxynivalenol induces toxicity and apoptosis in piglet hippocampal nerve cells via the MAPK signaling pathway.	deoxynivalenol	0-14	mitogen-activated protein kinase 1	Homo sapiens	88-92
30290166-4	2018	The results indicated that DON significantly inhibited cellular viability and promoted the release of LDH by damaging the membrane integrity of PHNCs, however, the cellular viability was increased and LDH leakage rate were decreased after adding MAPK inhibitors.	deoxynivalenol	27-30	mitogen-activated protein kinase 1	Homo sapiens	246-250
30169763-7	2018	Simultaneously, the signaling pathway of ROS/JNK/FOXO3a of DON-induced cytotoxicity was newly proposed.	deoxynivalenol	59-62	mitogen-activated protein kinase 8	Homo sapiens	45-48
30290166-5	2018	DON induced PHNCs apoptosis and phosphorylation of MAPK pathway proteins dose-dependently.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	51-55
30169763-7	2018	Simultaneously, the signaling pathway of ROS/JNK/FOXO3a of DON-induced cytotoxicity was newly proposed.	deoxynivalenol	59-62	forkhead box O3	Homo sapiens	49-55
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 8	Homo sapiens	24-27
30169763-8	2018	In total, FOXO3a via ROS/JNK/FOXO3a plays a critical role to function as negative regulator associating with DON-induced cytotoxicity, with the potential extending to other substances.	deoxynivalenol	109-112	forkhead box O3	Homo sapiens	10-16
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 8	Homo sapiens	28-31
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 14	Homo sapiens	38-41
30169763-8	2018	In total, FOXO3a via ROS/JNK/FOXO3a plays a critical role to function as negative regulator associating with DON-induced cytotoxicity, with the potential extending to other substances.	deoxynivalenol	109-112	mitogen-activated protein kinase 8	Homo sapiens	25-28
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 14	Homo sapiens	42-45
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 1	Homo sapiens	122-125
30169763-8	2018	In total, FOXO3a via ROS/JNK/FOXO3a plays a critical role to function as negative regulator associating with DON-induced cytotoxicity, with the potential extending to other substances.	deoxynivalenol	109-112	forkhead box O3	Homo sapiens	29-35
30290166-6	2018	The ratios of phospho p-JNK/JNK and p-p38/p38 significantly increased with the increase of DON concentration, while the p-ERK/ERK ratio significantly decreased.	deoxynivalenol	91-94	mitogen-activated protein kinase 1	Homo sapiens	126-129
30216983-0	2018	Oxidative Damage and Nrf2 Translocation Induced by Toxicities of Deoxynivalenol on the Placental and Embryo on Gestation Day 12.5 d and 18.5 d. Deoxynivalenol (DON) is a kind of natural pollutant belonging to the trichothecenes family.	deoxynivalenol	65-79	nuclear factor, erythroid derived 2, like 2	Mus musculus	21-25
30290166-10	2018	These data demonstrated that DON induces toxic effects and apoptosis in PHNCs via the MAPK signaling pathway.	deoxynivalenol	29-32	mitogen-activated protein kinase 1	Homo sapiens	86-90
30595795-0	2018	Pyrrolidine Dithiocarbamate (PDTC) Inhibits DON-Induced Mitochondrial Dysfunction and Apoptosis via the NF-kappaB/iNOS Pathway.	deoxynivalenol	44-47	nitric oxide synthase 2	Rattus norvegicus	114-118
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	125-128	synaptotagmin 1	Rattus norvegicus	244-247
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	125-128	nitric oxide synthase 2	Rattus norvegicus	296-300
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	205-208	synaptotagmin 1	Rattus norvegicus	244-247
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	205-208	nitric oxide synthase 2	Rattus norvegicus	296-300
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	205-208	synaptotagmin 1	Rattus norvegicus	244-247
30595795-6	2018	Morphological studies using transmission electron microscopy (TEM) and cell apoptosis analyses suggested that PDTC prevented DON-induced mitochondrial dysfunction and apoptosis, probably by preventing the DON-induced translocation of NF-kappaB p65 into the nucleus, and by inhibiting DON-induced iNOS expression.	deoxynivalenol	205-208	nitric oxide synthase 2	Rattus norvegicus	296-300
30171291-8	2018	DON impaired the morphology of the jejunum and the ileum, reduced villi height, decreased E-cadherin expression and modified the intestinal expression of cytokines.	deoxynivalenol	0-3	cadherin 1	Homo sapiens	90-100
30121250-0	2018	JNK-AKT-NF-kappaB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells.	deoxynivalenol	86-100	mitogen-activated protein kinase 8	Homo sapiens	0-3
30121250-0	2018	JNK-AKT-NF-kappaB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells.	deoxynivalenol	86-100	AKT serine/threonine kinase 1	Homo sapiens	4-7
30121250-0	2018	JNK-AKT-NF-kappaB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells.	deoxynivalenol	86-100	nuclear factor kappa B subunit 1	Homo sapiens	8-17
30121250-0	2018	JNK-AKT-NF-kappaB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells.	deoxynivalenol	86-100	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
30121250-2	2018	Previously, we reported that P-glycoprotein (P-gp) is the foremost efflux transporter of deoxynivalenol (DON), which is one of the most abundant mycotoxins.	deoxynivalenol	89-103	ATP binding cassette subfamily B member 1	Homo sapiens	29-43
30121250-2	2018	Previously, we reported that P-glycoprotein (P-gp) is the foremost efflux transporter of deoxynivalenol (DON), which is one of the most abundant mycotoxins.	deoxynivalenol	89-103	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
30121250-2	2018	Previously, we reported that P-glycoprotein (P-gp) is the foremost efflux transporter of deoxynivalenol (DON), which is one of the most abundant mycotoxins.	deoxynivalenol	105-108	ATP binding cassette subfamily B member 1	Homo sapiens	29-43
30121250-2	2018	Previously, we reported that P-glycoprotein (P-gp) is the foremost efflux transporter of deoxynivalenol (DON), which is one of the most abundant mycotoxins.	deoxynivalenol	105-108	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
30121250-4	2018	In this study, we found DON can induce the mRNA and protein levels of P-gp in a time- and dose-dependent manner.	deoxynivalenol	24-27	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
30121250-5	2018	Mechanistically, the upregulation of P-gp expression is attributable to the induction of DON-induced proapoptotic pathways as reflected by the c-Jun N-terminal kinases (JNK) phosphorylation, AKT phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation to the nucleus.	deoxynivalenol	89-92	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
30121250-5	2018	Mechanistically, the upregulation of P-gp expression is attributable to the induction of DON-induced proapoptotic pathways as reflected by the c-Jun N-terminal kinases (JNK) phosphorylation, AKT phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation to the nucleus.	deoxynivalenol	89-92	mitogen-activated protein kinase 8	Homo sapiens	143-167
30121250-5	2018	Mechanistically, the upregulation of P-gp expression is attributable to the induction of DON-induced proapoptotic pathways as reflected by the c-Jun N-terminal kinases (JNK) phosphorylation, AKT phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation to the nucleus.	deoxynivalenol	89-92	mitogen-activated protein kinase 8	Homo sapiens	169-172
30121250-5	2018	Mechanistically, the upregulation of P-gp expression is attributable to the induction of DON-induced proapoptotic pathways as reflected by the c-Jun N-terminal kinases (JNK) phosphorylation, AKT phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation to the nucleus.	deoxynivalenol	89-92	AKT serine/threonine kinase 1	Homo sapiens	191-194
30121250-5	2018	Mechanistically, the upregulation of P-gp expression is attributable to the induction of DON-induced proapoptotic pathways as reflected by the c-Jun N-terminal kinases (JNK) phosphorylation, AKT phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation to the nucleus.	deoxynivalenol	89-92	nuclear factor kappa B subunit 1	Homo sapiens	279-288
30121250-6	2018	In DON-treated cells, the mitogen-activated protein kinases (MAPK) pathways were activated; however, only JNK, but not ERK or p38, activation determined P-gp induction.	deoxynivalenol	3-6	mitogen-activated protein kinase 8	Homo sapiens	106-109
30121250-6	2018	In DON-treated cells, the mitogen-activated protein kinases (MAPK) pathways were activated; however, only JNK, but not ERK or p38, activation determined P-gp induction.	deoxynivalenol	3-6	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
30121250-8	2018	Importantly, long-term and low-dose exposure to DON induces multidrug resistance, thus attenuating the cytotoxicity of P-gp substrates, including DON, Digoxin, Sunitinib, and Etoposide.	deoxynivalenol	48-51	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	119-122	mitogen-activated protein kinase 8	Homo sapiens	60-63
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	119-122	AKT serine/threonine kinase 1	Homo sapiens	64-67
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	119-122	nuclear factor kappa B subunit 1	Homo sapiens	68-77
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	119-122	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	206-209	mitogen-activated protein kinase 8	Homo sapiens	60-63
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	206-209	AKT serine/threonine kinase 1	Homo sapiens	64-67
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	deoxynivalenol	206-209	nuclear factor kappa B subunit 1	Homo sapiens	68-77
29906473-4	2018	The IC50 values obtained ranged from 9.30 to 2.53 muM, from 33.69 to 44.37 nM and from 2.66 to 1.17 muM for DON, T-2 and PAT, respectively.	deoxynivalenol	108-111	latexin	Homo sapiens	100-103
30216983-0	2018	Oxidative Damage and Nrf2 Translocation Induced by Toxicities of Deoxynivalenol on the Placental and Embryo on Gestation Day 12.5 d and 18.5 d. Deoxynivalenol (DON) is a kind of natural pollutant belonging to the trichothecenes family.	deoxynivalenol	144-158	nuclear factor, erythroid derived 2, like 2	Mus musculus	21-25
30216983-0	2018	Oxidative Damage and Nrf2 Translocation Induced by Toxicities of Deoxynivalenol on the Placental and Embryo on Gestation Day 12.5 d and 18.5 d. Deoxynivalenol (DON) is a kind of natural pollutant belonging to the trichothecenes family.	deoxynivalenol	160-163	nuclear factor, erythroid derived 2, like 2	Mus musculus	21-25
30216983-1	2018	The aim of this study is to use diverse assays to evaluate oxidative damage as well as translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), and to investigate their mechanisms in DON-induced toxicities on a placenta and embryo.	deoxynivalenol	195-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	104-147
30216983-1	2018	The aim of this study is to use diverse assays to evaluate oxidative damage as well as translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), and to investigate their mechanisms in DON-induced toxicities on a placenta and embryo.	deoxynivalenol	195-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	149-153
29889651-1	2018	The peroxidase (POD) enzyme, obtained from different sources, has been described in the literature regarding its good results of reduction in concentration or degradation levels of mycotoxins, such as aflatoxin B1, deoxynivalenol and zearalenone (ZEA).	deoxynivalenol	215-229	peroxidase	Glycine max	4-14
29889651-1	2018	The peroxidase (POD) enzyme, obtained from different sources, has been described in the literature regarding its good results of reduction in concentration or degradation levels of mycotoxins, such as aflatoxin B1, deoxynivalenol and zearalenone (ZEA).	deoxynivalenol	215-229	peroxidase	Glycine max	16-19
29808618-7	2018	The concentration of tumor necrosis factor-alpha (TNF-alpha) and cyclooxgenase-2 (COX-2) significantly increased (p &lt; .001) in all DON-treated groups.	deoxynivalenol	134-137	tumor necrosis factor	Homo sapiens	21-48
29808618-7	2018	The concentration of tumor necrosis factor-alpha (TNF-alpha) and cyclooxgenase-2 (COX-2) significantly increased (p &lt; .001) in all DON-treated groups.	deoxynivalenol	134-137	tumor necrosis factor	Homo sapiens	50-59
29808618-8	2018	Gut anorexigenic hormone secretion of peptide YY (PYY) and cholecystokinin (CCK) had a time- and dose-dependent relationship with DON exposure; however, there was no effect on orexigenic hormone ghrelin secretion.	deoxynivalenol	130-133	peptide YY	Homo sapiens	38-48
29808618-8	2018	Gut anorexigenic hormone secretion of peptide YY (PYY) and cholecystokinin (CCK) had a time- and dose-dependent relationship with DON exposure; however, there was no effect on orexigenic hormone ghrelin secretion.	deoxynivalenol	130-133	peptide YY	Homo sapiens	50-53
29808618-8	2018	Gut anorexigenic hormone secretion of peptide YY (PYY) and cholecystokinin (CCK) had a time- and dose-dependent relationship with DON exposure; however, there was no effect on orexigenic hormone ghrelin secretion.	deoxynivalenol	130-133	cholecystokinin	Homo sapiens	59-74
29808618-8	2018	Gut anorexigenic hormone secretion of peptide YY (PYY) and cholecystokinin (CCK) had a time- and dose-dependent relationship with DON exposure; however, there was no effect on orexigenic hormone ghrelin secretion.	deoxynivalenol	130-133	cholecystokinin	Homo sapiens	76-79
30054545-7	2018	Sub-toxic concentrations of DON (0.1-1 muM) impaired the capability of A431 cells to respond to a biomechanical stimulation that normally sustains trophic effects in these cells.	deoxynivalenol	28-31	latexin	Homo sapiens	39-42
30054545-8	2018	Moreover, the effects of DON (0.1-10 muM) were partially modulated by the application of uniaxial stretching (0.5 Hz, 24 h, 15% deformation).	deoxynivalenol	25-28	latexin	Homo sapiens	37-40
29673318-3	2018	UDP-glycosyltransferase enzymes (UGTs) are known to contribute to detoxification and enhance FHB resistance by glycosylating DON into DON-3-glucoside (D3G) in wheat.	deoxynivalenol	125-128	UDP-glycosyltransferase 73C10	Triticum aestivum	0-23
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	IL2	Sus scrofa	130-134
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	interleukin 4	Sus scrofa	136-140
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	interleukin 6	Sus scrofa	142-146
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	IL10	Sus scrofa	148-153
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	interferon gamma	Sus scrofa	155-164
28948563-6	2018	Compared with control and Se-alone treatments, DON exposure significantly and dose dependently decreased the expression levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, IgG, and IgM mRNA and protein.	deoxynivalenol	47-50	Ig kappa chain	Sus scrofa	175-178
28948563-7	2018	By contrast, co-treatment with DON + Se significantly increased the mRNA and protein levels of all factors examined, except IL-4 and IL-6, compared with DON treatment alone.	deoxynivalenol	31-34	interleukin 4	Sus scrofa	124-128
28948563-7	2018	By contrast, co-treatment with DON + Se significantly increased the mRNA and protein levels of all factors examined, except IL-4 and IL-6, compared with DON treatment alone.	deoxynivalenol	31-34	interleukin 6	Sus scrofa	133-137
29954091-7	2018	Real-time quantitative polymerase chain reaction (RT-qPCR) analysis showed that DON upregulates innate immunity-related genes including C17H12.8 and K08D8.5 encoding PMK-1 (mitogen activated protein kinase-1)-regulated immune effectors, and F35E12.5 encoding a CUB-like domain-containing protein.	deoxynivalenol	80-83	CUB_2 domain-containing protein	Caenorhabditis elegans	136-144
29954091-7	2018	Real-time quantitative polymerase chain reaction (RT-qPCR) analysis showed that DON upregulates innate immunity-related genes including C17H12.8 and K08D8.5 encoding PMK-1 (mitogen activated protein kinase-1)-regulated immune effectors, and F35E12.5 encoding a CUB-like domain-containing protein.	deoxynivalenol	80-83	Mitogen-activated protein kinase pmk-1	Caenorhabditis elegans	166-171
32231947-6	2018	While exposure to 0.3 mug/mL DON greatly induced the secretion of anti-hematopoietic cytokines CCL3 and CCL4, treatment with NIV decreased the secretion of these cytokines in HL60 cells, indicating that the toxicity mechanisms of these mycotoxins differ.	deoxynivalenol	29-32	C-C motif chemokine ligand 3	Homo sapiens	95-99
32231947-6	2018	While exposure to 0.3 mug/mL DON greatly induced the secretion of anti-hematopoietic cytokines CCL3 and CCL4, treatment with NIV decreased the secretion of these cytokines in HL60 cells, indicating that the toxicity mechanisms of these mycotoxins differ.	deoxynivalenol	29-32	C-C motif chemokine ligand 4	Homo sapiens	104-108
32231947-8	2018	Radicicol counteracted the effect of DON on cytokine secretion, indicating that Hsp90 plays a crucial role in DON-induced cytokine secretion in HL60 cells.	deoxynivalenol	37-40	heat shock protein 90 alpha family class A member 1	Homo sapiens	80-85
32231947-8	2018	Radicicol counteracted the effect of DON on cytokine secretion, indicating that Hsp90 plays a crucial role in DON-induced cytokine secretion in HL60 cells.	deoxynivalenol	110-113	heat shock protein 90 alpha family class A member 1	Homo sapiens	80-85
29174985-0	2018	Role of P-glycoprotein in deoxynivalenol-mediated in vitro toxicity.	deoxynivalenol	26-40	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
29286883-7	2018	With regard to adsorption capacity, results indicate that only zeolite-Li+ were capable of DON adsorption significantly (P &lt; 0.001) with 37% at 2 mg mL-1 concentration.	deoxynivalenol	91-94	L1 cell adhesion molecule	Mus musculus	152-156
29497102-7	2018	Total DON was detected in all samples with a mean concentration at 47.6 ng mL-1.	deoxynivalenol	6-9	L1 cell adhesion molecule	Mus musculus	75-79
29474583-0	2018	Ochratoxin A, citrinin and deoxynivalenol decrease claudin-2 expression in mouse rectum CMT93-II cells.	deoxynivalenol	27-41	claudin 2	Mus musculus	51-60
29474583-6	2018	In this study, we examined whether ochratoxin A, citrinin and deoxynivalenol affect claudin-2 expression and ERK1/2 phosphorylation in CMT93-II cells.	deoxynivalenol	62-76	claudin 2	Homo sapiens	84-93
29474583-9	2018	While ochratoxin A and citrinin are known to be nephrotoxic, only deoxynivalenol reduced claudin-2 expression in MDCK II cells derived from the renal tubule.	deoxynivalenol	66-80	claudin 2	Canis lupus familiaris	89-98
29174985-5	2018	We found that DON was exported by Pgp and was less cytotoxic in Pgp-overexpressing cells.	deoxynivalenol	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	34-37
29174985-5	2018	We found that DON was exported by Pgp and was less cytotoxic in Pgp-overexpressing cells.	deoxynivalenol	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	64-67
29174985-6	2018	In the fluorometric calcein-acetoxymethylester (Calcein AM) assay DON reduced intracellular calcein retention, indicating a stimulation of Pgp-mediated efflux.	deoxynivalenol	66-69	ATP binding cassette subfamily B member 1	Homo sapiens	139-142
29174985-8	2018	Verrucarol, a structural analogue of DON, was much less effective indicating the importance of the alpha, beta-conjugated carbonyl group in the DON molecule for Pgp interaction.	deoxynivalenol	144-147	ATP binding cassette subfamily B member 1	Homo sapiens	161-164
29174985-9	2018	Our results confirmed that Pgp might have the potential to reduce intestinal absorption of DON in vivo.	deoxynivalenol	91-94	ATP binding cassette subfamily B member 1	Homo sapiens	27-30
29174985-10	2018	Furthermore, we were able to show that DON can modulate Pgp activity in vitro.	deoxynivalenol	39-42	ATP binding cassette subfamily B member 1	Homo sapiens	56-59
28945498-5	2017	The results of this study demonstrate that DON alone at the higher concentrations may act to stimulate P4 (at 1,000, 2,000, 3,000 and 5,000 ng mL-1 but not 10 and 100 ng mL-1) and E2 (at 2,000, 3,000 and 5,000 ng mL-1 but not 10, 100 and 1000 ng mL-1) secretion.	deoxynivalenol	43-46	L1 cell adhesion molecule	Mus musculus	143-147
29232919-4	2017	In this study, NIV, both alone and in combination with DON, induced inflammation and increased the inflammatory response induced by lipopolysaccharide (LPS) plus Interferon-gamma (IFN) in the non-tumorigenic intestinal epithelial cell line (IEC-6).	deoxynivalenol	55-58	interferon alpha 1	Homo sapiens	162-184
28684119-0	2017	Gene expression profiles and molecular mechanism of cultured human chondrocytes" exposure to T-2 toxin and deoxynivalenol.	deoxynivalenol	107-121	solute carrier family 25 member 5	Homo sapiens	93-96
28945498-5	2017	The results of this study demonstrate that DON alone at the higher concentrations may act to stimulate P4 (at 1,000, 2,000, 3,000 and 5,000 ng mL-1 but not 10 and 100 ng mL-1) and E2 (at 2,000, 3,000 and 5,000 ng mL-1 but not 10, 100 and 1000 ng mL-1) secretion.	deoxynivalenol	43-46	L1 cell adhesion molecule	Mus musculus	170-174
28945498-5	2017	The results of this study demonstrate that DON alone at the higher concentrations may act to stimulate P4 (at 1,000, 2,000, 3,000 and 5,000 ng mL-1 but not 10 and 100 ng mL-1) and E2 (at 2,000, 3,000 and 5,000 ng mL-1 but not 10, 100 and 1000 ng mL-1) secretion.	deoxynivalenol	43-46	L1 cell adhesion molecule	Mus musculus	170-174
28945498-5	2017	The results of this study demonstrate that DON alone at the higher concentrations may act to stimulate P4 (at 1,000, 2,000, 3,000 and 5,000 ng mL-1 but not 10 and 100 ng mL-1) and E2 (at 2,000, 3,000 and 5,000 ng mL-1 but not 10, 100 and 1000 ng mL-1) secretion.	deoxynivalenol	43-46	L1 cell adhesion molecule	Mus musculus	170-174
29045588-7	2017	Addition of DON or DOM-1 stimulated phosphorylation of EIF2AK2, MAPK3/1, and AKT.	deoxynivalenol	12-15	eukaryotic translation initiation factor 2 alpha kinase 2	Bos taurus	55-62
29045588-7	2017	Addition of DON or DOM-1 stimulated phosphorylation of EIF2AK2, MAPK3/1, and AKT.	deoxynivalenol	12-15	AKT serine/threonine kinase 1	Bos taurus	64-80
29045588-9	2017	DON increased the levels of mRNA encoding early-immediate genes EGR1, EGR3, and FOS, whereas DOM-1 was without effect.	deoxynivalenol	0-3	early growth response 1	Bos taurus	64-68
29045588-9	2017	DON increased the levels of mRNA encoding early-immediate genes EGR1, EGR3, and FOS, whereas DOM-1 was without effect.	deoxynivalenol	0-3	early growth response 3	Bos taurus	70-74
29045588-9	2017	DON increased the levels of mRNA encoding early-immediate genes EGR1, EGR3, and FOS, whereas DOM-1 was without effect.	deoxynivalenol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Bos taurus	80-83
29053594-6	2017	Expression of claudin-5 was increased in jejunum of female birds fed 2 and 5 mg/kg of DON, whereas decreased expression levels were found in male birds.	deoxynivalenol	86-89	claudin 5	Gallus gallus	14-23
28741250-6	2017	Additionally, NO was decreased (0.84 mumol/L DON), whereas interleukin (IL)-6 was increased (0.42 mumol/L DON) in lipopolysaccharide (LPS)-stimulated DON-, but not DOM-1-treated RAW cells.	deoxynivalenol	106-109	interleukin 6	Sus scrofa	59-77
28741250-6	2017	Additionally, NO was decreased (0.84 mumol/L DON), whereas interleukin (IL)-6 was increased (0.42 mumol/L DON) in lipopolysaccharide (LPS)-stimulated DON-, but not DOM-1-treated RAW cells.	deoxynivalenol	106-109	interleukin 6	Sus scrofa	59-77
28598396-0	2017	Embryotoxicity Caused by DON-Induced Oxidative Stress Mediated by Nrf2/HO-1 Pathway.	deoxynivalenol	25-28	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
28633506-0	2017	Role of Glucagon-Like Peptide-1 and Gastric Inhibitory Peptide in Anorexia Induction Following Oral Exposure to the Trichothecene Mycotoxin Deoxynivalenol (Vomitoxin).	deoxynivalenol	140-154	glucagon	Mus musculus	8-31
28633506-0	2017	Role of Glucagon-Like Peptide-1 and Gastric Inhibitory Peptide in Anorexia Induction Following Oral Exposure to the Trichothecene Mycotoxin Deoxynivalenol (Vomitoxin).	deoxynivalenol	156-165	glucagon	Mus musculus	8-31
28633506-3	2017	While anorexia induction in mice exposed to DON has been linked to the elevation of the satiety hormones cholecystokinin and peptide YY3-36 in plasma, the effects of DON on the release of other satiety hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have not been established.	deoxynivalenol	44-47	glucagon	Mus musculus	220-243
28633506-3	2017	While anorexia induction in mice exposed to DON has been linked to the elevation of the satiety hormones cholecystokinin and peptide YY3-36 in plasma, the effects of DON on the release of other satiety hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have not been established.	deoxynivalenol	44-47	glucagon	Mus musculus	245-250
28633506-3	2017	While anorexia induction in mice exposed to DON has been linked to the elevation of the satiety hormones cholecystokinin and peptide YY3-36 in plasma, the effects of DON on the release of other satiety hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have not been established.	deoxynivalenol	44-47	gastric inhibitory polypeptide	Mus musculus	284-287
28602893-7	2017	Maternal intake at the TDI exceeds the age-adjusted TDI (TDI/3) values for infants in case of deoxynivalenol and patulin in the single dose scenario.	deoxynivalenol	94-108	TLX1 neighbor	Homo sapiens	52-55
28602893-7	2017	Maternal intake at the TDI exceeds the age-adjusted TDI (TDI/3) values for infants in case of deoxynivalenol and patulin in the single dose scenario.	deoxynivalenol	94-108	TLX1 neighbor	Homo sapiens	52-55
27295033-8	2017	RESULTS: In comparison with PGOS, FOS and inulin, VGOS showed the most pronounced protective effect on the DON-induced impairment of the monolayer integrity, acceleration of the tight junction reassembly and the subsequent CXCL8 release.	deoxynivalenol	107-110	C-X-C motif chemokine ligand 8	Homo sapiens	223-228
27295033-9	2017	DP2 and DP3 in concentrations occurring in VGOS prevented the DON-induced epithelial barrier disruption, which could be related to their high prevalence in VGOS.	deoxynivalenol	62-65	transcription factor Dp-2	Homo sapiens	0-3
27295033-9	2017	DP2 and DP3 in concentrations occurring in VGOS prevented the DON-induced epithelial barrier disruption, which could be related to their high prevalence in VGOS.	deoxynivalenol	62-65	APC regulator of WNT signaling pathway	Homo sapiens	8-11
28598396-0	2017	Embryotoxicity Caused by DON-Induced Oxidative Stress Mediated by Nrf2/HO-1 Pathway.	deoxynivalenol	25-28	heme oxygenase 1	Homo sapiens	71-75
28598396-3	2017	In the present study, we focus on a hypothesis that DON alters the expressions of Nrf2/HO-1 pathway by inducing embryotoxicity in C57BL/6 mouse (5.0, 2.5, 1.0, and 0 mg/kg/day) and BeWo cell lines (0 and 50 nM; 3 h, 12 h and 24 h).	deoxynivalenol	52-55	nuclear factor, erythroid derived 2, like 2	Mus musculus	82-86
28598396-3	2017	In the present study, we focus on a hypothesis that DON alters the expressions of Nrf2/HO-1 pathway by inducing embryotoxicity in C57BL/6 mouse (5.0, 2.5, 1.0, and 0 mg/kg/day) and BeWo cell lines (0 and 50 nM; 3 h, 12 h and 24 h).	deoxynivalenol	52-55	heme oxygenase 1	Mus musculus	87-91
28598396-9	2017	Besides, Nrf2/HO-1 pathway accompanied by the "threshold effect" also plays an important role against DON-induced oxidative damage in this process.	deoxynivalenol	102-105	NFE2 like bZIP transcription factor 2	Homo sapiens	9-13
28598396-9	2017	Besides, Nrf2/HO-1 pathway accompanied by the "threshold effect" also plays an important role against DON-induced oxidative damage in this process.	deoxynivalenol	102-105	heme oxygenase 1	Homo sapiens	14-18
28865221-0	2017	Effect of deoxynivalenol on the levels of toll-like receptors 2 and 9 and their mRNA expression in enterocytes in the porcine large intestine: a preliminary study.	deoxynivalenol	10-24	toll like receptor 2	Homo sapiens	42-69
28865221-2	2017	The aim of this study was to determine the effect of feed contaminated with DON on the number of TLR2- and TLR9-positive cells and their mRNA expression in the porcine large intestine.	deoxynivalenol	76-79	toll like receptor 2	Homo sapiens	97-101
28865221-2	2017	The aim of this study was to determine the effect of feed contaminated with DON on the number of TLR2- and TLR9-positive cells and their mRNA expression in the porcine large intestine.	deoxynivalenol	76-79	toll like receptor 9	Homo sapiens	107-111
28013001-3	2017	In this study, we investigated the impact of three natural compounds, cyclosporine A (CsA), deoxynivalenol (DON) and cannabidiol (CBD) on mitochondrial functions in the THP-1 monocytic cell line.	deoxynivalenol	108-111	GLI family zinc finger 2	Homo sapiens	169-174
28380583-8	2017	A reduction ( &lt; 0.05) in expression of nuclear factor erythroid 2-related factor 2 was observed in the jejunal mucosa of broilers fed dietary supplementation with DON, whereas the mRNA levels of and its corresponding downstream gene increased ( &lt; 0.05) with JM113 treatment.	deoxynivalenol	166-169	nuclear factor, erythroid 2 like 2	Gallus gallus	42-85
28013001-9	2017	The basal respiration level and ATP-production decreased in the THP-1 cells exposed to the IC50 of DON with no major impact on mitochondrial function.	deoxynivalenol	99-102	GLI family zinc finger 2	Homo sapiens	64-69
27817099-7	2017	DON induced expression of cleaved caspase-3 (maximum induction 3.9-fold) and MAPK p38 and p42/p44 (maximum induction 2.51- and 2.30-fold, respectively).	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Homo sapiens	82-85
27817099-7	2017	DON induced expression of cleaved caspase-3 (maximum induction 3.9-fold) and MAPK p38 and p42/p44 (maximum induction 2.51- and 2.30-fold, respectively).	deoxynivalenol	0-3	cyclin dependent kinase 20	Homo sapiens	90-93
27817099-7	2017	DON induced expression of cleaved caspase-3 (maximum induction 3.9-fold) and MAPK p38 and p42/p44 (maximum induction 2.51- and 2.30-fold, respectively).	deoxynivalenol	0-3	interferon induced protein 44	Homo sapiens	94-97
27591283-3	2017	Mean plasma CORT levels were significantly higher in broiler chickens fed a DON contaminated and a DON and FBs contaminated diet compared to birds fed a control diet.	deoxynivalenol	76-79	CORT	Gallus gallus	12-16
26979077-0	2017	Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).	deoxynivalenol	135-149	calcium-sensing receptor	Mus musculus	46-50
26979077-0	2017	Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).	deoxynivalenol	135-149	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	56-94
26979077-0	2017	Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).	deoxynivalenol	135-149	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	96-101
26979077-0	2017	Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).	deoxynivalenol	151-160	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	56-94
26979077-0	2017	Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).	deoxynivalenol	151-160	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	96-101
27998766-6	2017	Western blot showed that DON significantly increased the expression levels of apoptosis-related protein including Caspase-9, Caspase-3, poly (ADP-ribose) polymerase (PARP) and the ratio of Bax/Bcl-2.	deoxynivalenol	25-28	caspase 9	Mus musculus	114-123
27998766-6	2017	Western blot showed that DON significantly increased the expression levels of apoptosis-related protein including Caspase-9, Caspase-3, poly (ADP-ribose) polymerase (PARP) and the ratio of Bax/Bcl-2.	deoxynivalenol	25-28	caspase 3	Mus musculus	125-164
27998766-6	2017	Western blot showed that DON significantly increased the expression levels of apoptosis-related protein including Caspase-9, Caspase-3, poly (ADP-ribose) polymerase (PARP) and the ratio of Bax/Bcl-2.	deoxynivalenol	25-28	poly (ADP-ribose) polymerase family, member 1	Mus musculus	166-170
27998766-6	2017	Western blot showed that DON significantly increased the expression levels of apoptosis-related protein including Caspase-9, Caspase-3, poly (ADP-ribose) polymerase (PARP) and the ratio of Bax/Bcl-2.	deoxynivalenol	25-28	BCL2-associated X protein	Mus musculus	189-192
27998766-6	2017	Western blot showed that DON significantly increased the expression levels of apoptosis-related protein including Caspase-9, Caspase-3, poly (ADP-ribose) polymerase (PARP) and the ratio of Bax/Bcl-2.	deoxynivalenol	25-28	B cell leukemia/lymphoma 2	Mus musculus	193-198
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cell division cycle 25C	Mus musculus	94-100
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cell division cycle 25C	Mus musculus	103-109
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cyclin-dependent kinase 1	Mus musculus	103-107
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cyclin B1	Mus musculus	127-135
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cyclin B1	Mus musculus	210-218
27998766-7	2017	After DON treatment, the expression levels of cell cycle-related protein including p38/p-p38, Cdc25C/p-Cdc25C, Cdc2/p-Cdc2 and cyclinB1 were significantly decreased and immunoprecipitation analysis showed that cyclinB1-Cdc2 complex was significantly decreased.	deoxynivalenol	6-9	cyclin-dependent kinase 1	Mus musculus	103-107
27998766-9	2017	Collectively, these data suggest that DON causes apoptosis via mitochondria apoptosis pathway and induces G2 arrest via p38 MAPK signaling pathway in mouse ESCs.	deoxynivalenol	38-41	mitogen-activated protein kinase 14	Mus musculus	120-123
26979077-3	2017	Recent in vitro studies in the murine STC-1 EEC model have linked DON-induced satiety hormone secretion to activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor, and transient receptor potential ankyrin-1 (TRPA1), a TRP channel.	deoxynivalenol	66-69	stanniocalcin 1	Mus musculus	38-43
26979077-3	2017	Recent in vitro studies in the murine STC-1 EEC model have linked DON-induced satiety hormone secretion to activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor, and transient receptor potential ankyrin-1 (TRPA1), a TRP channel.	deoxynivalenol	66-69	calcium-sensing receptor	Mus musculus	147-151
26979077-3	2017	Recent in vitro studies in the murine STC-1 EEC model have linked DON-induced satiety hormone secretion to activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor, and transient receptor potential ankyrin-1 (TRPA1), a TRP channel.	deoxynivalenol	66-69	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	188-226
26979077-3	2017	Recent in vitro studies in the murine STC-1 EEC model have linked DON-induced satiety hormone secretion to activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor, and transient receptor potential ankyrin-1 (TRPA1), a TRP channel.	deoxynivalenol	66-69	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	228-233
26979077-5	2017	Here, we tested the hypothesis that DON-induced food refusal and satiety hormone release in the mouse are linked to activation of CaSR and TRPA1.	deoxynivalenol	36-39	calcium-sensing receptor	Mus musculus	130-134
26979077-5	2017	Here, we tested the hypothesis that DON-induced food refusal and satiety hormone release in the mouse are linked to activation of CaSR and TRPA1.	deoxynivalenol	36-39	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	139-144
26979077-8	2017	Taken together, these in vivo data along with prior in vitro findings support the contention that activation of CaSR and TRPA1 contributes to DON-induced food refusal by mediating satiety hormone exocytosis from EEC.	deoxynivalenol	142-145	calcium-sensing receptor	Mus musculus	112-116
26979077-8	2017	Taken together, these in vivo data along with prior in vitro findings support the contention that activation of CaSR and TRPA1 contributes to DON-induced food refusal by mediating satiety hormone exocytosis from EEC.	deoxynivalenol	142-145	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	121-126
27591283-5	2017	Consequently, feeding broilers a diet contaminated with DON and/or FBs induced a CORT stress response, which may indicate a negative effect on animal welfare.	deoxynivalenol	56-59	CORT	Gallus gallus	81-85
27624824-8	2016	The myofibroblast-like A26 cells exhibited low responses in the induction of pro-inflammatory cytokines to LPS or DON; however, the expression of IL-6 was significantly observed 3 h after DON stimulation.	deoxynivalenol	188-191	interferon beta-2	Bos taurus	146-150
27667315-3	2017	In prior work utilizing a cloned EEC model, our laboratory discovered that DON-induced activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor (GPCR), and transient receptor ankyrin-1 (TRPA1), a transient receptor potential (TRP) channel, drives Ca2+-mediated hormone secretion.	deoxynivalenol	75-78	calcium-sensing receptor	Mus musculus	127-131
27667315-3	2017	In prior work utilizing a cloned EEC model, our laboratory discovered that DON-induced activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor (GPCR), and transient receptor ankyrin-1 (TRPA1), a transient receptor potential (TRP) channel, drives Ca2+-mediated hormone secretion.	deoxynivalenol	75-78	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	205-210
27667315-4	2017	Consistent with these in vitro findings, CaSR and TRPA1 mediate DON-induced satiety hormone release and food refusal in the mouse, an animal model incapable of vomiting.	deoxynivalenol	64-67	calcium-sensing receptor	Mus musculus	41-45
27667315-4	2017	Consistent with these in vitro findings, CaSR and TRPA1 mediate DON-induced satiety hormone release and food refusal in the mouse, an animal model incapable of vomiting.	deoxynivalenol	64-67	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	50-55
27667315-6	2017	To address this, we tested the hypothesis that DON triggers emesis in mink by activating CaSR and TRPA1.	deoxynivalenol	47-50	calcium-sensing receptor	Mus musculus	89-93
27667315-6	2017	To address this, we tested the hypothesis that DON triggers emesis in mink by activating CaSR and TRPA1.	deoxynivalenol	47-50	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	98-103
27667315-12	2017	To summarize, the observations here strongly suggest that activation of CaSR and TRPA1 might have critical roles in DON-induced emesis.	deoxynivalenol	116-119	calcium-sensing receptor	Mus musculus	72-76
27667315-12	2017	To summarize, the observations here strongly suggest that activation of CaSR and TRPA1 might have critical roles in DON-induced emesis.	deoxynivalenol	116-119	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	81-86
26883726-3	2016	C3H/HeOuJ mice, orally exposed to DON plus whey once a week for 5 consecutive weeks, showed whey-specific IgG1 and IgE in serum and an acute allergic skin response upon intradermal whey challenge, although early initiating mechanisms of sensitization in the intestine appeared to be different compared with the widely used mucosal adjuvant cholera toxin (CT).	deoxynivalenol	34-37	LOC105243590	Mus musculus	106-110
27389473-2	2016	Our prior studies suggest that Deoxynivalenol (DON), a mycotoxin, behaves as a tumor promoter by inducing edema, hyperplasia, ODC activity and activation of MAPK"s in mouse skin.	deoxynivalenol	31-45	mitogen-activated protein kinase 3	Homo sapiens	157-161
27389473-2	2016	Our prior studies suggest that Deoxynivalenol (DON), a mycotoxin, behaves as a tumor promoter by inducing edema, hyperplasia, ODC activity and activation of MAPK"s in mouse skin.	deoxynivalenol	47-50	mitogen-activated protein kinase 3	Homo sapiens	157-161
27389473-3	2016	In this study, topical application of DON, 336 and 672 nmol significantly enhanced ROS levels, DNA damage and apoptosis with concomitant downregulation of Ki-67, cyclin D, cyclin E, cyclin A and cyclin-dependent kinases (CDK4 and CDK2) thereby resulting in tumor initiation in mouse skin.	deoxynivalenol	38-41	antigen identified by monoclonal antibody Ki 67	Mus musculus	155-160
27389473-3	2016	In this study, topical application of DON, 336 and 672 nmol significantly enhanced ROS levels, DNA damage and apoptosis with concomitant downregulation of Ki-67, cyclin D, cyclin E, cyclin A and cyclin-dependent kinases (CDK4 and CDK2) thereby resulting in tumor initiation in mouse skin.	deoxynivalenol	38-41	cyclin A2	Mus musculus	182-190
27389473-3	2016	In this study, topical application of DON, 336 and 672 nmol significantly enhanced ROS levels, DNA damage and apoptosis with concomitant downregulation of Ki-67, cyclin D, cyclin E, cyclin A and cyclin-dependent kinases (CDK4 and CDK2) thereby resulting in tumor initiation in mouse skin.	deoxynivalenol	38-41	cyclin-dependent kinase 4	Mus musculus	221-225
27389473-3	2016	In this study, topical application of DON, 336 and 672 nmol significantly enhanced ROS levels, DNA damage and apoptosis with concomitant downregulation of Ki-67, cyclin D, cyclin E, cyclin A and cyclin-dependent kinases (CDK4 and CDK2) thereby resulting in tumor initiation in mouse skin.	deoxynivalenol	38-41	cyclin-dependent kinase 2	Mus musculus	230-234
26883726-4	2016	Notably, DON exposure modulated tight-junction mRNA and protein levels, and caused an early increase in IL-33, whereas CT exposure affected intestinal gammadelta T cells.	deoxynivalenol	9-12	interleukin 33	Mus musculus	104-109
26883726-5	2016	On the other hand, both DON- and CT-sensitized mice induced a time-dependent increase in the soluble IL-33 receptor ST2 (IL-1R1) in serum, and enhanced local innate lymphoid cells type 2 cell numbers.	deoxynivalenol	24-27	interleukin 33	Mus musculus	101-106
26883726-5	2016	On the other hand, both DON- and CT-sensitized mice induced a time-dependent increase in the soluble IL-33 receptor ST2 (IL-1R1) in serum, and enhanced local innate lymphoid cells type 2 cell numbers.	deoxynivalenol	24-27	interleukin 1 receptor, type I	Mus musculus	121-127
27456127-0	2016	Effects of chronic deoxynivalenol exposure on p53 heterozygous and p53 homozygous mice.	deoxynivalenol	19-33	transformation related protein 53, pseudogene	Mus musculus	46-49
27456127-0	2016	Effects of chronic deoxynivalenol exposure on p53 heterozygous and p53 homozygous mice.	deoxynivalenol	19-33	transformation related protein 53, pseudogene	Mus musculus	67-70
27456127-7	2016	The lack of inflammatory and proliferative lesions in mice may be attributed to the anorectic effects of DON, which resulted in dose-dependent reductions in body weight in p53+/+ and p53+/- mice.	deoxynivalenol	105-108	transformation related protein 53, pseudogene	Mus musculus	172-175
27481073-5	2016	In particular, deoxynivalenol and 15-acetyl-deoxynivalenol acted as antagonists for the PPARy2 receptor.	deoxynivalenol	15-29	peroxisome proliferator activated receptor gamma	Homo sapiens	88-94
27456127-7	2016	The lack of inflammatory and proliferative lesions in mice may be attributed to the anorectic effects of DON, which resulted in dose-dependent reductions in body weight in p53+/+ and p53+/- mice.	deoxynivalenol	105-108	transformation related protein 53, pseudogene	Mus musculus	183-186
27456127-9	2016	The effects of 26-week DON exposure on p53+/+ and p53+/-mice were consistent with those previously seen in B6C3F1 mice exposed to DON for two years.	deoxynivalenol	23-26	transformation related protein 53, pseudogene	Mus musculus	39-42
27456127-9	2016	The effects of 26-week DON exposure on p53+/+ and p53+/-mice were consistent with those previously seen in B6C3F1 mice exposed to DON for two years.	deoxynivalenol	23-26	transformation related protein 53, pseudogene	Mus musculus	50-53
27618100-0	2016	Early Activation of MAPK p44/42 Is Partially Involved in DON-Induced Disruption of the Intestinal Barrier Function and Tight Junction Network.	deoxynivalenol	57-60	interferon induced protein 44	Homo sapiens	25-28
27132852-8	2016	However, the presence of xylanase, alpha-amylase, cellulase and lipase resulted in bread with greater quantities of DON-3-glucoside when fermentation occurred at 30 C. The results showed that wheat bran and flour may contain hidden DON that may be enzymatically released during the breadmaking process when the fermentation temperature is close to 30 C.	deoxynivalenol	116-119	LOW QUALITY PROTEIN: endoglucanase 10	Triticum aestivum	50-70
27618100-5	2016	The present study confirms DON-induced activation of MAPK p44/42 and inhibition of p44/42 by MAPK-inhibitor U0126 monoethanolate.	deoxynivalenol	27-30	interferon induced protein 44	Homo sapiens	58-61
27618100-5	2016	The present study confirms DON-induced activation of MAPK p44/42 and inhibition of p44/42 by MAPK-inhibitor U0126 monoethanolate.	deoxynivalenol	27-30	interferon induced protein 44	Homo sapiens	83-86
27618100-8	2016	Inhibition of p44/42 counteracted DON-induced TEER decrease and restored claudin-3, but not claudin-1 expression.	deoxynivalenol	34-37	interferon induced protein 44	Homo sapiens	14-17
27618100-9	2016	Therefore, effects of DON on TEER and claudin-3 are at least partially p44/42 mediated, while effects on viability and claudin-1 are likely mediated via alternative pathways.	deoxynivalenol	22-25	claudin 3	Homo sapiens	38-47
27618100-9	2016	Therefore, effects of DON on TEER and claudin-3 are at least partially p44/42 mediated, while effects on viability and claudin-1 are likely mediated via alternative pathways.	deoxynivalenol	22-25	interferon induced protein 44	Homo sapiens	71-74
27245696-8	2016	Mutants in the E3 ligase Hel2, involved in ribosome quality control, and several members of the Rpd3 histone deacetylase complex were highly sensitive to DON.	deoxynivalenol	154-157	E3 ubiquitin-protein ligase HEL2	Saccharomyces cerevisiae S288C	25-29
27090011-4	2016	Exposure to DON (12.5 mg/kg bw) for 3 h significantly increased the hypothalamic mRNA levels of anorexic pro-opiomelanocortin (POMC) and its downstream targets, including melanocortin 4 receptor, brain-derived neurotrophic factor, and tyrosine kinase receptor B; at the same time, orexigenic hormones were not affected.	deoxynivalenol	12-15	pro-opiomelanocortin-alpha	Mus musculus	105-125
27090011-4	2016	Exposure to DON (12.5 mg/kg bw) for 3 h significantly increased the hypothalamic mRNA levels of anorexic pro-opiomelanocortin (POMC) and its downstream targets, including melanocortin 4 receptor, brain-derived neurotrophic factor, and tyrosine kinase receptor B; at the same time, orexigenic hormones were not affected.	deoxynivalenol	12-15	pro-opiomelanocortin-alpha	Mus musculus	127-131
27090011-4	2016	Exposure to DON (12.5 mg/kg bw) for 3 h significantly increased the hypothalamic mRNA levels of anorexic pro-opiomelanocortin (POMC) and its downstream targets, including melanocortin 4 receptor, brain-derived neurotrophic factor, and tyrosine kinase receptor B; at the same time, orexigenic hormones were not affected.	deoxynivalenol	12-15	melanocortin 4 receptor	Mus musculus	171-194
27090011-4	2016	Exposure to DON (12.5 mg/kg bw) for 3 h significantly increased the hypothalamic mRNA levels of anorexic pro-opiomelanocortin (POMC) and its downstream targets, including melanocortin 4 receptor, brain-derived neurotrophic factor, and tyrosine kinase receptor B; at the same time, orexigenic hormones were not affected.	deoxynivalenol	12-15	brain derived neurotrophic factor	Mus musculus	196-261
27090011-6	2016	These results suggest that DON-induced proinflammatory cytokines increased the POMC level via NF-kappaB activation.	deoxynivalenol	27-30	pro-opiomelanocortin-alpha	Mus musculus	79-83
27090011-6	2016	These results suggest that DON-induced proinflammatory cytokines increased the POMC level via NF-kappaB activation.	deoxynivalenol	27-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	94-103
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	22-25	cholecystokinin	Mus musculus	111-114
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	22-25	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	168-173
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	22-25	cholecystokinin	Mus musculus	272-275
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	22-25	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	291-296
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	cholecystokinin	Mus musculus	111-114
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	168-173
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	cholecystokinin	Mus musculus	272-275
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	291-296
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	cholecystokinin	Mus musculus	111-114
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	168-173
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	cholecystokinin	Mus musculus	272-275
27090011-7	2016	Moreover, exposure to DON significantly enhanced the gastrointestinal mRNA levels of anorexic cholecystokinin (CCK) and transient receptor potential ankyrin-1 channel (TRPA1), a possible target of DON; these findings suggest that DON induced anorexic action by increasing CCK production via TRPA1.	deoxynivalenol	197-200	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	291-296
27090011-8	2016	Taken together, these results suggest that DON induces anorexic POMC, perhaps via NF-kappaB activation, by increasing proinflammatory cytokines in the hypothalamus and brings about CCK production, possibly through increasing intestinal TRPA1 expression, leading to anorexic actions.	deoxynivalenol	43-46	pro-opiomelanocortin-alpha	Mus musculus	64-68
27090011-8	2016	Taken together, these results suggest that DON induces anorexic POMC, perhaps via NF-kappaB activation, by increasing proinflammatory cytokines in the hypothalamus and brings about CCK production, possibly through increasing intestinal TRPA1 expression, leading to anorexic actions.	deoxynivalenol	43-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	82-91
27090011-8	2016	Taken together, these results suggest that DON induces anorexic POMC, perhaps via NF-kappaB activation, by increasing proinflammatory cytokines in the hypothalamus and brings about CCK production, possibly through increasing intestinal TRPA1 expression, leading to anorexic actions.	deoxynivalenol	43-46	cholecystokinin	Mus musculus	181-184
27090011-8	2016	Taken together, these results suggest that DON induces anorexic POMC, perhaps via NF-kappaB activation, by increasing proinflammatory cytokines in the hypothalamus and brings about CCK production, possibly through increasing intestinal TRPA1 expression, leading to anorexic actions.	deoxynivalenol	43-46	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	236-241
26600019-10	2015	RESULTS: Deoxynivalenol reduced the barrier integrity and caused cytotoxic effects at 10 muM concentrations.	deoxynivalenol	9-23	latexin	Homo sapiens	89-92
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	113-116	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	26-29
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	113-116	lysosomal associated membrane protein 2	Homo sapiens	62-67
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	113-116	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	69-72
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	113-116	mechanistic target of rapamycin kinase	Homo sapiens	77-81
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	210-213	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	26-29
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	210-213	lysosomal associated membrane protein 2	Homo sapiens	62-67
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	210-213	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	69-72
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	210-213	mechanistic target of rapamycin kinase	Homo sapiens	77-81
26988607-5	2016	In addition, up-regulated LC3 protein expression and aberrant Lamp2, LC3 and mTOR mRNA levels were observed with DON exposure, together with Annexin V-FITC staining assay analysis, these results indicated that DON treatment induced autophagy/apoptosis in porcine oocytes.	deoxynivalenol	210-213	annexin A5	Homo sapiens	141-150
26988607-6	2016	We also showed that DON exposure increased DNA methylation level in porcine oocytes through altering DNMT3A mRNA levels.	deoxynivalenol	20-23	DNA methyltransferase 3 alpha	Homo sapiens	101-107
26809658-3	2016	With the DON exposure concentrations increased, the [Ca(2+)]i and CaM mRNA levels gradually increased in a dose-dependent manner, and all the evaluated conconcentrations affected ATPase activity to the same extent.	deoxynivalenol	9-12	calmodulin 2	Gallus gallus	66-69
26961612-0	2016	NF-kappaB activation via MyD88-dependent Toll-like receptor signaling is inhibited by trichothecene mycotoxin deoxynivalenol.	deoxynivalenol	110-124	MYD88 innate immune signal transduction adaptor	Homo sapiens	25-30
26961612-4	2016	The present study investigates the effect of DON on NF-kappaB in activated macrophages through MyD88-dependent pathways.	deoxynivalenol	45-48	MYD88 innate immune signal transduction adaptor	Homo sapiens	95-100
26961612-5	2016	DON inhibited NF-kappaB-dependent reporter activity induced by MyD88-dependent TLR agonists.	deoxynivalenol	0-3	MYD88 innate immune signal transduction adaptor	Homo sapiens	63-68
26961612-6	2016	In addition, lipopolysaccharide-induced phosphorylation of interleukin-1 receptor-associated kinase 1 and inhibitor kappaBalpha were attenuated by DON.	deoxynivalenol	147-150	interleukin 1 receptor associated kinase 1	Homo sapiens	59-127
26961612-7	2016	Furthermore, DON downregulated the expression level of MyD88.	deoxynivalenol	13-16	MYD88 innate immune signal transduction adaptor	Homo sapiens	55-60
26961612-8	2016	These results suggest that DON inhibits NF-kappaB activation in macrophages stimulated with TLR ligands via MyD88-dependent TLR signals.	deoxynivalenol	27-30	MYD88 innate immune signal transduction adaptor	Homo sapiens	108-113
26961612-9	2016	Therefore exposure to DON may lead to the inhibition of MyD88-dependent pathway of TLR signaling.	deoxynivalenol	22-25	MYD88 innate immune signal transduction adaptor	Homo sapiens	56-61
26857454-4	2016	Therefore, the aim of the present study was to investigate whether TLR2 stimulation enhances intestinal barrier function and protects against DON exposure.	deoxynivalenol	142-145	Tlr2	Cricetulus griseus	67-71
26857454-6	2016	In addition, pretreatment with TLR2 ligand, including Pam3CSK4 (PCSK) and lipoteichoic acid from Bacillus subtilis, prevented DON-induced barrier dysfunction by increasing the expression of TJ proteins via the PI3K-Akt-dependent pathway.	deoxynivalenol	126-129	TLR2	Sus scrofa	31-35
26857454-9	2016	Conclusively, TLR2 signaling on intestinal epithelial cells may enhance intestinal barrier function and prevent DON-induced barrier dysfunction of epithelial cells.	deoxynivalenol	112-115	TLR2	Sus scrofa	14-18
26763390-0	2016	MEIS3 is repressed in A549 lung epithelial cells by deoxynivalenol and the repression contributes to the deleterious effect.	deoxynivalenol	52-66	homeobox protein Meis3	Cricetulus griseus	0-5
26763390-7	2016	The result indicated that A549 cells that transiently expressed MEIS3 were tolerant to the deleterious effects of DON.	deoxynivalenol	114-117	homeobox protein Meis3	Cricetulus griseus	64-69
26763390-8	2016	Our data show that DON affected the expression of genes with various functions, and suggest that the repression of MEIS3 plays roles in the deleterious effect of DON in A549 lung epithelial cells.	deoxynivalenol	19-22	homeobox protein Meis3	Cricetulus griseus	115-120
26763390-8	2016	Our data show that DON affected the expression of genes with various functions, and suggest that the repression of MEIS3 plays roles in the deleterious effect of DON in A549 lung epithelial cells.	deoxynivalenol	162-165	homeobox protein Meis3	Cricetulus griseus	115-120
27058607-7	2016	Further mechanistic studies demonstrated that RES protects against DON-induced barrier dysfunction by promoting the assembly of claudin-4 in the tight junction complex.	deoxynivalenol	67-70	claudin 4	Homo sapiens	128-137
27017380-4	2016	DON treatment inhibited proliferation of PC12 cells, induced significant morphological changes and apoptosis, promoted the release of Cyt C and AIF from the mitochondria, and increased the activities of cleaved-Caspase9 and cleaved-Caspase3.	deoxynivalenol	0-3	apoptosis inducing factor, mitochondria associated 1	Rattus norvegicus	144-147
27017380-4	2016	DON treatment inhibited proliferation of PC12 cells, induced significant morphological changes and apoptosis, promoted the release of Cyt C and AIF from the mitochondria, and increased the activities of cleaved-Caspase9 and cleaved-Caspase3.	deoxynivalenol	0-3	caspase 9	Rattus norvegicus	211-219
27017380-5	2016	Bcl-2 expression decreased with increasing DON concentrations, in contrast to Bax and Bid, which were increased with increasing DON concentration.	deoxynivalenol	43-46	BCL2, apoptosis regulator	Rattus norvegicus	0-5
27017380-5	2016	Bcl-2 expression decreased with increasing DON concentrations, in contrast to Bax and Bid, which were increased with increasing DON concentration.	deoxynivalenol	128-131	BCL2, apoptosis regulator	Rattus norvegicus	0-5
27017380-5	2016	Bcl-2 expression decreased with increasing DON concentrations, in contrast to Bax and Bid, which were increased with increasing DON concentration.	deoxynivalenol	128-131	BCL2 associated X, apoptosis regulator	Rattus norvegicus	78-81
27017380-5	2016	Bcl-2 expression decreased with increasing DON concentrations, in contrast to Bax and Bid, which were increased with increasing DON concentration.	deoxynivalenol	128-131	BH3 interacting domain death agonist	Rattus norvegicus	86-89
26657070-5	2016	DON and beta-Zol increased CYP19A1 mRNA abundance.	deoxynivalenol	0-3	aromatase	Bos taurus	27-34
26657070-6	2016	CYP11A1 mRNA abundance was stimulated by DON, alone and combined with alpha-Zol and beta-Zol, whereas was inhibited by beta-Zol alone.	deoxynivalenol	41-44	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	0-7
24988111-7	2015	Induction of ER stress by DON was confirmed by immunocytology demonstrating increased protein expression of two major ER stress markers ATF3 and DDIT3.	deoxynivalenol	26-29	activating transcription factor 3	Homo sapiens	136-140
26192767-7	2015	Moreover, using c-Fos staining, a strong neuronal activation was observed in the solitary tract nucleus which contains the central pattern generator of swallowing and in the area postrema after DON intravenous injection.	deoxynivalenol	194-197	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	16-21
26259183-3	2015	Using cultured cells of Nicotiana tabacum BY2, we showed that DON-induced programmed cell death (PCD) could require transcription and translation processes, in contrast to what was observed in animal cells.	deoxynivalenol	62-65	F-box protein PP2-B11-like	Nicotiana tabacum	42-45
26259183-4	2015	DON could induce different cross-linked pathways involving (i) reactive oxygen species (ROS) generation linked, at least partly, to a mitochondrial dysfunction and a transcriptional down-regulation of the alternative oxidase (Aox1) gene and (ii) regulation of ion channel activities participating in cell shrinkage, to achieve PCD.	deoxynivalenol	0-3	ubiquinol oxidase 1, mitochondrial	Nicotiana tabacum	226-230
24988111-7	2015	Induction of ER stress by DON was confirmed by immunocytology demonstrating increased protein expression of two major ER stress markers ATF3 and DDIT3.	deoxynivalenol	26-29	DNA damage inducible transcript 3	Homo sapiens	145-150
24988111-10	2015	Lastly, this study showed that DON induced cleavage of caspase-3, an event known to mediate apoptosis.	deoxynivalenol	31-34	caspase 3	Homo sapiens	55-64
25727397-4	2015	Results showed that subtoxic doses of DON (as low as 1 muM) decreased mucin (MUC) production.	deoxynivalenol	38-41	latexin	Homo sapiens	55-58
26067367-5	2015	The mRNA expression of different tight junction (TJ) proteins, especially occludin, of inflammatory markers, like interleukin-1 beta and interleukin-10 and the oxidative stress marker heme-oxigenase1, were affected along the intestine by low levels of DON in the diet.	deoxynivalenol	252-255	occludin	Sus scrofa	74-82
24927789-0	2015	In vitro glucuronidation kinetics of deoxynivalenol by human and animal microsomes and recombinant human UGT enzymes.	deoxynivalenol	37-51	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	105-108
26019243-4	2015	METHODS: Human epithelial intestinal Caco-2 cells, pretreated with different concentrations of GOSs (0.5%, 1%, and 2%) for 24 h, were stimulated with 4.2-muM deoxynivalenol (24 h), and 6/7-wk-old male B6C3F1 mice were fed a diet supplemented with 1% GOSs for 2 wk before being orally exposed to deoxynivalenol (25 mg/kg body weight, 6 h).	deoxynivalenol	158-172	latexin	Homo sapiens	154-157
26019243-11	2015	Moreover, GOSs stabilized the expression and cellular distribution of claudin3 and suppressed by &gt;50% the deoxynivalenol-induced synthesis and release of interleukin-8 [IL8/chemokine CXC motif ligand (CXCL8)] (P &lt; 0.05).	deoxynivalenol	109-123	C-X-C motif chemokine ligand 8	Homo sapiens	157-170
26019243-11	2015	Moreover, GOSs stabilized the expression and cellular distribution of claudin3 and suppressed by &gt;50% the deoxynivalenol-induced synthesis and release of interleukin-8 [IL8/chemokine CXC motif ligand (CXCL8)] (P &lt; 0.05).	deoxynivalenol	109-123	C-X-C motif chemokine ligand 8	Homo sapiens	172-175
26019243-11	2015	Moreover, GOSs stabilized the expression and cellular distribution of claudin3 and suppressed by &gt;50% the deoxynivalenol-induced synthesis and release of interleukin-8 [IL8/chemokine CXC motif ligand (CXCL8)] (P &lt; 0.05).	deoxynivalenol	109-123	C-X-C motif chemokine ligand 8	Homo sapiens	204-209
26019243-12	2015	In mice, GOSs prevented the deoxynivalenol-induced mRNA overexpression of claudin3 (P = 0.022) and CXCL8 homolog keratinocyte hemoattractant (Kc) (Cxcl1) (P = 0.06) as well as the deoxynivalenol-induced morphologic defects.	deoxynivalenol	28-42	claudin 3	Mus musculus	74-82
26019243-12	2015	In mice, GOSs prevented the deoxynivalenol-induced mRNA overexpression of claudin3 (P = 0.022) and CXCL8 homolog keratinocyte hemoattractant (Kc) (Cxcl1) (P = 0.06) as well as the deoxynivalenol-induced morphologic defects.	deoxynivalenol	28-42	C-X-C motif chemokine ligand 8	Homo sapiens	99-104
26019243-12	2015	In mice, GOSs prevented the deoxynivalenol-induced mRNA overexpression of claudin3 (P = 0.022) and CXCL8 homolog keratinocyte hemoattractant (Kc) (Cxcl1) (P = 0.06) as well as the deoxynivalenol-induced morphologic defects.	deoxynivalenol	28-42	chemokine (C-X-C motif) ligand 1	Mus musculus	147-152
25727397-4	2015	Results showed that subtoxic doses of DON (as low as 1 muM) decreased mucin (MUC) production.	deoxynivalenol	38-41	LOC100508689	Homo sapiens	70-75
25727397-4	2015	Results showed that subtoxic doses of DON (as low as 1 muM) decreased mucin (MUC) production.	deoxynivalenol	38-41	LOC100508689	Homo sapiens	77-80
25727397-6	2015	Mechanistic studies demonstrated that DON effect relied on the activation of the protein kinase R and the mitogen-activated protein kinase p38 ultimately leading to the inhibition of the expression of resistin-like molecule beta, a known positive regulator of MUC expression.	deoxynivalenol	38-41	mitogen-activated protein kinase 14	Homo sapiens	139-142
25727397-6	2015	Mechanistic studies demonstrated that DON effect relied on the activation of the protein kinase R and the mitogen-activated protein kinase p38 ultimately leading to the inhibition of the expression of resistin-like molecule beta, a known positive regulator of MUC expression.	deoxynivalenol	38-41	LOC100508689	Homo sapiens	260-263
25766886-0	2015	The Food-Associated Ribotoxin Deoxynivalenol Modulates Inducible NO Synthase in Human Intestinal Cell Model.	deoxynivalenol	30-44	nitric oxide synthase 2	Homo sapiens	55-76
25766886-6	2015	We studied the impact of DON on the intestinal expression of iNOS using the Caco-2 cell model.	deoxynivalenol	25-28	nitric oxide synthase 2	Homo sapiens	61-65
25766886-7	2015	In line with its proinflammatory activity, we observed that DON dose-dependently up-regulates the expression of iNOS mRNA.	deoxynivalenol	60-63	nitric oxide synthase 2	Homo sapiens	112-116
25766886-9	2015	When testing the effects of DON on cytokine-mediated induction of iNOS, we found that very low concentrations of DON (ie, 1 microM) decrease the amount of iNOS protein but not of iNOS mRNA.	deoxynivalenol	28-31	nitric oxide synthase 2	Homo sapiens	66-70
25766886-9	2015	When testing the effects of DON on cytokine-mediated induction of iNOS, we found that very low concentrations of DON (ie, 1 microM) decrease the amount of iNOS protein but not of iNOS mRNA.	deoxynivalenol	113-116	nitric oxide synthase 2	Homo sapiens	66-70
25766886-9	2015	When testing the effects of DON on cytokine-mediated induction of iNOS, we found that very low concentrations of DON (ie, 1 microM) decrease the amount of iNOS protein but not of iNOS mRNA.	deoxynivalenol	113-116	nitric oxide synthase 2	Homo sapiens	155-159
25766886-9	2015	When testing the effects of DON on cytokine-mediated induction of iNOS, we found that very low concentrations of DON (ie, 1 microM) decrease the amount of iNOS protein but not of iNOS mRNA.	deoxynivalenol	113-116	nitric oxide synthase 2	Homo sapiens	155-159
25766886-11	2015	Taken together, our results demonstrate that although DON causes intestinal inflammation, it suppresses the ability of the gut epithelium to express iNOS and to produce NO, potentially explaining the increased susceptibility of animals to intestinal infection following exposure to low doses of DON.	deoxynivalenol	54-57	nitric oxide synthase 2	Homo sapiens	149-153
25787141-0	2015	Deoxynivalenol (Vomitoxin)-Induced Cholecystokinin and Glucagon-Like Peptide-1 Release in the STC-1 Enteroendocrine Cell Model Is Mediated by Calcium-Sensing Receptor and Transient Receptor Potential Ankyrin-1 Channel.	deoxynivalenol	0-14	cholecystokinin	Mus musculus	35-50
25787141-0	2015	Deoxynivalenol (Vomitoxin)-Induced Cholecystokinin and Glucagon-Like Peptide-1 Release in the STC-1 Enteroendocrine Cell Model Is Mediated by Calcium-Sensing Receptor and Transient Receptor Potential Ankyrin-1 Channel.	deoxynivalenol	0-14	stanniocalcin 1	Mus musculus	94-99
25787141-0	2015	Deoxynivalenol (Vomitoxin)-Induced Cholecystokinin and Glucagon-Like Peptide-1 Release in the STC-1 Enteroendocrine Cell Model Is Mediated by Calcium-Sensing Receptor and Transient Receptor Potential Ankyrin-1 Channel.	deoxynivalenol	16-25	cholecystokinin	Mus musculus	35-50
25787141-0	2015	Deoxynivalenol (Vomitoxin)-Induced Cholecystokinin and Glucagon-Like Peptide-1 Release in the STC-1 Enteroendocrine Cell Model Is Mediated by Calcium-Sensing Receptor and Transient Receptor Potential Ankyrin-1 Channel.	deoxynivalenol	16-25	stanniocalcin 1	Mus musculus	94-99
25787141-3	2015	To address this gap, we employed the murine neuroendocrine tumor STC-1 cell line, a widely used EEC model, to test the hypothesis that DON-induced hormone exocytosis is mediated by G protein-coupled receptor (GPCR)-mediated Ca(2+) signaling.	deoxynivalenol	135-138	stanniocalcin 1	Mus musculus	65-70
25813030-5	2015	Direct competitive enzyme-linked immunosorbent assay demonstrated that the H2 antibody could competitively bind to free FB1, FB2, and FB3, with an IC50 of 0.11, 0.04, and 0.10 muM, respectively; it had no cross-reactivity to deoxynivalenol, nivalenol and aflatoxin.	deoxynivalenol	225-239	TCF3 fusion partner	Homo sapiens	120-123
25731188-4	2015	Addition of DON inhibited estradiol and progesterone secretion, and reduced levels of mRNA encoding estrogenic (CYP19A1) but not progestogenic (CYP11A1 and STAR) proteins.	deoxynivalenol	12-15	steroidogenic acute regulatory protein, mitochondrial	Cricetulus griseus	156-160
25731188-7	2015	Addition of DON rapidly and transiently increased phosphorylation of MAPK3/1, and resulted in a more prolonged phosphorylation of MAPK14 (p38) and MAPK8 (JNK).	deoxynivalenol	12-15	mitogen-activated protein kinase 3	Cricetulus griseus	69-74
25731188-7	2015	Addition of DON rapidly and transiently increased phosphorylation of MAPK3/1, and resulted in a more prolonged phosphorylation of MAPK14 (p38) and MAPK8 (JNK).	deoxynivalenol	12-15	mitogen-activated protein kinase 14	Cricetulus griseus	130-136
25731188-7	2015	Addition of DON rapidly and transiently increased phosphorylation of MAPK3/1, and resulted in a more prolonged phosphorylation of MAPK14 (p38) and MAPK8 (JNK).	deoxynivalenol	12-15	mitogen-activated protein kinase 8	Cricetulus griseus	147-152
25731188-8	2015	Activation of these pathways by DON resulted in time- and dose-dependent increases in abundance of mRNA encoding the transcription factors FOS, FOSL1, EGR1, and EGR3.	deoxynivalenol	32-35	protein c-Fos	Cricetulus griseus	139-142
25731188-8	2015	Activation of these pathways by DON resulted in time- and dose-dependent increases in abundance of mRNA encoding the transcription factors FOS, FOSL1, EGR1, and EGR3.	deoxynivalenol	32-35	fos-related antigen 1	Cricetulus griseus	144-149
25731188-8	2015	Activation of these pathways by DON resulted in time- and dose-dependent increases in abundance of mRNA encoding the transcription factors FOS, FOSL1, EGR1, and EGR3.	deoxynivalenol	32-35	early growth response protein 1	Cricetulus griseus	151-155
25731188-8	2015	Activation of these pathways by DON resulted in time- and dose-dependent increases in abundance of mRNA encoding the transcription factors FOS, FOSL1, EGR1, and EGR3.	deoxynivalenol	32-35	early growth response protein 3	Cricetulus griseus	161-165
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	186-189	solute carrier family 5 member 1	Sus scrofa	33-61
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	186-189	solute carrier family 5 member 1	Sus scrofa	63-69
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	186-189	solute carrier family 2 member 2	Sus scrofa	72-98
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	186-189	solute carrier family 2 member 2	Sus scrofa	100-106
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	234-237	solute carrier family 5 member 1	Sus scrofa	33-61
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	234-237	solute carrier family 5 member 1	Sus scrofa	63-69
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	234-237	solute carrier family 2 member 2	Sus scrofa	72-98
25884909-6	2015	Furthermore, the mRNA levels for sodium-glucose transporter-1 (SGLT-1), glucose transporter type-2 (GLUT-2) and y(+)L-type amino acid transporter-1 (y(+)LAT-1) were downregulated in the DON group, but the values were increased in the DON + ARG group (p &lt; 0.05).	deoxynivalenol	234-237	solute carrier family 2 member 2	Sus scrofa	100-106
25542652-3	2015	The concentrations of IL-1RI, IL-6, IL-10, and IFN-gamma were increased with the DON concentrations increasing (P&lt;0.05 or P&lt;0.01).	deoxynivalenol	81-84	interferon gamma	Gallus gallus	47-56
25542652-4	2015	However, the concentrations of IL-1beta, IL-2, IL-4, and IL-12beta were decreased with the DON concentrations increasing (P&lt;0.05 or P&lt;0.01).	deoxynivalenol	91-94	interleukin 12B	Gallus gallus	57-66
25542652-6	2015	The highest mRNA expressions values of IL-1RI, IL-4, IL-10, IL-12beta, and IFN-gamma were at 50 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01), while the highest mRNA expressions values of IL-2 and IL-6 were at 12.5 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01).	deoxynivalenol	103-106	interleukin 10	Gallus gallus	53-58
25542652-6	2015	The highest mRNA expressions values of IL-1RI, IL-4, IL-10, IL-12beta, and IFN-gamma were at 50 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01), while the highest mRNA expressions values of IL-2 and IL-6 were at 12.5 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01).	deoxynivalenol	103-106	interleukin 12B	Gallus gallus	60-69
25542652-6	2015	The highest mRNA expressions values of IL-1RI, IL-4, IL-10, IL-12beta, and IFN-gamma were at 50 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01), while the highest mRNA expressions values of IL-2 and IL-6 were at 12.5 mug/mL DON treatment groups (P&lt;0.05 or P&lt;0.01).	deoxynivalenol	103-106	interferon gamma	Gallus gallus	75-84
26304032-8	2015	RESULTS: Dietary GOS counteracted the DON-induced IL-33 mRNA expression and changed the IL-33 distribution pattern in the mouse small intestine.	deoxynivalenol	38-41	interleukin 33	Mus musculus	50-55
26020884-8	2015	Increasing the DON level reduced (linear; &lt; 0.05) ADG, ADFI, and pig BW, and Biofix did not improve performance.	deoxynivalenol	15-18	ADG	Sus scrofa	53-56
25553575-5	2015	Enzyme linked immunosorbent assays revealed that the concentrations of p53, Bax, Bak-1, and Caspase-3 increased with increasing DON concentration (P&lt;0.05 or P&lt;0.01), whereas the concentrations of Bcl-2 decreased (P&lt;0.01) compared with the control.	deoxynivalenol	128-131	BCL2 antagonist/killer 1	Gallus gallus	81-86
25553575-5	2015	Enzyme linked immunosorbent assays revealed that the concentrations of p53, Bax, Bak-1, and Caspase-3 increased with increasing DON concentration (P&lt;0.05 or P&lt;0.01), whereas the concentrations of Bcl-2 decreased (P&lt;0.01) compared with the control.	deoxynivalenol	128-131	caspase 3	Gallus gallus	92-101
25553575-5	2015	Enzyme linked immunosorbent assays revealed that the concentrations of p53, Bax, Bak-1, and Caspase-3 increased with increasing DON concentration (P&lt;0.05 or P&lt;0.01), whereas the concentrations of Bcl-2 decreased (P&lt;0.01) compared with the control.	deoxynivalenol	128-131	BCL2, apoptosis regulator	Gallus gallus	202-207
25690693-3	2015	Using real-time cellular impedance measurements, we studied the effects exerted in vitro by low concentrations of DON (0.37-1.50 muM), relevant for mycotoxin-contaminated food, on the proliferation of undifferentiated Caco-2 cells presenting a tumorigenic phenotype.	deoxynivalenol	114-117	latexin	Homo sapiens	129-132
25690693-4	2015	A 1.5 muM concentration of DON maintained cell adherence of non-proliferating Caco-2 cells, whilst arresting the growth of actively proliferating cells compared with control Caco-2 cells in vitro.	deoxynivalenol	27-30	latexin	Homo sapiens	6-9
25690693-5	2015	At 0.37 muM, DON enhanced Caco-2 cell metabolism, thereby triggering a moderate increase in cell proliferation.	deoxynivalenol	13-16	latexin	Homo sapiens	8-11
25958646-1	2015	OBJECTIVE: To synthesize the complete antigen of T-2 toxin and deoxynivalenol (DON), respectively.	deoxynivalenol	63-77	solute carrier family 25 member 5	Homo sapiens	49-52
25844862-6	2015	Similarly, a stimulatory effect of amygdalin co-administered with DON was detected with respect to the 17-beta-estradiol secretion at the highest dose (10,000 mug mL(1)) of amygdalin and 1 mug mL(1) of DON.	deoxynivalenol	66-69	L1 cell adhesion molecule	Mus musculus	163-168
25844862-6	2015	Similarly, a stimulatory effect of amygdalin co-administered with DON was detected with respect to the 17-beta-estradiol secretion at the highest dose (10,000 mug mL(1)) of amygdalin and 1 mug mL(1) of DON.	deoxynivalenol	66-69	L1 cell adhesion molecule	Mus musculus	193-198
25928907-1	2015	To improve our knowledge of the role of microRNAs (miRs) in responses of the porcine digestive system to two Fusarium mycotoxins, zearalenone (ZEN) and deoxynivalenol (DON), we examined the expression of 7 miRs (miR-9, miR-15a, miR-21, miR-34a, miR-122, miR-125b, and miR-192), previously found to be deregulated in diseased liver and colon cells.	deoxynivalenol	152-166	myosin regulatory light chain interacting protein	Homo sapiens	51-54
25958646-1	2015	OBJECTIVE: To synthesize the complete antigen of T-2 toxin and deoxynivalenol (DON), respectively.	deoxynivalenol	79-82	solute carrier family 25 member 5	Homo sapiens	49-52
25011710-9	2014	The study provides evidence that the suppressive effect of DON on the electrogenic transport of glucose may be due to an inhibitory activity of the PI3 kinase pathway and intestinal SGLT1.	deoxynivalenol	59-62	solute carrier family 5 member 1	Gallus gallus	182-187
25521494-0	2014	Direct activation of ribosome-associated double-stranded RNA-dependent protein kinase (PKR) by deoxynivalenol, anisomycin and ricin: a new model for ribotoxic stress response induction.	deoxynivalenol	95-109	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	87-90
25521494-1	2014	Double-stranded RNA (dsRNA)-activated protein kinase (PKR) is a critical upstream mediator of the ribotoxic stress response (RSR) to the trichothecene deoxynivalenol (DON) and other translational inhibitors.	deoxynivalenol	151-165	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	54-57
25521494-1	2014	Double-stranded RNA (dsRNA)-activated protein kinase (PKR) is a critical upstream mediator of the ribotoxic stress response (RSR) to the trichothecene deoxynivalenol (DON) and other translational inhibitors.	deoxynivalenol	167-170	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	54-57
25521494-5	2014	Treatment of ATP-containing HeLa lysates with DON or the ribotoxins anisomycin and ricin concentration-dependently elicited phosphorylation of PKR and its substrate eIF2alpha.	deoxynivalenol	46-49	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	143-146
25521494-5	2014	Treatment of ATP-containing HeLa lysates with DON or the ribotoxins anisomycin and ricin concentration-dependently elicited phosphorylation of PKR and its substrate eIF2alpha.	deoxynivalenol	46-49	eukaryotic translation initiation factor 2A	Homo sapiens	165-174
25502722-8	2014	Addition glutamic acid to DON treatment increased the plasma activities of SOD and GSH-Px and the proliferating cell nuclear antigen (PCNA) labeling indexes for the jejunum and ileum (P&lt;0.05).	deoxynivalenol	26-29	proliferating cell nuclear antigen	Homo sapiens	98-132
25502722-8	2014	Addition glutamic acid to DON treatment increased the plasma activities of SOD and GSH-Px and the proliferating cell nuclear antigen (PCNA) labeling indexes for the jejunum and ileum (P&lt;0.05).	deoxynivalenol	26-29	proliferating cell nuclear antigen	Homo sapiens	134-138
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	glutamic pyruvic transaminase, soluble	Mus musculus	123-147
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	glutamic pyruvic transaminase, soluble	Mus musculus	149-152
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	161-187
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	189-192
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	albumin	Mus musculus	216-223
25445755-4	2014	The results showed that AFB1, ZEA and DON induced liver injury, indicated by elevated relative liver weight, activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), as well as decreased albumin (ALB) and/or total protein (TP) concentration in the serum.	deoxynivalenol	38-41	albumin	Mus musculus	225-228
24793808-1	2014	The foodborne mycotoxin deoxynivalenol (DON) induces a ribotoxic stress response in mononuclear phagocytes that mediate aberrant multi-organ upregulation of TNF-alpha, interleukins and chemokines in experimental animals.	deoxynivalenol	24-38	tumor necrosis factor	Mus musculus	157-166
25279298-7	2014	Conversely, cytotoxicity was valued as zearalenone &gt; deoxynivalenol &gt; ochratoxin A in relation to the acetylcholinesterase enzymatic activity.	deoxynivalenol	56-70	acetylcholinesterase (Cartwright blood group)	Gallus gallus	108-128
24937323-0	2014	Deoxynivalenol induced mouse skin cell proliferation and inflammation via MAPK pathway.	deoxynivalenol	0-14	mitogen-activated protein kinase 1	Mus musculus	74-78
24937323-4	2014	DON (336 and 672nmol) caused significant enhancement in [(3)H]-thymidine uptake in DNA along with increased myeloperoxidase and ornithine decarboxylase activities, suggesting tissue inflammation and cell proliferation.	deoxynivalenol	0-3	myeloperoxidase	Mus musculus	108-123
24937323-4	2014	DON (336 and 672nmol) caused significant enhancement in [(3)H]-thymidine uptake in DNA along with increased myeloperoxidase and ornithine decarboxylase activities, suggesting tissue inflammation and cell proliferation.	deoxynivalenol	0-3	ornithine decarboxylase, structural 1	Mus musculus	128-151
24937323-5	2014	Furthermore, DON (168nmol) caused enhanced expression of RAS, and phosphorylation of PI3K/Akt, ERK, JNK and p38 MAPKs.	deoxynivalenol	13-16	thymoma viral proto-oncogene 1	Mus musculus	90-93
24937323-5	2014	Furthermore, DON (168nmol) caused enhanced expression of RAS, and phosphorylation of PI3K/Akt, ERK, JNK and p38 MAPKs.	deoxynivalenol	13-16	mitogen-activated protein kinase 1	Mus musculus	95-98
24937323-5	2014	Furthermore, DON (168nmol) caused enhanced expression of RAS, and phosphorylation of PI3K/Akt, ERK, JNK and p38 MAPKs.	deoxynivalenol	13-16	mitogen-activated protein kinase 14	Mus musculus	108-111
24937323-6	2014	DON exposure also showed activation of transcription factors, c-fos, c-jun and NF-kappaB along with phosphorylation of IkBalpha.	deoxynivalenol	0-3	FBJ osteosarcoma oncogene	Mus musculus	62-67
24937323-6	2014	DON exposure also showed activation of transcription factors, c-fos, c-jun and NF-kappaB along with phosphorylation of IkBalpha.	deoxynivalenol	0-3	jun proto-oncogene	Mus musculus	69-74
24937323-7	2014	Enhanced phosphorylation of NF-kappaB by DON caused over expression of target proteins, COX-2, cyclin D1 and iNOS in skin.	deoxynivalenol	41-44	cytochrome c oxidase II, mitochondrial	Mus musculus	88-93
24937323-7	2014	Enhanced phosphorylation of NF-kappaB by DON caused over expression of target proteins, COX-2, cyclin D1 and iNOS in skin.	deoxynivalenol	41-44	cyclin D1	Mus musculus	95-104
24937323-7	2014	Enhanced phosphorylation of NF-kappaB by DON caused over expression of target proteins, COX-2, cyclin D1 and iNOS in skin.	deoxynivalenol	41-44	nitric oxide synthase 2, inducible	Mus musculus	109-113
24937323-10	2014	These results suggest that DON induced cell proliferation in mouse skin is through the activation of MAPK signaling pathway involving transcription factors NFkappaB and AP-1, further leading to transcriptional activation of downstream target proteins c-fos, c-jun, cyclin D1, iNOS and COX-2 which might be responsible for its inflammatory potential.	deoxynivalenol	27-30	FBJ osteosarcoma oncogene	Mus musculus	251-256
24937323-10	2014	These results suggest that DON induced cell proliferation in mouse skin is through the activation of MAPK signaling pathway involving transcription factors NFkappaB and AP-1, further leading to transcriptional activation of downstream target proteins c-fos, c-jun, cyclin D1, iNOS and COX-2 which might be responsible for its inflammatory potential.	deoxynivalenol	27-30	jun proto-oncogene	Mus musculus	258-263
24937323-10	2014	These results suggest that DON induced cell proliferation in mouse skin is through the activation of MAPK signaling pathway involving transcription factors NFkappaB and AP-1, further leading to transcriptional activation of downstream target proteins c-fos, c-jun, cyclin D1, iNOS and COX-2 which might be responsible for its inflammatory potential.	deoxynivalenol	27-30	cyclin D1	Mus musculus	265-274
24937323-10	2014	These results suggest that DON induced cell proliferation in mouse skin is through the activation of MAPK signaling pathway involving transcription factors NFkappaB and AP-1, further leading to transcriptional activation of downstream target proteins c-fos, c-jun, cyclin D1, iNOS and COX-2 which might be responsible for its inflammatory potential.	deoxynivalenol	27-30	nitric oxide synthase 2, inducible	Mus musculus	276-280
24937323-10	2014	These results suggest that DON induced cell proliferation in mouse skin is through the activation of MAPK signaling pathway involving transcription factors NFkappaB and AP-1, further leading to transcriptional activation of downstream target proteins c-fos, c-jun, cyclin D1, iNOS and COX-2 which might be responsible for its inflammatory potential.	deoxynivalenol	27-30	cytochrome c oxidase II, mitochondrial	Mus musculus	285-290
24793808-1	2014	The foodborne mycotoxin deoxynivalenol (DON) induces a ribotoxic stress response in mononuclear phagocytes that mediate aberrant multi-organ upregulation of TNF-alpha, interleukins and chemokines in experimental animals.	deoxynivalenol	40-43	tumor necrosis factor	Mus musculus	157-166
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	tumor necrosis factor	Mus musculus	47-56
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	interleukin 1 beta	Mus musculus	57-65
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	interleukin 6	Mus musculus	67-71
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	chemokine (C-X-C motif) ligand 2	Mus musculus	73-79
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	chemokine (C-C motif) ligand 2	Mus musculus	81-86
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	chemokine (C-C motif) ligand 7	Mus musculus	91-96
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	annexin A5	Mus musculus	104-113
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	caspase 3	Mus musculus	181-190
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	caspase 8	Mus musculus	192-201
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	caspase 9	Mus musculus	203-212
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	poly (ADP-ribose) polymerase family, member 1	Mus musculus	217-244
24952344-3	2014	MTEC1 cell apoptosis induced by DON was confirmed by nuclei morphology change, TUNEL positive staining, annexin V/propidium iodide positive staining and increased protein levels of caspase-3, caspase-8, caspase-9 and poly(ADP-ribose) polymerase (PARP).	deoxynivalenol	32-35	poly (ADP-ribose) polymerase family, member 1	Mus musculus	246-250
24952344-5	2014	In addition, DON could significantly increase the protein levels of p53 and Bax/Bcl-2 ratio in MTEC1 cells.	deoxynivalenol	13-16	transformation related protein 53, pseudogene	Mus musculus	68-71
24952344-5	2014	In addition, DON could significantly increase the protein levels of p53 and Bax/Bcl-2 ratio in MTEC1 cells.	deoxynivalenol	13-16	BCL2-associated X protein	Mus musculus	76-79
24952344-5	2014	In addition, DON could significantly increase the protein levels of p53 and Bax/Bcl-2 ratio in MTEC1 cells.	deoxynivalenol	13-16	B cell leukemia/lymphoma 2	Mus musculus	80-85
24952344-6	2014	Taken together, our results suggest that DON causes the activation of p53, increased levels of ROS and the induction of mitochondrial dysfunction, which may contribute to DON-induced apoptosis in MTEC1 cells.	deoxynivalenol	41-44	transformation related protein 53, pseudogene	Mus musculus	70-73
24984001-8	2014	Moreover, the inhibition of DON on Akt/mTOR/4EBP1 signal pathway was reduced by glutamic acid supplementation.	deoxynivalenol	28-31	AKT serine/threonine kinase 1	Homo sapiens	35-38
24984001-8	2014	Moreover, the inhibition of DON on Akt/mTOR/4EBP1 signal pathway was reduced by glutamic acid supplementation.	deoxynivalenol	28-31	mechanistic target of rapamycin kinase	Homo sapiens	39-43
24984001-8	2014	Moreover, the inhibition of DON on Akt/mTOR/4EBP1 signal pathway was reduced by glutamic acid supplementation.	deoxynivalenol	28-31	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	44-49
28962245-5	2014	DON induced a significant increase in caspase-3 (83%) and cyclooxygenase-2 (71.3%) expression compared with the control.	deoxynivalenol	0-3	caspase 3	Sus scrofa	38-47
28962245-5	2014	DON induced a significant increase in caspase-3 (83%) and cyclooxygenase-2 (71.3%) expression compared with the control.	deoxynivalenol	0-3	prostaglandin-endoperoxide synthase 2	Sus scrofa	58-74
25139221-6	2014	DON was only detected in samples of hens which fed the FUS diet while none of the samples analysed had detectable levels of de-epoxy-DON.	deoxynivalenol	0-3	FUS RNA binding protein	Gallus gallus	55-58
24385417-3	2014	While anorexia induction in mice exposed intraperitoneally to DON has been linked to plasma elevation of the satiety hormones cholecystokinin (CCK) and peptide YY3-36 (PYY3-36), the effects of oral gavage of DON or of other 8-keotrichothecenes on release of these gut peptides have not been established.	deoxynivalenol	62-65	cholecystokinin	Mus musculus	126-141
24385417-3	2014	While anorexia induction in mice exposed intraperitoneally to DON has been linked to plasma elevation of the satiety hormones cholecystokinin (CCK) and peptide YY3-36 (PYY3-36), the effects of oral gavage of DON or of other 8-keotrichothecenes on release of these gut peptides have not been established.	deoxynivalenol	62-65	cholecystokinin	Mus musculus	143-146
24385417-3	2014	While anorexia induction in mice exposed intraperitoneally to DON has been linked to plasma elevation of the satiety hormones cholecystokinin (CCK) and peptide YY3-36 (PYY3-36), the effects of oral gavage of DON or of other 8-keotrichothecenes on release of these gut peptides have not been established.	deoxynivalenol	62-65	peptide YY 3 (pseudogene)	Homo sapiens	168-172
24385417-5	2014	Elevation of plasma CCK markedly corresponded to anorexia induction by DON and all other 8-ketotrichothecenes tested.	deoxynivalenol	71-74	cholecystokinin	Homo sapiens	20-23
24385417-6	2014	Furthermore, the CCK1 receptor antagonist SR 27897 and the CCK2 receptor antagonist L-365,260 dose-dependently attenuated both CCK- and DON-induced anorexia, which was consistent with this gut satiety hormone being an important mediator of 8-ketotrichothecene-induced food refusal.	deoxynivalenol	136-139	C-C motif chemokine ligand 28	Homo sapiens	17-21
24385417-6	2014	Furthermore, the CCK1 receptor antagonist SR 27897 and the CCK2 receptor antagonist L-365,260 dose-dependently attenuated both CCK- and DON-induced anorexia, which was consistent with this gut satiety hormone being an important mediator of 8-ketotrichothecene-induced food refusal.	deoxynivalenol	136-139	cholecystokinin B receptor	Homo sapiens	59-72
24385417-6	2014	Furthermore, the CCK1 receptor antagonist SR 27897 and the CCK2 receptor antagonist L-365,260 dose-dependently attenuated both CCK- and DON-induced anorexia, which was consistent with this gut satiety hormone being an important mediator of 8-ketotrichothecene-induced food refusal.	deoxynivalenol	136-139	cholecystokinin	Homo sapiens	17-20
24385417-7	2014	In contrast to CCK, PYY3-36 was moderately elevated by oral gavage with DON and NIV but not by 3-ADON, 15-ADON, or FX.	deoxynivalenol	72-75	peptide YY 3 (pseudogene)	Homo sapiens	20-24
25049991-7	2014	In addition, ZO-1 expression of IPEC-J2 cells treated with B. subtilis was up-regulated against DON-induced damage.	deoxynivalenol	96-99	zonula occludens 1	Sus scrofa	13-17
25119735-8	2014	Mutation of the CCAAT/enhancer-binding protein (CEBP) beta binding site of the IL-8 promoter affected only DON-, but not VA- and TNFalpha-induced luciferase expression.	deoxynivalenol	107-110	CCAAT enhancer binding protein alpha	Homo sapiens	16-46
25392278-0	2014	Role of tumor necrosis factor-alpha and interleukin-1beta in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.	deoxynivalenol	125-139	tumor necrosis factor	Mus musculus	8-35
25119735-8	2014	Mutation of the CCAAT/enhancer-binding protein (CEBP) beta binding site of the IL-8 promoter affected only DON-, but not VA- and TNFalpha-induced luciferase expression.	deoxynivalenol	107-110	CCAAT enhancer binding protein alpha	Homo sapiens	48-52
25392278-0	2014	Role of tumor necrosis factor-alpha and interleukin-1beta in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.	deoxynivalenol	125-139	interleukin 1 beta	Mus musculus	40-57
25119735-8	2014	Mutation of the CCAAT/enhancer-binding protein (CEBP) beta binding site of the IL-8 promoter affected only DON-, but not VA- and TNFalpha-induced luciferase expression.	deoxynivalenol	107-110	C-X-C motif chemokine ligand 8	Homo sapiens	79-83
25392278-3	2014	The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia.	deoxynivalenol	165-168	tumor necrosis factor	Mus musculus	89-116
25392278-3	2014	The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia.	deoxynivalenol	165-168	tumor necrosis factor	Mus musculus	118-127
25392278-3	2014	The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia.	deoxynivalenol	165-168	interleukin 1 beta	Mus musculus	133-150
25392278-3	2014	The purpose of this research was to determine the role of two proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in DON-induced anorexia.	deoxynivalenol	165-168	interleukin 1 beta	Mus musculus	152-160
23965387-10	2013	There were no effects (P &gt; 0.05) on other relative weights of viscera, except the relative weight of the gallbladder, but the diamine oxidase activity in the liver decreased in DON-treated piglets (P &lt; 0.05).	deoxynivalenol	180-183	amine oxidase copper containing 1	Sus scrofa	129-144
25392278-6	2014	Oral exposure to DON at 5 mg/kg bw stimulated splenic and hepatic mRNA and plasma protein elevations of TNF-alpha and IL-1beta that corresponded to anorexia induction.	deoxynivalenol	17-20	tumor necrosis factor	Mus musculus	104-113
25392278-6	2014	Oral exposure to DON at 5 mg/kg bw stimulated splenic and hepatic mRNA and plasma protein elevations of TNF-alpha and IL-1beta that corresponded to anorexia induction.	deoxynivalenol	17-20	interleukin 1 beta	Mus musculus	118-126
25392278-9	2014	Taken together, the results suggest that both TNF-alpha and IL-1beta play contributory role in anorexia induction following oral exposure to DON.	deoxynivalenol	141-144	tumor necrosis factor	Mus musculus	46-55
25392278-9	2014	Taken together, the results suggest that both TNF-alpha and IL-1beta play contributory role in anorexia induction following oral exposure to DON.	deoxynivalenol	141-144	interleukin 1 beta	Mus musculus	60-68
24287571-8	2013	Expression of E-cadherin was significantly reduced in explants exposed to FB1 (40%), DON (93%) and FB1 plus DON (100%).	deoxynivalenol	85-88	cadherin 1	Sus scrofa	14-24
24287571-8	2013	Expression of E-cadherin was significantly reduced in explants exposed to FB1 (40%), DON (93%) and FB1 plus DON (100%).	deoxynivalenol	108-111	cadherin 1	Sus scrofa	14-24
23965392-9	2013	The proliferating cell nuclear antigen (PCNA) labeling indexes for the jejunum and ileum in the DON + CAP treatment were greater than those in the DON treatment (P &lt; 0.05).	deoxynivalenol	96-99	proliferating cell nuclear antigen	Homo sapiens	4-38
23965392-9	2013	The proliferating cell nuclear antigen (PCNA) labeling indexes for the jejunum and ileum in the DON + CAP treatment were greater than those in the DON treatment (P &lt; 0.05).	deoxynivalenol	96-99	proliferating cell nuclear antigen	Homo sapiens	40-44
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	CD19 molecule	Homo sapiens	18-22
23827195-7	2013	Our results provide molecular insights into the gene expression differences of DON-induced toxic effects and suggest that p53 signaling pathway may play an important role in the inhibition of MTEC1 cell proliferation.	deoxynivalenol	79-82	transformation related protein 53, pseudogene	Mus musculus	122-125
23977054-7	2013	The results showed that the plasma TNF-alpha decreased in response to DON, while in combination with MS, the effect of DON was reduced.	deoxynivalenol	70-73	lipopolysaccharide induced TNF factor	Gallus gallus	35-44
23977054-8	2013	DON down-regulated the relative gene expression of IL-1beta, TGFBR1 and IFN-gamma, and addition of MS to the DON contaminated diet compensates these effects on IL-1beta, TGFBR1 but not for IFN-gamma.	deoxynivalenol	0-3	interleukin 1, beta	Gallus gallus	51-59
23977054-8	2013	DON down-regulated the relative gene expression of IL-1beta, TGFBR1 and IFN-gamma, and addition of MS to the DON contaminated diet compensates these effects on IL-1beta, TGFBR1 but not for IFN-gamma.	deoxynivalenol	0-3	transforming growth factor beta receptor 1	Gallus gallus	61-67
23977054-8	2013	DON down-regulated the relative gene expression of IL-1beta, TGFBR1 and IFN-gamma, and addition of MS to the DON contaminated diet compensates these effects on IL-1beta, TGFBR1 but not for IFN-gamma.	deoxynivalenol	0-3	interferon gamma	Gallus gallus	72-81
23792671-7	2013	The most remarkable gene induced by DON and 15ADON was inflammatory chemokine IL-8 and thus mRNA expression and secretion of IL-8 were analyzed by PCR and ELISA.	deoxynivalenol	36-39	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
23792671-7	2013	The most remarkable gene induced by DON and 15ADON was inflammatory chemokine IL-8 and thus mRNA expression and secretion of IL-8 were analyzed by PCR and ELISA.	deoxynivalenol	36-39	C-X-C motif chemokine ligand 8	Homo sapiens	125-129
23792671-8	2013	Both DON and acetylated DONs could induce mRNA expression and production of IL-8.	deoxynivalenol	5-8	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
23792671-10	2013	Our results indicated that 15ADON caused the highest permeability and highest IL-8 secretion among DON, 3ADON, and 15ADON in human intestinal cell.	deoxynivalenol	30-33	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	integrin subunit alpha X	Homo sapiens	30-35
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	adhesion G protein-coupled receptor E1	Mus musculus	98-103
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	CD4 antigen	Mus musculus	208-211
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	interleukin 2 receptor, alpha chain	Mus musculus	214-218
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	CD4 antigen	Mus musculus	254-257
23791694-11	2013	Furthermore, DON induced apoptosis in spleen, MLNs, and PPs, and DON-induced apoptosis was promoted by increased expression of Bax and decreased expression of Bcl-2.	deoxynivalenol	13-16	BCL2-associated X protein	Mus musculus	127-130
23791694-11	2013	Furthermore, DON induced apoptosis in spleen, MLNs, and PPs, and DON-induced apoptosis was promoted by increased expression of Bax and decreased expression of Bcl-2.	deoxynivalenol	65-68	BCL2-associated X protein	Mus musculus	127-130
23791694-11	2013	Furthermore, DON induced apoptosis in spleen, MLNs, and PPs, and DON-induced apoptosis was promoted by increased expression of Bax and decreased expression of Bcl-2.	deoxynivalenol	65-68	B cell leukemia/lymphoma 2	Mus musculus	159-164
23791694-13	2013	After priming of the RAW 264.7 macrophage cell line with different TLR ligands, DON exposure differentially modulated IL-1beta, IL-10, and TNF-alpha production.	deoxynivalenol	80-83	interleukin 1 beta	Mus musculus	118-126
23791694-13	2013	After priming of the RAW 264.7 macrophage cell line with different TLR ligands, DON exposure differentially modulated IL-1beta, IL-10, and TNF-alpha production.	deoxynivalenol	80-83	interleukin 10	Mus musculus	128-133
23791694-13	2013	After priming of the RAW 264.7 macrophage cell line with different TLR ligands, DON exposure differentially modulated IL-1beta, IL-10, and TNF-alpha production.	deoxynivalenol	80-83	tumor necrosis factor	Mus musculus	139-148
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	interleukin 2	Mus musculus	22-26
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	interleukin 4	Mus musculus	28-32
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	mast cell protease 1	Mus musculus	42-47
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	34-40
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	interleukin 1 alpha	Mus musculus	73-82
23436220-8	2013	The concentrations of IL-2, IL-4, GM-CSF, MCP-1 and Rantes in serum, and IL-1alpha in mesenteric lymph node and MIP-1beta in spleen were significantly increased by DON treatment compared to control.	deoxynivalenol	164-167	chemokine (C-C motif) ligand 4	Mus musculus	112-121
23628787-9	2013	Moreover, DON (10 mg DON/kg feed) decreased tumor necrosis factor alpha (TNF-alpha) in the plasma of broilers.	deoxynivalenol	10-13	lipopolysaccharide induced TNF factor	Gallus gallus	44-71
23813191-8	2013	These results suggest that YAC-1 lymphoma cells are a suitable model to investigate and elucidate the basic molecular and cellular mechanisms for possible immunotoxic effects of DON.	deoxynivalenol	178-181	ADP-ribosyltransferase 1	Mus musculus	27-32
23707852-0	2013	Deoxynivalenol-induced weight loss in the diet-induced obese mouse is reversible and PKR-independent.	deoxynivalenol	0-14	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	85-88
23707852-4	2013	Here, we extended these findings by characterizing: (1) reversibility of DON-induced body weight loss and anorexia in DIO mice and (2) the role of double-stranded RNA-activated protein kinase (PKR) which has been previously linked to initiation of the ribotoxic stress response.	deoxynivalenol	73-76	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	193-196
23922676-7	2013	A qRT-PCR analysis revealed that deoxynivalenol acts in a very specific way on the intestinal barrier, since only an up-regulation in mRNA expression of claudin 5 in jejunum was observed, while no effects were seen on claudin 1, zona occludens 1 and 2.	deoxynivalenol	33-47	claudin 5	Gallus gallus	153-162
23922676-9	2013	Up-regulation of Toll-like receptor 4 and two markers of oxidative stress (heme-oxigenase or HMOX and xanthine oxidoreductase or XOR) were mainly seen in the jejunum and to a lesser extent in the ileum in response to deoxynivalenol, while in combination with an adsorbing agent main effect was seen in the ileum.	deoxynivalenol	217-231	toll like receptor 4	Gallus gallus	17-37
23628787-9	2013	Moreover, DON (10 mg DON/kg feed) decreased tumor necrosis factor alpha (TNF-alpha) in the plasma of broilers.	deoxynivalenol	10-13	lipopolysaccharide induced TNF factor	Gallus gallus	73-82
23628787-9	2013	Moreover, DON (10 mg DON/kg feed) decreased tumor necrosis factor alpha (TNF-alpha) in the plasma of broilers.	deoxynivalenol	21-24	lipopolysaccharide induced TNF factor	Gallus gallus	44-71
23628787-9	2013	Moreover, DON (10 mg DON/kg feed) decreased tumor necrosis factor alpha (TNF-alpha) in the plasma of broilers.	deoxynivalenol	21-24	lipopolysaccharide induced TNF factor	Gallus gallus	73-82
23357557-7	2013	Our results demonstrate that deoxynivalenol induces the TACE-dependent ectodomain shedding of TNF receptor 1 via the activation of ERK and p38 MAP kinase, and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	29-43	ADAM metallopeptidase domain 17	Homo sapiens	56-60
23357557-0	2013	Deoxynivalenol induces ectodomain shedding of TNF receptor 1 and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	0-14	tumor necrosis factor	Homo sapiens	86-95
23357557-7	2013	Our results demonstrate that deoxynivalenol induces the TACE-dependent ectodomain shedding of TNF receptor 1 via the activation of ERK and p38 MAP kinase, and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	29-43	mitogen-activated protein kinase 14	Homo sapiens	139-142
23357557-0	2013	Deoxynivalenol induces ectodomain shedding of TNF receptor 1 and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	0-14	nuclear factor kappa B subunit 1	Homo sapiens	104-113
23357557-2	2013	In this study, we found that deoxynivalenol induced the ectodomain shedding of tumor necrosis factor (TNF) receptor 1 (TNFRSF1A) and thereby inhibited the TNF-alpha-induced signaling pathway.	deoxynivalenol	29-43	TNF receptor superfamily member 1A	Homo sapiens	119-127
23357557-7	2013	Our results demonstrate that deoxynivalenol induces the TACE-dependent ectodomain shedding of TNF receptor 1 via the activation of ERK and p38 MAP kinase, and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	29-43	tumor necrosis factor	Homo sapiens	180-189
23357557-2	2013	In this study, we found that deoxynivalenol induced the ectodomain shedding of tumor necrosis factor (TNF) receptor 1 (TNFRSF1A) and thereby inhibited the TNF-alpha-induced signaling pathway.	deoxynivalenol	29-43	tumor necrosis factor	Homo sapiens	155-164
23357557-3	2013	In human lung carcinoma A549 cells, deoxynivalenol and 3-acetyldeoxynivalenol inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) induced by TNF-alpha more strongly than that induced by interleukin 1alpha (IL-1alpha), whereas T-2 toxin and verrucarin A exerted nonselective inhibitory effects.	deoxynivalenol	36-50	intercellular adhesion molecule 1	Homo sapiens	106-139
23357557-7	2013	Our results demonstrate that deoxynivalenol induces the TACE-dependent ectodomain shedding of TNF receptor 1 via the activation of ERK and p38 MAP kinase, and thereby inhibits the TNF-alpha-induced NF-kappaB signaling pathway.	deoxynivalenol	29-43	nuclear factor kappa B subunit 1	Homo sapiens	198-207
23357557-3	2013	In human lung carcinoma A549 cells, deoxynivalenol and 3-acetyldeoxynivalenol inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) induced by TNF-alpha more strongly than that induced by interleukin 1alpha (IL-1alpha), whereas T-2 toxin and verrucarin A exerted nonselective inhibitory effects.	deoxynivalenol	36-50	intercellular adhesion molecule 1	Homo sapiens	141-147
23357557-3	2013	In human lung carcinoma A549 cells, deoxynivalenol and 3-acetyldeoxynivalenol inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) induced by TNF-alpha more strongly than that induced by interleukin 1alpha (IL-1alpha), whereas T-2 toxin and verrucarin A exerted nonselective inhibitory effects.	deoxynivalenol	36-50	tumor necrosis factor	Homo sapiens	160-169
23357557-3	2013	In human lung carcinoma A549 cells, deoxynivalenol and 3-acetyldeoxynivalenol inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) induced by TNF-alpha more strongly than that induced by interleukin 1alpha (IL-1alpha), whereas T-2 toxin and verrucarin A exerted nonselective inhibitory effects.	deoxynivalenol	36-50	interleukin 1 alpha	Homo sapiens	205-223
23357557-3	2013	In human lung carcinoma A549 cells, deoxynivalenol and 3-acetyldeoxynivalenol inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) induced by TNF-alpha more strongly than that induced by interleukin 1alpha (IL-1alpha), whereas T-2 toxin and verrucarin A exerted nonselective inhibitory effects.	deoxynivalenol	36-50	interleukin 1 alpha	Homo sapiens	225-234
23357557-4	2013	Deoxynivalenol and 3-acetyldeoxynivalenol also inhibited the nuclear factor kappaB (NF-kappaB) signaling pathway induced by TNF-alpha, but not that induced by IL-1alpha.	deoxynivalenol	0-14	nuclear factor kappa B subunit 1	Homo sapiens	84-93
22982764-7	2012	Thirteen of the 16 steroidogenic genes analyzed by quantitative real time PCR (RT-qPCR) were significantly regulated (P&lt;0.05) by DON (100ng/ml), T-2 toxin (0.5ng/ml) and HT-2 toxin (5ng/ml) compared to the control, with reference genes (B2M, ATP5B and ACTB).	deoxynivalenol	132-135	beta-2 microglobulin	Mus musculus	240-243
23357557-4	2013	Deoxynivalenol and 3-acetyldeoxynivalenol also inhibited the nuclear factor kappaB (NF-kappaB) signaling pathway induced by TNF-alpha, but not that induced by IL-1alpha.	deoxynivalenol	0-14	tumor necrosis factor	Homo sapiens	124-133
23357557-5	2013	Consistent with these findings, deoxynivalenol and 3-acetyldeoxynivalenol induced the ectodomain shedding of TNF receptor 1 by TNF-alpha-converting enzyme (TACE), also known as a disintegrin and metalloproteinase 17 (ADAM17).	deoxynivalenol	32-46	ADAM metallopeptidase domain 17	Homo sapiens	127-154
23357557-5	2013	Consistent with these findings, deoxynivalenol and 3-acetyldeoxynivalenol induced the ectodomain shedding of TNF receptor 1 by TNF-alpha-converting enzyme (TACE), also known as a disintegrin and metalloproteinase 17 (ADAM17).	deoxynivalenol	32-46	ADAM metallopeptidase domain 17	Homo sapiens	156-160
23357557-5	2013	Consistent with these findings, deoxynivalenol and 3-acetyldeoxynivalenol induced the ectodomain shedding of TNF receptor 1 by TNF-alpha-converting enzyme (TACE), also known as a disintegrin and metalloproteinase 17 (ADAM17).	deoxynivalenol	32-46	ADAM metallopeptidase domain 17	Homo sapiens	177-215
23357557-5	2013	Consistent with these findings, deoxynivalenol and 3-acetyldeoxynivalenol induced the ectodomain shedding of TNF receptor 1 by TNF-alpha-converting enzyme (TACE), also known as a disintegrin and metalloproteinase 17 (ADAM17).	deoxynivalenol	32-46	ADAM metallopeptidase domain 17	Homo sapiens	217-223
23298694-0	2013	Evaluation of insulin-like growth factor acid-labile subunit as a potential biomarker of effect for deoxynivalenol-induced proinflammatory cytokine expression.	deoxynivalenol	100-114	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	14-60
23298694-2	2013	DON ingestion has been recently found to suppress plasma insulin-like growth factor acid-labile subunit (IGFALS), a protein essential for growth.	deoxynivalenol	0-3	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	57-103
23298694-2	2013	DON ingestion has been recently found to suppress plasma insulin-like growth factor acid-labile subunit (IGFALS), a protein essential for growth.	deoxynivalenol	0-3	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	105-111
23298694-3	2013	Studies were conducted to explore the feasibility of using plasma IGFALS as a biomarker of effect for DON.	deoxynivalenol	102-105	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	66-72
23298694-8	2013	Benchmark dose modeling revealed the BMDL and BMD for plasma IGFALS reduction were 1.1 and 3.0 ppm DON and for weight reduction were 2.1 and 4.5 ppm DON.	deoxynivalenol	99-102	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	61-67
23298694-9	2013	In the second study, it was demonstrated that mice fed 15 ppm DON diet had significantly less plasma IGFALS than mice fed identical amounts of control diet.	deoxynivalenol	62-65	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	101-107
23205852-0	2013	Study of the interaction of deoxynivalenol with human serum albumin by spectroscopic technique and molecular modelling.	deoxynivalenol	28-42	albumin	Homo sapiens	54-67
23205852-1	2013	The mechanism of interaction between deoxynivalenol (DON) and human serum albumin (HSA) was studied using spectroscopic methods including fluorescence spectra, UV-VIS, Fourier transform infrared (FT-IR) and circular dichroism (CD).	deoxynivalenol	37-51	albumin	Homo sapiens	68-81
23205852-1	2013	The mechanism of interaction between deoxynivalenol (DON) and human serum albumin (HSA) was studied using spectroscopic methods including fluorescence spectra, UV-VIS, Fourier transform infrared (FT-IR) and circular dichroism (CD).	deoxynivalenol	53-56	albumin	Homo sapiens	68-81
23164930-0	2013	c-Fos immunoreactivity in the pig brain following deoxynivalenol intoxication: focus on NUCB2/nesfatin-1 expressing neurons.	deoxynivalenol	50-64	protein c-Fos	Sus scrofa	0-5
23164930-5	2013	We showed that per os administration of Fusarium graminearum extracts (containing the equivalent of 1mg DON per kg of body weight) induced an increase in c-Fos immunoreactivity in several central structures, including the ventrolateral medulla (VLM), dorsal vagal complex (DVC), paraventricular nucleus of the hypothalamus (PVN), arcuate nucleus (Arc), supraoptic nucleus (SON) and amygdala (CeA).	deoxynivalenol	104-107	protein c-Fos	Sus scrofa	154-159
23164930-6	2013	Moreover, we coupled c-Fos staining with phenotypic markers detection in order to specify the neuronal populations activated during DON intoxication.	deoxynivalenol	132-135	protein c-Fos	Sus scrofa	21-26
23326479-8	2013	RESULTS: DON induced a pro-inflammatory response with a significant increase of expression of mRNA encoding for IL-8, IL-1alpha and IL-1beta, TNF-alpha in all used models.	deoxynivalenol	9-12	C-X-C motif chemokine ligand 8	Homo sapiens	112-116
23326479-8	2013	RESULTS: DON induced a pro-inflammatory response with a significant increase of expression of mRNA encoding for IL-8, IL-1alpha and IL-1beta, TNF-alpha in all used models.	deoxynivalenol	9-12	interleukin 1 alpha	Homo sapiens	118-127
23326479-8	2013	RESULTS: DON induced a pro-inflammatory response with a significant increase of expression of mRNA encoding for IL-8, IL-1alpha and IL-1beta, TNF-alpha in all used models.	deoxynivalenol	9-12	interleukin 1 beta	Homo sapiens	132-140
23326479-8	2013	RESULTS: DON induced a pro-inflammatory response with a significant increase of expression of mRNA encoding for IL-8, IL-1alpha and IL-1beta, TNF-alpha in all used models.	deoxynivalenol	9-12	tumor necrosis factor	Homo sapiens	142-151
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	signal transducer and activator of transcription 3	Homo sapiens	111-116
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	interleukin 17A	Homo sapiens	118-124
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	interleukin 6	Homo sapiens	126-130
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	interleukin 1 beta	Homo sapiens	132-140
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	forkhead box P3	Homo sapiens	203-208
23326479-9	2013	Additionally, DON significantly induced the expression of genes involved in the differentiation of Th17 cells (STAT3, IL-17A, IL-6, IL-1beta) at the expenses of the pathway of regulatory T cells (Treg) (FoxP3, RALDH1).	deoxynivalenol	14-17	aldehyde dehydrogenase 1 family member A1	Homo sapiens	210-216
23326479-10	2013	DON also induced genes related to the pathogenic Th17 cells subset such as IL-23A, IL-22 and IL-21 and not genes related to the regulatory Th17 cells (rTh17) such as TGF-beta and IL-10.	deoxynivalenol	0-3	interleukin 23 subunit alpha	Homo sapiens	75-81
23326479-10	2013	DON also induced genes related to the pathogenic Th17 cells subset such as IL-23A, IL-22 and IL-21 and not genes related to the regulatory Th17 cells (rTh17) such as TGF-beta and IL-10.	deoxynivalenol	0-3	interleukin 22	Homo sapiens	83-88
23326479-10	2013	DON also induced genes related to the pathogenic Th17 cells subset such as IL-23A, IL-22 and IL-21 and not genes related to the regulatory Th17 cells (rTh17) such as TGF-beta and IL-10.	deoxynivalenol	0-3	interleukin 21	Homo sapiens	93-98
23022514-1	2012	The Type B trichothecene deoxynivalenol (DON), a ribotoxic mycotoxin known to contaminate cereal-based foods, induces ribosomal RNA (rRNA) cleavage in the macrophage via p38-directed activation of caspases.	deoxynivalenol	25-39	mitogen-activated protein kinase 14	Mus musculus	170-173
23022514-1	2012	The Type B trichothecene deoxynivalenol (DON), a ribotoxic mycotoxin known to contaminate cereal-based foods, induces ribosomal RNA (rRNA) cleavage in the macrophage via p38-directed activation of caspases.	deoxynivalenol	25-39	caspase 8	Mus musculus	197-205
23022514-1	2012	The Type B trichothecene deoxynivalenol (DON), a ribotoxic mycotoxin known to contaminate cereal-based foods, induces ribosomal RNA (rRNA) cleavage in the macrophage via p38-directed activation of caspases.	deoxynivalenol	41-44	mitogen-activated protein kinase 14	Mus musculus	170-173
23022514-1	2012	The Type B trichothecene deoxynivalenol (DON), a ribotoxic mycotoxin known to contaminate cereal-based foods, induces ribosomal RNA (rRNA) cleavage in the macrophage via p38-directed activation of caspases.	deoxynivalenol	41-44	caspase 8	Mus musculus	197-205
23022514-4	2012	Also, as found for DON, inhibition of p38, double-stranded RNA-activated kinase (PKR) and hematopoietic cell kinase (Hck) suppressed MAPK anisomycin-induced rRNA cleavage, while, in contrast, their inhibition did not affect SG- and ricin-induced rRNA fragmentation.	deoxynivalenol	19-22	mitogen-activated protein kinase 14	Mus musculus	38-41
23022514-4	2012	Also, as found for DON, inhibition of p38, double-stranded RNA-activated kinase (PKR) and hematopoietic cell kinase (Hck) suppressed MAPK anisomycin-induced rRNA cleavage, while, in contrast, their inhibition did not affect SG- and ricin-induced rRNA fragmentation.	deoxynivalenol	19-22	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	81-84
23022514-4	2012	Also, as found for DON, inhibition of p38, double-stranded RNA-activated kinase (PKR) and hematopoietic cell kinase (Hck) suppressed MAPK anisomycin-induced rRNA cleavage, while, in contrast, their inhibition did not affect SG- and ricin-induced rRNA fragmentation.	deoxynivalenol	19-22	hemopoietic cell kinase	Mus musculus	117-120
23253260-5	2013	Remarkably, DON (2 muM) downregulated genes involved in T cell activation, ER stress and apoptosis, which is opposite to results obtained before for DON-exposed Jurkat cells and mouse primary thymocytes.	deoxynivalenol	12-15	latexin	Homo sapiens	19-22
22903826-0	2012	Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY.	deoxynivalenol	40-54	peptide YY	Homo sapiens	121-131
22903826-0	2012	Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY.	deoxynivalenol	56-65	peptide YY	Homo sapiens	121-131
22903826-5	2012	Specifically, ip exposure to DON at 1 and 5mg/kg bw induced PYY by up to 2.5-fold and CCK by up to 4.1-fold.	deoxynivalenol	29-32	peptide YY	Homo sapiens	60-63
22903826-5	2012	Specifically, ip exposure to DON at 1 and 5mg/kg bw induced PYY by up to 2.5-fold and CCK by up to 4.1-fold.	deoxynivalenol	29-32	cholecystokinin	Homo sapiens	86-89
22903826-8	2012	Food intake experiments using the NPY2 receptor antagonist BIIE0246 and the CCK1A receptor antagonist devazepide, individually, suggested that PYY mediated DON-induced anorexia but CCK did not.	deoxynivalenol	156-159	peptide YY	Homo sapiens	143-146
22903826-9	2012	Orolingual exposure to DON induced plasma PYY and CCK elevation and anorexia comparable with that observed for ip exposure.	deoxynivalenol	23-26	peptide YY	Homo sapiens	42-45
22903826-9	2012	Orolingual exposure to DON induced plasma PYY and CCK elevation and anorexia comparable with that observed for ip exposure.	deoxynivalenol	23-26	cholecystokinin	Homo sapiens	50-53
22903826-10	2012	Taken together, these findings suggest that PYY might be one critical mediator of DON-induced anorexia and, ultimately, growth suppression.	deoxynivalenol	82-85	peptide YY	Homo sapiens	44-47
23022514-8	2012	Taken together, the data suggest that (1) all four ribotoxins induced p53-dependent rRNA cleavage via activation of cathepsin L and caspase 3, and (2) activation of p53 by DON and anisomycin involved p38 whereas SG and ricin activated p53 by an alternative mechanism.	deoxynivalenol	172-175	transformation related protein 53, pseudogene	Mus musculus	165-168
23022514-8	2012	Taken together, the data suggest that (1) all four ribotoxins induced p53-dependent rRNA cleavage via activation of cathepsin L and caspase 3, and (2) activation of p53 by DON and anisomycin involved p38 whereas SG and ricin activated p53 by an alternative mechanism.	deoxynivalenol	172-175	transformation related protein 53, pseudogene	Mus musculus	165-168
22982764-7	2012	Thirteen of the 16 steroidogenic genes analyzed by quantitative real time PCR (RT-qPCR) were significantly regulated (P&lt;0.05) by DON (100ng/ml), T-2 toxin (0.5ng/ml) and HT-2 toxin (5ng/ml) compared to the control, with reference genes (B2M, ATP5B and ACTB).	deoxynivalenol	132-135	ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit	Mus musculus	245-250
22982764-7	2012	Thirteen of the 16 steroidogenic genes analyzed by quantitative real time PCR (RT-qPCR) were significantly regulated (P&lt;0.05) by DON (100ng/ml), T-2 toxin (0.5ng/ml) and HT-2 toxin (5ng/ml) compared to the control, with reference genes (B2M, ATP5B and ACTB).	deoxynivalenol	132-135	actin, beta	Mus musculus	255-259
23606197-4	2012	Feeding the FUS diet was clearly reflected by the DON levels in blood.	deoxynivalenol	50-53	FUS RNA binding protein	Sus scrofa	12-15
22964157-0	2012	Opposite effects of two trichothecene mycotoxins, deoxynivalenol and nivalenol, on the levels of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in HL60 cells.	deoxynivalenol	50-64	C-C motif chemokine ligand 3	Homo sapiens	97-141
22964157-0	2012	Opposite effects of two trichothecene mycotoxins, deoxynivalenol and nivalenol, on the levels of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in HL60 cells.	deoxynivalenol	50-64	C-C motif chemokine ligand 4	Homo sapiens	146-155
23606197-6	2012	The urinary excretion of DON and its metabolite de-epoxy-DON as percentage of DON intake was not significantly influenced by HS supplementation and amounted to 24.1 and 20.2% for groups FUS and FUS-HS, respectively.	deoxynivalenol	25-28	FUS RNA binding protein	Sus scrofa	186-189
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	cytochrome c, somatic	Homo sapiens	272-284
23606123-0	2012	Thioredoxin-1 contributes to protection against DON-induced oxidative damage in HepG2 cells.	deoxynivalenol	48-51	thioredoxin	Homo sapiens	0-13
23606123-8	2012	Further experiments showed that thioredoxin-1 (Trx-1) protein levels but not glutathione increased in the cells treated with 10 mumol/l DON.	deoxynivalenol	136-139	thioredoxin	Homo sapiens	32-45
23606123-8	2012	Further experiments showed that thioredoxin-1 (Trx-1) protein levels but not glutathione increased in the cells treated with 10 mumol/l DON.	deoxynivalenol	136-139	thioredoxin	Homo sapiens	47-52
23606123-10	2012	These results suggest that DON-induced accumulation of Trx-1 in HepG2 cells plays one of the key roles in protection against cytotoxicity caused by DON and that the mechanism may be mediated by the antioxidant properties of Trx-1.	deoxynivalenol	27-30	thioredoxin	Homo sapiens	55-60
23606123-10	2012	These results suggest that DON-induced accumulation of Trx-1 in HepG2 cells plays one of the key roles in protection against cytotoxicity caused by DON and that the mechanism may be mediated by the antioxidant properties of Trx-1.	deoxynivalenol	27-30	thioredoxin	Homo sapiens	224-229
22281158-4	2012	Using flow cytometric analyses and immunofluorescence, we showed that DON at 100 muM induced a mitochondria-dependent apoptotic pathway associated with opening of the mitochondrial permeability transition pore (PTP), loss of the mitochondrial transmembrane potential (DeltaPsim), downstream generation of O2 - and cytochrome c release.	deoxynivalenol	70-73	cytochrome c, somatic	Homo sapiens	314-326
22281158-5	2012	The DON-induced apoptosis was accompanied by an activation of caspase 9 and 3, as demonstrated by Western blot and caspase activity assay.	deoxynivalenol	4-7	caspase 9	Homo sapiens	62-77
22641926-6	2012	Serum haptoglobin concentration was significantly elevated after feeding DON (p = 0.04).	deoxynivalenol	73-76	haptoglobin	Equus caballus	6-17
21466594-6	2012	It was concluded that the use of FUS in high concentrate diets can influence ruminal fermentation and microbial protein synthesis at a dietary deoxynivalenol concentration below 5 mg/kg dry matter.	deoxynivalenol	143-157	FUS RNA binding protein	Homo sapiens	33-36
22859312-11	2012	At the molecular level, the 15-ADON activated the mitogen-activated protein kinases (MAPK) ERK1/2, p38, and JNK in the intestinal cell line, explants, and the jejunum from exposed animals at lower dose than DON and 3-ADON.	deoxynivalenol	32-35	mitogen-activated protein kinase 3	Homo sapiens	85-89
22859312-11	2012	At the molecular level, the 15-ADON activated the mitogen-activated protein kinases (MAPK) ERK1/2, p38, and JNK in the intestinal cell line, explants, and the jejunum from exposed animals at lower dose than DON and 3-ADON.	deoxynivalenol	32-35	mitogen-activated protein kinase 3	Homo sapiens	91-97
22859312-11	2012	At the molecular level, the 15-ADON activated the mitogen-activated protein kinases (MAPK) ERK1/2, p38, and JNK in the intestinal cell line, explants, and the jejunum from exposed animals at lower dose than DON and 3-ADON.	deoxynivalenol	32-35	mitogen-activated protein kinase 1	Homo sapiens	99-102
22859312-11	2012	At the molecular level, the 15-ADON activated the mitogen-activated protein kinases (MAPK) ERK1/2, p38, and JNK in the intestinal cell line, explants, and the jejunum from exposed animals at lower dose than DON and 3-ADON.	deoxynivalenol	32-35	mitogen-activated protein kinase 8	Homo sapiens	108-111
22846391-9	2012	Other biochemical experiments confirmed that DON activates calcium-dependent proteins such as calcineurin and M-calpain that are known to be involved in T cell activation and apoptosis.	deoxynivalenol	45-48	calpain 2	Homo sapiens	110-119
22846391-10	2012	Induction of T cell activation was also confirmed by demonstrating that DON activates NFATC1 and induces its translocation from the cytoplasm to the nucleus.	deoxynivalenol	72-75	nuclear factor of activated T cells 1	Homo sapiens	86-92
22897823-4	2012	Here, the yeast PDR5 mutant was used for toxicity evaluation, and the growth test revealed that DON, 15-AcDON, and 4-AcNIV had higher toxicity compared to 3-AcDON and NIV.	deoxynivalenol	96-99	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	16-20
22922639-6	2012	Over-expression of AtUGt73C5 in Arabidopsis led to increased DON resistance of seedlings but also to dwarfing of transgenic plants due to the formation of brassinosteroid-glucosides.	deoxynivalenol	61-64	don-glucosyltransferase 1	Arabidopsis thaliana	19-28
23606123-10	2012	These results suggest that DON-induced accumulation of Trx-1 in HepG2 cells plays one of the key roles in protection against cytotoxicity caused by DON and that the mechanism may be mediated by the antioxidant properties of Trx-1.	deoxynivalenol	148-151	thioredoxin	Homo sapiens	55-60
22659418-0	2012	A novel biosensor regulated by the rotator of F0F1-ATPase to detect deoxynivalenol rapidly.	deoxynivalenol	68-82	ATP synthase F1 subunit epsilon	Homo sapiens	46-57
22659418-1	2012	A novel biosensor (immuno-rotary biosensor) was developed by conjugating deoxynivalenol (DON) monoclonal antibodies with the "rotator" epsilon-subunit of F(0)F(1)-ATPase within chromatophores with an epsilon-subunit monoclonal antibody-biotin-avidin-biotin linker to capture DON residues.	deoxynivalenol	73-87	ATP synthase F1 subunit epsilon	Homo sapiens	154-169
22659418-1	2012	A novel biosensor (immuno-rotary biosensor) was developed by conjugating deoxynivalenol (DON) monoclonal antibodies with the "rotator" epsilon-subunit of F(0)F(1)-ATPase within chromatophores with an epsilon-subunit monoclonal antibody-biotin-avidin-biotin linker to capture DON residues.	deoxynivalenol	89-92	ATP synthase F1 subunit epsilon	Homo sapiens	154-169
22659418-1	2012	A novel biosensor (immuno-rotary biosensor) was developed by conjugating deoxynivalenol (DON) monoclonal antibodies with the "rotator" epsilon-subunit of F(0)F(1)-ATPase within chromatophores with an epsilon-subunit monoclonal antibody-biotin-avidin-biotin linker to capture DON residues.	deoxynivalenol	275-278	ATP synthase F1 subunit epsilon	Homo sapiens	154-169
22491426-7	2012	DON activated caspases 3, 8, and 9, thus suggesting the possible coinvolvement of both extrinsic and intrinsic apoptotic pathways in rRNA cleavage.	deoxynivalenol	0-3	caspase 3	Homo sapiens	14-34
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	149-152
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	153-156
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	mitogen-activated protein kinase 14	Homo sapiens	158-161
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	tumor protein p53	Homo sapiens	162-165
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	caspase 8	Homo sapiens	166-175
22491426-9	2012	Taken together, DON-induced rRNA cleavage is likely to be closely linked to apoptosis activation and appears to involve the sequential activation of PKR/Hck  p38 p53 caspase 8/9 caspase 3.	deoxynivalenol	16-19	caspase 3	Homo sapiens	178-187
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	caspase 9	Homo sapiens	286-295
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	caspase 3	Homo sapiens	297-306
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	BCL2 apoptosis regulator	Homo sapiens	308-313
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	BCL2 associated X, apoptosis regulator	Homo sapiens	315-318
22269384-4	2012	To this aim, we have monitored the effects of DON on (i) cellular morphological changes via optical and transmission electron microscopy, especially in regards to cell viability and mitochondria changes, and (ii) its effects on key regulators of cell apoptosis, including cytochrome c, caspase-9, caspase-3, Bcl-2, Bax, and Bid.	deoxynivalenol	46-49	BH3 interacting domain death agonist	Homo sapiens	324-327
22269384-5	2012	Our results showed that DON treatment inhibited cell proliferation, induced significant morphological changes, and promoted the activation of cytochrome c and caspases.	deoxynivalenol	24-27	cytochrome c	Cricetulus griseus	142-154
22269384-5	2012	Our results showed that DON treatment inhibited cell proliferation, induced significant morphological changes, and promoted the activation of cytochrome c and caspases.	deoxynivalenol	24-27	caspase 9	Homo sapiens	159-167
22269384-7	2012	The relative expression profile of Bcl-2 was contrary to that of Bax and Bid, as Bcl-2 expression decreased as the concentrations DON increased, reaching a minimum at the highest concentration of DON.	deoxynivalenol	130-133	BCL2 apoptosis regulator	Homo sapiens	35-40
22269384-8	2012	We concluded that DON-induced apoptosis was caused by mitochondrial dysfunction and subsequent release of cytochrome c into the cytoplasm and successive activation of caspases, and this was likely regulated by Bcl-2 family proteins.	deoxynivalenol	18-21	cytochrome c, somatic	Homo sapiens	106-118
22269384-8	2012	We concluded that DON-induced apoptosis was caused by mitochondrial dysfunction and subsequent release of cytochrome c into the cytoplasm and successive activation of caspases, and this was likely regulated by Bcl-2 family proteins.	deoxynivalenol	18-21	caspase 9	Homo sapiens	167-175
22269384-8	2012	We concluded that DON-induced apoptosis was caused by mitochondrial dysfunction and subsequent release of cytochrome c into the cytoplasm and successive activation of caspases, and this was likely regulated by Bcl-2 family proteins.	deoxynivalenol	18-21	BCL2 apoptosis regulator	Homo sapiens	210-215
21892639-11	2011	Enzymatic digestion with beta-glucuronidase/sulfatase resulted in increased concentrations of the biomarkers, in both human and pig urine, in most samples containing measurable concentrations of DON, DOM-1, OTA, alpha-ZOL, or beta-ZOL.	deoxynivalenol	195-198	arylsulfatase family member H	Homo sapiens	44-53
22222930-5	2012	DON residues were detected exclusively in the blood of pigs exposed to the FUS diets (7-21 ng/mL) but their levels were not affected by HS, suggesting their inefficiency in preventing DON absorption.	deoxynivalenol	0-3	FUS RNA binding protein	Sus scrofa	75-78
22375418-0	2011	[Enhancing effect of deoxynivalenol-mediated GRP78 down-regulation on heavy chain secretion and bioactivity of two-chain FVIII gene co-transfected cells].	deoxynivalenol	21-35	heat shock protein family A (Hsp70) member 5	Homo sapiens	45-50
22375418-0	2011	[Enhancing effect of deoxynivalenol-mediated GRP78 down-regulation on heavy chain secretion and bioactivity of two-chain FVIII gene co-transfected cells].	deoxynivalenol	21-35	coagulation factor VIII	Homo sapiens	121-126
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	218-232	coagulation factor VIII	Homo sapiens	72-77
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	218-232	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-147
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	218-232	heat shock protein family A (Hsp70) member 5	Homo sapiens	149-154
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	218-232	heat shock protein family A (Hsp70) member 5	Homo sapiens	251-256
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	218-232	coagulation factor VIII	Homo sapiens	263-268
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	234-237	coagulation factor VIII	Homo sapiens	72-77
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	234-237	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-147
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	234-237	heat shock protein family A (Hsp70) member 5	Homo sapiens	149-154
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	234-237	heat shock protein family A (Hsp70) member 5	Homo sapiens	251-256
22375418-2	2011	In this study we aimed to improve the efficacy of two chain strategy in FVIII gene delivery through the degradation of glucose-regulated protein 78 (GRP78) known as a protein chaperone in endoplasmic reticulum (ER) by deoxynivalenol (DON) to decrease GRP78-bound FVIII heavy chain.	deoxynivalenol	234-237	coagulation factor VIII	Homo sapiens	263-268
22375418-4	2011	Data showed that 293 cells after three hours post-treatment with DON at a concentration of 500 ng mL(-1) resulted in obvious decrease the level of GRP78 but no effect on the cell proliferation.	deoxynivalenol	65-68	heat shock protein family A (Hsp70) member 5	Homo sapiens	147-152
22375418-6	2011	Taken together, these data suggest that DON-mediated GRP78 down-regulation could improve the efficacy of two-chain FVIII gene transfering by facilitating HC secretion, providing an experimental basis for in vivo dual-AAV application in FVIII gene delivery.	deoxynivalenol	40-43	heat shock protein family A (Hsp70) member 5	Homo sapiens	53-58
22375418-6	2011	Taken together, these data suggest that DON-mediated GRP78 down-regulation could improve the efficacy of two-chain FVIII gene transfering by facilitating HC secretion, providing an experimental basis for in vivo dual-AAV application in FVIII gene delivery.	deoxynivalenol	40-43	coagulation factor VIII	Homo sapiens	115-120
22375418-6	2011	Taken together, these data suggest that DON-mediated GRP78 down-regulation could improve the efficacy of two-chain FVIII gene transfering by facilitating HC secretion, providing an experimental basis for in vivo dual-AAV application in FVIII gene delivery.	deoxynivalenol	40-43	coagulation factor VIII	Homo sapiens	236-241
23251682-5	2012	Both Nivalenol and Deoxynivalenol (5-80 microM) significantly affected IEC-6 viability through a pro-apoptotic process which mainly involved the following steps: (i) Bax induction; (ii) Bcl-2 inhibition, and (iii) caspase-3 activation.	deoxynivalenol	19-33	BCL2 associated X, apoptosis regulator	Rattus norvegicus	166-169
23251682-5	2012	Both Nivalenol and Deoxynivalenol (5-80 microM) significantly affected IEC-6 viability through a pro-apoptotic process which mainly involved the following steps: (i) Bax induction; (ii) Bcl-2 inhibition, and (iii) caspase-3 activation.	deoxynivalenol	19-33	BCL2, apoptosis regulator	Rattus norvegicus	186-191
23251682-5	2012	Both Nivalenol and Deoxynivalenol (5-80 microM) significantly affected IEC-6 viability through a pro-apoptotic process which mainly involved the following steps: (i) Bax induction; (ii) Bcl-2 inhibition, and (iii) caspase-3 activation.	deoxynivalenol	19-33	caspase 3	Rattus norvegicus	214-223
21364771-5	2011	RESULTS: Application of DON in concentrations up to 4000 ng/mL for 24, 48 and 72 hours on the basolateral side of membrane cultured polarised IPEC-J2 cells resulted in a breakdown of the integrity of cell connections measured by transepithelial electrical resistance (TEER), as well as a reduced expression of the tight junction proteins ZO-1 and claudin 3.	deoxynivalenol	24-27	zonula occludens 1	Sus scrofa	338-356
21873375-6	2011	Using c-Fos expression mapping, we identified the neuronal structures activated in response to DON and observed that the pattern of neuronal populations activated by the toxin resembled those induced by inflammatory signals.	deoxynivalenol	95-98	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	6-11
21873375-7	2011	By real-time PCR, we report the first evidences for a DON-induced central inflammation, attested by the strong upregulation of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, cyclooxygenase-2, and microsomal prostaglandin synthase-1 (mPGES-1) messenger RNA.	deoxynivalenol	54-57	interleukin 1 beta	Homo sapiens	127-144
21873375-7	2011	By real-time PCR, we report the first evidences for a DON-induced central inflammation, attested by the strong upregulation of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, cyclooxygenase-2, and microsomal prostaglandin synthase-1 (mPGES-1) messenger RNA.	deoxynivalenol	54-57	interleukin 6	Homo sapiens	146-188
21873375-7	2011	By real-time PCR, we report the first evidences for a DON-induced central inflammation, attested by the strong upregulation of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, cyclooxygenase-2, and microsomal prostaglandin synthase-1 (mPGES-1) messenger RNA.	deoxynivalenol	54-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	190-206
21873375-7	2011	By real-time PCR, we report the first evidences for a DON-induced central inflammation, attested by the strong upregulation of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, cyclooxygenase-2, and microsomal prostaglandin synthase-1 (mPGES-1) messenger RNA.	deoxynivalenol	54-57	prostaglandin E synthase	Mus musculus	249-256
22041568-10	2011	The levels of MMP-13 in DON groups were 0.25 - 0.56 micromol/L, which were significantly higher than that in control (0 micromol/L, F = 78.420, P &lt; 0.05).	deoxynivalenol	24-27	matrix metallopeptidase 13	Homo sapiens	14-20
22041568-12	2011	The proportions of cells with positive iNOS in DON groups were 14.8% - 56.8% which were significantly higher than that in controls (7.1%, F = 214.614, P &lt; 0.05).	deoxynivalenol	47-50	nitric oxide synthase 2	Homo sapiens	39-43
22041568-14	2011	The relative absorbance values of iNOS mRNA in DON groups were 1.07 - 1.33, which were significantly higher than that in control (0.62, F = 8.358, P &lt; 0.05).	deoxynivalenol	47-50	nitric oxide synthase 2	Homo sapiens	34-38
22041568-16	2011	CONCLUSION: DON could promote anabolism of NO in articular cartilage cells by which up-regulated the expression of PGE2 and MMP-13, which both promoted resolution of articular cartilage matrix such as collagen II.	deoxynivalenol	12-15	matrix metallopeptidase 13	Homo sapiens	124-130
21224530-6	2011	These results suggest that acute exposure to DON induced a temporary recruitment of neutrophils in the peripheral blood by IL-8 and subsequent activation of the bactericidal function, and a transient increase of proinflammatory cytokines and acute-phase proteins, indicating the immunomodulatory effects of DON in pigs.	deoxynivalenol	45-48	C-X-C motif chemokine ligand 8	Sus scrofa	123-127
21138346-8	2011	Deletion of HDF1 resulted in a significant reduction in virulence and deoxynivalenol (DON) production.	deoxynivalenol	70-84	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	12-16
21138346-8	2011	Deletion of HDF1 resulted in a significant reduction in virulence and deoxynivalenol (DON) production.	deoxynivalenol	86-89	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	12-16
23605930-5	2011	Additionally, EGCG suppressed the DON-induced activation of caspase-3/7, which is an indicator of apoptosis.	deoxynivalenol	34-37	caspase 3	Mus musculus	60-71
21538849-8	2011	DON exposure reduced plasma insulin, leptin, insulin-like growth factor 1, and insulin-like growth factor acid labile subunit as well as increased hypothalamic mRNA level of the orexigenic agouti-related protein.	deoxynivalenol	0-3	leptin	Mus musculus	37-43
21538849-8	2011	DON exposure reduced plasma insulin, leptin, insulin-like growth factor 1, and insulin-like growth factor acid labile subunit as well as increased hypothalamic mRNA level of the orexigenic agouti-related protein.	deoxynivalenol	0-3	insulin-like growth factor 1	Mus musculus	45-125
21442537-4	2011	IGF-I release by GCs was inhibited by DON, while progesterone release and the expression of cyclin B1 was stimulated by DON (at 1000 ng/mL but not at 10 and 100 ng/mL).	deoxynivalenol	38-41	insulin-like growth factor I	Cricetulus griseus	0-5
23605622-8	2011	Exposure of dairy cows to the FUS diet resulted in maximum serum de-epoxy-DON levels of 52 ng/ml (0.19 muM), while levels of the unmetabolized DON reached maximum levels of 9 ng/ml (0.03 muM).	deoxynivalenol	74-77	FUS RNA binding protein	Bos taurus	30-33
20937367-5	2011	Activation of caspase 3 was found as an early event in the high DON concentration with an initial maximum after 6-8 h. In contrast, application of 200 ng/mL DON exhibited a response pattern distinct from the high dose DON toxicity.	deoxynivalenol	64-67	caspase-3	Cricetulus griseus	14-23
20937367-5	2011	Activation of caspase 3 was found as an early event in the high DON concentration with an initial maximum after 6-8 h. In contrast, application of 200 ng/mL DON exhibited a response pattern distinct from the high dose DON toxicity.	deoxynivalenol	157-160	caspase-3	Cricetulus griseus	14-23
20937367-5	2011	Activation of caspase 3 was found as an early event in the high DON concentration with an initial maximum after 6-8 h. In contrast, application of 200 ng/mL DON exhibited a response pattern distinct from the high dose DON toxicity.	deoxynivalenol	157-160	caspase-3	Cricetulus griseus	14-23
21442537-4	2011	IGF-I release by GCs was inhibited by DON, while progesterone release and the expression of cyclin B1 was stimulated by DON (at 1000 ng/mL but not at 10 and 100 ng/mL).	deoxynivalenol	120-123	G2/mitotic-specific cyclin-B1	Cricetulus griseus	92-101
21442537-7	2011	In conclusion, our results indicate, (1) a direct effect of DON on secretion of growth factor IGF-I and steroid hormone progesterone, (2) expression of markers of proliferation (cyclin B1 and PCNA) but not on the (3) expression of marker of apoptosis (caspase-3) in porcine ovarian granulosa cells.	deoxynivalenol	60-63	insulin-like growth factor I	Cricetulus griseus	94-99
20708668-0	2010	Impact of DUSP1 on the apoptotic potential of deoxynivalenol in the epithelial cell line HepG2.	deoxynivalenol	46-60	dual specificity protein phosphatase 1	Cricetulus griseus	10-15
20708668-4	2010	In this report we evaluated, for the first time, the impact of mitogen-activated protein kinase phosphatases (MKPs), particularly dual specific phosphatase 1 (DUSP1), on the toxic potential of DON in the epithelial cell line HepG2.	deoxynivalenol	193-196	dual specificity protein phosphatase 1	Cricetulus griseus	159-164
20708668-5	2010	Our results indicate that both low and high concentrations of DON trigger a strong and sustained DUSP1 mRNA and protein expression, mediated by the sustained activation of MEK/ERK pathway.	deoxynivalenol	62-65	dual specificity protein phosphatase 1	Cricetulus griseus	97-102
20708668-6	2010	Furthermore, the expression of DUSP1 protein correlates with the inactivation of JNK1/2, whereas a sustained activation of p38 and ERK1/2 was observed in the presence of DON.	deoxynivalenol	170-173	dual specificity protein phosphatase 1	Cricetulus griseus	31-36
20708668-7	2010	In contrast, treatment of DUSP1 knock-down cells with DON triggers a prolonged activation of JNK1/2, which leads to the induction of apoptosis.	deoxynivalenol	54-57	dual specificity protein phosphatase 1	Cricetulus griseus	26-31
20708668-8	2010	Taken together, we propose DUSP1 as a novel target gene of DON, which is essential for the prevention of DON induced apoptosis in the epithelial cell line HepG2.	deoxynivalenol	59-62	dual specificity protein phosphatase 1	Cricetulus griseus	27-32
20708668-8	2010	Taken together, we propose DUSP1 as a novel target gene of DON, which is essential for the prevention of DON induced apoptosis in the epithelial cell line HepG2.	deoxynivalenol	105-108	dual specificity protein phosphatase 1	Cricetulus griseus	27-32
20633634-3	2010	IL-8 secretion and PGE-2 synthesizing capacity were dose-dependently upregulated in differentiated Caco-2 cells exposed to DON during 24h, reaching an increase of ~25 and 1.7-fold respectively, whereas transcript level of IL-8 and COX-2 were increased by ~40 and 17-fold.	deoxynivalenol	123-126	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
20889551-3	2010	Several representative ribotoxic agents (deoxynivalenol, anisomycin, and 15-acetyldeoxynivalenol) enhanced CHOP expression and its nuclear translocation in human intestinal epithelial cells.	deoxynivalenol	41-55	DNA damage inducible transcript 3	Homo sapiens	107-111
20861219-0	2010	Deoxynivalenol impairs porcine intestinal barrier function and decreases the protein expression of claudin-4 through a mitogen-activated protein kinase-dependent mechanism.	deoxynivalenol	0-14	claudin 4	Homo sapiens	99-108
20861219-3	2010	DON contributes to the loss of barrier function of the intestine through the decreased expression of claudin-4 protein, a tight junction protein.	deoxynivalenol	0-3	claudin 4	Homo sapiens	101-110
20861219-5	2010	Therefore, we investigated the involvement of mitogen-activated protein kinases (MAPK) in the DON-induced loss of barrier function.	deoxynivalenol	94-97	mitogen-activated protein kinase 1	Homo sapiens	81-85
20861219-6	2010	We first verified that 30 mumol/L of DON activated MAPK in a highly sensitive porcine intestinal epithelial cell line (IPEC-1).	deoxynivalenol	37-40	mitogen-activated protein kinase 1	Homo sapiens	51-55
20861219-11	2010	In conclusion, we demonstrated that DON-induced activation of the p44/42 ERK signaling pathway inhibits the expression of claudin-4 protein, which leads to impaired intestinal barrier function.	deoxynivalenol	36-39	interferon induced protein 44	Homo sapiens	66-69
20861219-11	2010	In conclusion, we demonstrated that DON-induced activation of the p44/42 ERK signaling pathway inhibits the expression of claudin-4 protein, which leads to impaired intestinal barrier function.	deoxynivalenol	36-39	mitogen-activated protein kinase 1	Homo sapiens	73-76
20861219-11	2010	In conclusion, we demonstrated that DON-induced activation of the p44/42 ERK signaling pathway inhibits the expression of claudin-4 protein, which leads to impaired intestinal barrier function.	deoxynivalenol	36-39	claudin 4	Homo sapiens	122-131
21351637-5	2010	At the 75th percentile food consumption level, the dietary exposure of populations to DON was higher than its TDI, 1.72 and 2.02 times (adults) as well as 1.19 and 1.09 times higher than TDI (children), respectively, based on the higher DON exposure (adults : P90 for wheat flour and P97.	deoxynivalenol	86-89	cellular inhibitor of PP2A	Homo sapiens	260-263
21351637-5	2010	At the 75th percentile food consumption level, the dietary exposure of populations to DON was higher than its TDI, 1.72 and 2.02 times (adults) as well as 1.19 and 1.09 times higher than TDI (children), respectively, based on the higher DON exposure (adults : P90 for wheat flour and P97.	deoxynivalenol	86-89	melanotransferrin	Homo sapiens	284-287
20633634-3	2010	IL-8 secretion and PGE-2 synthesizing capacity were dose-dependently upregulated in differentiated Caco-2 cells exposed to DON during 24h, reaching an increase of ~25 and 1.7-fold respectively, whereas transcript level of IL-8 and COX-2 were increased by ~40 and 17-fold.	deoxynivalenol	123-126	C-X-C motif chemokine ligand 8	Homo sapiens	222-226
20633634-3	2010	IL-8 secretion and PGE-2 synthesizing capacity were dose-dependently upregulated in differentiated Caco-2 cells exposed to DON during 24h, reaching an increase of ~25 and 1.7-fold respectively, whereas transcript level of IL-8 and COX-2 were increased by ~40 and 17-fold.	deoxynivalenol	123-126	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	231-236
20633634-6	2010	IL-8 secretion and PGE-2 synthesizing capacity increased respectively by ~15 and 2-fold after chronic 21 day incubation with DON (50 ng/ml).	deoxynivalenol	125-128	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
20672443-6	2010	The observed up-regulation of MYBBP1A, a known repressor of a number of transcription factors such as PGC-1 alpha, C-myb, and p65 of the NF-kappaB family, suggests that this protein might play a role in the mechanism of DON toxicity.	deoxynivalenol	220-223	MYB binding protein (P160) 1a	Mus musculus	30-37
20798930-10	2010	From the perspective of human health translation, a particularly exciting development is the availability of biomarkers of exposure (e.g. DON glucuronide) and effect (e.g. IGF1) now make it possible to study the relationship between DON consumption and growth retardation in susceptible human populations such as children and vegetarians.	deoxynivalenol	138-141	insulin like growth factor 1	Homo sapiens	172-176
20672443-6	2010	The observed up-regulation of MYBBP1A, a known repressor of a number of transcription factors such as PGC-1 alpha, C-myb, and p65 of the NF-kappaB family, suggests that this protein might play a role in the mechanism of DON toxicity.	deoxynivalenol	220-223	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	102-113
20672443-6	2010	The observed up-regulation of MYBBP1A, a known repressor of a number of transcription factors such as PGC-1 alpha, C-myb, and p65 of the NF-kappaB family, suggests that this protein might play a role in the mechanism of DON toxicity.	deoxynivalenol	220-223	myeloblastosis oncogene	Mus musculus	115-120
20672443-6	2010	The observed up-regulation of MYBBP1A, a known repressor of a number of transcription factors such as PGC-1 alpha, C-myb, and p65 of the NF-kappaB family, suggests that this protein might play a role in the mechanism of DON toxicity.	deoxynivalenol	220-223	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	126-129
20362602-8	2010	These results demonstrate a dual toxicological effect of DON on differentiated Caco-2 cells consisting in an inhibition of protein synthesis as well as an increase in monolayer permeability, and moreover suggest a possible link between them through diminished synthesis of the tight junction constituent claudin-4.	deoxynivalenol	57-60	claudin 4	Homo sapiens	304-313
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	18-32	mitogen-activated protein kinase 14	Homo sapiens	82-85
20181660-10	2010	Taken together, PKR and Hck were critical for DON-induced ribosomal recruitment of p38, its subsequent phosphorylation, and, ultimately, p38-driven proinflammatory cytokine expression.	deoxynivalenol	46-49	mitogen-activated protein kinase 14	Homo sapiens	83-86
20181660-10	2010	Taken together, PKR and Hck were critical for DON-induced ribosomal recruitment of p38, its subsequent phosphorylation, and, ultimately, p38-driven proinflammatory cytokine expression.	deoxynivalenol	46-49	mitogen-activated protein kinase 14	Homo sapiens	137-140
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	18-32	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	226-229
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	18-32	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	262-265
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	34-37	mitogen-activated protein kinase 14	Homo sapiens	82-85
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	34-37	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	226-229
20181660-1	2010	The trichothecene deoxynivalenol (DON) binds to eukaryotic ribosomes and triggers p38-driven proinflammatory gene expression in the macrophage-a response that is dependent on both double-stranded RNA-activated protein kinase (PKR) and hematopoietic cell kinase (Hck).	deoxynivalenol	34-37	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	262-265
20181660-4	2010	U937 cells stably transfected with a PKR antisense vector (U9K-A1) displayed marked reduction of DON-induced p38 activation and IL-8 expression as compared to cells transfected with empty vector (U9K-C2), with both responses being completely ablated by PP2.	deoxynivalenol	97-100	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	37-40
20181660-4	2010	U937 cells stably transfected with a PKR antisense vector (U9K-A1) displayed marked reduction of DON-induced p38 activation and IL-8 expression as compared to cells transfected with empty vector (U9K-C2), with both responses being completely ablated by PP2.	deoxynivalenol	97-100	mitogen-activated protein kinase 14	Homo sapiens	109-112
20181660-4	2010	U937 cells stably transfected with a PKR antisense vector (U9K-A1) displayed marked reduction of DON-induced p38 activation and IL-8 expression as compared to cells transfected with empty vector (U9K-C2), with both responses being completely ablated by PP2.	deoxynivalenol	97-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	253-256
20181660-7	2010	Consistent with U937 cells, DON induced p38 association with the ribosome and phosphorylation in peritoneal macrophages from wild-type but not PKR-deficient mice.	deoxynivalenol	28-31	mitogen-activated protein kinase 14	Homo sapiens	40-43
20181660-8	2010	DON-induced phosphorylation of ribosome-associated Hck in RAW 264.7 murine macrophages was also suppressed by 2-aminopurine (2-AP).	deoxynivalenol	0-3	hemopoietic cell kinase	Mus musculus	51-54
22069639-5	2010	The initiating mechanisms for DON-induced ribotoxic stress response appear to involve the (1) activation of constitutive protein kinases on the damaged ribosome and (2) autophagy of the chaperone GRP78 with consequent activation of the ER stress response.	deoxynivalenol	30-33	heat shock protein family A (Hsp70) member 5	Homo sapiens	196-201
20181660-9	2010	Both 2-AP and PP2 inhibited DON-induced phosphorylation of p38 as well as two kinases, apoptosis signal-regulating kinase 1 and mitogen-activated protein kinase 3/6, known to be upstream of p38.	deoxynivalenol	28-31	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
20181660-9	2010	Both 2-AP and PP2 inhibited DON-induced phosphorylation of p38 as well as two kinases, apoptosis signal-regulating kinase 1 and mitogen-activated protein kinase 3/6, known to be upstream of p38.	deoxynivalenol	28-31	mitogen-activated protein kinase 14	Homo sapiens	59-62
20181660-9	2010	Both 2-AP and PP2 inhibited DON-induced phosphorylation of p38 as well as two kinases, apoptosis signal-regulating kinase 1 and mitogen-activated protein kinase 3/6, known to be upstream of p38.	deoxynivalenol	28-31	mitogen-activated protein kinase 14	Homo sapiens	190-193
20181660-10	2010	Taken together, PKR and Hck were critical for DON-induced ribosomal recruitment of p38, its subsequent phosphorylation, and, ultimately, p38-driven proinflammatory cytokine expression.	deoxynivalenol	46-49	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	16-19
20181660-10	2010	Taken together, PKR and Hck were critical for DON-induced ribosomal recruitment of p38, its subsequent phosphorylation, and, ultimately, p38-driven proinflammatory cytokine expression.	deoxynivalenol	46-49	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	24-27
19805407-0	2010	Suppression of insulin-like growth factor acid-labile subunit expression--a novel mechanism for deoxynivalenol-induced growth retardation.	deoxynivalenol	96-110	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	15-61
19585272-0	2010	Molecular cloning and characterization of an up-regulated UDP-glucosyltransferase gene induced by DON from Triticum aestivum L. cv.	deoxynivalenol	98-101	UDP-glucose flavonoid 3-O-glucosyltransferase 7	Triticum aestivum	58-81
19585272-8	2010	TaUGT3 showed high similarity in amino acid level with DOGT1 gene in Arabidopsis, which is able to detoxify DON.	deoxynivalenol	108-111	don-glucosyltransferase 1	Arabidopsis thaliana	55-60
19805407-5	2010	Subchronic dietary exposure of young (4-week old) mice to DON (20 ppm) over a period of 2-8 weeks was found to (1) impair weight gain, (2) result in a steady-state plasma DON concentration (40-60 ng/ml), (3) downregulate hepatic insulin-like growth factor acid-labile subunit (IGFALS) mRNA expression, and (4) reduce circulating insulin-like growth factor 1 (IGF1) and IGFALS levels.	deoxynivalenol	58-61	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	229-275
19805407-5	2010	Subchronic dietary exposure of young (4-week old) mice to DON (20 ppm) over a period of 2-8 weeks was found to (1) impair weight gain, (2) result in a steady-state plasma DON concentration (40-60 ng/ml), (3) downregulate hepatic insulin-like growth factor acid-labile subunit (IGFALS) mRNA expression, and (4) reduce circulating insulin-like growth factor 1 (IGF1) and IGFALS levels.	deoxynivalenol	58-61	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	277-283
19805407-5	2010	Subchronic dietary exposure of young (4-week old) mice to DON (20 ppm) over a period of 2-8 weeks was found to (1) impair weight gain, (2) result in a steady-state plasma DON concentration (40-60 ng/ml), (3) downregulate hepatic insulin-like growth factor acid-labile subunit (IGFALS) mRNA expression, and (4) reduce circulating insulin-like growth factor 1 (IGF1) and IGFALS levels.	deoxynivalenol	58-61	insulin-like growth factor 1	Mus musculus	329-357
19805407-5	2010	Subchronic dietary exposure of young (4-week old) mice to DON (20 ppm) over a period of 2-8 weeks was found to (1) impair weight gain, (2) result in a steady-state plasma DON concentration (40-60 ng/ml), (3) downregulate hepatic insulin-like growth factor acid-labile subunit (IGFALS) mRNA expression, and (4) reduce circulating insulin-like growth factor 1 (IGF1) and IGFALS levels.	deoxynivalenol	58-61	insulin-like growth factor 1	Mus musculus	359-363
19805407-5	2010	Subchronic dietary exposure of young (4-week old) mice to DON (20 ppm) over a period of 2-8 weeks was found to (1) impair weight gain, (2) result in a steady-state plasma DON concentration (40-60 ng/ml), (3) downregulate hepatic insulin-like growth factor acid-labile subunit (IGFALS) mRNA expression, and (4) reduce circulating insulin-like growth factor 1 (IGF1) and IGFALS levels.	deoxynivalenol	58-61	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	369-375
19805407-6	2010	Acute oral exposure to DON at 0.5-12.5 mg/kg body weight (bw) markedly suppressed hepatic IGFALS mRNA levels within 2 h in a dose-dependent fashion, whereas 0.1 mg/kg bw was without effect.	deoxynivalenol	23-26	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	90-96
19805407-7	2010	DON-induced IGFALS mRNA upregulation occurred both with and without exogenous GH treatment.	deoxynivalenol	0-3	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	12-18
19805407-9	2010	Taken together, these data suggest that oral DON exposure perturbs GH axis by suppressing two clinically relevant growth-related proteins, IGFALS and IGF1.	deoxynivalenol	45-48	insulin-like growth factor binding protein, acid labile subunit	Mus musculus	139-145
23605236-8	2010	DON-induced expression of FOS was mainly observed in Hep-G2 (96-fold) and U937 cells (59-fold).	deoxynivalenol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-29
19805407-9	2010	Taken together, these data suggest that oral DON exposure perturbs GH axis by suppressing two clinically relevant growth-related proteins, IGFALS and IGF1.	deoxynivalenol	45-48	insulin-like growth factor 1	Mus musculus	150-154
19591856-0	2009	HuR/ELAVL1 RNA binding protein modulates interleukin-8 induction by muco-active ribotoxin deoxynivalenol.	deoxynivalenol	90-104	ELAV like RNA binding protein 1	Homo sapiens	0-3
19635492-7	2010	On the other hand, the secretion of the proinflammatory cytokine TNF-alpha was increased as a direct consequence of DON and NIV exposure.	deoxynivalenol	116-119	tumor necrosis factor	Mus musculus	65-74
19607891-5	2009	In co-cultures and hepatocytes, a DON dose dependent induction of IL-6 mRNA was detected in cells not exposed to LPS.	deoxynivalenol	34-37	interleukin-6	Cricetulus griseus	66-70
19607891-6	2009	Supernatant concentrations of LPS-induced IL-6 were significantly decreased by 2000 nM DON in both types of cell cultures.	deoxynivalenol	87-90	interleukin-6	Cricetulus griseus	42-46
19607891-7	2009	Also the mRNA expression of the anti-inflammatory IL-10 was increased by DON to various degrees depending on DON-dose, stimulation with LPS and time point of measurement.	deoxynivalenol	73-76	interleukin-10	Cricetulus griseus	50-55
19591856-0	2009	HuR/ELAVL1 RNA binding protein modulates interleukin-8 induction by muco-active ribotoxin deoxynivalenol.	deoxynivalenol	90-104	ELAV like RNA binding protein 1	Homo sapiens	4-10
19591856-0	2009	HuR/ELAVL1 RNA binding protein modulates interleukin-8 induction by muco-active ribotoxin deoxynivalenol.	deoxynivalenol	90-104	RNA binding motif single stranded interacting protein 3	Homo sapiens	11-30
19625342-0	2009	Induction of suppressors of cytokine signaling by the trichothecene deoxynivalenol in the mouse.	deoxynivalenol	68-82	cytokine inducible SH2-containing protein	Mus musculus	13-46
19625342-4	2009	We hypothesized that oral exposure to DON will induce SOCS expression in the mouse.	deoxynivalenol	38-41	cytokine inducible SH2-containing protein	Mus musculus	54-58
19625342-5	2009	Real-time PCR and cytokine bead array revealed that oral gavage with DON rapidly (1 h) induced tumor necrosis factor-alpha and interleukin-6 mRNA and protein expression in several organs and plasma, respectively.	deoxynivalenol	69-72	interleukin 6	Mus musculus	127-140
19591856-0	2009	HuR/ELAVL1 RNA binding protein modulates interleukin-8 induction by muco-active ribotoxin deoxynivalenol.	deoxynivalenol	90-104	C-X-C motif chemokine ligand 8	Homo sapiens	41-54
19625342-7	2009	Notably, DON-induced SOCS3 mRNAs in muscle, spleen and liver, with CIS1, SOCS1, and SOCS2 occurring to a lesser extent.	deoxynivalenol	9-12	suppressor of cytokine signaling 3	Mus musculus	21-26
19591856-3	2009	We investigated the effects of ribotoxin deoxynivalenol (DON) on HuR translocation and its involvement in the regulation of the pro-inflammatory interleukin-8 (IL-8) mRNA stability.	deoxynivalenol	41-55	ELAV like RNA binding protein 1	Homo sapiens	65-68
19625342-7	2009	Notably, DON-induced SOCS3 mRNAs in muscle, spleen and liver, with CIS1, SOCS1, and SOCS2 occurring to a lesser extent.	deoxynivalenol	9-12	cytokine inducible SH2-containing protein	Mus musculus	67-71
19591856-3	2009	We investigated the effects of ribotoxin deoxynivalenol (DON) on HuR translocation and its involvement in the regulation of the pro-inflammatory interleukin-8 (IL-8) mRNA stability.	deoxynivalenol	57-60	ELAV like RNA binding protein 1	Homo sapiens	65-68
19591856-3	2009	We investigated the effects of ribotoxin deoxynivalenol (DON) on HuR translocation and its involvement in the regulation of the pro-inflammatory interleukin-8 (IL-8) mRNA stability.	deoxynivalenol	57-60	C-X-C motif chemokine ligand 8	Homo sapiens	145-158
19625342-7	2009	Notably, DON-induced SOCS3 mRNAs in muscle, spleen and liver, with CIS1, SOCS1, and SOCS2 occurring to a lesser extent.	deoxynivalenol	9-12	suppressor of cytokine signaling 1	Mus musculus	73-78
19591856-3	2009	We investigated the effects of ribotoxin deoxynivalenol (DON) on HuR translocation and its involvement in the regulation of the pro-inflammatory interleukin-8 (IL-8) mRNA stability.	deoxynivalenol	57-60	C-X-C motif chemokine ligand 8	Homo sapiens	160-164
19625342-7	2009	Notably, DON-induced SOCS3 mRNAs in muscle, spleen and liver, with CIS1, SOCS1, and SOCS2 occurring to a lesser extent.	deoxynivalenol	9-12	suppressor of cytokine signaling 2	Mus musculus	84-89
19625342-8	2009	Hepatic SOCS3 mRNA was a very sensitive indicator of DON exposure with SOCS3 protein being detectable in the liver well after the onset of cytokine decline (5 h).	deoxynivalenol	53-56	suppressor of cytokine signaling 3	Mus musculus	8-13
19625342-10	2009	Taken together, DON-induced cytokine upregulation corresponded to increased expression of several SOCS, and was associated with suppression of GH-inducible gene expression in the liver.	deoxynivalenol	16-19	cytokine inducible SH2-containing protein	Mus musculus	98-102
19625342-10	2009	Taken together, DON-induced cytokine upregulation corresponded to increased expression of several SOCS, and was associated with suppression of GH-inducible gene expression in the liver.	deoxynivalenol	16-19	growth hormone	Mus musculus	143-145
19591856-4	2009	Exposure to the muco-active DON induced nuclear export of both endogenous and exogenous HuR RNA binding protein in human intestinal epithelial cells.	deoxynivalenol	28-31	ELAV like RNA binding protein 1	Homo sapiens	88-91
19591856-4	2009	Exposure to the muco-active DON induced nuclear export of both endogenous and exogenous HuR RNA binding protein in human intestinal epithelial cells.	deoxynivalenol	28-31	RNA binding motif single stranded interacting protein 3	Homo sapiens	92-111
19591856-5	2009	Moreover, the interference with HuR protein production suppressed ribotoxic DON-induced IL-8 secretion and its mRNA stability.	deoxynivalenol	76-79	ELAV like RNA binding protein 1	Homo sapiens	32-35
19591856-5	2009	Moreover, the interference with HuR protein production suppressed ribotoxic DON-induced IL-8 secretion and its mRNA stability.	deoxynivalenol	76-79	C-X-C motif chemokine ligand 8	Homo sapiens	88-92
19591856-7	2009	Partly in terms of IL-8-modulating transcription factors, HuR protein was demonstrated to be positively and negatively associated with DON-induced early growth response gene 1 (EGR-1) and activating transcription factor 3 (ATF3), respectively.	deoxynivalenol	135-138	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
19591856-7	2009	Partly in terms of IL-8-modulating transcription factors, HuR protein was demonstrated to be positively and negatively associated with DON-induced early growth response gene 1 (EGR-1) and activating transcription factor 3 (ATF3), respectively.	deoxynivalenol	135-138	ELAV like RNA binding protein 1	Homo sapiens	58-61
19591856-7	2009	Partly in terms of IL-8-modulating transcription factors, HuR protein was demonstrated to be positively and negatively associated with DON-induced early growth response gene 1 (EGR-1) and activating transcription factor 3 (ATF3), respectively.	deoxynivalenol	135-138	early growth response 1	Homo sapiens	177-182
19591856-7	2009	Partly in terms of IL-8-modulating transcription factors, HuR protein was demonstrated to be positively and negatively associated with DON-induced early growth response gene 1 (EGR-1) and activating transcription factor 3 (ATF3), respectively.	deoxynivalenol	135-138	activating transcription factor 3	Homo sapiens	188-221
19591856-7	2009	Partly in terms of IL-8-modulating transcription factors, HuR protein was demonstrated to be positively and negatively associated with DON-induced early growth response gene 1 (EGR-1) and activating transcription factor 3 (ATF3), respectively.	deoxynivalenol	135-138	activating transcription factor 3	Homo sapiens	223-227
19680982-3	2009	Using flow cytometry with staining for leukocyte surface markers, the percentage of CD19(+) leukocytes (B cells) in peripheral blood was decreased in both sexes of BALB/c mice after 14 days of exposure to 1.0 or 2.0 mg kg(-1) DON, whereas exposure to DON over 28 days did not inhibit B cells compared to the control diet.	deoxynivalenol	226-229	CD19 antigen	Mus musculus	84-88
19680982-3	2009	Using flow cytometry with staining for leukocyte surface markers, the percentage of CD19(+) leukocytes (B cells) in peripheral blood was decreased in both sexes of BALB/c mice after 14 days of exposure to 1.0 or 2.0 mg kg(-1) DON, whereas exposure to DON over 28 days did not inhibit B cells compared to the control diet.	deoxynivalenol	251-254	CD19 antigen	Mus musculus	84-88
19680982-5	2009	The percentage of CD11b(+) leukocytes (monocytes) in peripheral blood and total CD11b(+) splenic leukocytes were decreased only in female mice fed 1.0 and 2.0 mg kg(-1) DON after 28 days compared with control diet, which shows the greater sensitivity to DON in females compared to males.	deoxynivalenol	169-172	integrin alpha M	Mus musculus	18-23
19360757-6	2009	An inverse relation was noticed for the level of DON induced expression of transcription factors (JUN, FOS, EGR1 and ATF3) and the susceptibility of the cell lines towards the mycotoxin.	deoxynivalenol	49-52	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-106
19689068-0	2009	[Effects of deoxynivalenol on apoptosis of human gastric carcinoma cell line SGC-7901, BGC-823 in vitro].	deoxynivalenol	12-26	sarcoglycan beta	Homo sapiens	77-80
19689068-1	2009	OBJECTIVE: To explore the putative effects and possible mechanisms of deoxynivalenol (DON) on the apoptosis of human gastric carcinoma cell line SGC-7901, BGC-823 in vitro.	deoxynivalenol	70-84	sarcoglycan beta	Homo sapiens	145-148
19689068-1	2009	OBJECTIVE: To explore the putative effects and possible mechanisms of deoxynivalenol (DON) on the apoptosis of human gastric carcinoma cell line SGC-7901, BGC-823 in vitro.	deoxynivalenol	86-89	sarcoglycan beta	Homo sapiens	145-148
19689068-2	2009	METHODS: SGC-7901 and BGC-823 cells were treated with DON (50, 100, 1000 microg/L) for 72 hours, and then cells were harvested for the studies of apoptosis and the expression of Bax and Bcl-2 with flow cytometry (FCM), immunocytochemical staining and Western blot.	deoxynivalenol	54-57	sarcoglycan beta	Homo sapiens	9-12
19689068-3	2009	RESULTS: FCM results showed that the apoptosis rates of SGC-7901 and BGC-823 cells in DON treatment groups were higher than that in control, and positive dose-effect correlations could be found in both cell lines (SGC-7901: r = 0.660, P &lt; 0.05, n=4, BGC-823: r = 0.750, P &lt; 0.01, n=4).	deoxynivalenol	86-89	sarcoglycan beta	Homo sapiens	56-59
19689068-3	2009	RESULTS: FCM results showed that the apoptosis rates of SGC-7901 and BGC-823 cells in DON treatment groups were higher than that in control, and positive dose-effect correlations could be found in both cell lines (SGC-7901: r = 0.660, P &lt; 0.05, n=4, BGC-823: r = 0.750, P &lt; 0.01, n=4).	deoxynivalenol	86-89	sarcoglycan beta	Homo sapiens	214-217
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	sarcoglycan beta	Homo sapiens	69-72
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 associated X, apoptosis regulator	Homo sapiens	184-187
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 associated X, apoptosis regulator	Homo sapiens	188-191
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 associated X, apoptosis regulator	Homo sapiens	188-191
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 apoptosis regulator	Homo sapiens	237-242
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 associated X, apoptosis regulator	Homo sapiens	188-191
19689068-5	2009	CONCLUSION: The results suggested that DON could induce apoptosis of SGC-7901, BGC-823 cells in vitro in a dose-dependent manner, and possible mechanisms may be increased formation of Bax-Bax homology dimer and decreased formationof Bax-Bcl-2 dimer by up-regulation of the expression of Bax and down-regulation of that Bcl-2.	deoxynivalenol	39-42	BCL2 apoptosis regulator	Homo sapiens	319-324
19475690-8	2009	The VEGF-A up-regulation by pre-S mutants could be suppressed by vomitoxin, an ER stress inhibitor.	deoxynivalenol	65-74	vascular endothelial growth factor A	Homo sapiens	4-10
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	43-57	interleukin 6	Mus musculus	72-85
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	43-57	interleukin 6	Mus musculus	87-91
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	59-62	interleukin 6	Mus musculus	72-85
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	59-62	interleukin 6	Mus musculus	87-91
18602807-3	2009	The purpose of this study was to identify the signal transduction pathways by which DON up-regulates IL-6 in the peritoneal macrophage and how consumption of fish oil enriched with the n-3 PUFA docosahexaenoic acid (DHA) suppresses these processes.	deoxynivalenol	84-87	interleukin 6	Mus musculus	101-105
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	interleukin 6	Mus musculus	28-32
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	cAMP responsive element binding protein 1	Mus musculus	121-158
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	cAMP responsive element binding protein 1	Mus musculus	160-164
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	cAMP responsive element binding protein 1	Mus musculus	201-205
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	thymoma viral proto-oncogene 1	Mus musculus	214-220
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	ribosomal protein S6 kinase, polypeptide 5	Mus musculus	222-226
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	ribosomal protein S6 kinase polypeptide 1	Mus musculus	231-235
18602807-10	2009	These data suggest that DON-induced IL-6 expression is CREB mediated and PKR dependent, and that requisite kinase activities for these pathways were suppressed in macrophages from mice fed DHA for an extended period.	deoxynivalenol	24-27	interleukin 6	Mus musculus	36-40
18602807-10	2009	These data suggest that DON-induced IL-6 expression is CREB mediated and PKR dependent, and that requisite kinase activities for these pathways were suppressed in macrophages from mice fed DHA for an extended period.	deoxynivalenol	24-27	cAMP responsive element binding protein 1	Mus musculus	55-59
18602807-10	2009	These data suggest that DON-induced IL-6 expression is CREB mediated and PKR dependent, and that requisite kinase activities for these pathways were suppressed in macrophages from mice fed DHA for an extended period.	deoxynivalenol	24-27	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	73-76
19438726-0	2009	Overexpression of human histone methylase MLL1 upon exposure to a food contaminant mycotoxin, deoxynivalenol.	deoxynivalenol	94-108	lysine methyltransferase 2A	Homo sapiens	42-46
19438726-3	2009	Herein, to understand the effects of toxic stress on MLL gene regulation, we treated human cells with a common food contaminant mycotoxin, deoxynivalenol (DON).	deoxynivalenol	139-153	lysine methyltransferase 2A	Homo sapiens	53-56
19438726-3	2009	Herein, to understand the effects of toxic stress on MLL gene regulation, we treated human cells with a common food contaminant mycotoxin, deoxynivalenol (DON).	deoxynivalenol	155-158	lysine methyltransferase 2A	Homo sapiens	53-56
19438726-5	2009	Studies using specific inhibitors demonstrated that Src kinase families are involved in upstream events in DON-mediated upregulation of MLL1.	deoxynivalenol	107-110	lysine methyltransferase 2A	Homo sapiens	136-140
19438726-7	2009	Moreover, antisense-mediated knockdown of Sp1 diminished DON-induced MLL1 upregulation.	deoxynivalenol	57-60	lysine methyltransferase 2A	Homo sapiens	69-73
19336499-0	2009	Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage.	deoxynivalenol	47-61	heat shock protein 5	Mus musculus	8-13
19336499-0	2009	Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage.	deoxynivalenol	47-61	heat shock protein 5	Mus musculus	14-17
19336499-0	2009	Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage.	deoxynivalenol	47-61	interleukin 6	Mus musculus	70-83
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	28-42	interleukin 6	Mus musculus	84-97
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	28-42	interleukin 6	Mus musculus	99-103
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	44-47	interleukin 6	Mus musculus	84-97
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	44-47	interleukin 6	Mus musculus	99-103
19336499-2	2009	The purpose of this study was to test the hypothesis that DON triggers an endoplasmic reticulum (ER) stress response in murine macrophages capable of driving IL-6 gene expression.	deoxynivalenol	58-61	interleukin 6	Mus musculus	158-162
19336499-6	2009	Inhibitor studies suggested that DON-induced GRP78 degradation was cathepsin and calpain dependent but was proteosome-independent.	deoxynivalenol	33-36	heat shock protein 5	Mus musculus	45-50
19336499-9	2009	DON exposure was found to increase IRE1alpha protein, its modified products spliced XBP1 mRNA and XBP1 protein as well as ATF6.	deoxynivalenol	0-3	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	35-44
19336499-9	2009	DON exposure was found to increase IRE1alpha protein, its modified products spliced XBP1 mRNA and XBP1 protein as well as ATF6.	deoxynivalenol	0-3	X-box binding protein 1	Mus musculus	84-88
19336499-9	2009	DON exposure was found to increase IRE1alpha protein, its modified products spliced XBP1 mRNA and XBP1 protein as well as ATF6.	deoxynivalenol	0-3	X-box binding protein 1	Mus musculus	98-102
19336499-9	2009	DON exposure was found to increase IRE1alpha protein, its modified products spliced XBP1 mRNA and XBP1 protein as well as ATF6.	deoxynivalenol	0-3	activating transcription factor 6	Mus musculus	122-126
19336499-10	2009	Knockdown of ATF6 but not XBP1 partially inhibited DON-induced IL-6 expression in the macrophages.	deoxynivalenol	51-54	activating transcription factor 6	Mus musculus	13-17
19336499-10	2009	Knockdown of ATF6 but not XBP1 partially inhibited DON-induced IL-6 expression in the macrophages.	deoxynivalenol	51-54	interleukin 6	Mus musculus	63-67
19336499-12	2009	Taken together, these data suggest that in the macrophage DON induces GRP78 degradation and evokes an ER stress response that could contribute, in part, to DON-induced IL-6 gene expression.	deoxynivalenol	58-61	heat shock protein 5	Mus musculus	70-75
19336499-12	2009	Taken together, these data suggest that in the macrophage DON induces GRP78 degradation and evokes an ER stress response that could contribute, in part, to DON-induced IL-6 gene expression.	deoxynivalenol	58-61	interleukin 6	Mus musculus	168-172
19336499-12	2009	Taken together, these data suggest that in the macrophage DON induces GRP78 degradation and evokes an ER stress response that could contribute, in part, to DON-induced IL-6 gene expression.	deoxynivalenol	156-159	interleukin 6	Mus musculus	168-172
19360757-6	2009	An inverse relation was noticed for the level of DON induced expression of transcription factors (JUN, FOS, EGR1 and ATF3) and the susceptibility of the cell lines towards the mycotoxin.	deoxynivalenol	49-52	early growth response 1	Homo sapiens	108-112
19360757-6	2009	An inverse relation was noticed for the level of DON induced expression of transcription factors (JUN, FOS, EGR1 and ATF3) and the susceptibility of the cell lines towards the mycotoxin.	deoxynivalenol	49-52	activating transcription factor 3	Homo sapiens	117-121
18433975-6	2008	The functional significance of elevated DON tissue concentrations was assessed by measuring IL-1beta, IL-6, and TNF-alpha mRNA responses in spleen, liver and lung.	deoxynivalenol	40-43	interleukin 1 beta	Mus musculus	92-100
19101521-3	2009	ATF3 expression was up-regulated by chemical agents causing ribotoxic stress such as deoxynivalenol and anisomycin in different types of intestinal epithelial cells.	deoxynivalenol	85-99	activating transcription factor 3	Homo sapiens	0-4
19680889-11	2009	The intakes of OTA and DON were found to be below the threshold of toxicological concern established for these mycotoxins by international expert groups, although the intake of DON in children at the highest percentile (P95) was close to its PTDI.	deoxynivalenol	177-180	nibrin	Homo sapiens	220-223
19027837-5	2009	The expression of interleukin (IL)-1beta was significantly induced by DON (except for 12h) and LPS.	deoxynivalenol	70-73	interleukin 1 beta	Homo sapiens	18-40
19027837-6	2009	An induction of the mRNA expression of IL-6 by DON was evident only at 3h, whereas the supernatant concentrations of LPS stimulated PAM incubated with 500nM DON were significantly decreased at most time points.	deoxynivalenol	47-50	interleukin 6	Homo sapiens	39-43
19027837-8	2009	The results of the present investigation suggest a contribution of cytokines, especially TNF-alpha and IL-1beta, induced by DON in porcine macrophages to the effects observed in vivo.	deoxynivalenol	124-127	tumor necrosis factor	Homo sapiens	89-98
19027837-8	2009	The results of the present investigation suggest a contribution of cytokines, especially TNF-alpha and IL-1beta, induced by DON in porcine macrophages to the effects observed in vivo.	deoxynivalenol	124-127	interleukin 1 beta	Homo sapiens	103-111
19382558-2	2009	Deoxynivalenol (DON); aflatoxins B1, B2, G1, G2; ochratoxin A; zearalenone; and fumonisins FB1 and FB2 are extracted from corn grain samples with water-methanol, and extracts are cleaned up using immunoaffinity and solid-phase extraction columns.	deoxynivalenol	16-19	Protein DEHYDRATION-INDUCED 19 homolog 5	Zea mays	99-102
18599499-0	2008	Double-stranded RNA-activated protein kinase mediates induction of interleukin-8 expression by deoxynivalenol, Shiga toxin 1, and ricin in monocytes.	deoxynivalenol	95-109	C-X-C motif chemokine ligand 8	Homo sapiens	67-80
18599499-3	2008	We have previously shown that PKR mediates DON-induced MAPK phosphorylation in macrophages and monocytes.	deoxynivalenol	43-46	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	30-33
18599499-5	2008	Preincubation of human monocytic U937 cells with the PKR inhibitors C16 and 2-aminopurine (2-AP) blocked DON-induced expression of IL-8 protein and mRNA.	deoxynivalenol	105-108	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	53-56
18599499-5	2008	Preincubation of human monocytic U937 cells with the PKR inhibitors C16 and 2-aminopurine (2-AP) blocked DON-induced expression of IL-8 protein and mRNA.	deoxynivalenol	105-108	C-X-C motif chemokine ligand 8	Homo sapiens	131-135
18599499-7	2008	Nuclear factor-kappa B binding, which has been previously shown to be a requisite for DON-induced IL-8 transcription, was markedly reduced in UK9M cells as compared with UK9C cells.	deoxynivalenol	86-89	C-X-C motif chemokine ligand 8	Homo sapiens	98-102
18599499-8	2008	As observed for DON, ricin-, and Stx1-induced IL-8 expression was suppressed by the PKR inhibitors C16 and 2-AP as well as impaired in UK9M cells.	deoxynivalenol	16-19	C-X-C motif chemokine ligand 8	Homo sapiens	46-50
18599499-8	2008	As observed for DON, ricin-, and Stx1-induced IL-8 expression was suppressed by the PKR inhibitors C16 and 2-AP as well as impaired in UK9M cells.	deoxynivalenol	16-19	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	84-87
18599499-9	2008	Taken together, these data indicate that PKR plays a common role in IL-8 induction by DON and the two RIPs, suggesting that this kinase might be a critical factor in RSR.	deoxynivalenol	86-89	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	41-44
18599499-9	2008	Taken together, these data indicate that PKR plays a common role in IL-8 induction by DON and the two RIPs, suggesting that this kinase might be a critical factor in RSR.	deoxynivalenol	86-89	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
18716445-0	2008	Plasma haptoglobin and immunoglobulins as diagnostic indicators of deoxynivalenol intoxication.	deoxynivalenol	67-81	haptoglobin	Rattus norvegicus	7-18
18502741-0	2008	Deoxynivalenol induces p38 interaction with the ribosome in monocytes and macrophages.	deoxynivalenol	0-14	mitogen-activated protein kinase 14	Mus musculus	23-26
18502741-2	2008	We hypothesized that the trichothecene deoxynivalenol (DON) induces interaction of p38 with the ribosome.	deoxynivalenol	39-53	mitogen-activated protein kinase 14	Mus musculus	83-86
18502741-2	2008	We hypothesized that the trichothecene deoxynivalenol (DON) induces interaction of p38 with the ribosome.	deoxynivalenol	55-58	mitogen-activated protein kinase 14	Mus musculus	83-86
18502741-3	2008	Two models, U937 human monocytes and RAW 264.7 murine macrophages, were used to test this hypothesis based on their capacity to evoke rapid and robust p38 phosphorylation responses to DON.	deoxynivalenol	184-187	mitogen-activated protein kinase 14	Mus musculus	151-154
18502741-5	2008	p38 content in fractions containing ribosomal subunits and monosomes (RS + M) increased within 5 min of DON treatment and continued to increase up to 30 min.	deoxynivalenol	104-107	mitogen-activated protein kinase 14	Homo sapiens	0-3
18502741-8	2008	In RAW 264.7 cells, radiolabeled DON uptake occurred within 15 min and this corresponded to sequential increases nonphosphorylated p38 and phosphorylated p38 in the RS + M fraction.	deoxynivalenol	33-36	mitogen-activated protein kinase 14	Mus musculus	131-134
18502741-8	2008	In RAW 264.7 cells, radiolabeled DON uptake occurred within 15 min and this corresponded to sequential increases nonphosphorylated p38 and phosphorylated p38 in the RS + M fraction.	deoxynivalenol	33-36	mitogen-activated protein kinase 14	Mus musculus	154-157
18502741-9	2008	As observed for p38, DON similarly induced both ribosomal interaction with two mitogen-activated protein kinases, c-Jun N-terminal kinase, and extracellular signal-regulated kinase, and their subsequent phosphorylation in RAW 264.7 cells.	deoxynivalenol	21-24	mitogen-activated protein kinase 14	Mus musculus	16-19
18502741-10	2008	Taken together, these data suggest that, in mononuclear phagocytes, DON induced p38 mobilization to the ribosome and its subsequent phosphorylation.	deoxynivalenol	68-71	mitogen-activated protein kinase 14	Mus musculus	80-83
18485432-0	2008	Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol.	deoxynivalenol	173-187	C-X-C motif chemokine ligand 8	Homo sapiens	23-36
18433975-6	2008	The functional significance of elevated DON tissue concentrations was assessed by measuring IL-1beta, IL-6, and TNF-alpha mRNA responses in spleen, liver and lung.	deoxynivalenol	40-43	interleukin 6	Mus musculus	102-106
18433975-6	2008	The functional significance of elevated DON tissue concentrations was assessed by measuring IL-1beta, IL-6, and TNF-alpha mRNA responses in spleen, liver and lung.	deoxynivalenol	40-43	tumor necrosis factor	Mus musculus	112-121
18006205-0	2008	Ribotoxic mycotoxin deoxynivalenol induces G2/M cell cycle arrest via p21Cip/WAF1 mRNA stabilization in human epithelial cells.	deoxynivalenol	20-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	77-81
18343010-0	2008	Lactobacillus rhamnosus strain GG restores alkaline phosphatase activity in differentiating Caco-2 cells dosed with the potent mycotoxin deoxynivalenol.	deoxynivalenol	137-151	alkaline phosphatase, placental	Homo sapiens	43-63
18343010-5	2008	DON (200ng/mL) caused a significant (p&lt;0.001) 36% reduction in ALP activity (1598+/-137U/mg protein) compared to untreated cells (2502+/-80U/mg).	deoxynivalenol	0-3	alkaline phosphatase, placental	Homo sapiens	66-69
18343010-6	2008	A dose dependant restoration of ALP activity was observed where DON treated cells were co-incubated with heat inactivated GG (1719+/-84; 2007+/-142; 2272+/-160U/mg for GG at 1x10(4) (p&gt;0.9), 1x10(7) (p&lt;0.001), and 1x10(10)CFU/mL (p&lt;0.001), respectively).	deoxynivalenol	64-67	alkaline phosphatase, placental	Homo sapiens	32-35
18343010-9	2008	These combined data suggest that the major effect of GG on restoring ALP activity, and therefore Caco-2 cell differentiation, was due to specific binding of DON, with possibly a more minor role of non-specific bacterial interference.	deoxynivalenol	157-160	alkaline phosphatase, placental	Homo sapiens	69-72
18329193-10	2008	In the mesenteric lymph node, a significantly lower expression of both TGF-beta and IFN-gamma mRNA expression levels is observed in animals feed with DON when compared with control piglets.	deoxynivalenol	150-153	interferon gamma	Sus scrofa	84-93
18343055-5	2008	Dose-dependent increases in NF-kappaB activity and IL-8 secretion were observed, reaching 1.4- and 7.6-fold, respectively using DON at 10 microg/ml.	deoxynivalenol	128-131	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
18343055-9	2008	These data show that DON induces NF-kappaB activation and IL-8 secretion dose-dependently in Caco-2 cells, and this effect was accentuated upon pro-inflammatory stimulation, suggesting DON exposure could cause or exacerbate intestinal inflammation.	deoxynivalenol	21-24	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
18343055-9	2008	These data show that DON induces NF-kappaB activation and IL-8 secretion dose-dependently in Caco-2 cells, and this effect was accentuated upon pro-inflammatory stimulation, suggesting DON exposure could cause or exacerbate intestinal inflammation.	deoxynivalenol	185-188	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
18243380-3	2008	Inactivation of the stress inducible polyubiquitin gene UBI4 or the ubiquitin protease UBP6 increased DON sensitivity, the inactivation of both genes had a synergistic effect.	deoxynivalenol	102-105	ubiquitin	Saccharomyces cerevisiae S288C	56-60
18243380-3	2008	Inactivation of the stress inducible polyubiquitin gene UBI4 or the ubiquitin protease UBP6 increased DON sensitivity, the inactivation of both genes had a synergistic effect.	deoxynivalenol	102-105	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	87-91
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	14-18
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	ATP-binding cassette multidrug transporter PDR10	Saccharomyces cerevisiae S288C	19-24
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	ATP-binding cassette multidrug transporter PDR15	Saccharomyces cerevisiae S288C	25-30
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	acetyltransferase	Saccharomyces cerevisiae S288C	31-35
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	36-40
18243380-4	2008	The resulting pdr5 pdr10 pdr15 ayt1 ubp6 ubi4 mutant strain showed 50% growth inhibition at a DON concentration of 5 mg/l under optimal conditions.	deoxynivalenol	94-97	ubiquitin	Saccharomyces cerevisiae S288C	41-45
18308354-5	2008	Deoxynivalenol was the only mycotoxin able to directly increase IL-8 secretion (10- to 15-fold increase).	deoxynivalenol	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	64-68
18308354-7	2008	We found that deoxynivalenol, ochratoxin A and patulin all potentiated the effect of IL-1beta on IL-8 secretion (ranging from 35% to 138% increase) and increased the transepithelial passage of commensal bacteria (ranging from 12- to 1544-fold increase).	deoxynivalenol	14-28	interleukin 1 beta	Homo sapiens	85-93
18308354-7	2008	We found that deoxynivalenol, ochratoxin A and patulin all potentiated the effect of IL-1beta on IL-8 secretion (ranging from 35% to 138% increase) and increased the transepithelial passage of commensal bacteria (ranging from 12- to 1544-fold increase).	deoxynivalenol	14-28	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
18006205-5	2008	Gene expression of p21 was also induced by DON treatment in a dose-dependent manner with no increase in p53 protein levels, suggesting p53-independent p21 induction.	deoxynivalenol	43-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	19-22
18006205-5	2008	Gene expression of p21 was also induced by DON treatment in a dose-dependent manner with no increase in p53 protein levels, suggesting p53-independent p21 induction.	deoxynivalenol	43-46	tumor protein p53	Homo sapiens	135-138
18006205-5	2008	Gene expression of p21 was also induced by DON treatment in a dose-dependent manner with no increase in p53 protein levels, suggesting p53-independent p21 induction.	deoxynivalenol	43-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	151-154
18006205-6	2008	Signaling pathways associated with DON-induced p21 gene expression included PI3 kinase and ERK1/2 MAP kinase cascade.	deoxynivalenol	35-38	cyclin dependent kinase inhibitor 1A	Homo sapiens	47-50
18006205-6	2008	Signaling pathways associated with DON-induced p21 gene expression included PI3 kinase and ERK1/2 MAP kinase cascade.	deoxynivalenol	35-38	mitogen-activated protein kinase 3	Homo sapiens	91-97
18006205-7	2008	Particularly, ERK1/2 signal was associated with DON-induced p21 mRNA stabilization in the human epithelial cells.	deoxynivalenol	48-51	mitogen-activated protein kinase 3	Homo sapiens	14-20
18006205-7	2008	Particularly, ERK1/2 signal was associated with DON-induced p21 mRNA stabilization in the human epithelial cells.	deoxynivalenol	48-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-63
18006205-8	2008	Taken together, deoxynivalenol arrested epithelial cell cycle at G(2)/M phase via elevated p21 gene expression.	deoxynivalenol	16-30	cyclin dependent kinase inhibitor 1A	Homo sapiens	91-94
18179606-7	2008	The map1 mutant caused minimal disease and DON accumulation in both hosts.	deoxynivalenol	43-46	Transmembrane amino acid transporter family protein	Arabidopsis thaliana	4-8
17543436-0	2007	Epithelial transport of deoxynivalenol: involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2).	deoxynivalenol	24-38	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	85-99	early growth response 1	Homo sapiens	14-42
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	85-99	C-X-C motif chemokine ligand 8	Homo sapiens	47-60
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	85-99	mitogen-activated protein kinase 3	Homo sapiens	116-122
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	101-110	early growth response 1	Homo sapiens	14-42
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	101-110	C-X-C motif chemokine ligand 8	Homo sapiens	47-60
17707346-0	2007	Modulation of early growth response gene 1 and interleukin-8 expression by ribotoxin deoxynivalenol (vomitoxin) via ERK1/2 in human epithelial intestine 407 cells.	deoxynivalenol	101-110	mitogen-activated protein kinase 3	Homo sapiens	116-122
17543436-0	2007	Epithelial transport of deoxynivalenol: involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2).	deoxynivalenol	24-38	ATP binding cassette subfamily B member 1	Homo sapiens	77-82
17543436-0	2007	Epithelial transport of deoxynivalenol: involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2).	deoxynivalenol	24-38	ATP binding cassette subfamily C member 2	Homo sapiens	88-129
17543436-0	2007	Epithelial transport of deoxynivalenol: involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2).	deoxynivalenol	24-38	ATP binding cassette subfamily C member 2	Homo sapiens	131-136
17543436-7	2007	Intracellular DON accumulation was increased and DON efflux was decreased by ATP depletion, by P-glycoprotein inhibitor valspodar and by MRP2 inhibitor MK571, but not by BCRP inhibitor Ko143.	deoxynivalenol	49-52	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
17543436-7	2007	Intracellular DON accumulation was increased and DON efflux was decreased by ATP depletion, by P-glycoprotein inhibitor valspodar and by MRP2 inhibitor MK571, but not by BCRP inhibitor Ko143.	deoxynivalenol	49-52	ATP binding cassette subfamily C member 2	Homo sapiens	137-141
17543436-8	2007	Intracellular DON accumulation was then investigated using epithelial cell lines transfected with human P-glycoprotein or MRP2.	deoxynivalenol	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	104-118
17543436-8	2007	Intracellular DON accumulation was then investigated using epithelial cell lines transfected with human P-glycoprotein or MRP2.	deoxynivalenol	14-17	ATP binding cassette subfamily C member 2	Homo sapiens	122-126
17543436-10	2007	Taken together, these results suggest that DON is a substrate for both P-glycoprotein and MRP2.	deoxynivalenol	43-46	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
17543436-10	2007	Taken together, these results suggest that DON is a substrate for both P-glycoprotein and MRP2.	deoxynivalenol	43-46	ATP binding cassette subfamily C member 2	Homo sapiens	90-94
17636245-0	2007	Transcriptional regulation of deoxynivalenol-induced IL-8 expression in human monocytes.	deoxynivalenol	30-44	C-X-C motif chemokine ligand 8	Homo sapiens	53-57
17636245-5	2007	In contrast, mutating the activator protein-1 binding site resulted in significantly increased DON- and LPS-induced luciferase expression.	deoxynivalenol	95-98	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-45
17636245-7	2007	Consistent with reporter studies, the NF-kappaB inhibitor caffeic acid phenethyl ester completely ablated both DON-induced IL-8 mRNA and protein expression.	deoxynivalenol	111-114	C-X-C motif chemokine ligand 8	Homo sapiens	123-127
17636245-10	2007	Taken together, these data suggest that DON-induced IL-8 expression is likely to be mediated at the transcriptional level by NF-kappaB, specifically p65, but does not appear to involve mRNA stabilization.	deoxynivalenol	40-43	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
17636245-10	2007	Taken together, these data suggest that DON-induced IL-8 expression is likely to be mediated at the transcriptional level by NF-kappaB, specifically p65, but does not appear to involve mRNA stabilization.	deoxynivalenol	40-43	RELA proto-oncogene, NF-kB subunit	Homo sapiens	149-152
19070152-0	2007	Double mutation in tomato ribosomal protein L3 cDNA confers tolerance to deoxynivalenol (DON) in transgenic tobacco.	deoxynivalenol	73-87	ribosomal protein L3	Solanum lycopersicum	26-46
19070152-0	2007	Double mutation in tomato ribosomal protein L3 cDNA confers tolerance to deoxynivalenol (DON) in transgenic tobacco.	deoxynivalenol	89-92	ribosomal protein L3	Solanum lycopersicum	26-46
19070152-3	2007	The putative site of action of DON is 60s ribosomal protein L3 (RPL3).	deoxynivalenol	31-34	50S ribosomal protein L3, chloroplastic	Nicotiana tabacum	42-62
19070152-3	2007	The putative site of action of DON is 60s ribosomal protein L3 (RPL3).	deoxynivalenol	31-34	50S ribosomal protein L3, chloroplastic	Nicotiana tabacum	64-68
17411352-0	2007	Induction of apoptosis and activation of JNK and p38 MAPK pathways in deoxynivalenol-treated cell lines.	deoxynivalenol	70-84	mitogen-activated protein kinase 8	Homo sapiens	41-44
17411352-0	2007	Induction of apoptosis and activation of JNK and p38 MAPK pathways in deoxynivalenol-treated cell lines.	deoxynivalenol	70-84	mitogen-activated protein kinase 14	Homo sapiens	49-52
17411352-6	2007	In blood-derived REH and Jurkat cells, DON-induced apoptotic changes were preceded by an increase in JNK and p38 MAPKs phosphorylation, as well as in c-Jun expression.	deoxynivalenol	39-42	mitogen-activated protein kinase 8	Homo sapiens	101-104
17411352-6	2007	In blood-derived REH and Jurkat cells, DON-induced apoptotic changes were preceded by an increase in JNK and p38 MAPKs phosphorylation, as well as in c-Jun expression.	deoxynivalenol	39-42	mitogen-activated protein kinase 14	Homo sapiens	109-112
17411352-6	2007	In blood-derived REH and Jurkat cells, DON-induced apoptotic changes were preceded by an increase in JNK and p38 MAPKs phosphorylation, as well as in c-Jun expression.	deoxynivalenol	39-42	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	150-155
17411352-9	2007	In contrast, studies on the role of p38 MAPK revealed that p38 signalling is required for DON-induced apoptosis in REH cells.	deoxynivalenol	90-93	mitogen-activated protein kinase 14	Homo sapiens	36-39
17411352-9	2007	In contrast, studies on the role of p38 MAPK revealed that p38 signalling is required for DON-induced apoptosis in REH cells.	deoxynivalenol	90-93	mitogen-activated protein kinase 14	Homo sapiens	59-62
17166419-1	2006	OBJECTIVE: To explore the effects of Vitamin C (Vit C) on the apoptosis and proliferation inhibition of human peripheral blood mononuclear cells (HPBMCs) induced by deoxynivalenol (DON) in vitro.	deoxynivalenol	165-179	vitrin	Homo sapiens	37-40
17256175-1	2007	Despite inhibition of protein synthesis being its mode of action, the trichothecene mycotoxin deoxynivalenol (DON) induced accumulation of transcripts encoding translation elongation factor 1alpha (EF-1alpha), class III plant peroxidase (POX), structure specific recognition protein, basic leucine zipper protein transcription factor (bZIP), retrotransposon-like homologs and genes of unknown function in the roots of wheat cultivars CM82036 and Remus.	deoxynivalenol	94-108	peroxidase-like	Triticum aestivum	226-236
17256175-1	2007	Despite inhibition of protein synthesis being its mode of action, the trichothecene mycotoxin deoxynivalenol (DON) induced accumulation of transcripts encoding translation elongation factor 1alpha (EF-1alpha), class III plant peroxidase (POX), structure specific recognition protein, basic leucine zipper protein transcription factor (bZIP), retrotransposon-like homologs and genes of unknown function in the roots of wheat cultivars CM82036 and Remus.	deoxynivalenol	94-108	peroxidase-like	Triticum aestivum	238-241
17256175-1	2007	Despite inhibition of protein synthesis being its mode of action, the trichothecene mycotoxin deoxynivalenol (DON) induced accumulation of transcripts encoding translation elongation factor 1alpha (EF-1alpha), class III plant peroxidase (POX), structure specific recognition protein, basic leucine zipper protein transcription factor (bZIP), retrotransposon-like homologs and genes of unknown function in the roots of wheat cultivars CM82036 and Remus.	deoxynivalenol	110-113	peroxidase-like	Triticum aestivum	226-236
17256175-1	2007	Despite inhibition of protein synthesis being its mode of action, the trichothecene mycotoxin deoxynivalenol (DON) induced accumulation of transcripts encoding translation elongation factor 1alpha (EF-1alpha), class III plant peroxidase (POX), structure specific recognition protein, basic leucine zipper protein transcription factor (bZIP), retrotransposon-like homologs and genes of unknown function in the roots of wheat cultivars CM82036 and Remus.	deoxynivalenol	110-113	peroxidase-like	Triticum aestivum	238-241
17090620-10	2007	DON markedly enhanced viral-induced elevations of protein, MCP-1, TNF-alpha, and inflammatory cells in the BALF at 3-day PI.	deoxynivalenol	0-3	mast cell protease 1	Mus musculus	59-64
17090620-10	2007	DON markedly enhanced viral-induced elevations of protein, MCP-1, TNF-alpha, and inflammatory cells in the BALF at 3-day PI.	deoxynivalenol	0-3	tumor necrosis factor	Mus musculus	66-75
17179409-15	2007	The results imply that the exposure to DON-contaminated feeds may negatively affect animal health and performance by local (i.e., inhibition of intestinal SGLT-1) and systemic effects.	deoxynivalenol	39-42	solute carrier family 5 member 1	Gallus gallus	155-161
16524712-2	2006	The early stages of IgAN can be mimicked by feeding mice the mycotoxin deoxynivalenol (DON).	deoxynivalenol	71-85	IGAN1	Homo sapiens	20-24
16524712-2	2006	The early stages of IgAN can be mimicked by feeding mice the mycotoxin deoxynivalenol (DON).	deoxynivalenol	87-90	IGAN1	Homo sapiens	20-24
16524712-3	2006	Here, the effects of consuming the (n-3) PUFA eicosapentaenoic acid (EPA) on DON-induced IgAN were assessed relative to dose dependency and to expression of interleukin (IL-6).	deoxynivalenol	77-80	IGAN1	Homo sapiens	89-93
16524712-9	2006	Acute DON exposure increased serum levels of IL-6, a cytokine that drives differentiation of IgA-committed B cells to IgA secretion.	deoxynivalenol	6-9	interleukin 6	Mus musculus	45-49
16472964-5	2006	In addition, the mechanism whereby DON and NIV induced cytotoxicity is mainly via apoptosis as we observed phosphatidylserine externalization, mitochondrial release of cytochrome c, procaspase-3 degradation and Bcl-2 degradation.	deoxynivalenol	35-38	cytochrome c, somatic	Homo sapiens	168-180
16472964-5	2006	In addition, the mechanism whereby DON and NIV induced cytotoxicity is mainly via apoptosis as we observed phosphatidylserine externalization, mitochondrial release of cytochrome c, procaspase-3 degradation and Bcl-2 degradation.	deoxynivalenol	35-38	caspase 3	Homo sapiens	182-194
16472964-5	2006	In addition, the mechanism whereby DON and NIV induced cytotoxicity is mainly via apoptosis as we observed phosphatidylserine externalization, mitochondrial release of cytochrome c, procaspase-3 degradation and Bcl-2 degradation.	deoxynivalenol	35-38	BCL2 apoptosis regulator	Homo sapiens	211-216
16480848-2	2006	In the present study, the effect of deoxynivalenol (DON) on the proliferation of ConA stimulated porcine peripheral blood lymphocytes (PBL) was assessed in vitro after adding of 70-560 ng DON per ml medium, and in vivo after chronic and acute (one single dose) dietary DON exposure (5.7 mg/kg).	deoxynivalenol	36-50	CONA	Sus scrofa	81-85
16480848-2	2006	In the present study, the effect of deoxynivalenol (DON) on the proliferation of ConA stimulated porcine peripheral blood lymphocytes (PBL) was assessed in vitro after adding of 70-560 ng DON per ml medium, and in vivo after chronic and acute (one single dose) dietary DON exposure (5.7 mg/kg).	deoxynivalenol	52-55	CONA	Sus scrofa	81-85
16480848-2	2006	In the present study, the effect of deoxynivalenol (DON) on the proliferation of ConA stimulated porcine peripheral blood lymphocytes (PBL) was assessed in vitro after adding of 70-560 ng DON per ml medium, and in vivo after chronic and acute (one single dose) dietary DON exposure (5.7 mg/kg).	deoxynivalenol	188-191	CONA	Sus scrofa	81-85
16480848-2	2006	In the present study, the effect of deoxynivalenol (DON) on the proliferation of ConA stimulated porcine peripheral blood lymphocytes (PBL) was assessed in vitro after adding of 70-560 ng DON per ml medium, and in vivo after chronic and acute (one single dose) dietary DON exposure (5.7 mg/kg).	deoxynivalenol	188-191	CONA	Sus scrofa	81-85
17869643-12	2007	If MoDC derived from pigs fed the DON-diet were exposed to DON in vitro, this resulted in an up-regulation of MHC-II and CD80/86, but not CD40.	deoxynivalenol	34-37	CD80 molecule	Sus scrofa	121-125
17869643-12	2007	If MoDC derived from pigs fed the DON-diet were exposed to DON in vitro, this resulted in an up-regulation of MHC-II and CD80/86, but not CD40.	deoxynivalenol	59-62	CD80 molecule	Sus scrofa	121-125
17869643-12	2007	If MoDC derived from pigs fed the DON-diet were exposed to DON in vitro, this resulted in an up-regulation of MHC-II and CD80/86, but not CD40.	deoxynivalenol	59-62	CD40 molecule	Sus scrofa	138-142
18958698-10	2006	IL-4 secretion from mitogen-stimulated splenocytes was elevated by DON alone (p &lt; 0.05) while IL-2 was elevated by DON with exercise stress (p &lt; 0.05).	deoxynivalenol	67-70	interleukin 4	Mus musculus	0-4
18958698-10	2006	IL-4 secretion from mitogen-stimulated splenocytes was elevated by DON alone (p &lt; 0.05) while IL-2 was elevated by DON with exercise stress (p &lt; 0.05).	deoxynivalenol	118-121	interleukin 2	Mus musculus	97-101
17166736-6	2006	DON administration elicited a similar profile for IL-8 and IFNgamma, whilst IL-2 mRNA was induced in a broader range of concentrations.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
17166736-6	2006	DON administration elicited a similar profile for IL-8 and IFNgamma, whilst IL-2 mRNA was induced in a broader range of concentrations.	deoxynivalenol	0-3	interferon gamma	Homo sapiens	59-67
17166419-1	2006	OBJECTIVE: To explore the effects of Vitamin C (Vit C) on the apoptosis and proliferation inhibition of human peripheral blood mononuclear cells (HPBMCs) induced by deoxynivalenol (DON) in vitro.	deoxynivalenol	181-184	vitrin	Homo sapiens	37-40
17166419-4	2006	Compared with DON group, the apoptosis rate of HPBMCs in 25 micromol/L Vit C pretreatment group was significantly decreased (28.82 +/- 1.67)% vs (22.39 +/- 1.05)%, P &lt; 0.05, while that in 100 micromol/L Vit C pretreatment group was obviously increased (36.07 +/- 2.92)%, P &lt; 0.05.	deoxynivalenol	14-17	vitrin	Homo sapiens	71-74
17166419-5	2006	Western blotting analysis showed that the expression of Bax and Caspase-3 up-regulated by DON was markedly decreased, while the expression of Bcl-2 down-regulated by DON was increased by 25 micromol/L Vit C pretreatment (P &lt; 0.05).	deoxynivalenol	90-93	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
17166419-5	2006	Western blotting analysis showed that the expression of Bax and Caspase-3 up-regulated by DON was markedly decreased, while the expression of Bcl-2 down-regulated by DON was increased by 25 micromol/L Vit C pretreatment (P &lt; 0.05).	deoxynivalenol	90-93	caspase 3	Homo sapiens	64-73
17166419-5	2006	Western blotting analysis showed that the expression of Bax and Caspase-3 up-regulated by DON was markedly decreased, while the expression of Bcl-2 down-regulated by DON was increased by 25 micromol/L Vit C pretreatment (P &lt; 0.05).	deoxynivalenol	166-169	BCL2 apoptosis regulator	Homo sapiens	142-147
17166419-5	2006	Western blotting analysis showed that the expression of Bax and Caspase-3 up-regulated by DON was markedly decreased, while the expression of Bcl-2 down-regulated by DON was increased by 25 micromol/L Vit C pretreatment (P &lt; 0.05).	deoxynivalenol	166-169	vitrin	Homo sapiens	201-204
17166419-6	2006	100 micromol/L Vit C pretreatment could further increase the expression of Bax and Caspase-3 of HPBMCs induced by DON, while no significant effects on the Bcl-2 expression induced by DON were seen.	deoxynivalenol	114-117	vitrin	Homo sapiens	15-18
17166419-6	2006	100 micromol/L Vit C pretreatment could further increase the expression of Bax and Caspase-3 of HPBMCs induced by DON, while no significant effects on the Bcl-2 expression induced by DON were seen.	deoxynivalenol	114-117	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
17166419-6	2006	100 micromol/L Vit C pretreatment could further increase the expression of Bax and Caspase-3 of HPBMCs induced by DON, while no significant effects on the Bcl-2 expression induced by DON were seen.	deoxynivalenol	114-117	caspase 3	Homo sapiens	83-92
17166419-8	2006	CONCLUSION: 25 micromol/L Vit C pretreatment could at certain extent inhibit the apoptosis and reverse the abnormal expression of apoptosis related genes of HPBMCs induced by DON in vitro, while 100 micromol/L Vit C pretreatment could further increase the apoptosis rate of HPBMCs induced by DON.	deoxynivalenol	175-178	vitrin	Homo sapiens	26-29
17166419-8	2006	CONCLUSION: 25 micromol/L Vit C pretreatment could at certain extent inhibit the apoptosis and reverse the abnormal expression of apoptosis related genes of HPBMCs induced by DON in vitro, while 100 micromol/L Vit C pretreatment could further increase the apoptosis rate of HPBMCs induced by DON.	deoxynivalenol	292-295	vitrin	Homo sapiens	26-29
17166419-9	2006	Vit C pretreatment could reverse the proliferation inhibition of HPBMCs induced by DON in vitro.	deoxynivalenol	83-86	vitrin	Homo sapiens	0-3
17166420-2	2006	METHODS: The effects of Vit C on the changes of HLA-I expression of HPBMCs induced by DON in vitro were evaluated with cell culture, flow cytometry (FCM), Western blotting and immunocytochemical methods.	deoxynivalenol	86-89	vitrin	Homo sapiens	24-27
17166420-4	2006	As compared with DON group, the HLA-I expressions of HPBMCs in the two Vit C (25 micromol/L and 100 micromol/L) pretreatment groups were all significantly increased (1.15 +/- 0.06 and 1.10 +/- 0.02 vs 0.88 +/- 0.02, P &lt; 0.05).	deoxynivalenol	17-20	vitrin	Homo sapiens	71-74
16442754-8	2006	A prolonged exposure to DON provokes the phosphorylation of the mitogen-activated protein kinases (MAPKs) Erk1/2, p38 and SAPK/JNK, as well as a decrease of the transepithelial resistance, suggesting that DON could trigger intestinal inflammation.	deoxynivalenol	24-27	mitogen-activated protein kinase 3	Homo sapiens	106-112
16687389-5	2006	LPS priming also potentiated IL-1beta mRNA induction by DON in human whole-blood cultures, suggesting the relevance of the murine findings.	deoxynivalenol	56-59	interleukin 1 beta	Homo sapiens	29-37
16442754-8	2006	A prolonged exposure to DON provokes the phosphorylation of the mitogen-activated protein kinases (MAPKs) Erk1/2, p38 and SAPK/JNK, as well as a decrease of the transepithelial resistance, suggesting that DON could trigger intestinal inflammation.	deoxynivalenol	24-27	mitogen-activated protein kinase 1	Homo sapiens	114-117
16442754-8	2006	A prolonged exposure to DON provokes the phosphorylation of the mitogen-activated protein kinases (MAPKs) Erk1/2, p38 and SAPK/JNK, as well as a decrease of the transepithelial resistance, suggesting that DON could trigger intestinal inflammation.	deoxynivalenol	24-27	mitogen-activated protein kinase 9	Homo sapiens	122-126
16442754-8	2006	A prolonged exposure to DON provokes the phosphorylation of the mitogen-activated protein kinases (MAPKs) Erk1/2, p38 and SAPK/JNK, as well as a decrease of the transepithelial resistance, suggesting that DON could trigger intestinal inflammation.	deoxynivalenol	24-27	mitogen-activated protein kinase 9	Homo sapiens	127-130
16364386-0	2006	p38 Mitogen-activated protein kinase mediates IL-8 induction by the ribotoxin deoxynivalenol in human monocytes.	deoxynivalenol	78-92	mitogen-activated protein kinase 14	Homo sapiens	0-3
16364386-0	2006	p38 Mitogen-activated protein kinase mediates IL-8 induction by the ribotoxin deoxynivalenol in human monocytes.	deoxynivalenol	78-92	C-X-C motif chemokine ligand 8	Homo sapiens	46-50
16364386-5	2006	Significantly increased IL-6 and IL-1beta intracellular protein and mRNA expression was also observed in PBMC treated with DON (500 ng/ml) which were also partially p38-dependent.	deoxynivalenol	123-126	mitogen-activated protein kinase 14	Homo sapiens	165-168
16364386-1	2006	The effects of the ribotoxic trichothecene deoxynivalenol (DON) on mitogen-activated protein kinase (MAPK)-mediated IL-8 expression were investigated in cloned human monocytes and peripheral blood mononuclear cells (PBMC).	deoxynivalenol	43-57	C-X-C motif chemokine ligand 8	Homo sapiens	116-120
16364386-6	2006	Flow cytometry of PBMC revealed that DON-induced p38 phosphorylation varied among individuals relative to both threshold toxin concentrations (25-100 ng/ml) and relative increases in percentages of phospho-p38(+) cells.	deoxynivalenol	37-40	mitogen-activated protein kinase 14	Homo sapiens	49-52
16364386-6	2006	Flow cytometry of PBMC revealed that DON-induced p38 phosphorylation varied among individuals relative to both threshold toxin concentrations (25-100 ng/ml) and relative increases in percentages of phospho-p38(+) cells.	deoxynivalenol	37-40	mitogen-activated protein kinase 14	Homo sapiens	206-209
16364386-7	2006	DON-induced p38 activation occurred exclusively in the CD14(+) monocyte population.	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Homo sapiens	12-15
16364386-7	2006	DON-induced p38 activation occurred exclusively in the CD14(+) monocyte population.	deoxynivalenol	0-3	CD14 molecule	Homo sapiens	55-59
16364386-1	2006	The effects of the ribotoxic trichothecene deoxynivalenol (DON) on mitogen-activated protein kinase (MAPK)-mediated IL-8 expression were investigated in cloned human monocytes and peripheral blood mononuclear cells (PBMC).	deoxynivalenol	59-62	C-X-C motif chemokine ligand 8	Homo sapiens	116-120
16364386-2	2006	DON (250 to 1000 ng/ml) induced both IL-8 mRNA and IL-8 heteronuclear RNA (hnRNA), an indicator of IL-8 transcription, in the human U937 monocytic cell line in a concentration-dependent manner.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
16364386-2	2006	DON (250 to 1000 ng/ml) induced both IL-8 mRNA and IL-8 heteronuclear RNA (hnRNA), an indicator of IL-8 transcription, in the human U937 monocytic cell line in a concentration-dependent manner.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
16364386-2	2006	DON (250 to 1000 ng/ml) induced both IL-8 mRNA and IL-8 heteronuclear RNA (hnRNA), an indicator of IL-8 transcription, in the human U937 monocytic cell line in a concentration-dependent manner.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
16364386-4	2006	DON at 500 ng/ml similarly induced p38-dependent IL-8 protein and mRNA expression in PBMC cultures from healthy volunteers.	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Homo sapiens	35-38
16364386-4	2006	DON at 500 ng/ml similarly induced p38-dependent IL-8 protein and mRNA expression in PBMC cultures from healthy volunteers.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
16364386-10	2006	Taken together, these data suggest that (1) p38 activation was required for induction of IL-8 and proinflammatory gene expression in the monocyte and (2) DON induced p38 activation in human monocytes via the ribotoxic stress response.	deoxynivalenol	154-157	mitogen-activated protein kinase 14	Homo sapiens	44-47
16364386-5	2006	Significantly increased IL-6 and IL-1beta intracellular protein and mRNA expression was also observed in PBMC treated with DON (500 ng/ml) which were also partially p38-dependent.	deoxynivalenol	123-126	interleukin 6	Homo sapiens	24-28
16364386-10	2006	Taken together, these data suggest that (1) p38 activation was required for induction of IL-8 and proinflammatory gene expression in the monocyte and (2) DON induced p38 activation in human monocytes via the ribotoxic stress response.	deoxynivalenol	154-157	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
16364386-5	2006	Significantly increased IL-6 and IL-1beta intracellular protein and mRNA expression was also observed in PBMC treated with DON (500 ng/ml) which were also partially p38-dependent.	deoxynivalenol	123-126	interleukin 1 beta	Homo sapiens	33-41
16364386-10	2006	Taken together, these data suggest that (1) p38 activation was required for induction of IL-8 and proinflammatory gene expression in the monocyte and (2) DON induced p38 activation in human monocytes via the ribotoxic stress response.	deoxynivalenol	154-157	mitogen-activated protein kinase 14	Homo sapiens	166-169
16099139-7	2006	The results show that DNV in vitro strongly reduce the abundance of p38 MAPk, protein kinase Akt and the alpha- and beta-4E-BP1 bands.	deoxynivalenol	22-25	AKT serine/threonine kinase 1	Homo sapiens	93-96
16424113-0	2006	Docosahexaenoic acid consumption inhibits deoxynivalenol-induced CREB/ATF1 activation and IL-6 gene transcription in mouse macrophages.	deoxynivalenol	42-56	cAMP responsive element binding protein 1	Mus musculus	65-69
16424113-0	2006	Docosahexaenoic acid consumption inhibits deoxynivalenol-induced CREB/ATF1 activation and IL-6 gene transcription in mouse macrophages.	deoxynivalenol	42-56	activating transcription factor 1	Mus musculus	70-74
16424113-1	2006	The mycotoxin deoxynivalenol (DON) induces IgA nephropathy in mice by upregulating IL-6 expression, which is suppressed by (n-3) PUFA consumption.	deoxynivalenol	14-28	interleukin 6	Mus musculus	83-87
16424113-1	2006	The mycotoxin deoxynivalenol (DON) induces IgA nephropathy in mice by upregulating IL-6 expression, which is suppressed by (n-3) PUFA consumption.	deoxynivalenol	30-33	interleukin 6	Mus musculus	83-87
16424113-2	2006	The purpose of this study was to test the hypothesis that consumption of the (n-3) PUFA docosahexaenoic acid (DHA) interferes with DON-induced transcriptional and post-transcriptional upregulation of IL-6 mRNA in murine macrophages.	deoxynivalenol	131-134	interleukin 6	Mus musculus	200-204
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	25-29
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	39-43
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	39-43
16424113-4	2006	DON enhanced IL-6 mRNA stability similarly in macrophages from control and DHA-fed mice suggesting that (n-3) PUFA effects were not post-transcriptional.	deoxynivalenol	0-3	interleukin 6	Mus musculus	13-17
16424113-5	2006	DON upregulated binding activity of cAMP response element binding protein (CREB) and activator protein (AP-1) to their respective consensus sequences in nuclear extracts from control-fed mice, whereas both activities were suppressed in nuclear extracts from DHA-fed mice.	deoxynivalenol	0-3	cAMP responsive element binding protein 1	Mus musculus	36-73
16009389-1	2006	Simultaneous exposure to lipopolysaccharide (LPS) markedly amplifies induction of proinflammatory cytokine expression as well as IL-1-driven lymphocyte apoptosis by trichothecene deoxynivalenol (DON) in the mouse.	deoxynivalenol	195-198	interleukin 1 complex	Mus musculus	129-133
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	27-30	interleukin 1 alpha	Mus musculus	71-80
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	27-30	interleukin 6	Mus musculus	92-96
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	27-30	tumor necrosis factor	Mus musculus	101-110
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	48-51	interleukin 1 alpha	Mus musculus	71-80
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	48-51	interleukin 1 beta	Mus musculus	82-90
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	48-51	interleukin 6	Mus musculus	92-96
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	48-51	tumor necrosis factor	Mus musculus	101-110
16009389-8	2006	LPS priming decreased DON-induced p38 and ERK 1/2 phosphorylation suggesting that enhanced mitogen-activated protein kinase activation was not involved in increased cytokine responses.	deoxynivalenol	22-25	mitogen-activated protein kinase 14	Mus musculus	34-37
16009389-8	2006	LPS priming decreased DON-induced p38 and ERK 1/2 phosphorylation suggesting that enhanced mitogen-activated protein kinase activation was not involved in increased cytokine responses.	deoxynivalenol	22-25	mitogen-activated protein kinase 3	Mus musculus	42-49
16424113-5	2006	DON upregulated binding activity of cAMP response element binding protein (CREB) and activator protein (AP-1) to their respective consensus sequences in nuclear extracts from control-fed mice, whereas both activities were suppressed in nuclear extracts from DHA-fed mice.	deoxynivalenol	0-3	cAMP responsive element binding protein 1	Mus musculus	75-79
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	cAMP responsive element binding protein 1	Mus musculus	31-35
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	activating transcription factor 1	Mus musculus	51-55
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	cAMP responsive element binding protein 1	Mus musculus	109-113
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	activating transcription factor 1	Mus musculus	114-118
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	interleukin 6	Mus musculus	145-149
16424113-7	2006	DHA consumption blocked DON-induced phosphorylation of the CREB kinase AKT.	deoxynivalenol	24-27	cAMP responsive element binding protein 1	Mus musculus	59-63
16424113-7	2006	DHA consumption blocked DON-induced phosphorylation of the CREB kinase AKT.	deoxynivalenol	24-27	thymoma viral proto-oncogene 1	Mus musculus	71-74
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	interleukin 6	Mus musculus	63-67
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	thymoma viral proto-oncogene 1	Mus musculus	125-128
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	cAMP responsive element binding protein 1	Mus musculus	181-185
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	activating transcription factor 1	Mus musculus	186-190
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	interleukin 6	Mus musculus	198-202
16099139-9	2006	In contrast, the eIF4E phosphorylation was strongly reduced in DNV treated cells.	deoxynivalenol	63-66	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	55-58	mitogen-activated protein kinase 1	Homo sapiens	86-89
15958657-10	2005	ELISPOT revealed that mRNA expression data corresponded to suppression of IFN-gamma- and enhancement of IL-4-producing cell responses in PP cultures from DON-treated mice.	deoxynivalenol	154-157	interleukin 4	Mus musculus	104-108
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	55-58	mitogen-activated protein kinase 3	Homo sapiens	94-101
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	55-58	caspase 3	Homo sapiens	246-255
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	55-58	mitogen-activated protein kinase 1	Homo sapiens	337-340
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	55-58	mitogen-activated protein kinase 1	Homo sapiens	94-97
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	211-214	mitogen-activated protein kinase 1	Homo sapiens	86-89
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	211-214	mitogen-activated protein kinase 3	Homo sapiens	94-101
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	211-214	caspase 3	Homo sapiens	246-255
15976193-3	2005	At concentrations which partially inhibit translation, DON induced phosphorylation of p38 and ERK 1/2 mitogen activated protein kinases within 15 min in RAW 264.7 macrophages and these effects lasted up to 3 h. DON-exposed cells exhibited marked caspase 3-dependent DNA fragmentation after 6 h which was suppressed and attenuated by the p38 inhibitor SB203580 and ERK inhibitor PD98059, respectively.	deoxynivalenol	211-214	mitogen-activated protein kinase 1	Homo sapiens	337-340
15976193-4	2005	DON readily induced the phosphorylation and activity of p53 and this was inhibitable by SB203580.	deoxynivalenol	0-3	tumor protein p53	Homo sapiens	56-59
15976193-5	2005	DON exposure evoked BAX translocation to mitochondria and corresponding cytochrome C release but did not alter mitochondrial membrane potential.	deoxynivalenol	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	20-23
15976193-5	2005	DON exposure evoked BAX translocation to mitochondria and corresponding cytochrome C release but did not alter mitochondrial membrane potential.	deoxynivalenol	0-3	cytochrome c, somatic	Homo sapiens	72-84
15976193-6	2005	The p53 inhibitor PFTalpha reduced both DON-induced phosphorylation of p53 and p53 binding activity.	deoxynivalenol	40-43	tumor protein p53	Homo sapiens	4-7
15976193-6	2005	The p53 inhibitor PFTalpha reduced both DON-induced phosphorylation of p53 and p53 binding activity.	deoxynivalenol	40-43	tumor protein p53	Homo sapiens	71-74
15976193-6	2005	The p53 inhibitor PFTalpha reduced both DON-induced phosphorylation of p53 and p53 binding activity.	deoxynivalenol	40-43	tumor protein p53	Homo sapiens	71-74
15976193-7	2005	Moreover, both PFTalpha and p53 siRNA transfection suppressed DON-induced caspase-3 activity and subsequent DNA fragmentation.	deoxynivalenol	62-65	tumor protein p53	Homo sapiens	28-31
15976193-7	2005	Moreover, both PFTalpha and p53 siRNA transfection suppressed DON-induced caspase-3 activity and subsequent DNA fragmentation.	deoxynivalenol	62-65	caspase 3	Homo sapiens	74-83
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	mitogen-activated protein kinase 1	Homo sapiens	77-80
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	tumor protein p53	Homo sapiens	81-84
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	BCL2 associated X, apoptosis regulator	Homo sapiens	85-88
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	caspase 3	Homo sapiens	102-111
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	mitogen-activated protein kinase 1	Homo sapiens	127-130
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	AKT serine/threonine kinase 1	Homo sapiens	131-134
15976193-9	2005	Taken together, the results indicate that DON initiates competing apoptotic (p38/p53/Bax/Mitochondria/Caspase-3) and survival (ERK/AKT/p90Rsk/Bad) pathways in the macrophage.	deoxynivalenol	42-45	ribosomal protein S6 kinase A1	Homo sapiens	135-141
15772366-0	2005	Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.	deoxynivalenol	47-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	93-96
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	inorganic pyrophosphatase 1	Homo sapiens	0-3
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	mitogen-activated protein kinase 1	Homo sapiens	50-54
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-71
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	activating transcription factor 2	Homo sapiens	73-78
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	cellular inhibitor of PP2A	Homo sapiens	84-87
15772366-6	2005	PP1 suppressed DON-induced phosphorylation of the MAPK substrates c-jun, ATF-2, and p90(Rsk).	deoxynivalenol	15-18	ribosomal protein S6 kinase A2	Homo sapiens	88-91
15772366-8	2005	PP1 reduced DON-induced increases in nuclear levels and binding activities of several transcription factors (NF-kappaB, AP-1, and C/EBP), which corresponded to decreases in TNF-alpha production, caspase-3 activation, and apoptosis.	deoxynivalenol	12-15	inorganic pyrophosphatase 1	Homo sapiens	0-3
15772366-8	2005	PP1 reduced DON-induced increases in nuclear levels and binding activities of several transcription factors (NF-kappaB, AP-1, and C/EBP), which corresponded to decreases in TNF-alpha production, caspase-3 activation, and apoptosis.	deoxynivalenol	12-15	CCAAT enhancer binding protein alpha	Homo sapiens	130-135
15772366-8	2005	PP1 reduced DON-induced increases in nuclear levels and binding activities of several transcription factors (NF-kappaB, AP-1, and C/EBP), which corresponded to decreases in TNF-alpha production, caspase-3 activation, and apoptosis.	deoxynivalenol	12-15	tumor necrosis factor	Homo sapiens	173-182
15772366-8	2005	PP1 reduced DON-induced increases in nuclear levels and binding activities of several transcription factors (NF-kappaB, AP-1, and C/EBP), which corresponded to decreases in TNF-alpha production, caspase-3 activation, and apoptosis.	deoxynivalenol	12-15	caspase 3	Homo sapiens	195-204
15772366-9	2005	Tyrosine phosphorylation of hematopoeitic cell kinase (Hck), a Src found in macrophages, was detectable within 1 to 5 min after DON addition, and this was suppressed by PP1.	deoxynivalenol	128-131	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	28-53
15772366-9	2005	Tyrosine phosphorylation of hematopoeitic cell kinase (Hck), a Src found in macrophages, was detectable within 1 to 5 min after DON addition, and this was suppressed by PP1.	deoxynivalenol	128-131	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	55-58
15772366-9	2005	Tyrosine phosphorylation of hematopoeitic cell kinase (Hck), a Src found in macrophages, was detectable within 1 to 5 min after DON addition, and this was suppressed by PP1.	deoxynivalenol	128-131	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	63-66
15772366-9	2005	Tyrosine phosphorylation of hematopoeitic cell kinase (Hck), a Src found in macrophages, was detectable within 1 to 5 min after DON addition, and this was suppressed by PP1.	deoxynivalenol	128-131	inorganic pyrophosphatase 1	Homo sapiens	169-172
15772366-11	2005	Taken together, activation of Hck and possibly other Src family tyrosine kinases are likely to be critical signals that precede both MAPK activation and induction of resultant downstream sequelae by DON and other ribotoxic stressors.	deoxynivalenol	199-202	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	30-33
15772366-11	2005	Taken together, activation of Hck and possibly other Src family tyrosine kinases are likely to be critical signals that precede both MAPK activation and induction of resultant downstream sequelae by DON and other ribotoxic stressors.	deoxynivalenol	199-202	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	53-56
15772366-11	2005	Taken together, activation of Hck and possibly other Src family tyrosine kinases are likely to be critical signals that precede both MAPK activation and induction of resultant downstream sequelae by DON and other ribotoxic stressors.	deoxynivalenol	199-202	mitogen-activated protein kinase 1	Homo sapiens	133-137
15772366-0	2005	Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.	deoxynivalenol	47-61	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	111-114
15772366-3	2005	DON (100 to 1000 ng/ml) dose-dependently induced phosphorylation of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Homo sapiens	68-99
15772366-3	2005	DON (100 to 1000 ng/ml) dose-dependently induced phosphorylation of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Homo sapiens	101-104
15772366-3	2005	DON (100 to 1000 ng/ml) dose-dependently induced phosphorylation of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	107-144
15772366-3	2005	DON (100 to 1000 ng/ml) dose-dependently induced phosphorylation of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	146-149
15772366-3	2005	DON (100 to 1000 ng/ml) dose-dependently induced phosphorylation of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	156-159
15772366-4	2005	MAPK phosphorylation in response to DON exposure occurred as early as 5 min, was maximal from 15 to 30 min, and lasted up to 8 h. Preincubation with inhibitors of protein kinase C, protein kinase A, or phospholipase C had no effect on DON-induced MAPK phosphorylation.	deoxynivalenol	36-39	mitogen-activated protein kinase 1	Homo sapiens	0-4
15772366-4	2005	MAPK phosphorylation in response to DON exposure occurred as early as 5 min, was maximal from 15 to 30 min, and lasted up to 8 h. Preincubation with inhibitors of protein kinase C, protein kinase A, or phospholipase C had no effect on DON-induced MAPK phosphorylation.	deoxynivalenol	36-39	mitogen-activated protein kinase 1	Homo sapiens	247-251
15772366-4	2005	MAPK phosphorylation in response to DON exposure occurred as early as 5 min, was maximal from 15 to 30 min, and lasted up to 8 h. Preincubation with inhibitors of protein kinase C, protein kinase A, or phospholipase C had no effect on DON-induced MAPK phosphorylation.	deoxynivalenol	235-238	mitogen-activated protein kinase 1	Homo sapiens	0-4
15766417-0	2005	[The inhibitory effect of deoxynivalenol on TAP-1 expression in human peripheral blood mononuclear cells in vitro].	deoxynivalenol	26-40	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	44-49
15778012-0	2005	Role of cyclooxygenase-2 in deoxynivalenol-induced immunoglobulin a nephropathy.	deoxynivalenol	28-42	prostaglandin-endoperoxide synthase 2	Mus musculus	8-24
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	41-55	CD79a molecule	Homo sapiens	76-79
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	41-55	CD79a molecule	Homo sapiens	111-114
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	41-55	IGAN1	Homo sapiens	170-185
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	41-55	IGAN1	Homo sapiens	187-191
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	57-60	CD79a molecule	Homo sapiens	76-79
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	57-60	CD79a molecule	Homo sapiens	111-114
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	57-60	IGAN1	Homo sapiens	170-185
15778012-1	2005	Ingestion of the trichothecene mycotoxin deoxynivalenol (DON) induces serum IgA elevation and kidney mesangial IgA deposition in a manner that mimics the early stages of IgA nephropathy (IgAN), the most common human glomerulonephritis.	deoxynivalenol	57-60	IGAN1	Homo sapiens	187-191
15778012-2	2005	Previous studies indicate that elevated interleukin-6 (IL-6) expression is crucial for this model and that DON induction of cyclooxygenase-2 (COX-2) might drive IL-6 upregulation.	deoxynivalenol	107-110	prostaglandin-endoperoxide synthase 2	Mus musculus	124-140
15778012-2	2005	Previous studies indicate that elevated interleukin-6 (IL-6) expression is crucial for this model and that DON induction of cyclooxygenase-2 (COX-2) might drive IL-6 upregulation.	deoxynivalenol	107-110	prostaglandin-endoperoxide synthase 2	Mus musculus	142-147
15778012-2	2005	Previous studies indicate that elevated interleukin-6 (IL-6) expression is crucial for this model and that DON induction of cyclooxygenase-2 (COX-2) might drive IL-6 upregulation.	deoxynivalenol	107-110	interleukin 6	Mus musculus	161-165
15778012-3	2005	We hypothesized that COX-2 and its metabolites are essential for DON-induced IgAN and thus might be a suitable target for prophylaxis against aberrant IgA upregulation.	deoxynivalenol	65-68	prostaglandin-endoperoxide synthase 2	Mus musculus	21-26
15778012-3	2005	We hypothesized that COX-2 and its metabolites are essential for DON-induced IgAN and thus might be a suitable target for prophylaxis against aberrant IgA upregulation.	deoxynivalenol	65-68	IGAN1	Homo sapiens	77-81
15778012-3	2005	We hypothesized that COX-2 and its metabolites are essential for DON-induced IgAN and thus might be a suitable target for prophylaxis against aberrant IgA upregulation.	deoxynivalenol	65-68	immunoglobulin heavy constant alpha	Mus musculus	77-80
15778012-5	2005	Study 1 results demonstrated that DON consumption induced serum IgA and IgA-immune complex (IC) accumulation, IgA kidney deposition and splenic IgA secretion in wild-type mice.	deoxynivalenol	34-37	immunoglobulin heavy constant alpha	Mus musculus	64-67
15778012-5	2005	Study 1 results demonstrated that DON consumption induced serum IgA and IgA-immune complex (IC) accumulation, IgA kidney deposition and splenic IgA secretion in wild-type mice.	deoxynivalenol	34-37	CD79a molecule	Homo sapiens	72-75
15778012-5	2005	Study 1 results demonstrated that DON consumption induced serum IgA and IgA-immune complex (IC) accumulation, IgA kidney deposition and splenic IgA secretion in wild-type mice.	deoxynivalenol	34-37	immunoglobulin heavy constant alpha	Mus musculus	72-75
15778012-5	2005	Study 1 results demonstrated that DON consumption induced serum IgA and IgA-immune complex (IC) accumulation, IgA kidney deposition and splenic IgA secretion in wild-type mice.	deoxynivalenol	34-37	immunoglobulin heavy constant alpha	Mus musculus	72-75
15778012-6	2005	COX-2 deficiency did not affect upregulation of these parameters but rather, promoted DON-induced serum IgA elevation.	deoxynivalenol	86-89	prostaglandin-endoperoxide synthase 2	Mus musculus	0-5
15778012-6	2005	COX-2 deficiency did not affect upregulation of these parameters but rather, promoted DON-induced serum IgA elevation.	deoxynivalenol	86-89	immunoglobulin heavy constant alpha	Mus musculus	104-107
15766417-1	2005	AIM: To explore the effects of deoxynivalenol (DON) on transporter associated with antigen processing-1 (TAP-1) expression in human peripheral blood mononuclear cells (PBMCs).	deoxynivalenol	31-45	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	105-110
15766417-1	2005	AIM: To explore the effects of deoxynivalenol (DON) on transporter associated with antigen processing-1 (TAP-1) expression in human peripheral blood mononuclear cells (PBMCs).	deoxynivalenol	47-50	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	105-110
15766417-2	2005	METHODS: Effects of various concentrations of DON on TAP-1 expression of in vitro cultured human PBMCs and the dose-effect relationship were analyzed by flow cytometry (FCM) and semi-quantitative RT-PCR at the protein and mRNA levels.	deoxynivalenol	46-49	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	53-58
15766417-3	2005	RESULTS: FCM analysis indicated that treatment with various concentrations of DON could inhibit TAP-1 expressions in PBMCs, showing a negative correlation between DON concentration and TAP-1 expression.	deoxynivalenol	78-81	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	96-101
15766417-3	2005	RESULTS: FCM analysis indicated that treatment with various concentrations of DON could inhibit TAP-1 expressions in PBMCs, showing a negative correlation between DON concentration and TAP-1 expression.	deoxynivalenol	78-81	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	185-190
15766417-5	2005	CONCLUSION: DON can down-regulate TAP-1 expression in human PBMCs in a dose-dependent manner in vitro, which suggests DON may interfere with host immunosurveillance, and this may account for the correlation between DON-contaminated grain and esophagus cancer in high risk area.	deoxynivalenol	12-15	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	34-39
15766417-5	2005	CONCLUSION: DON can down-regulate TAP-1 expression in human PBMCs in a dose-dependent manner in vitro, which suggests DON may interfere with host immunosurveillance, and this may account for the correlation between DON-contaminated grain and esophagus cancer in high risk area.	deoxynivalenol	118-121	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	34-39
15766417-5	2005	CONCLUSION: DON can down-regulate TAP-1 expression in human PBMCs in a dose-dependent manner in vitro, which suggests DON may interfere with host immunosurveillance, and this may account for the correlation between DON-contaminated grain and esophagus cancer in high risk area.	deoxynivalenol	118-121	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	34-39
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	jun proto-oncogene	Mus musculus	173-192
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	FBJ osteosarcoma oncogene	Mus musculus	230-235
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	interleukin 1 alpha	Mus musculus	68-77
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	interleukin 1 beta	Mus musculus	79-87
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	fos-like antigen 2	Mus musculus	237-245
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	interleukin 6	Mus musculus	93-97
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	interleukin 11	Mus musculus	102-107
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	mast cell protease 1	Mus musculus	122-127
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	jun B proto-oncogene	Mus musculus	254-258
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	dual specificity phosphatase 1	Mus musculus	288-292
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	protein phosphatase 3, catalytic subunit, beta isoform	Mus musculus	294-301
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	mast cell protease 3	Mus musculus	129-134
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	interleukin 11	Mus musculus	120-125
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	chemokine (C-X-C motif) ligand 2	Mus musculus	147-152
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	interleukin 1 alpha	Mus musculus	226-235
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	interleukin 6	Mus musculus	237-241
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	interleukin 11	Mus musculus	243-248
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	mast cell protease 1	Mus musculus	250-255
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	mast cell protease 3	Mus musculus	257-262
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	chemokine (C-X-C motif) ligand 2	Mus musculus	264-269
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	fos-like antigen 2	Mus musculus	274-279
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	dual specificity phosphatase 1	Mus musculus	356-360
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	protein phosphatase 3, catalytic subunit, beta isoform	Mus musculus	365-372
15588914-2	2005	DON (250-1000 ng/ml) readily induced caspase-3 and apoptosis in Jurkat cells.	deoxynivalenol	0-3	caspase 3	Homo sapiens	37-46
15588914-3	2005	DON (62.5-500 ng/ml) also significantly upregulated IL-2 and IL-8 production following prestimulation with phorbol myristate acetate and ionomycin.	deoxynivalenol	0-3	interleukin 2	Homo sapiens	52-56
15588914-3	2005	DON (62.5-500 ng/ml) also significantly upregulated IL-2 and IL-8 production following prestimulation with phorbol myristate acetate and ionomycin.	deoxynivalenol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	61-65
15588914-4	2005	DON markedly induced phosphorylation of p38, JNK 1/2, and ERK2.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	40-43
15588914-4	2005	DON markedly induced phosphorylation of p38, JNK 1/2, and ERK2.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Homo sapiens	45-52
15588914-4	2005	DON markedly induced phosphorylation of p38, JNK 1/2, and ERK2.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Homo sapiens	58-62
15588914-5	2005	SB203580, a specific inhibitor of p38, reduced DON-induced apoptosis.	deoxynivalenol	47-50	mitogen-activated protein kinase 1	Homo sapiens	34-37
15588914-6	2005	The MEK1 inhibitor PD98059 which blocks ERK activation had only a small inhibitory effect on DON-induced apoptosis while the JNK inhibitor SP600125 was without effect.	deoxynivalenol	93-96	mitogen-activated protein kinase kinase 1	Homo sapiens	4-8
15588914-7	2005	Inhibition of p38 attenuated DON-induced upregulation of IL-2 while all three MAPK inhibitors suppressed IL-8 upregulation.	deoxynivalenol	29-32	mitogen-activated protein kinase 1	Homo sapiens	14-17
15588914-7	2005	Inhibition of p38 attenuated DON-induced upregulation of IL-2 while all three MAPK inhibitors suppressed IL-8 upregulation.	deoxynivalenol	29-32	interleukin 2	Homo sapiens	57-61
15588914-12	2005	Although DON shared its capacity to induce apoptosis and potentiate IL-8 production with other 8-ketotrichothecenes, it appeared to be unique in its capacity to upregulate IL-2.	deoxynivalenol	9-12	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
15588914-12	2005	Although DON shared its capacity to induce apoptosis and potentiate IL-8 production with other 8-ketotrichothecenes, it appeared to be unique in its capacity to upregulate IL-2.	deoxynivalenol	9-12	interleukin 2	Homo sapiens	172-176
15371230-7	2004	DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11.	deoxynivalenol	0-3	interleukin 1 alpha	Mus musculus	38-61
15570035-5	2004	In a subsequent study, acute DON exposure (25 mg/kg body weight) induced splenic IL-6 mRNA and hnRNA as well as COX-2 mRNA in mice fed the control diet, whereas induction of both RNA species was significantly inhibited in mice fed 30 g/kg DHA.	deoxynivalenol	29-32	interleukin 6	Mus musculus	81-85
15570035-5	2004	In a subsequent study, acute DON exposure (25 mg/kg body weight) induced splenic IL-6 mRNA and hnRNA as well as COX-2 mRNA in mice fed the control diet, whereas induction of both RNA species was significantly inhibited in mice fed 30 g/kg DHA.	deoxynivalenol	29-32	cytochrome c oxidase II, mitochondrial	Mus musculus	112-117
15570035-6	2004	These latter inhibitory effects corresponded to a reduction in DON-induced phosphorylation of p38, extracellular-signal related kinase 1/2, and c-Jun N-terminal kinase 1/2 MAPKs in the spleen.	deoxynivalenol	63-66	mitogen-activated protein kinase 14	Mus musculus	94-97
15570035-6	2004	These latter inhibitory effects corresponded to a reduction in DON-induced phosphorylation of p38, extracellular-signal related kinase 1/2, and c-Jun N-terminal kinase 1/2 MAPKs in the spleen.	deoxynivalenol	63-66	mitogen-activated protein kinase 8	Mus musculus	99-171
15388250-10	2004	These results indicate that DON induced apoptosis through the caspase-3 activation pathway and caused functional disorder in porcine hepatocytes.	deoxynivalenol	28-31	caspase 3	Sus scrofa	62-71
15369845-2	2004	Moreover, since DON reportedly induces increased levels of Th2 cytokines and total IgE, and we have observed that mould extracts adjuvated allergy development in mice, possible adjuvant effect of DON on allergy was studied in a mouse model.	deoxynivalenol	16-19	heart and neural crest derivatives expressed 2	Mus musculus	59-62
15369845-2	2004	Moreover, since DON reportedly induces increased levels of Th2 cytokines and total IgE, and we have observed that mould extracts adjuvated allergy development in mice, possible adjuvant effect of DON on allergy was studied in a mouse model.	deoxynivalenol	16-19	immunoglobulin heavy constant epsilon	Homo sapiens	83-86
15369845-4	2004	In addition, production of IL-8 in the U937 cell line increased up to eight-fold at levels of DON just lower than the most toxic one, suggesting that IL-8 can be used as an additional index for cytotoxicity in mononuclear phagocytes.	deoxynivalenol	94-97	C-X-C motif chemokine ligand 8	Homo sapiens	27-31
15369845-4	2004	In addition, production of IL-8 in the U937 cell line increased up to eight-fold at levels of DON just lower than the most toxic one, suggesting that IL-8 can be used as an additional index for cytotoxicity in mononuclear phagocytes.	deoxynivalenol	94-97	C-X-C motif chemokine ligand 8	Homo sapiens	150-154
15371230-7	2004	DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11.	deoxynivalenol	0-3	interleukin 1 beta	Mus musculus	63-71
15371230-7	2004	DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11.	deoxynivalenol	0-3	interleukin 6	Mus musculus	73-77
15371230-7	2004	DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11.	deoxynivalenol	0-3	interleukin 11	Mus musculus	82-87
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	chemokine (C-X-C motif) ligand 2	Mus musculus	67-98
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	chemokine (C-X-C motif) ligand 2	Mus musculus	100-105
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	chemokine (C-C motif) ligand 2	Mus musculus	161-201
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	mast cell protease 3	Mus musculus	203-208
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	chemokine (C-X-C motif) ligand 10	Mus musculus	214-240
15371230-8	2004	In analogous fashion, DON upregulated expression of the chemokines macrophage inhibitory protein-2 (MIP-2), cytokine-induced chemoattractant protein-1 (CINC-1), monocyte chemoattractant protein (MCP)-1, MCP-3, and cytokine-responsive gene-2 (CRG-2).	deoxynivalenol	22-25	chemokine (C-X-C motif) ligand 10	Mus musculus	242-247
17134394-6	2004	Expression of an engineered tomato RPL3 (LeRPL3) cDNA, into which one of the amino acid changes identified in yeast was introduced, improved the ability of transgenic tobacco plants to adapt to the trichothecene deoxynivalenol (DON), but did not result in constitutive resistance.	deoxynivalenol	228-231	ribosomal protein L3	Solanum lycopersicum	35-39
14644621-6	2003	The p38 inhibitor SB203580 reduced induction of luciferase activity by DON, LPS, and DON + LPS.	deoxynivalenol	85-88	mitogen-activated protein kinase 14	Mus musculus	4-7
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	deoxynivalenol	71-74	interleukin 6	Mus musculus	102-120
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	deoxynivalenol	147-150	interleukin 6	Mus musculus	102-120
14690764-0	2003	Deoxynivalenol-induced mitogen-activated protein kinase phosphorylation and IL-6 expression in mice suppressed by fish oil.	deoxynivalenol	0-14	interleukin 6	Mus musculus	76-80
14690764-1	2003	The trichothecene mycotoxin deoxynivalenol (DON) induces IgA hyperelevation and mesangial IgA deposition in mice that mimics the early stages of human IgA nephropathy (IgAN).	deoxynivalenol	28-42	IGAN1	Homo sapiens	151-166
14690764-1	2003	The trichothecene mycotoxin deoxynivalenol (DON) induces IgA hyperelevation and mesangial IgA deposition in mice that mimics the early stages of human IgA nephropathy (IgAN).	deoxynivalenol	28-42	IGAN1	Homo sapiens	168-172
14690764-1	2003	The trichothecene mycotoxin deoxynivalenol (DON) induces IgA hyperelevation and mesangial IgA deposition in mice that mimics the early stages of human IgA nephropathy (IgAN).	deoxynivalenol	44-47	IGAN1	Homo sapiens	151-166
14690764-1	2003	The trichothecene mycotoxin deoxynivalenol (DON) induces IgA hyperelevation and mesangial IgA deposition in mice that mimics the early stages of human IgA nephropathy (IgAN).	deoxynivalenol	44-47	IGAN1	Homo sapiens	168-172
14690764-3	2003	Based on previous findings that dietary fish oil (FO) suppresses DON-induced IgAN, we hypothesized that FO inhibits the induction of IL-6 expression by this mycotoxin in vivo and in vitro.	deoxynivalenol	65-68	IGAN1	Homo sapiens	77-81
14690764-5	2003	DON-induced plasma IL-6 and splenic mRNA elevation in FO-fed mice were significantly suppressed after 8 weeks when compared to the CO-fed group.	deoxynivalenol	0-3	interleukin 6	Mus musculus	19-23
14690764-7	2003	DON-induced phosphorylation of extracellular signal regulated protein kinases 1 and 2 (ERK1/2) and c-Jun N-terminal kinases 1 and 2 (JNK1/2) was significantly suppressed in spleens of mice fed with FO, whereas p38 was not.	deoxynivalenol	0-3	mitogen-activated protein kinase 3	Mus musculus	87-93
14690764-7	2003	DON-induced phosphorylation of extracellular signal regulated protein kinases 1 and 2 (ERK1/2) and c-Jun N-terminal kinases 1 and 2 (JNK1/2) was significantly suppressed in spleens of mice fed with FO, whereas p38 was not.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Mus musculus	99-131
14690764-7	2003	DON-induced phosphorylation of extracellular signal regulated protein kinases 1 and 2 (ERK1/2) and c-Jun N-terminal kinases 1 and 2 (JNK1/2) was significantly suppressed in spleens of mice fed with FO, whereas p38 was not.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Mus musculus	133-139
14690764-7	2003	DON-induced phosphorylation of extracellular signal regulated protein kinases 1 and 2 (ERK1/2) and c-Jun N-terminal kinases 1 and 2 (JNK1/2) was significantly suppressed in spleens of mice fed with FO, whereas p38 was not.	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Mus musculus	210-213
14690764-8	2003	Splenic COX-2 mRNA expression, which has been previously shown to enhance DON-induced IL-6, was also significantly decreased by FO, whereas plasma levels of the COX-2 metabolite, prostaglandin E2, were not affected.	deoxynivalenol	74-77	cytochrome c oxidase II, mitochondrial	Mus musculus	8-13
14690764-8	2003	Splenic COX-2 mRNA expression, which has been previously shown to enhance DON-induced IL-6, was also significantly decreased by FO, whereas plasma levels of the COX-2 metabolite, prostaglandin E2, were not affected.	deoxynivalenol	74-77	interleukin 6	Mus musculus	86-90
14690764-10	2003	Consistent with the in vivo findings, both EPA and DHA significantly suppressed IL-6 superinduction by DON, as well as impaired DON-induced ERK1/2 and JNK1/2 phosphorylation.	deoxynivalenol	103-106	interleukin 6	Mus musculus	80-84
14690764-10	2003	Consistent with the in vivo findings, both EPA and DHA significantly suppressed IL-6 superinduction by DON, as well as impaired DON-induced ERK1/2 and JNK1/2 phosphorylation.	deoxynivalenol	128-131	mitogen-activated protein kinase 3	Mus musculus	140-146
14690764-10	2003	Consistent with the in vivo findings, both EPA and DHA significantly suppressed IL-6 superinduction by DON, as well as impaired DON-induced ERK1/2 and JNK1/2 phosphorylation.	deoxynivalenol	128-131	mitogen-activated protein kinase 8	Mus musculus	151-157
14644621-0	2003	Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin).	deoxynivalenol	130-144	mitogen-activated protein kinase 14	Mus musculus	50-53
14644621-0	2003	Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin).	deoxynivalenol	130-144	tumor necrosis factor	Mus musculus	106-115
14644621-0	2003	Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin).	deoxynivalenol	146-155	mitogen-activated protein kinase 14	Mus musculus	50-53
14644621-0	2003	Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin).	deoxynivalenol	146-155	tumor necrosis factor	Mus musculus	106-115
14644621-2	2003	The purpose of this study was to test the hypothesis that DON-induced activation of mitogen-activated protein kinases (MAPKs) mediates transcriptional and posttranscriptional upregulation of TNF-alpha gene expression.	deoxynivalenol	58-61	tumor necrosis factor	Mus musculus	191-200
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	tumor necrosis factor	Mus musculus	88-97
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	interleukin 6	Mus musculus	109-113
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	interferon gamma	Mus musculus	115-124
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	transforming growth factor, beta 1	Mus musculus	126-135
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	transforming growth factor, beta 3	Mus musculus	141-150
14644621-4	2003	DON was found to induce phosphorylation of p38 kinase, extracellular signal-regulated kinases (ERKs), and c-Jun amino terminal kinases (JNKs) in a dose-dependent manner in the RAW 264.7 murine macrophage model.	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Mus musculus	43-46
14644621-4	2003	DON was found to induce phosphorylation of p38 kinase, extracellular signal-regulated kinases (ERKs), and c-Jun amino terminal kinases (JNKs) in a dose-dependent manner in the RAW 264.7 murine macrophage model.	deoxynivalenol	0-3	mitogen-activated protein kinase 1	Mus musculus	95-99
14644621-4	2003	DON was found to induce phosphorylation of p38 kinase, extracellular signal-regulated kinases (ERKs), and c-Jun amino terminal kinases (JNKs) in a dose-dependent manner in the RAW 264.7 murine macrophage model.	deoxynivalenol	0-3	jun proto-oncogene	Mus musculus	106-111
14644621-6	2003	The p38 inhibitor SB203580 reduced induction of luciferase activity by DON, LPS, and DON + LPS.	deoxynivalenol	71-74	mitogen-activated protein kinase 14	Mus musculus	4-7
14644621-7	2003	In addition, the ERK inhibitor PD 98059 blocked DON- and DON + LPS-induced luciferase activity whereas the JNK inhibitor impaired LPS- and DON + LPS-induced luciferase activity.	deoxynivalenol	48-51	mitogen-activated protein kinase 1	Mus musculus	17-20
14644621-7	2003	In addition, the ERK inhibitor PD 98059 blocked DON- and DON + LPS-induced luciferase activity whereas the JNK inhibitor impaired LPS- and DON + LPS-induced luciferase activity.	deoxynivalenol	57-60	mitogen-activated protein kinase 1	Mus musculus	17-20
14644621-7	2003	In addition, the ERK inhibitor PD 98059 blocked DON- and DON + LPS-induced luciferase activity whereas the JNK inhibitor impaired LPS- and DON + LPS-induced luciferase activity.	deoxynivalenol	57-60	mitogen-activated protein kinase 1	Mus musculus	17-20
14644621-8	2003	To study the effects of MAPKs on DON-induced TNF-alpha mRNA stability, an asynchronous model was used whereby cells were pretreated with LPS for 4 h and the medium was removed.	deoxynivalenol	33-36	tumor necrosis factor	Mus musculus	45-54
12970342-5	2003	The enzyme, previously assigned the identifier UGT73C5, catalyzes the transfer of glucose from UDP-glucose to the hydroxyl group at carbon 3 of deoxynivalenol.	deoxynivalenol	144-158	don-glucosyltransferase 1	Arabidopsis thaliana	47-54
14644621-10	2003	DON-induced TNF-alpha mRNA stabilization was abrogated in the presence of SB 203580, whereas the stabilization by DON was not affected by PD 98059 or SP 600125.	deoxynivalenol	0-3	tumor necrosis factor	Mus musculus	12-21
14644621-11	2003	To verify the role of MAPKs in DON + LPS-induced TNF-alpha production, cells were incubated with LPS, DON, or LPS + DON for 18 h in the presence of inhibitors.	deoxynivalenol	31-34	tumor necrosis factor	Mus musculus	49-58
14644621-12	2003	ELISA of supernatant indicated that induction of TNF-alpha production by DON alone was significantly reduced by SB 203580 and PD 98059, whereas all three inhibitors blocked LPS- and DON + LPS-induced TNF-alpha production.	deoxynivalenol	73-76	tumor necrosis factor	Mus musculus	49-58
14644621-12	2003	ELISA of supernatant indicated that induction of TNF-alpha production by DON alone was significantly reduced by SB 203580 and PD 98059, whereas all three inhibitors blocked LPS- and DON + LPS-induced TNF-alpha production.	deoxynivalenol	182-185	tumor necrosis factor	Mus musculus	49-58
14644621-12	2003	ELISA of supernatant indicated that induction of TNF-alpha production by DON alone was significantly reduced by SB 203580 and PD 98059, whereas all three inhibitors blocked LPS- and DON + LPS-induced TNF-alpha production.	deoxynivalenol	182-185	tumor necrosis factor	Mus musculus	200-209
14644621-13	2003	Taken together, these results suggest that relative to DON-induced TNF-alpha mRNA expression, p38 and ERK activation contribute to DON-induced transcriptional upregulation whereas p38 plays a role in increasing mRNA stability.	deoxynivalenol	55-58	tumor necrosis factor	Mus musculus	67-76
14644621-13	2003	Taken together, these results suggest that relative to DON-induced TNF-alpha mRNA expression, p38 and ERK activation contribute to DON-induced transcriptional upregulation whereas p38 plays a role in increasing mRNA stability.	deoxynivalenol	55-58	mitogen-activated protein kinase 14	Mus musculus	180-183
14644621-13	2003	Taken together, these results suggest that relative to DON-induced TNF-alpha mRNA expression, p38 and ERK activation contribute to DON-induced transcriptional upregulation whereas p38 plays a role in increasing mRNA stability.	deoxynivalenol	131-134	mitogen-activated protein kinase 14	Mus musculus	94-97
14644621-13	2003	Taken together, these results suggest that relative to DON-induced TNF-alpha mRNA expression, p38 and ERK activation contribute to DON-induced transcriptional upregulation whereas p38 plays a role in increasing mRNA stability.	deoxynivalenol	131-134	mitogen-activated protein kinase 1	Mus musculus	102-105
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	28-42	prostaglandin-endoperoxide synthase 2	Mus musculus	113-129
14597125-3	2003	The objective of this study was to test the hypothesis that the trichothecene deoxynivalenol (DON, vomitoxin) can interact with LPS directly and other mediators or agonists associated with immune/inflammatory responses to induce apoptosis in primary murine leukocyte cultures.	deoxynivalenol	78-92	toll-like receptor 4	Mus musculus	128-131
14597125-3	2003	The objective of this study was to test the hypothesis that the trichothecene deoxynivalenol (DON, vomitoxin) can interact with LPS directly and other mediators or agonists associated with immune/inflammatory responses to induce apoptosis in primary murine leukocyte cultures.	deoxynivalenol	94-97	toll-like receptor 4	Mus musculus	128-131
14597125-3	2003	The objective of this study was to test the hypothesis that the trichothecene deoxynivalenol (DON, vomitoxin) can interact with LPS directly and other mediators or agonists associated with immune/inflammatory responses to induce apoptosis in primary murine leukocyte cultures.	deoxynivalenol	99-108	toll-like receptor 4	Mus musculus	128-131
14597125-6	2003	DON was found to inhibit LPS-induced proliferation and dexamethasone-induced apoptosis in SP cultures.	deoxynivalenol	0-3	toll-like receptor 4	Mus musculus	25-28
14597125-7	2003	In contrast, potentiation of DON-induced apoptosis and cytotoxicity was observed in BM cultures treated with anti-Fas and in TH cultures treated with TNF-alpha.	deoxynivalenol	29-32	tumor necrosis factor	Mus musculus	150-159
14597125-8	2003	When potentiation of DON-induced apoptosis by TNF-alpha was assessed using pharmacological inhibitors, generation of ROS, intracellular Ca2+, p38/SAPK, and caspase-3 activation were found to play roles.	deoxynivalenol	21-24	tumor necrosis factor	Mus musculus	46-55
14597125-8	2003	When potentiation of DON-induced apoptosis by TNF-alpha was assessed using pharmacological inhibitors, generation of ROS, intracellular Ca2+, p38/SAPK, and caspase-3 activation were found to play roles.	deoxynivalenol	21-24	mitogen-activated protein kinase 14	Mus musculus	142-145
14597125-8	2003	When potentiation of DON-induced apoptosis by TNF-alpha was assessed using pharmacological inhibitors, generation of ROS, intracellular Ca2+, p38/SAPK, and caspase-3 activation were found to play roles.	deoxynivalenol	21-24	caspase 3	Mus musculus	156-165
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	28-42	prostaglandin-endoperoxide synthase 2	Mus musculus	131-136
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	28-42	mitogen-activated protein kinase 1	Mus musculus	244-248
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	44-47	prostaglandin-endoperoxide synthase 2	Mus musculus	113-129
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	44-47	prostaglandin-endoperoxide synthase 2	Mus musculus	131-136
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	44-47	mitogen-activated protein kinase 1	Mus musculus	244-248
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	49-58	prostaglandin-endoperoxide synthase 2	Mus musculus	113-129
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	49-58	prostaglandin-endoperoxide synthase 2	Mus musculus	131-136
14514436-1	2003	The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin), when at partially cytotoxic concentrations, induces cyclooxygenase-2 (COX-2) expression by promoting transcriptional activity and mRNA stability via mitogen-activated protein kinase (MAPK) signaling pathways.	deoxynivalenol	49-58	mitogen-activated protein kinase 1	Mus musculus	244-248
12773753-0	2003	Role of double-stranded RNA-activated protein kinase R (PKR) in deoxynivalenol-induced ribotoxic stress response.	deoxynivalenol	64-78	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	56-59
12773753-3	2003	The purpose of this research was to test the hypothesis that double-stranded, RNA-activated protein kinase R (PKR) is a critical upstream mediator of the ribotoxic stress response induced by the trichothecene deoxynivalenol (DON) and other translational inhibitors.	deoxynivalenol	209-223	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	110-113
12773753-3	2003	The purpose of this research was to test the hypothesis that double-stranded, RNA-activated protein kinase R (PKR) is a critical upstream mediator of the ribotoxic stress response induced by the trichothecene deoxynivalenol (DON) and other translational inhibitors.	deoxynivalenol	225-228	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	110-113
12773753-4	2003	DON was found to readily induce phosphorylation of JNK 1/2, ERK 1/2, and p38 in the murine macrophage RAW 264.7 cell line, within 5 min of culture addition, in a concentration-dependent fashion.	deoxynivalenol	0-3	mitogen-activated protein kinase 8	Mus musculus	51-58
12773753-4	2003	DON was found to readily induce phosphorylation of JNK 1/2, ERK 1/2, and p38 in the murine macrophage RAW 264.7 cell line, within 5 min of culture addition, in a concentration-dependent fashion.	deoxynivalenol	0-3	mitogen-activated protein kinase 3	Mus musculus	60-67
12773753-4	2003	DON was found to readily induce phosphorylation of JNK 1/2, ERK 1/2, and p38 in the murine macrophage RAW 264.7 cell line, within 5 min of culture addition, in a concentration-dependent fashion.	deoxynivalenol	0-3	mitogen-activated protein kinase 14	Mus musculus	73-76
12773753-6	2003	DON rapidly activated PKR within 1 to 5 min, as evidenced by autophosphorylation and by phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha).	deoxynivalenol	0-3	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	22-25
12773753-6	2003	DON rapidly activated PKR within 1 to 5 min, as evidenced by autophosphorylation and by phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha).	deoxynivalenol	0-3	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	144-153
12773753-9	2003	The capacity of DON to induce MAPK phosphorylation was also markedly suppressed in a stable transformant of the human promonocytic U-937 cell line containing an antisense PKR expression vector.	deoxynivalenol	16-19	mitogen-activated protein kinase 1	Mus musculus	30-34
12773753-9	2003	The capacity of DON to induce MAPK phosphorylation was also markedly suppressed in a stable transformant of the human promonocytic U-937 cell line containing an antisense PKR expression vector.	deoxynivalenol	16-19	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	171-174
12773753-11	2003	Apoptosis induction by DON and two other translational inhibitors, anisomycin and emetine, was almost completely abrogated in PKR-deficient cells.	deoxynivalenol	23-26	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	126-129
12480302-7	2003	DON was detected in all 15 samples following beta-glucuronidase treatment and IAC enrichment with the identity of DON being confirmed by mass spectrometry.	deoxynivalenol	0-3	glucuronidase beta	Homo sapiens	45-63
12773775-0	2003	Role of IL-1(beta) in endotoxin potentiation of deoxynivalenol-induced corticosterone response and leukocyte apoptosis in mice.	deoxynivalenol	48-62	interleukin 1 beta	Mus musculus	8-18
12773775-4	2003	Coexposure to LPS (0.1 mg/kg, ip) plus DON (12.5 mg/kg, po) was found to significantly upregulate splenic IL-1beta mRNA and IL-1beta protein expression in B6C3F1 mice, as compared to treatments with vehicle or either of the toxins alone.	deoxynivalenol	39-42	interleukin 1 beta	Mus musculus	106-114
12773775-4	2003	Coexposure to LPS (0.1 mg/kg, ip) plus DON (12.5 mg/kg, po) was found to significantly upregulate splenic IL-1beta mRNA and IL-1beta protein expression in B6C3F1 mice, as compared to treatments with vehicle or either of the toxins alone.	deoxynivalenol	39-42	interleukin 1 beta	Mus musculus	124-132
12773775-10	2003	Plasma adrenocorticotropic hormone (ACTH) levels in LPS plus DON-treated B6C3F1 mice did not correlate with the induction of plasma corticosterone or leukocyte apoptosis.	deoxynivalenol	61-64	pro-opiomelanocortin-alpha	Mus musculus	7-34
12773775-11	2003	Taken together, the results indicate that IL-1beta is an important mediator of LPS plus DON-induced corticosterone and subsequent leukocyte apoptosis and, furthermore, this cytokine possibly acts through an ACTH-independent mechanism.	deoxynivalenol	88-91	interleukin 1 beta	Mus musculus	42-50
12773775-11	2003	Taken together, the results indicate that IL-1beta is an important mediator of LPS plus DON-induced corticosterone and subsequent leukocyte apoptosis and, furthermore, this cytokine possibly acts through an ACTH-independent mechanism.	deoxynivalenol	88-91	pro-opiomelanocortin-alpha	Mus musculus	207-211
12676476-0	2003	Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal immune response with systemic repercussions.	deoxynivalenol	0-14	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	23-26
12676476-1	2003	Dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) selectively upregulates serum immunoglobulin A (IgA) in the mouse, most of which is polymeric, thus suggesting that the mucosal immune system is a primary target.	deoxynivalenol	51-65	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	102-118
12676476-1	2003	Dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) selectively upregulates serum immunoglobulin A (IgA) in the mouse, most of which is polymeric, thus suggesting that the mucosal immune system is a primary target.	deoxynivalenol	51-65	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	120-123
12676476-1	2003	Dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) selectively upregulates serum immunoglobulin A (IgA) in the mouse, most of which is polymeric, thus suggesting that the mucosal immune system is a primary target.	deoxynivalenol	67-70	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	102-118
12676476-1	2003	Dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) selectively upregulates serum immunoglobulin A (IgA) in the mouse, most of which is polymeric, thus suggesting that the mucosal immune system is a primary target.	deoxynivalenol	67-70	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	120-123
12676476-2	2003	When ingested, DON has no adjuvant or antigen properties but, rather, induces polyclonal IgA synthesis and serum elevation in an isotype-specific fashion.	deoxynivalenol	15-18	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	89-92
12676476-5	2003	At the cellular level, DON upregulates production of T helper cytokines and enhances T cell help for IgA secretion.	deoxynivalenol	23-26	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	101-104
12676476-8	2003	Interestingly, dietary omega-3 fatty acids can downregulate these processes and ameliorate DON-induced IgA nephropathy.	deoxynivalenol	91-94	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	103-106
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	56-65	prostaglandin-endoperoxide synthase 2	Mus musculus	0-16
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	56-65	interleukin 6	Mus musculus	26-39
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	67-81	prostaglandin-endoperoxide synthase 2	Mus musculus	0-16
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	67-81	interleukin 6	Mus musculus	26-39
12604170-0	2003	Up-regulation of macrophage inflammatory protein-2 and complement 3A receptor by the trichothecenes deoxynivalenol and satratoxin G.	deoxynivalenol	100-114	chemokine (C-X-C motif) ligand 2	Mus musculus	17-50
12604170-0	2003	Up-regulation of macrophage inflammatory protein-2 and complement 3A receptor by the trichothecenes deoxynivalenol and satratoxin G.	deoxynivalenol	100-114	complement component 3a receptor 1	Mus musculus	55-77
12377986-9	2002	Taken together, these results indicate that VT-induced PGE(2) production and COX-2 expression by elevating transcriptional activity and mRNA stability.	deoxynivalenol	44-46	prostaglandin-endoperoxide synthase 2	Mus musculus	77-82
12377986-0	2002	Vomitoxin-induced cyclooxygenase-2 gene expression in macrophages mediated by activation of ERK and p38 but not JNK mitogen-activated protein kinases.	deoxynivalenol	0-9	prostaglandin-endoperoxide synthase 2	Mus musculus	18-34
12377986-0	2002	Vomitoxin-induced cyclooxygenase-2 gene expression in macrophages mediated by activation of ERK and p38 but not JNK mitogen-activated protein kinases.	deoxynivalenol	0-9	mitogen-activated protein kinase 1	Mus musculus	92-95
11893416-0	2002	Vomitoxin (deoxynivalenol)-mediated inhibition of nuclear protein binding to NRE-A, an IL-2 promoter negative regulatory element, in EL-4 cells.	deoxynivalenol	0-9	patatin-like phospholipase domain containing 7	Mus musculus	77-80
12377986-0	2002	Vomitoxin-induced cyclooxygenase-2 gene expression in macrophages mediated by activation of ERK and p38 but not JNK mitogen-activated protein kinases.	deoxynivalenol	0-9	mitogen-activated protein kinase 14	Mus musculus	100-103
12377986-2	2002	The purpose of this study was to test the hypothesis that VT induces cyclooxygenase-2 (COX-2) gene expression in macrophages and that this is regulated at the level of mitogen-activated protein kinases (MAPKs).	deoxynivalenol	58-60	prostaglandin-endoperoxide synthase 2	Mus musculus	69-85
12377986-2	2002	The purpose of this study was to test the hypothesis that VT induces cyclooxygenase-2 (COX-2) gene expression in macrophages and that this is regulated at the level of mitogen-activated protein kinases (MAPKs).	deoxynivalenol	58-60	prostaglandin-endoperoxide synthase 2	Mus musculus	87-92
12221236-4	2002	The passive transporters of D-glucose (GLUT) were slightly inhibited by DON (15% inhibition at 1 micro mol/L, P &lt; 0.01), whereas the transport of palmitate was increased by 35% at 10 micro mol/L DON (P &lt; 0.001).	deoxynivalenol	72-75	solute carrier family 2 member 1	Homo sapiens	39-43
12221236-4	2002	The passive transporters of D-glucose (GLUT) were slightly inhibited by DON (15% inhibition at 1 micro mol/L, P &lt; 0.01), whereas the transport of palmitate was increased by 35% at 10 micro mol/L DON (P &lt; 0.001).	deoxynivalenol	198-201	solute carrier family 2 member 1	Homo sapiens	39-43
12167214-0	2002	Effects of vomitoxin (deoxynivalenol) on the binding of transcription factors AP-1, NF-kappaB, and NF-IL6 in raw 264.7 macrophage cells.	deoxynivalenol	11-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
12167214-0	2002	Effects of vomitoxin (deoxynivalenol) on the binding of transcription factors AP-1, NF-kappaB, and NF-IL6 in raw 264.7 macrophage cells.	deoxynivalenol	11-20	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	99-105
12167214-0	2002	Effects of vomitoxin (deoxynivalenol) on the binding of transcription factors AP-1, NF-kappaB, and NF-IL6 in raw 264.7 macrophage cells.	deoxynivalenol	22-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
12167214-0	2002	Effects of vomitoxin (deoxynivalenol) on the binding of transcription factors AP-1, NF-kappaB, and NF-IL6 in raw 264.7 macrophage cells.	deoxynivalenol	22-36	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	99-105
11893416-0	2002	Vomitoxin (deoxynivalenol)-mediated inhibition of nuclear protein binding to NRE-A, an IL-2 promoter negative regulatory element, in EL-4 cells.	deoxynivalenol	0-9	interleukin 2	Mus musculus	87-91
11893416-0	2002	Vomitoxin (deoxynivalenol)-mediated inhibition of nuclear protein binding to NRE-A, an IL-2 promoter negative regulatory element, in EL-4 cells.	deoxynivalenol	11-25	patatin-like phospholipase domain containing 7	Mus musculus	77-80
11893416-0	2002	Vomitoxin (deoxynivalenol)-mediated inhibition of nuclear protein binding to NRE-A, an IL-2 promoter negative regulatory element, in EL-4 cells.	deoxynivalenol	11-25	interleukin 2	Mus musculus	87-91
11893416-1	2002	Interleukin-2 (IL-2) gene expression is superinduced by the trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) in primary and cloned murine T cells-an activity that relates to this toxin"s capacity to inhibit protein synthesis.	deoxynivalenol	84-93	interleukin 2	Mus musculus	0-13
11893416-1	2002	Interleukin-2 (IL-2) gene expression is superinduced by the trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) in primary and cloned murine T cells-an activity that relates to this toxin"s capacity to inhibit protein synthesis.	deoxynivalenol	84-93	interleukin 2	Mus musculus	15-19
11893416-1	2002	Interleukin-2 (IL-2) gene expression is superinduced by the trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) in primary and cloned murine T cells-an activity that relates to this toxin"s capacity to inhibit protein synthesis.	deoxynivalenol	99-113	interleukin 2	Mus musculus	0-13
11893416-1	2002	Interleukin-2 (IL-2) gene expression is superinduced by the trichothecene mycotoxin vomitoxin (VT, deoxynivalenol) in primary and cloned murine T cells-an activity that relates to this toxin"s capacity to inhibit protein synthesis.	deoxynivalenol	99-113	interleukin 2	Mus musculus	15-19
11823588-2	2002	Using an experimental mouse model in which early immunopathological hallmarks of IgAN are induced by the mycotoxin vomitoxin (VT), the ameliorative effects of FO ingestion on this disease were evaluated in two studies.	deoxynivalenol	115-124	IGAN1	Homo sapiens	81-85
23605752-4	2001	Using yeast as a model system we have found the following resistance mechanisms and genes: a) reduced uptake of deoxynivalenol (PDR5), b) toxin modification and reduction of toxicity (AYT1), and c) formation of a resistant toxin target (RPL3).	deoxynivalenol	112-126	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	128-132
11766169-0	2001	Differential upregulation of TNF-alpha, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model.	deoxynivalenol	69-83	tumor necrosis factor	Homo sapiens	29-38
11766169-0	2001	Differential upregulation of TNF-alpha, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model.	deoxynivalenol	69-83	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
11766169-0	2001	Differential upregulation of TNF-alpha, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model.	deoxynivalenol	85-94	tumor necrosis factor	Homo sapiens	29-38
11766169-0	2001	Differential upregulation of TNF-alpha, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model.	deoxynivalenol	85-94	interleukin 6	Homo sapiens	40-44
11766169-0	2001	Differential upregulation of TNF-alpha, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model.	deoxynivalenol	85-94	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
11434990-8	2001	Short-term treatment of PHA-stimulated lymphocytes with DON (100, 200 and 400 ng/ml) modulated the kinetics of IL-2, IL-4 and IL-6 production.	deoxynivalenol	56-59	interleukin 2	Homo sapiens	111-115
11434990-8	2001	Short-term treatment of PHA-stimulated lymphocytes with DON (100, 200 and 400 ng/ml) modulated the kinetics of IL-2, IL-4 and IL-6 production.	deoxynivalenol	56-59	interleukin 4	Homo sapiens	117-121
11434990-8	2001	Short-term treatment of PHA-stimulated lymphocytes with DON (100, 200 and 400 ng/ml) modulated the kinetics of IL-2, IL-4 and IL-6 production.	deoxynivalenol	56-59	interleukin 6	Homo sapiens	126-130
11434990-10	2001	IL-4 levels were only slightly elevated and IL-6 levels were slightly inhibited by these DON concentrations.	deoxynivalenol	89-92	interleukin 4	Homo sapiens	0-4
11434990-10	2001	IL-4 levels were only slightly elevated and IL-6 levels were slightly inhibited by these DON concentrations.	deoxynivalenol	89-92	interleukin 6	Homo sapiens	44-48
11434990-12	2001	At the lower DON concentration (200 ng/ml), IL-2 levels were elevated 17-25-fold with a concomitant mild elevation in IFN-gamma.	deoxynivalenol	13-16	interleukin 2	Homo sapiens	44-48
11434990-12	2001	At the lower DON concentration (200 ng/ml), IL-2 levels were elevated 17-25-fold with a concomitant mild elevation in IFN-gamma.	deoxynivalenol	13-16	interferon gamma	Homo sapiens	118-127
11434990-13	2001	Consistent with earlier experiments, IL-6 levels were slightly suppressed by DON at this concentration.	deoxynivalenol	77-80	interleukin 6	Homo sapiens	37-41
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	55-64	tumor necrosis factor	Mus musculus	18-27
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	55-64	interleukin 6	Mus musculus	32-36
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	66-80	tumor necrosis factor	Mus musculus	18-27
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	66-80	interleukin 6	Mus musculus	32-36
23605752-4	2001	Using yeast as a model system we have found the following resistance mechanisms and genes: a) reduced uptake of deoxynivalenol (PDR5), b) toxin modification and reduction of toxicity (AYT1), and c) formation of a resistant toxin target (RPL3).	deoxynivalenol	112-126	ribosomal 60S subunit protein L3	Saccharomyces cerevisiae S288C	237-241
23605763-0	2001	Deoxynivalenol (DON) in raw and cooked Pasta.	deoxynivalenol	0-14	solute carrier family 45 member 1	Homo sapiens	39-44
23605763-0	2001	Deoxynivalenol (DON) in raw and cooked Pasta.	deoxynivalenol	16-19	solute carrier family 45 member 1	Homo sapiens	39-44
12520964-5	2000	Double antibody sandwich enzyme linked immunosorbent assay (ELISA) showed that the secretion of TNF-alpha in cells treated with DON(500-1000 ng/ml) was significantly lower than that in the control (P &lt; 0.01).	deoxynivalenol	128-131	tumor necrosis factor	Homo sapiens	96-105
12520964-7	2000	In general, DON mainly inhibited the proliferation of HPBM and decrease TNF-alpha secretion in vitro.	deoxynivalenol	12-15	tumor necrosis factor	Homo sapiens	72-81
9707511-9	1998	When mice were fed 0, 10, and 25 ppm VT for 4 weeks, increased expression of mRNAs for TNF-alpha, IL-2, IFN-gamma, and IL-10 was most prominent.	deoxynivalenol	37-39	tumor necrosis factor	Mus musculus	87-96
10764628-10	2000	Apoptosis induction by satratoxin G and vomitoxin was markedly enhanced when ERK activation was selectively inhibited by ERK-specific inhibitor PD98059, thus indicating a negative role for ERK.	deoxynivalenol	40-49	mitogen-activated protein kinase 1	Homo sapiens	77-80
10764628-10	2000	Apoptosis induction by satratoxin G and vomitoxin was markedly enhanced when ERK activation was selectively inhibited by ERK-specific inhibitor PD98059, thus indicating a negative role for ERK.	deoxynivalenol	40-49	mitogen-activated protein kinase 1	Homo sapiens	121-124
10764628-10	2000	Apoptosis induction by satratoxin G and vomitoxin was markedly enhanced when ERK activation was selectively inhibited by ERK-specific inhibitor PD98059, thus indicating a negative role for ERK.	deoxynivalenol	40-49	mitogen-activated protein kinase 1	Homo sapiens	121-124
10662601-0	2000	Modulation of transcription factor AP-1 activity in murine EL-4 thymoma cells by vomitoxin (deoxynivalenol).	deoxynivalenol	81-90	jun proto-oncogene	Mus musculus	35-39
10662601-0	2000	Modulation of transcription factor AP-1 activity in murine EL-4 thymoma cells by vomitoxin (deoxynivalenol).	deoxynivalenol	92-106	jun proto-oncogene	Mus musculus	35-39
10662601-3	2000	Here, the effect of trichothecene vomitoxin (VT, deoxynivalenol) on activator protein-1 (AP-1) activity was determined in the murine EL-4 thymoma.	deoxynivalenol	49-63	jun proto-oncogene	Mus musculus	68-87
10662601-3	2000	Here, the effect of trichothecene vomitoxin (VT, deoxynivalenol) on activator protein-1 (AP-1) activity was determined in the murine EL-4 thymoma.	deoxynivalenol	49-63	jun proto-oncogene	Mus musculus	89-93
10652249-0	2000	Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (Deoxynivalenol).	deoxynivalenol	68-77	heat shock protein 5	Mus musculus	55-60
10652249-0	2000	Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (Deoxynivalenol).	deoxynivalenol	68-77	heat shock protein 5	Mus musculus	61-64
10652249-0	2000	Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (Deoxynivalenol).	deoxynivalenol	79-93	heat shock protein 5	Mus musculus	55-60
10652249-0	2000	Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (Deoxynivalenol).	deoxynivalenol	79-93	heat shock protein 5	Mus musculus	61-64
9862652-0	1998	Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies.	deoxynivalenol	72-81	IGAN1	Homo sapiens	20-35
9862652-1	1998	Oral exposure of mice to vomitoxin (VT) induces elevated levels of serum IgA, circulating IgA immune complexes (IgA-IC), mesangial IgA deposition and haematuria, which all mimic the clinical signs of human IgA nephropathy (IgAN).	deoxynivalenol	25-34	IGAN1	Homo sapiens	206-221
9862652-1	1998	Oral exposure of mice to vomitoxin (VT) induces elevated levels of serum IgA, circulating IgA immune complexes (IgA-IC), mesangial IgA deposition and haematuria, which all mimic the clinical signs of human IgA nephropathy (IgAN).	deoxynivalenol	25-34	IGAN1	Homo sapiens	223-227
9862652-1	1998	Oral exposure of mice to vomitoxin (VT) induces elevated levels of serum IgA, circulating IgA immune complexes (IgA-IC), mesangial IgA deposition and haematuria, which all mimic the clinical signs of human IgA nephropathy (IgAN).	deoxynivalenol	36-38	IGAN1	Homo sapiens	206-221
9862652-1	1998	Oral exposure of mice to vomitoxin (VT) induces elevated levels of serum IgA, circulating IgA immune complexes (IgA-IC), mesangial IgA deposition and haematuria, which all mimic the clinical signs of human IgA nephropathy (IgAN).	deoxynivalenol	36-38	IGAN1	Homo sapiens	223-227
9862652-10	1998	In total, these data indicate that passive administration of VT-induced IgAs can induce the hallmarks of IgA nephropathy.	deoxynivalenol	61-63	IGAN1	Homo sapiens	105-120
9707511-9	1998	When mice were fed 0, 10, and 25 ppm VT for 4 weeks, increased expression of mRNAs for TNF-alpha, IL-2, IFN-gamma, and IL-10 was most prominent.	deoxynivalenol	37-39	interleukin 2	Mus musculus	98-102
9707511-9	1998	When mice were fed 0, 10, and 25 ppm VT for 4 weeks, increased expression of mRNAs for TNF-alpha, IL-2, IFN-gamma, and IL-10 was most prominent.	deoxynivalenol	37-39	interferon gamma	Mus musculus	104-113
9707511-9	1998	When mice were fed 0, 10, and 25 ppm VT for 4 weeks, increased expression of mRNAs for TNF-alpha, IL-2, IFN-gamma, and IL-10 was most prominent.	deoxynivalenol	37-39	interleukin 10	Mus musculus	119-124
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 1 beta	Mus musculus	171-179
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 6	Mus musculus	181-185
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	tumor necrosis factor	Mus musculus	187-196
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 12b	Mus musculus	198-206
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 12a	Mus musculus	208-216
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 2	Mus musculus	218-222
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interferon gamma	Mus musculus	224-233
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 4	Mus musculus	235-239
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 10	Mus musculus	245-250
9662416-0	1998	Modulation of IL-1beta, IL-6 and TNF-alpha secretion and mRNA expression by the trichothecene vomitoxin in the RAW 264.7 murine macrophage cell line.	deoxynivalenol	94-103	interleukin 1 beta	Mus musculus	14-22
9662416-0	1998	Modulation of IL-1beta, IL-6 and TNF-alpha secretion and mRNA expression by the trichothecene vomitoxin in the RAW 264.7 murine macrophage cell line.	deoxynivalenol	94-103	tumor necrosis factor	Mus musculus	33-42